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Bovine leukaemia virus (BLV) and lumpy skin disease virus (LSDV) are endemic to Africa and 
cause significant economic losses to the beef and dairy industries. Vaccines are the most 
cost-effective and efficient way to prevent infection and outbreaks. Currently, there is no 
commercially available vaccine against BLV. In contrast, there are several live attenuated 
vaccines against LSDV. A recombinant LSDV which could protect cattle against both LSDV 
and BLV would be of great benefit to the African continent.  
This Master’s degree project involved three objectives. Firstly, the genetic variabilities and 
phylogenetic relationships of eight South African BLV isolates with other BLV strains from 
different geographical regions worldwide with known genotypes were determined. The BLV 
full-length envelope (env) and gag genes were successfully sequenced from total DNA 
extracted from the blood of BLV-infected cattle from a single herd. The analyses indicated that 
the seven of the South African isolates characterised in this study belonged to genotype 4 and 
the eighth to genotype 1. Furthermore, amino acid substitutions in the BLV Env and Gag 
sequences unique to the South African isolates were identified.  
Secondly, the activity of five selected poxvirus promoters in cells infected with LSDV was 
assessed by the detection of transient expression of an enhanced green fluorescent protein 
(eGFP) reporter gene driven by the poxvirus promoters. The promoters tested were a modified 
early fowlpox virus promoter (pmFP), an early-late promoter of a 7.5 kilodalton polypeptide 
gene of vaccinia virus (VACV) (p7.5), a synthetic early-late promoter of VACV (pS), a modified 
early-late promoter of the H5 gene of VACV (pmH5) and a synthetic early-late optimised 
promoter of VACV (pLEO). The results showed that all the poxvirus promoters were functional 
in the LSDV-infected cells and the eGFP expression was stable over the 72-hour study period. 
Lastly, two LSDV-vectored dual vaccines containing BLV immunogen(s) were developed and 
characterised. The first recombinant LSDV-vectored vaccine contained the BLV Env and Gag 
immunogens and the second recombinant LSDV-vectored vaccine contained the BLV Env 
immunogen alone. The presence of the BLV env gene in the recombinant LSDV vaccine was 
confirmed by polymerase chain reaction (PCR) and the BLV env sequence was confirmed by 
Sanger sequencing. Furthermore, BLV Env and Gag protein expression were confirmed by 
immunofluorescent staining and Western blotting, respectively.  
Future work will involve further purification of the recombinant viruses, confirmation of the 
production of BLV Gag virus-like particles and the preparation of high titre stocks of the 
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1.1. LUMPY SKIN DISEASE VIRUS (LSDV)  
Lumpy skin disease (LSD) is a notifiable disease of cattle in South Africa [1] and is endemic 
in Africa and the Middle East [2]. LSD is caused by lumpy skin disease virus (LSDV), which is 
a DNA virus from the Capripoxvirus (CaPV) genus of the Poxviridae family. LSDV naturally 
infects cattle and Asian water buffalo and the transmission of LSDV is predominantly mediated 
by arthropod vectors [3, 4]. LSDV infection causes acute or subclinical diseases including high 
fever (> 41C), lymphadenopathy, salivation, nasal discharge, lachrymation and skin nodules 
that are characteristic of poxvirus infection [5-7]. The morbidity rate varies depending on age, 
breeds and immune status of animals but it is usually less than 20% [8, 9]. The mortality rate 
is less than 10% but it can reach more than 75% during outbreaks [8-11].  
 
1.1.1. Epizootiology of lumpy skin disease (LSD) 
LSD has never been eradicated from the endemic countries. Rather, endemic countries have 
been plagued with recurrent outbreaks and LSDV geographic distribution has been rapidly 
expanding from Africa to the Middle East and further into Europe (Figure 1.1) [2]. Furthermore, 
there has been a concern about the incursion of LSD into Asia if LSDV continues expanding 
its geographic distribution at this alarming rate. The financial cost to control outbreaks is 
generally enormous and the economic damages of an LSD outbreak can be severe 
particularly in resource-limited countries.  
Since LSDV virions are stable in cutaneous lesions and body fluids such as blood, saliva, and 
semen for several days or even more than a month, extensive transmission of LSDV is 
possible in the presence of efficient vectors such as blood-sucking insects and ticks that 
directly transfer the virus into the vascular system of naïve animals [5, 6, 12-15]. The 
transmission of LSDV by insect vectors and unrestricted movement of cattle have been shown 
to have contributed to recent spread into the Middle East and recurrent outbreaks in Africa 
and the Middle East [8, 16]. In general, eradication of arboviruses, such as LSDV and dengue 
virus, is extremely difficult as standing water that harbours insects exists everywhere 
throughout the year. Controlling movement of cattle is also challenging as nomadic 
pastoralists and refugees can mediate the spread of the disease [17]. Although the eradication 





Figure 1.1: Geographic distribution of lumpy skin disease outbreaks from January 2005 to July 2019. 
Adapted from World Organisation for Animal Health (OIE) (2019)[2].  
 
1.1.2. LSDV vaccines  
There are several manufacturers marketing LSDV vaccines. All commercially available LSDV 
vaccines are live-attenuated vaccines based on the LSDV strains, Kenyan sheep and goat 
poxvirus (KSGP) strains or sheep poxvirus (SPPV) strains as there is cross-protection 
amongst CaPV strains. The use of SPPV- and KSGP-based vaccines against LSDV, however, 
is not allowed in sub-Saharan countries, where SPPV and KSGP are not co-circulating with 
LSDV. Therefore, vaccines based on LSDV strains are the only option in such a region. 
However, local reaction at the injection site, adverse effects following immunisation (AEFI), 
incomplete protection amongst cattle vaccinated with non-homologous LSDV strains, 
insufficient attenuation and residual virulence of vaccine viruses have been reported [18-23]. 
Together, these issues discourage cattle owners from using LSDV vaccines in fear of reduced 
milk and beef production and damage to skin and hides [8, 18, 22-24]. 
 
1.1.3. Recombinant LSDV-vectored dual vaccines  
As a member of the poxvirus family, LSDV has been explored as a vaccine vector for several 
infectious diseases including HIV and rabies [25-28]. In addition to the use as a homologous 
vaccine, LSDV-vectored dual vaccines have been developed to protect animals against lumpy 
skin disease and other ruminant pathogens such as peste des petits ruminant virus (PPRV), 
Rift Valley fever virus (RVFV), rinderpest virus (RPV) and SPPV [29-34]. The use of the LSDV 
4 
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vector is particularly useful for the protection against ruminant pathogens as the vaccine 
expresses LSDV antigens and only infects and replicates in goats, sheep and cattle, thereby 
preventing the transfer of vaccine viruses to non-target animals, including humans [35]. Some 
of the previous vaccine studies showed complete dual protection against homologous virus 
(LSDV or SPPV) and heterologous virus (RVFV, RPV or PPRV) [30-34]. In addition, long-term 
protection (~2 years after vaccination) against LSDV was demonstrated and recombinant 
LSDV vaccines did not transmit the vaccine virus to in-contact animals nor induce adverse 
effects [32, 33]. These studies motivated us to develop a recombinant LSDV-vectored dual 
vaccine expressing heterologous bovine leukaemia virus (BLV) envelope (Env) and group-
specific antigen (Gag) proteins to protect animals from both LSDV and BLV infections.  
 
1.2. BOVINE LEUKAEMIA VIRUS (BLV) 
Bovine leukosis is the most common neoplastic disease in cattle and consists of two types of 
leukosis: enzootic bovine leukosis (EBL) and sporadic bovine leukosis (SBL). The occurrence 
of EBL is more frequent than that of SBL [36, 37]. SBL is not transmissible and a causative 
agent of SLB remains unknown. The aetiological agent of EBL is bovine leukaemia virus (BLV), 
which is a B-lymphotropic oncovirus, belonging to the deltaretrovirus genus of the Retroviridae 
family [38]. BLV naturally infects cattle, water buffalo and zebu [39]. BLV infection is 
characterised by chronic lymphoproliferative disorder, termed persistent lymphocytosis (PL), 
and development of multicentric lymphomas (or lymphosarcoma) in various organs [40, 41].  
 
1.2.1. Host animals and transmission of BLV 
1.2.1.1. Host animals 
As a natural reservoir, BLV persistently infects four domesticated bovine species: domestic 
cattle (Bos taurus), zebu (Bos indicus), water buffalo (Bubalus bubalis) and yak (Bos 
grunniens). There is no viral reservoir in wild animals. However, there is a concern about the 
establishment of the BLV reservoir in other bovine species, particularly indigenous cattle [42]. 
BLV infection in indigenous cattle has been reported in Asia and Africa (see Section 1.2.2.3) 
but the BLV seroprevalence appeared to vary amongst different breeds. For example, 
previous serosurveys in Asia found that individual BLV seroprevalence of Pakistan water 
buffaloes and Cambodian draught cattle was 0.8% [43] and 5.3% [44], respectively, whereas 




It has been shown that dairy cattle, particularly highly productive European cattle raised in 
modern cattle farming systems are more susceptible to various diseases possibly due to 
negative energy balance [46-51] and nature of the housing system (crowded environment in 
tie-stall barns or increased physical contact under the loose housing system) [52-54]. In 
addition, host genetic backgrounds also influence disease progression. Studies on genotyping 
of the bovine major histocompatibility complex (BoLA) and its association with PL status of 
BLV-infected cattle have shown that polymorphism in BoLA class II DRB3 gene exon 2 
(DRB3.2) is highly associated with proviral load and resistance or susceptibility to the 
progression to PL or lymphosarcoma in BLV-infected animals [55-66]. Previous studies have 
demonstrated that DRB3.2*0902 and DRB3.2*0201 alleles are associated with low proviral 
load (LPL) and resistance to progression to PL and lymphosarcoma whereas DRB3.2*1201 
and DRB3.2*1501 alleles are associated with high proviral load (HPL) and susceptibility to PL 
[57-63]. Higher allelic frequency of the susceptible alleles, compared to that of the resistant 
alleles, have been observed in Philippine, Chilean, Korean, Argentina and Japanese Holstein 
and Holstein crossbreeds [63, 64, 67-70]. High frequency of susceptible alleles in the Holstein 
cattle can partly explain why BLV is highly prevalent in dairy cattle and in Japan and Argentina 
(see Section 1.2.2.2).  
In addition to its natural host, BLV can infect a wide variety of mammalian cells [71] and BLV 
can experimentally infect rats [72], sheep [73-78], goats [75, 79] and rabbits [80-82]. However, 
pathogenesis and disease symptoms in these BLV-infected animals differ. Sheep develop 
lymphosarcoma at a higher frequency (i.e., almost all infected sheep) and disease progress 
faster (i.e, a 1-4 year latency period) than cattle [75, 78, 83-87]. For these reasons, sheep 
were considered to be a useful animal model to monitor the disease progression and 
protective effects of vaccines [87-96]. However, it has been shown that BLV-infected cattle 
and sheep display different kinetics of proliferating B cells and protective effects on vaccines 
[87, 93, 97]. Therefore, cattle are a more suitable animal model to assess vaccine-induced 
immune responses and efficacy of vaccines. In contrast to sheep and cattle, experimental 
infection of BLV in rabbits results in immune dysfunction but do not develop lymphoma [80-
82]. Therefore, rabbits are not an ideal animal model to study mechanisms of pathogenesis 
and disease progression but can be used to test the safety of vaccines and monitor the 
presence of anti-BLV immune responses [82].  
Recently, anti-BLV Gag antibodies were detected from human sera [98] and a segment of the 
BLV genome was detected from human mammary epithelium [99] and breast tissue [100]. 
These observations indicate that BLV has a wider host tropism than previously thought and 
this has raised a concern about the zoonotic infection of BLV into humans through BLV-
infected milk and possible association of BLV infection in women with breast cancer [99].  
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1.2.1.2. Pathogenesis – silent infection 
EBL is a chronic infection, characterised by abnormal proliferation of non-neoplastic B cells 
(10,000 cells/µl blood) during the PL stage and culminating in the development of malignant 
neoplastic lymphosarcoma in various organs (Figure 1.2) [41]. All animals with 




Figure 1.2: Mass of neoplastic tissues formed in abdominal and thoracic organs.  (A) White enlarged 
mesenteric lymph nodes (arrows) in the intestine. (B) Nodular neoplastic masses bulging from the endocardial 
surface of the right atrium and ventricles. (C) White nodules of leukotic tissues on the surface of cortex and 
medulla of a kidney. (D) Pink neoplastic masses on the mucosal surface of the urinary bladder. Adapted from 
Yoon et al. (2005) [41]. 
 
Despite the devastating results following the infection, BLV infection is characterised by its 
silent nature. Firstly, infected animals do not show visible disease symptoms such as 
lymphadenopathy and nasal discharge and thus, BLV infection can be only confirmed by 
serological or molecular tests. Secondly, BLV infection does not cause PL or lymphosarcoma 
to all infected cattle (Figure 1.3) and the disease progresses slowly without apparent viremia 
during a 7 to 10 year latency period [83, 101]. Up to 30% of infected animals (PL animals) 
develop persistent lymphocytosis (PL) within 3 to 6 years after infection. The remaining 70% 
of the infected animals are aleukemic and asymptomatic without any haematological or clinical 
abnormalities. These aleukemic or non-PL animals harbour high (≥100,000 copies) or low 
(≤100 copies) proviruses in their infected lymphocytes (HPL and LPL, respectively) [102]. The 
non-PL animals with HPL are able to transmit the infection as efficiently as PL animals [102]. 
Of all the infected animals, irrespective of PL status, only 5 to 10% of the cows eventually 
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develop lymphoma after a long latency period. The lymphosarcoma stage is characterised by 
increased monoclonal populations of neoplastic B lymphocytes and eventually results in death 
[101].  
Without appropriate diagnostic tests, it is difficult to accurately determine infectious status 
amongst herds as only less than 10% of the infected animals exhibit clinical symptoms. 
However, since both PL animals (30%) and non-PL animals with HPL (28%) are efficient 
transmitters of infection, actual infectious animals constitute approximately 60% of the infected 
animals. Thus, infectious status at the herd level is often underestimated and as a result, 
adherence to sterile methods during veterinary procedures tends to be neglected by 
veterinarians and cattle owners. Consequently, the infection can be spread extensively within 




Figure 1.3: Disease progression of BLV-infected cows. BLV-infected animals with persistent lymphocytosis 
(PL) or without PL (non-PL) are determined by total lymphocyte count (TLC) (Bendixen (1965) [103]; Ferrer, et 
al. (1978) [83]). These animals are further classified into two groups, animals with high proviral load (HPL) or 
low proviral load (LPL), based on the number of proviral copies  per microgram of DNA in infected peripheral 
blood lymphocytes (PBLs) and antibody titres against  BLV p24 and gp51 proteins as specified by Juliarena et 
al. (2007) [102]. The dark yellow boxes indicate highly infectious animals whereas the light-yellow box indicates 
less infectious animals. 
 
1.2.1.3. Within-herd transmission 
BLV infection can spread in two ways, horizontal and vertical transmissions. Horizontal 
transmission occurs by physical contact with infected animals, BLV-carrying insect vectors 
and iatrogenic procedures. Since BLV virions are unstable, the transmission of BLV is 
considered to occur exclusively through the transfer of infected cells in blood or milk  [104]. 
As a result, the majority of the transmission is mediated by direct transfer of infected bloodily 
fluids during iatrogenic procedures such as ear tattooing, dehorning, reuse of needles and 
gloves for veterinary procedures and plastic sleeves for rectal palpation for artificial 
insemination, detection of pregnancy and embryo transfer [105-109], which are common 
practices in the management of dairy and beef cattle. Ear tattooing, dehorning and vaccination 
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inevitably involve bleeding from an applied area, and reuse of instruments, gloves, needles 
permit transfer and spread of BLV-infected blood between animals. Due to a large number of 
animals that have to be processed at a time and lack of awareness of BLV infection, septic 
practices during veterinary examination have been frequently neglected [110, 111].  
Vertical transmission from dam to calf involves utero/placental transmission, perinatal 
transmission during delivery or postnatal transmission through the consumption of infected 
colostrum and milk. BLV provirus and antibodies have been detected in colostrum [111-118] 
and a study examining 129 calves born to infected dams showed that overall, 18.6% of the 
calves were infected by vertical transmission, in which 10.8% and 7.7% of infected calves 
were due to transplacental and perinatal transmission, respectively. In another study 
examining 26 calves born to infected dams, no transplacental transmission was observed 
[119]. Although vertical transmission appears inefficient, the consequence of vertical 
transmission is not negligible. A study conducted [117] in Argentina showed that despite 
stringent management practices during iatrogenic procedures, BLV seroprevalence in a dairy 
farm increased with age: 11.4% amongst calves, 61.7% following first delivery and 86.5% in 
adult cows. Their follow-up study [112] showed that all calves born to infected dams reached 
high proviral load at 12 months of birth, which persisted during a 3-year study period. Since 
calves are immunosuppressed during the first 4 months after birth [120, 121], unlike infected 
adult cows [122, 123], infected calves could not efficiently control BLV infection. Therefore, 
infected calves can become a source of infection and facilitate the spread and persistence of 
BLV infection within-herd if dams are not tested regularly.  
In addition to new-born calves, an Iranian study [110] revealed that imported animals and 
newly-brought heifers examined in this study did not undergo a serological test for BLV 
infection and these animals were subsequently placed in existing herds. These studies 
together highlight the significance of the compulsory serological tests for pregnant dams, 
newly-brought animals as well as semen and embryos for artificial insemination and 
fertilisation.  
Once BLV-infected animals are detected, these animals need to be slaughtered or separated 
from uninfected animals to prevent further spread of infection. As a result, additional facilities 
and costs are required and these measures are indubitably expensive for small-scale and 
private farmers if governmental subsidiaries are not available. Therefore, a more cost-effective 
and less labour-intensive preventative measure should be implemented, and vaccines can 
live up to such requirements.  
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1.2.2. Epizootiology of enzootic bovine leukosis (EBL) 
1.2.2.1. History of BLV prevalence 
The occurrence of leukosis in cattle was first reported by Leisering [124] in 1871 in Germany, 
who found yellowish nodules in the enlarged spleen of a cow. However, the causative agent 
of the leukosis in cattle remained unknown for the next 100 years. During the early to mid-
1990s, various studies demonstrated that C-type retroviruses would cause leukaemia and 
lymphosarcoma in other animal species [125] such as chicken [126-128], mice [129-132] and 
cats [133-135]. It had long been suspected that a C-type virus was also associated with 
enzootic bovine leukosis (EBL) [136-139]. In 1969, bovine leukaemia virus (BLV) was isolated 
from cattle with lymphosarcoma and it was identified as the aetiological agent of EBL [140].  
The origin of BLV is unknown but an initial epicentre of the EBL incidence is considered to be 
in Klaipeda in Lithuania [141]. Early studies in the late 1800s and early 1900s indicate that 
ELB was already endemic in Europe and spreading to BLV-free countries in Western Europe 
[142-144]. The importation of BLV-infected cattle into BLV-free countries appeared to facilitate 
the global spread of BLV [145]. BLV is thought to have been introduced into North America 
during the early 1900s and it is assumed that BLV was reintroduced from Canada into some 
BLV-free European countries through the importation of BLV-infected cattle [146, 147]. BLV 
was also thought to be introduced into other geographic regions worldwide, such as Ireland 
[148, 149], Bulgaria [150], Russia [151], Egypt [145] and Mongolia [152] through the 
importation of BLV-infected cattle.  
 
1.2.2.2 Current status of BLV prevalence 
1.2.2.2.1. Europe  
Geo-economic situations in the European Community (now European Union) particularly 
facilitated the spread of BLV amongst European countries in the early and mid-1990s. For 
example, in the Netherlands, due to the strict national import policy, EBL incidence amongst 
imported and exported cattle was not reported prior to 1965 [153]. However, following the 
amendment of European Economic Community regulations in 1965, importation of cattle from 
partner countries became easier, resulting in the introduction of BLV in the Netherlands [153].  
Despite the persistence of BLV for many decades, Europe became a role model as a BLV-
free region. The European Community played a pivotal role in the successful eradication and 
elimination of EBL from the majority of the European countries (Figure 1.4). A framework to 
monitor, control and eradicate, animal diseases (e.g., bovine tuberculosis, brucellosis and 
EBL) was established in 1977 to protect livestock sectors from influences of animal disease 
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outbreaks [154]. The EU co-financed the EBL eradication program was started in 1993 and 
covers the cost of serological and milk tests as well as compensation for slaughtering animals 




Figure 1.4: Disease status of enzootic bovine leukosis in Europe in 2017. A year BLV-free status achieved 
[157-162] and herd-prevalence (percent) in 2015 [160] are shown in the figure. Map adapted from Bovine and 
Swine Diseases Situation 2017 [160]. 
 
Since the implementation of this program, the EBL incidence has significantly decreased in 
the EU Member States. In 2006, another program [163] was started to co-finance several 
countries (Italy, Lithuania, Latvia, Poland and Portugal) to accelerate the eradication process 
where BLV still persisted. All these countries except Portugal achieved BLV-free status by 
2017 and EBL is near eradication in Portugal, being present only in specific areas with low 
herd prevalence (0.02% in 2015) [164]. In 2010, the EU co-financed EBL eradication program 
was terminated following the successful eradication of EBL in the vast majority of the Member 
States [165]. As of 2017, 22 Member States have achieved EBL-free status and EBL remains 
present only in six countries (Figure 1.4). A 2015 survey showed low herd prevalence in five 
of these countries (Greece, Hungary, Croatia, Romania and Portugal), approximately 1% or 
less (Figure 1.4). Only in Bulgaria, was there a high herd prevalence of 12.95%. 
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1.2.2.2.2. Global trend  
Currently, BLV is endemic globally (Figure 1.5). Although it is possible to eradicate BLV, some 
countries have extremely high BLV seroprevalence. Table 1.1 summarises herd and individual 
BLV seroprevalence of dairy and beef cattle in Japan, Canada, USA and Argentina. Although 
it is difficult to compare seroprevalence between study years, different regions and countries, 
these countries show more than 65% of herd prevalence in dairy herds and varying degrees 
of individual seroprevalence (20.8% to 70.0%) in dairy cattle, which is generally higher than 
the individual seroprevalence of beef cattle. Furthermore, herd and individual seroprevalence 
of dairy cattle in all four countries remains high or has been increasing during 10- to 20-year 
study periods. Figure 1.6 is a graph showing higher individual BLV seroprevalence in dairy 
cattle compared to beef cattle and an increasing trend of individual BLV seroprevalence in 




Figure 1.5: Worldwide infectious status of enzootic bovine leukosis from January to June in 2016. Taken 
from World Organisation for Animal Health (OIE) (2019) [166]. 
 
Persistence and high prevalence of BLV in some countries such as Bulgaria, Argentina, Japan, 
Canada and the USA appears to be mainly due to the delayed implementation of national 
eradication programmes in formerly non-EU countries (i.e., prior to the enlargement of the 
European Union in 2007), the absence of national compulsory disease control schemes [52, 
167], modern housing system (tie-stall vs loose housing system; the latter increases physical 
contact between animals) [52-54, 168] and low awareness of BLV infection amongst 
veterinarians and cattle farmers [111, 169]. Currently, there is no national BLV eradication 
program in these countries including Japan [170], Canada [171, 172] and the USA [111, 173]. 
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Table 1.1: Nationwide and regional BLV seroprevalence for various years in Japan, Canada, USA and Argentina.    
Country Region Study year Test method 
Herd prevalence Individual prevalence 
References 
Dairy cattle Beef cattle Dairy cattle Beef cattle 
Japan 7 prefectures 2007 ELISA and AGID 67.5% (overall) 28.6% (overall) [52, 174] 
    79.1% 22.0% 34.7% 11.9%  
 Nationwide 2009-2011 ELISA  35.2% (overall) [170] 
    78.0% 69. 0% 40.9% 28.7%  
Canada Maritime region 1998-1999 ELISA 70.0%  20.8%  [175] 
 Alberta 2002 ELISA 86.7%  26.9%  [176] 
 Manitoba 2002 ELISA 97.4%  60.8% 10.3% [177] 
 Saskatchewan 2001 ELISA 89.1%  37.4%  [178] 
 Maritime region 2013 ELISA 90.8%  30.4%  [179] 
USA Nationwide 1996 AGID 89.0%  43.5%  [180, 181] 
 Nationwide 1997 AGID  38.0%  10.3% [181] 
 Kansas 2004 AGID    8.5% [182] 
 17 states 2007 ELISA 83.9%    [183] 
 Nationwide 2014-2015 ELISA   38.6% (overall) [184] 
      47.6% 33.6%  
 11 states 2018 ELISA 94.2%    [111] 
Argentina 4 provinces 1998-1999 
ELISA, AGID and 
PCR 
84%  32.9%  [167] 
 5 sites 2004 ELISA and PCR 73.5%  70.0%  [185] 
 Rafaela (Santa Fe) 2009 ELISA and PCR 86%    [185] 
 General Roca (Río Negro) 2009 ELISA and PCR 90.5%    [185] 
 Susana (Santa Fe) 2009 ELISA and PCR 92%    [185] 
 Ataliva (La Pampa) 2009 ELISA and PCR 85%    [185] 





Figure 1.6: Individual BLV seroprevalence in dairy and beef cattle in Japan in 1980, 1982 and 2007. Taken 
from Murakami et al. (2011) [52]. 
 
Eradication of BLV is a lengthy process and achievement of BLV-free status following the 
implementation of eradication programmes usually takes more than 10 years. Therefore, 
implementation of proper disease control schemes and adherence to disease control 
programmes also play essential roles in accelerating eradication processes. For example, an 
increase in BLV seroprevalence from 8.49% to 33.38% in Bulgaria from 1997 to 2012 [150, 
186] was due to the implementation of the serological tests alone (i.e., no culling of BLV-
positive animals or herds) amongst underfinanced cattle farmers [150]. In Malta, EU co-
financed serological testing was implemented in 2002 but it was interrupted until 2007 [187]. 
A national control scheme started only recently, in 2010 [187], and as of 2018, BLV is still 
present in Malta [188]. In contrast, Australia is an exemplary country for the successful and 
speedy elimination of BLV from dairy herds. Australia is officially declared BLV-free status in 
dairy herds in 2013 following the implementation of the National Dairy EBL Eradication 
Program in 2008 [189-191].  
 
1.2.2.2.3. Africa  
Since serosurveys for the occurrence of BLV in Africa have not been conducted, the 
prevalence of BLV in Africa is largely unknown. Available data indicate relatively low 
seroprevalence amongst African dairy and beef cattle (Table 1.2). However, the individual 
seroprevalence of dairy and beef cattle in Tanzania was 41% and 21.4%, respectively during 
a study period between 1991 and 1994 [192]. Dairy cattle in Tanzania originated from Europe 
and Canada whereas beef cattle originated from an area where there was no contact with 
exotic European cattle [192]. Therefore, it was suspected that BLV was introduced into dairy 
cattle by the importation of cattle from BLV-present countries, and beef cattle were infected 
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through contact with infected dairy cattle in communal pastoral sites. To the best of our 
knowledge, there is no recent data of BLV seroprevalence in South Africa, but high EBL 
incidence has been reported in South Africa (Afrivet, 2018). 
 
Table 1.2: BLV seroprevalence for various years in six selected African countries. 
Country Study year Herd prevalence 
Individual prevalence 
References 
Dairy cattle Beef cattle 
Botswana 1990  7.75% (overall) [193] 
   5.55% 8.67%  
Kenya 2016  7.6% (overall) [194] 
Somalia 2008-2009 30.0% for native Somali 
breed  
1.5% for native Somali breed  [195] 
South 
Africa 
1996  12.6% for mixed herds (Mafikeng 
area of the North West province) 
[196] 
 2011  4.54% for dairy cattle (Gauteng and 
Mpumalanga provinces) 
[169] 
Tanzania 1991-1994  41% 21.4% [192] 
Zambia 2001  5.0% for indigenous cattle [197] 
 
1.2.3. Virology of BLV  
1.2.3.1. BLV virion and genomic structures 
BLV is a member of the Deltaretrovirus genus of the Retroviridae family. BLV is 
phylogenetically related to human T-lymphocyte leukaemia virus (HTLV), which is a T-
lymphotropic oncovirus in humans [198, 199].  BLV is an enveloped virus and has pleomorphic 
shapes, with its diameter ranging from 80 to 130 nm [140, 200, 201]. The outer layer of the 
BLV virion is a lipid bilayer in which envelope glycoproteins (Env) are embedded (Figure 1.7). 
Two copies of a positive-sense single-stranded RNA, reverse transcriptase (RT) and integrase 
(IN) are packed in each BLV virion and they are surrounded by capsid protein (p24) and matrix 
protein (p15). Genomic RNAs are associated with nucleocapsid proteins (p12). These 
structural proteins have been poorly studied, and only the Env transmembrane protein [202] 
and capsid protein [203] have been resolved by crystallography. More studies on structural 
proteins will help identify major antibody target sites and immunodominant epitopes useful for 





Figure 1.7: Schematic representations of BLV virion. SU, surface protein; TM, transmembrane 
protein; NC, nucleocapsid; CA, capsid; MA, matrix. Adapted from Barez et al. (2015) [204], Gillet 
et al. (2007) [200] and Polat et al. (2017) [205].  
 
The complete BLV proviral DNA genome consists of 8,714bp [206]. As a complex retrovirus, 
BLV genome has a conserved modular genomic organisation with a set of structural genes 
(gag, pro, pol and env) at the 5’ end of the proviral genome, followed by accessory genes (G4, 
R3 and microRNAs) and regulatory genes (tax, rex) at the 3’ end (Figure 1.8). The BLV proviral 
genome is flanked by two identical long terminal repeats (LTRs) at the 5’ and 3’ ends of the 
BLV genome. Both LTRs comprise three consecutive regions, U3, R and U5 regions, and 
contain a number of cis-acting regulatory sequences such as an enhancer sequence called 
Tax responsive element (TxRE), E box regulatory sequences and NF-B binding site.  
The structural genes encode proteins essential for the viral infection and replication whereas 
the regulatory gene products modulate viral gene expression and are involved in 
leukemogenesis. Functions of the accessory genes remain largely unknown but they are likely 
to be involved in the posttranslational regulation of the viral gene expression and pathogenesis. 
The genomic organisation of a 1.8 kb region between the env gene and 3’ LTR was long 
unknown (thereby called pX region). Subsequently, it was discovered that the pX region 
contains a microRNA (miRNA) ORF, regulatory [207, 208] and accessory genes [209]. Later 
studies [73, 74, 210] demonstrated that deletion in the R3/G4 genes or G4 gene resulted in 
reduced proviral load. Viral propagation and pathogenesis in rabbits and sheep inoculated 
with BLV deletion mutant showed that the deletion mutants were infectious. These studies led 






Figure 1.8: Modular organisation of BLV proviral genome. LTR, long terminal repeat; Pro, protease; Pol, 
DNA-dependent RNA polymerase; Env, envelope; miRNA, microRNA. pX, pX region. Adapted from Barez et 
al. (2015) [204], Gillet et al. (2007) [200], Polat et al. (2017) [205] and Rice et al. (1985) [211].  
 
1.2.3.2. Replication, transcription and translation of BLV  
The mechanism of BLV replication is identical to that of the human immunodeficiency virus 
(HIV), using the viral reverse transcriptase and strand transfer events to synthesise double-
stranded viral DNA, which is subsequently integrated into the host genome [212, 213]. It has 
been shown that only 25-30% of circulating lymphocytes in leukemic animals harbour the 
provirus whereas approximately 70% of the tumour cells harbour the provirus [214, 215]. It 
has been also demonstrated that 1 to 4 copies of the provirus can be integrated as an intact 
or truncated viral genome [216]. The proviral integration appears to be random and not site-
specific and thus, it is unlikely that insertional mutation contributes to BLV leukemogenesis 
[101, 216, 217].  
All promoters except for those driving the expression of viral miRNAs are located in the 5’ LTR 
[218]. Transcription initiates from the CAP site at the 3’ end of the U3 region and terminates 
at the transcription terminal signal at the 3’ end of the R region in the 3’ LTR (Figure 1.9). The 
viral mRNAs are then polyadenylated [219] and exported into the cytoplasm [220], where the 
synthesis of viral proteins and posttranslational processing of polyproteins takes place [221]. 
The genomic RNA also serves as a template to transcribe the monocistronic Gag-Pro-Pol 
mRNA containing three different ORFs with the termination signal at the 3’ end of each ORF 
[211]. The translation of the Gag-Pro-Pol mRNA produces Gag precursor (pr45) (see Section 
1.2.3.4), Gag-Pro precursor (pr66) or Gag-Pro-Pol precursor (pr145) proteins (Figure 1.10). 
Normal translational termination in the gag ORF results in the production of the Gag precursor 
whereas the frameshift translation produces the Gag-Pro or Gag-Pro-Pol precursors [211]. 
The posttranslational cleavage of the Gag-Pro precursor by the viral protease [221] results in 
the production of the protease whereas that of the Gag-Pro-Pol precursor protein (pr145) 
produces the reverse transcriptase (RT) [211]. The BLV RT has RNA-dependent DNA 
polymerase, DNA-dependent DNA polymerase, RNase H and integrase activities. The BLV 
RT has the mutation rate of 1.2x10-5 mutation per bp per replication cycle [222], which is lower 
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than that of the HIV RT, ranging from 1.4x10-5 to 3.4x10-5 mutation per bp per replication cycle 








Figure 1.9: Schematic representations of BLV proviral genomic RNA and transcript organisation. (A) 
Genomic RNA and a template for transcription of a Gag-Pro-Pol precursor. (B) Messenger RNAs of a Gag-Pro-
Pol precursor, Env precursor (pr72), Tax, Rex, R3 and G4 proteins. Nucleotide positions of splicing donor and 
acceptor sites are indicated by numbers. LTR, long terminal repeat; Pro, protease; Pol, polymerase; Env, 
envelope; miRNA, microRNA. +1, transcription start site; Poly(A) site, polyadenylation site; pr, precursor; sd, 
splice donor; sa, splice acceptor. AAAAAA, polyadenylation. Adapted from Alexandersen et al. (1993) [209], 
Barez et al. (2015) [204], Gillet et al. (2007) [200], Polat et al. (2017) [205] and Rice et al. (1985) [211]. 
 
The Env, R3 and G4 mRNAs are also monocistronic and single spliced Env and G4 mRNAs 
encode Env precursor (pr72) (see Section 1.2.3.3) and G4 protein (p11), respectively whereas 
the double spliced R3 mRNA encodes R3 protein (p5) [209]. The G4 expression appears to 
have oncogenic potential. Alexandersen et al. (1993) [209] demonstrated that the G4 mRNA 
was expressed at the beginning of the PL stage and the abundance of the G4 protein 
correlated with high lymphocyte counts in PL cows. Furthermore, Kerkhofs et al. (1997) [210] 
showed that the co-transfection of primary rat embryo fibroblast (REF) cells with plasmids 
expressing the G4 gene and Harvey rat sarcoma virus (H-ras) oncogene transformed the REF 
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cells and induced tumours in mice. The function of the R3 protein remains unknown but is 




Figure 1.10: Schematic representation of precursor polyproteins and posttranslationally processed 
proteins. Gag-Pro-Pol, precursor polyprotein of Gag, protease and polymerase; Gag-pro, precursor 
polyprotein of Gag and protease; MA, matrix; NC, nucleocapsid; CA, capsid; Pro, protease; Pol, DNA-
dependent RNA polymerase;  Env, envelope; SU, surface protein; TM, transmembrane protein. Adapted from 
Barez et al. (2015) [204], Gillet et al. (2007) [200] and Polat et al. (2017) [205]. 
 
Transcription of tax and rex genes also initiates in the U3 region of the 5’ LTR, producing a 
bicistronic mRNA [225]. The double spliced Tax-Rex mRNA encodes Tax and Rex proteins 
from two different but overlapping open reading frames (ORFs). The Tax protein appears to 
remain in the nucleus of the infected cells, where like the HIV Tat protein, the Tax protein 
functions as a transcriptional activator (transactivator) [207, 226-228] through its binding on 
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the cyclic-AMP responsive (CRE) site in the 5’ LTR [227]. Like G4 protein, Tax protein also 
appears to be involved in pathogenesis and leukemogenesis. Co-transfection of primary REF 
cells with expression vectors containing the BLV tax gene and the H-ras oncogene 
immortalised and transformed the REF cells [229].  
The Rex protein, a nuclear phosphoprotein, was also found to act as a trans-activating protein 
in the nucleus [220]. The Rex protein is likely to play a role in the nuclear export of full-length 
genomic mRNA (also Gag-Pro-Pol mRNA) and single spliced mRNA (Env mRNA) through the 
nuclear export signal in the R region of the 3’ LTR [220]. This leads to increased production 
of structural proteins and decreased production of a double spliced tax-rex mRNA.  
In 2012, Kincaid et al. [230] identified five precursor hairpins of viral miRNAs (named B1 to 
B5) in a persistently infected bovine B -cell line, which were transcribed from a region between 
env and R3 genes. Subsequent studies have indicated that the BLV miRNAs are likely to be 
oncomiR [230-232] and they are abundantly expressed (i.e., up to 40% of the total miRNA in 
BLV-infected cells) in pre-leukemic cells, BLV-infected plasma, PBMC and tumours, where 
the structural and regulatory gene expression is suppressed [232, 233]. It was also shown that 
the level of the BLV miRNA expression appears to correlate with proviral load [232]. 
Furthermore, a functional reporter assay identified host transcripts that are targeted by the 
BLV miRNAs and demonstrated that the BLV miRNAs are likely to be involved in the 
suppression of apoptosis, tumorigenesis and viral persistence in BLV-infected cells [232].  
 
1.2.3.3. Envelope (Env) 
The BLV envelope (Env) proteins are glycoproteins presented on the surface of the virion as 
a trimer of surface (gp51) and transmembrane protein (gp30) heterodimers. The BLV env 
gene is 1,548bp in size with the 55bp 5’ end of the env ORF overlapping with the 3’ end of the 
pol ORF [189]. The env gene encodes the Env precursor (pr72), which is cleaved at the RVRR 
cleavage site by subtilisin/kexin-like convertases, such as furin, into the gp51 and gp30 
glycoproteins [234] (also see Section 4.2.2.1). Disulphide bonds between the gp51 and gp30 
glycoproteins link them together, conferring stability to the gp51-gp30 complex [235]. The Env 
glycoproteins play an important role in receptor binding [236] and cell fusion during the natural 
infection [237].  
The gp51 surface protein is rich in binding domains and epitopes such as putative receptor-
binding domain (RBD) [236, 237], antibody epitopes (conformational and linear epitopes) [238-
243], T-cell epitopes [244, 245], neutralising domains [241, 246-248] and Zn2+-binding site 
[237], which are important in cell fusion and entry during the natural infection we as well as 
immunogenicity (also see Chapter 2). The gp51 glycoprotein also contains a leader sequence, 
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which is important to target the Env proteins to the endoplasmic reticulum (ER) membrane 
[249] (also see Section 4.2.1.2). The gp30 transmembrane protein contains a fusion peptide 
at the N-terminus, which is important for cell fusion and entry [250-252], and a cytoplasmic tail 
at the C-terminus, which is essential for viral entry and immune evasion [250, 253]. Unlike the 
gp51, the gp30 is not rich in domains and epitopes and poorly immunogenic. Yet, the gp30 
contains some important domains and epitopes such as highly immunogenic GD21 epitope, 
which is conserved in all primate T-lymphotropic viruses and BLV genus [247], 
immunosuppressive domain (ISD) [254, 255] and immunoreceptor tyrosine-based activation 
motif (ITAM) [250, 253]. The ITMA in the cytoplasmic tail appears to play a role in viral 
infectivity and propagation, packaging of Env glycoproteins in nascent virions, and 
downregulation of Env expression on the virion surface to evade host immune responses [250, 
253]. Importantly, the Env protein is one of the major antibody targets and thus, has been 
used as an antigen in various BLV vaccines (see Section 1.2.4). The Env sequence is also 
utilised for phylogenetic analyses and genotyping of BLV natural isolates (see Chapter 2).  
 
1.2.3.4. Group-specific antigen (Gag) 
The group-specific antigen (Gag) is another structural protein essential to form a BLV virion. 
The gag gene is 1,180bp in size and encodes the Gag-Pro precursor (pr66) from the Gag-
Pro-Pol mRNA [256, 257]. The Gag-Pro precursor is then, proteolytically cleaved by the viral 
protease into the Gag precursor (pr45). The Gag pr45 is further processed by the viral 
protease into the matrix (p15), capsid (p24) and nucleocapsid (p12). The nucleocapsid, which 
is tightly interacted with the secondary structure of the genomic RNA at the 5’ end, is 
necessary for morphogenesis and encapsidation [258-260]. The capsid contains T-cell 
epitopes [261] and a major homology region (MHR) [262], which is conserved amongst 
Retroviridae [263] and indispensable for viral infectivity. The capsid is another major target of 
host immune response but unlike the anti-gp51 antibody, which is persistently detectable in 
leukemic and aleukemic animals with low proviral load, the anti-p24 antibody is undetectable 
in aleukemic animals with low proviral load [102]. 
The matrix is myristoylated at the N terminus [264] and plays an essential role in encapsidation 
and localisation of nascent BLV virions to the host cellular membrane as well as subsequent 
budding from the infected cells [264-270]. It has been shown that the presence of the Gag-
Pro or Gag-Pro-Pol sequences are sufficient for the formation of the virus-like particles (VLPs) 
and budding [260, 271]. In other words, the VLP formation and budding do not require other 
viral genes and genomic RNA. This minimum genetic requirement and self-assembly capacity 
are useful for the formation of VLPs from a simple Gag expression vector and VLPs derived 
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from other families of viruses have been widely used and tested in various vaccines [272, 273] 
such as human papillomavirus (HPV) [274] and hepatitis B virus (HBV) [275]. As a vaccine 
platform, VLPs serve as a scaffold to present an antigen(s) in a dense and repetitive manner 
[276]. For this reason, VLPs are highly immunogenic and known to induce strong and long-
lasting humoral and cellular responses [274, 277-279], both of which are particularly important 
for the protection against virus infection [280]. Furthermore, since the VLPs are hollow virions 
and lack the viral genome inside them, they are non-infectious and safe as vaccines [276, 
281]. 
 
1.2.4. Vaccines  
Currently, there is no commercially available BLV vaccine. Although several BLV vaccine 
modalities have been explored in the last 30 years, research on the development of efficacious 
BLV vaccines has not progressed significantly. Furthermore, none of the vaccines developed 
so far were able to achieve complete protection in vaccinated animals. Most of these vaccines 
focused on the induction of anti-Env antibody. The development of this type of vaccine was 
motivated by early studies showing that the anti-gp51 antibody neutralised viral cell fusion in 
vitro [282] and in vivo [283, 284] and maternal antibody from BLV infected dam and anti-Env 
antibody isolated from BLV-infected animals protected vaccinated animals from BLV infection 
[285, 286]. However, recent studies demonstrated that BLV spreads its infection through lytic 
cycle (i.e., infection into new cells after cell lysis) immediately after the infection [287, 288] and 
then, these viruses stay inside infected cells and infection continues through mitotic infection 
(i.e., clonal expansion of infected cells) at later stage [204, 289-292]. This indicates that both 
humoral and cellular immunities are critical in controlling BLV infection. 
 
1.2.4.1. Inactivated vaccines and cell-derived vaccines 
Early attempts to protect animals from BLV infection using inactivated viruses were 
unsatisfactory as the antibody (Ab) responses that were induced were weak and short-lived 
and complete protection was not achieved even against a low challenge dose of BLV [283, 
293, 294]. However, these studies did show that high Ab titres prior to the challenge were 
essential for protection [293, 294].  Based on the lessons learnt from these inactivated vaccine 
trials, cell-derived vaccines were developed with the aim of inducing high Ab titres and long-
lasting immune responses [295-297]. NP-2 cells derived from foetal lamb kidney cells infected 
with BLV were utilised. They contained a defective viral genome, which only expressed p24 
capsid proteins of Gag and all Env protein derivatives (pr72 precursor, gp 51 and gp30 
proteins). The results of vaccine studies appeared to be promising but not convincing. This 
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vaccine was shown to be safe and the vaccination induced the rapid development of binding 
Ab responses and high anti-Env neutralising antibody (NAb) titres which were retained for up 
to 1 year following repeated vaccination. In addition, all vaccinated cattle were protected over 
the 4-year study period [296, 297]. However, the absence of the challenge virus in these 
animals should be verified using PCR.  
 
1.2.4.2. Live-attenuated vaccines 
Two research groups have extensively explored the use of modified BLV proviruses as a live 
attenuated vaccine [74, 82, 88, 96, 298-301]. Boris-Lawrie et al. constructed a hybrid virus 
consisting of BLV and spleen necrosis virus (SNV) that was replication-competent but non-
pathogenic. This hybrid virus contained BLV structural genes and sequences essential for 
viral replication, integration and translation but the BLV regulatory genes, promoters and 
regulatory sequences were replaced with the corresponding sequences from SNV to reduce 
viral pathogenicity [82, 298-300]. Their experiments in rats and rabbits demonstrated 
persistent infection of the vector virus and the formation of the provirus as well as transcription 
of vector genes in these animals. Furthermore, the presence of anti-Gag and anti-Env Abs 
and complete protection from the challenge virus were confirmed in all three vaccinated 
rabbits [82, 299, 300]. However, the statistical significance of protection is questionable due 
to the small sample size and the vaccine efficacy in the rabbit animal model cannot be 
translated into cattle as rabbits do not develop the lymphoproliferative disease nor lymphoma 
[80, 81]. Furthermore, although the vector virus was shown to be non-pathogenic in vivo, there 
remains the possibility of the induction of insertional mutagenesis and oncogenesis as the 
integration of the vector BLV provirus was shown in the vaccinated animals [302, 303].   
Willems et al. developed an attenuated BLV provirus in which the nucleotide sequences for 
accessory R3 and G4 proteins were deleted. These proteins are dispensable for viral infection 
in vivo and BLV lacking these genes has shown low levels of transcription and propagation in 
sheep and cows and is thus less pathogenic than the wild type virus [73, 74, 96, 210]. All 
vaccinated animals seroconverted prior to challenge and all vaccinated sheep and two out of 
three cows were protected from the viral challenge for at least 18 months following the 
challenge [88]. However, despite the lower challenge dose than the dose used by Boris-Lawrie 
et al., complete protection was not achieved in vaccinated cows and the challenge virus in a 
vaccinated cow at 12 months after the challenge was detected. This incomplete protection 
amongst the vaccinated cows might have been attributed to low anti-Env Ab titres prior to and 
following the challenge It is also possible that the vaccine virus was too attenuated for the 
vaccinated cows to induce strong, sustained immune responses, which subsequently allowed 
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the challenge virus to propagate in these animals. In contrast, vaccinated sheep generated 
much higher anti-Env Ab titres than vaccinated cows before and after the challenge and thus, 
the level of the vaccine virus attenuation could be appropriate to induce protective immune 
responses in sheep.  
Live attenuated vaccines generally have an intrinsic risk of reversion of the vaccine virus to 
the virulent virus through back mutation and compensatory mutation, which arise during 
manufacturing processes using serial passages in different cell lines and are driven by the 
persistent infection and replication of vaccine viruses in their hosts or in immunocompromised 
individuals [304-309]. Even though these reversions are rare, this possibility cannot be 
excluded if revertants exhibit wild-type persistent infection and if they propagate in BLV-
infected animals with altered immunity. In addition, the transmission of vaccine viruses to non-
vaccinated animals can also facilitate the reversion of vaccine viruses to virulent viruses [310-
313]. Recombination between wild-type and vaccine viruses and between a vaccine virus and 
related species is a mechanism that results in an emergence of virulent viruses, which has 
been reported for some veterinary vaccines [314-319]. 
 
1.2.4.3. Peptide vaccines 
In addition to humoral immune responses, cellular immune responses have been shown to 
correlate with the protection from BLV infection [320-323]. One approach to induce cellular 
immune responses is to design and synthesise k-mer peptides in silico that span T-cell epitope 
sequences of the gp51 glycoprotein. However, previous studies demonstrated that vaccination 
of peptide vaccines in mice and sheep only induced weak cytotoxic T cell (CTL) and T helper 
(Th) 1-type immune responses [320-323]. Furthermore, not all vaccinated animals were 
protected or vaccination only resulted in the delayed emergence of BLV in challenged animals 
[321-323].  
To solve issues relating to weak induction of immune responses, Aida et al. used more 
immunogenic carbonate apatite as a delivery system and optimised the binding affinity of 
peptides using in silico screening [324, 325]. Their preliminary results demonstrated the 
induction of cellar immune responses in mice and significant suppression of viral propagation 
in vaccinated cows harbouring BLV-susceptible BoLA alleles [324, 325]. However, the 
suppression of viral growth was only seen in three out of six cows. In addition, in another study, 
Hislop et al. demonstrated that the re-stimulation of peripheral blood mononuclear cells 
(PBMCs) from sheep vaccinated with BLV-infected cells, which reflects natural infection, did 
not induce sufficient CTL responses [322]. These results together suggest the difficulties in 
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inducing strong, protective cellular immune responses in animals vaccinated with peptide 
vaccines.  
 
1.2.4.4. Recombinant vaccinia virus vaccines  
Another extensively explored vaccine modality is a recombinant vaccinia virus (RVV). This 
vaccine modality is different from traditional vaccines, such as inactivated vaccines and live-
attenuated vaccines, in that the RVV encodes vaccine antigens in situ to prime immune 
responses. Despite its theoretically simple mode of action, it is not easy to induce solid 
immune responses in vaccinated animals. RVV vaccine studies have shown variable and 
inconsistent results depending on the experimental animals, vaccine dose, challenge dose, 
vaccine virus strains and promoters to drive the antigen expression. RVVs (Lister strain) 
expressing the whole Env protein under the control of the p7.5 promoter or a promoter of A-
type inclusion bodies were tested in rabbits, sheep and cows and binding and neutralising Ab 
responses were detected only in vaccinated rabbits [90-92, 95, 326]. The vaccines failed to 
induce Ab responses in sheep and cows but induced cellular immune responses in these 
animals [90-92, 95]. However, none of the vaccinated sheep and cows was protected when 
challenged with BLV and the vaccination only suppressed BLV growth in these animals.  
A study using the Copenhagen strain of vaccinia virus (VV) expressing gp51 and partial gp30 
proteins or the complete Env protein under the control of the p7.5 or fowlpox virus early/late 
(PFE/L) promoter demonstrated that all sheep vaccinated with RVV expressing the full-length 
Env protein under the control of the p7.5 promoter were protected whereas only two out of six 
sheep vaccinated with RVV expressing the full-length Env protein under the control of the 
PFE/L promoter were protected [94, 327]. In another study using an RVV (Copenhagen strain) 
expressing gp51, the full-length Env protein or uncleaved precursor Env protein from the H6 
or three different vaccinia virus promoters, all vaccinated rabbits and sheep induced NAbs 
and all except one sheep were protected [93]. Finally, cows vaccinated with RVV expressing 
BLV Gag-Pol-Env proteins or uncleaved precursor Env protein all induced binding and 
neutralising Abs with varying degrees [97]. Despite the induction of Ab responses, no cows 
were protected. Therefore, none of these vaccine studies were able to demonstrate sufficient 
efficacy and correlates of protection, whether humoral or cellular immune responses or both. 
These previous vaccine studies also highlight the need for reassessment of vaccine strains, 




1.3. RATIONALE AND AIMS 
This Master’s degree project involved three aims. 
Aim 1: To sequence the BLV env and gag genes of some South African BLV isolates 
and investigate phylogenetic relationships with other BLV strains from different 
geographical regions worldwide with known genotypes.  
Molecular characterisation of BLV strains from Africa is limited and a Zambian isolate is the 
only isolate that has been genotyped so far. More studies on genetic variations and genotypes 
of BLV strains currently circulating in Africa will be necessary and such knowledge will provide 
valuable insight into the development of efficacious BLV vaccines tailored to the African BLV 
strains.  
Aim 2: To assess the activity of five selected poxvirus promoters (a modified early 
fowlpox virus promoter, an early-late promoter of a 7.5 kilodalton polypeptide gene of 
vaccinia virus (VACV), a synthetic early-late promoter of VACV, a modified early-late 
promoter of the H5 gene of VACV and a synthetic early-late optimised promoter of 
VACV) in cells infected with lumpy skin disease virus.  
To the best of our knowledge, the activity of these poxvirus promoters that have been 
extensively used in various recombinant poxvirus vectors has not been assessed in 
recombinant LSDV. This study will fill the gap in the knowledge in the selection of the poxvirus 
promoters so that genes of interest can be expressed from recombinant LSDV vaccines.  
Aim 3: To construct and characterise two recombinant LSDV-vectored dual vaccines 
designed to protect cattle against BLV and LSDV. 
These vaccines are based on a recombinant LSDV which is the only CaPV strain that is 
allowed to be used in sub-Saharan Africa, where sheep poxvirus and/or goat poxvirus are 
absent. These dual vaccines were designed to express BLV envelope and Gag proteins so 
that virus-like particles (VLPs) consisting of arrays of Env proteins embedded into the Gag 
proteins elicit humoral and cellular responses against BLV antigens. The LSDV vector 
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2.1. INTRODUCTION  
Globally, ten genotypes of the BLV strains have been identified based on the phylogenetic 
analyses of the BLV env nucleotide sequences and BLV whole-genome sequences as well as 
the genotype-specific amino acid substitutions [249, 328-330] (Table 2.1). The use of the BLV 
env nucleotide sequence for phylogenetic analysis has been a gold standard owing to its 
critical functions during the viral life cycle. The Env protein is necessary for cell entry and viral 
infection and contains various motifs and domains that are important for receptor binding, cell 
fusion and syncytium [237, 239, 331, 332]. Due to its location on the surface of the virus, the 
Env protein is a target for neutralising antibodies as well as CD4+ and CD8+ T cells [244, 245]. 
As a result, Env protein is subject to strong selective pressure [185, 249, 333, 334], which 
drives the generation of BLV variants.  
During the late 1990s and early 2000s, the env sequences of the BLV isolates from Belgium, 
France, Italy, America, Japan, Australia, Brazil and Argentina were utilised to assess the 
relationships between genetic variants of the env gene and the serological status of infected 
animals [335-337]. Identification of genetic variants of the env gene subsequently aided the 
classification of different BLV strains into distinct groups using the restriction fragment length 
polymorphism (RFLP) analysis (often in conjunction with sequencing) [185, 335-338]. 
Restriction digestion of PCR products from various BLV isolates with BamHI, BclI, BglI, HaeIII 
and PvuII was thought to be a useful marker to differentiate BLV strains [335-337]. However, 
classification based on the RFLP was not comprehensive nor consistent [336-339]. This led 
to the misclassification of BLV genotypes in some studies [335-337]. In addition, BLV isolates 
initially used for genotyping were obtained from the limited number of countries, whereby only 
allowing classification of two to four genotypes [185, 338, 340].  
Later, sequencing-based genotyping replaced the RFLP-based genotyping and sequencing 
of the BLV env gene or the BLV whole genome from a variety of countries have been providing 
more comprehensive insights into the genetic variabilities and global distribution of different 
BLV strains. Currently, BLV whole-genome sequences are available from genotypes 1, 2, 4, 
6, 9 and 10. Whilst the BLV whole-genome sequences provide more phylogenetically 
informative sites and phylogenetic analyses based on the BLV whole-genome sequences are 
supported by high bootstrap values and posterior probabilities [330, 341, 342], Rola-Łuszczak 
et al. [151] and Yang et al. [343] amongst others [45, 329, 344-347] correctly grouped BLV 
global isolates using partial env sequences. In 2009, Rodríguez et al. [328] conducted a 
seminal study by comparing the BLV full-length env sequences of 28 Argentine isolates and 
46 sequences that had been previously described in various studies but had different genotype 
classification amongst different studies.  
28 
Chapter 2 
Table 2.1: Global distribution of ten BLV genotypes 
Region Country Genotype Reference 
  1 2 3 4 5 6 7 8 9 10  
Europe Belarus    ✓       [151] 
 Belgium    ✓       [253, 301, 
348] 
 Croatia        ✓   [151, 349] 
 France   ✓ ✓       [249, 348, 
350] 
 Germany ✓          [336, 350] 
 Italy  ✓    ✓ ✓ ✓   [351-353] 
 Moldova    ✓   ✓    [334] 
 Poland    ✓   ✓    [151] 
 Russia  ✓   ✓   ✓ ✓   [151, 354, 
355] 
 Ukraine    ✓   ✓ ✓   [151] 
Africa Zambia    ✓       [345]  
Middle East Egypt ✓          [145] 
 Iran ✓          [53] 
 Jordan ✓     ✓     [356] 
 Turkey ✓          [357, 358] 
Oceania Australia ✓          [189] 
Asia China      ✓    ✓ [344] 
 India      ✓     [359] 
 Japan ✓ ✓ ✓  ✓      [206, 249, 
329, 360] 
 Korea ✓  ✓        [346, 361] 
 Mongolia ✓   ✓   ✓    [152] 
 Myanmar          ✓ [341] 
 Philippines ✓     ✓     [45] 
 Thailand ✓     ✓    ✓ [329] 
 Vietnam ✓     ✓     [342] 
North America Costa Rica ✓    ✓      [249, 353] 
 Dominica           [343] 
 U.S.A. ✓  ✓ ✓       [249, 348] 
 Mexico ✓          [362, 363] 
 St. Kitts  ✓          [343] 
South America Argentina ✓ ✓  ✓  ✓     [185, 247, 
249, 340, 
353, 364] 
 Bolivia ✓ ✓    ✓   ✓  [330] 
 Brazil ✓ ✓   ✓ ✓ ✓    [249, 339, 
353, 365-
367] 
 Chile    ✓   ✓    [249, 338] 
 Colombia ✓  ✓        [368] 
 Paraguay ✓ ✓    ✓     [330] 
 Peru ✓ ✓    ✓     [330] 
 Uruguay ✓          [248, 353]    
Checkmark (✓) indicates the presence of BLV strains with relevant genotype. This table combines genotype data from 
RFLP-based and sequencing-based genotyping of the BLV full-length or partial env nucleotide sequences or whole genome. 
Genotypes of historical isolates in the currently BVL-free countries are also included. 
 
They re-classified these isolates into seven genotypes (G1 to G7) using neighbour-joining, 
Bayesian, maximum-likelihood and parsimony methods. In 2012, genotype 8 (G8) was 
identified in Croatia [349] and subsequently in Ukraine and Russia in 2013 [151]. In 2016, 
using the BLV whole-genome sequences of genotype-1, 2, 4 and 6 strains as well as 25 newly 
identified isolates from Peru, Bolivia and Paraguay, Polat et al. [330] identified genotype 9 
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(G9) from Bolivian isolates [330]. Recently, genotype 10 (G10) was identified in three Asian 
counties, Thailand in 2016 [329], Myanmar in 2017 [341] and China in 2018 [344].   
Genotype 1, 4 and 6 (G1, G4 and G6, respectively) are circulating in all continents. G1 was 
called a Japan-USA subgroup [348] or a Japanese group [340] whereas G4 was considered 
to be a European genotype (Belgium-France subgroup [348] or European cluster [249]). 
However, G1 and G4 are currently distributed worldwide as a result of international trades of 
cattle, semen and embryo, particularly from some European countries such as the 
Netherlands, Germany and Denmark that have been actively exporting cattle worldwide since 
the post-World War II [151, 369]. Previously, Licursi et al. [370] identified G2 from Argentine 
isolates and classified them as an Argentine group. Later studies conducted by Polat et al. 
[330] and Camargos et al. [339] revealed the greater geographical distribution of G2 strains in 
other South American countries such as Bolivia, Paraguay, Peru and Brazil. G3 was previously 
classified as a US-Californian cluster [249] but G3 isolates have been sporadically detected 
in Japan [360], Korea [346] and Colombia [371]. G6 had been identified in the Middle East, 
Asian, South America but it was recently identified in Italy in 2016 [352], which was the first 
case in Europe. In Europe, along with the classic European genotype G4, the presence of G7 
and/or G8 isolates was recently confirmed in Poland, Ukraine and Russia [151]. A G7 isolate 
(GenBank accession number: S83530) was identified in Italy in 1996 [351] and genotyped in 
2010 [353]. A recent study conducted between 2012 and 2016 in Italy showed that the newly 
identified G7 isolates were clustered with this old G7 isolate (S83530) [352]. Therefore, the 
G7 isolates appeared to persist since at least 1996. The same study also identified the 
presence of G2, G4, G6 and G8 isolates in Italy [352]. Italy was declared BLV-free in 2017 
(seroprevalence < 0.2%) [372, 373]. The presence of multiple strains and the long persistence 
of the G7 isolates prior to the BLV-free status suggest multiple introductions into Italy and 
highlights the significance of continued efforts in conducting preventative measures such as 
restriction on the movement of infected animals and serological tests for the newly- acquired 
animals.  
In addition to the worldwide spread of 10 genotypes, multiple genotypes are circulating in 
Western Europe, Asia and South America. Coincidently, some countries in these regions such 
as Italy, Japan and Argentina had/have a long history of BLV prevalence or high BLV 
prevalence rates (See Section 1.2.2.2), indicating that the prolonged or delayed eradication 
process not only results in the persistence of BLV but also may allow the introduction of new 
and multiple genotypic strains. This is a serious concern regarding the development of an 
efficacious BLV vaccine. 
To date, only one Zambian isolate has been genotyped from Africa. Although high BLV 
prevalence has been reported in South Africa [169, 196], there has been no molecular 
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characterisation of South African BLV strains. Therefore, the aim of this chapter is to sequence 
the env and gag genes of some South African BLV isolates and investigate phylogenetic 
relationships with other BLV strains from different geographical regions worldwide with known 
genotypes. A Japanese strain (GenBank accession number, AP018021) that was used to 
design the recombinant LSDV-BLV-Env-Gag and LSDV-BLV-Env (See Chapter 4) was 
included in the phylogenetic analyses. Since this study was conducted in parallel with the 
development and characterisation of the recombinant LSDV-BLV-Env-Gag and LSDV-BLV-
Env, the phylogenetic analyses between the South African isolates and the Japanese strain 
AP018021 were also conducted concurrently to assess whether the Japanese isolate 
AP018021 is closely related to the South African isolates. 
 
2.2. MATERIALS AND METHODS 
 
2.2.1. Collection of bovine whole blood samples  
Whole blood samples were obtained from a single herd, where leukosis case was suspected, 
in Port Elizabeth, Eastern Cape province, South Africa in 2018. The blood samples were 
delivered to the University of Cape Town for further analyses.  
 
2.2.2. Extraction of total bovine genomic DNA 
The bovine genomic DNA was extracted from the eight whole blood samples using New 
MagNA Pure Compact Nucleic Acid Isolation Kits and MagNA Pure Compact Instrument 
(Roche, Switzerland). Following the thawing of the frozen blood samples at room temperature, 
the vials were vortexed briefly and 400µl of each blood sample were transferred into sample 
tubes. The blood samples, elution tubes and DNA extraction reagents were placed in MagNA 
Pure Compact Instrument and the whole bovine genomic DNA was extracted in 100µl of an 
elution volume as per manufacturer’s instructions. The extracted DNA was stored at -20°C 
until needed. 
 
2.2.3. Amplification of the BLV full-length env and gag sequences by nested polymerase 
chain reaction (nPCR) and Sanger sequencing of the complete env and gag genes 
The BLV full-length env and gag sequences were amplified from the eight samples by nested 
polymerase chain reaction (nPCR) using primers outlined in Table 2.2. To amplify the full-
length BLV env sequence, both rounds of nPCR were performed in a 20µl reaction mixture 
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containing 1µl of the total genomic DNA or PCR product from the first round of nPCR, 1µl of 
2x KAPA 2G Robust HotStart ReadyMix (KAPA BIOSYSTEMS, USA), 1µl of each primer 
(10µM each) and high-performance liquid chromatography (HPLC) water (Sigma-Aldrich, 
USA) using a thermal cycler (Applied Biosystems, USA). A reaction mixture without template 
DNA was included as a PCR control. The cycling parameters were as follows: 95°C for 3 
minutes followed by 25 cycles (30 cycles for the second round) of 95°C for 15 seconds, 55°C 
(61°C for the second round) for 15 seconds, 72°C for 2 minutes and 72°C for 4 minutes.  
 
Table 2.2: Primer sets designed and used to amplify BLV full-length env and gag sequences     
Amplified gene  Orientation Primers Primer sequence 
env Outer  Forward Env4594OF 5’- CCTCCTACCAATTCTAAAGACC -3’ 
  Reverse Env6535OR 5’- CACGCAGAAGCGACAATCTC-3’  
 Inner  Forward Env4660if 5’ - GGGCGGAGAAACACCYAAGG-3’ 
  Reverse Env6421ir 5’- CACTGACTATTCCACTAAGCC -3’ 
gag Outer  Forward Gag551OF 5’- GATTGATCACCCCGGAACCC -3’ 
 Reverse Gag1988OR 5’- GTATTTTCAGCCCCGGTGTCC -3’ 
Inner  Forward Gag579if 5’- CTCTGGACCCACCCCCTCG -3’ 
 Reverse Gag1866ir 5’- CATTCTARTTCGGCCTCACTAAG-3’ 
 
To amplify the full-length BLV gag sequence, both rounds of nPCR were conducted in a 20µl 
reaction mixture containing 5µl of the total genomic DNA or 1µl of the PCR product from the 
first round of nPCR, 1µl of 2x KAPA 2G Robust HotStart ReadyMix (KAPA BIOSYSTEMS, 
USA), 1µl of each primer (10µM each) and high-performance liquid chromatography (HPLC) 
water (Sigma-Aldrich, USA) using a thermal cycler (Applied Biosystems, USA). A reaction 
mixture without the template DNA was included as a PCR control. The cycling parameters 
were as follows: 95°C for 3 minutes followed by 40 cycles (35 cycles for the second round) of 
95°C for 15 seconds, 56°C (61°C for the second round) for 15 seconds, 72°C for 2 minutes 
and 72°C for 4 minutes.  
Both gag and env PCR products were separated on 0.8% agarose TBE gel stained with 
ethidium bromide (0.5μg/ml) at 100V. A 1,782bp fragment of the BLV env gene and a 1,307bp 
fragment of the BLV gag gene were gel purified using the Zymoclean Gel DNA Recovery Kit 
(Zymo Research, USA) as per the manufacturer’s protocol. Sanger sequencing of the full-
length env and gag genes was conducted using primers outlined in Table 2.3 and  
Table 2.4 by Central Analytical Facilities at the University of Stellenbosch (South Africa). The 
eight env and gag genes sequenced were designated sample ID K1170, K1194, M1878, 
M2746, P591, P2152, P2677 and L3401. 
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Table 2.3: Primers used to sequence the BLV full-length env sequence   
Primers Primer sequence 
Env4763 fwd  5’- AGGCGCTCTCCTGGCTAC -3’ 
Env5044 fwd 5’- CARGTCTCCCAGATACAC -3’ 
Env5185 rev 5’- ATCTGCCCCCACATAAGG -3’ 
Env5312 fwd 5’- TGGGGATATGATCCCCTG -3’ 
Env5524 rev 5’- GATGGTTTTGTTATATAC -3’ 
Env5636 fwd 5’- AATGTTTCTCAAGGCAAC -3’ 
Env5820 rev 5’- AGTCTCTGATGGCTAAGG -3’ 
Env 5919 fwd 5’- CCCAGAACCGACGGGGGC -3’ 
Env6067 rev 5’- GACTCTTTGCGAGAGAGG -3’ 
Env6198 fwd 5’- AATGCTTGACCTCTCGCC - 3’ 
Env6404 rev 5’- ACAGCCTGGGGGTGCGTG -3’ 
Fwd, forward primer; rev, reverse primer. 
 
Table 2.4: Primers used to sequence the BLV full-length gag sequence 
Primers Primer sequence 
Gag590 fwd 5’ - CCCTCGGCGGCRTTTTGG - 3’ 
Gag928 rev 5’- GGGTTGTTCYTCKGGGGC-3’ 
Gag1229 rev 5’- GRTTAAAACCCTGGAGGG -3’  
Gag1300 fwd  5’ CCTYTGGCTTCAGGCCTG -3’ 
Gag1543 rev 5’ YCCCACCGGGGCGGCCAC -3’ 
Gag1665 fwd 5’- GACCATGCTATCGATGCC -3’  
Gag1870 rev 5’- CCTCACTAAGRGRATCTG - 3’ 
Fwd, forward primer; rev, reverse primer. 
 
2.2.4. Phylogenetic analysis of the BLV full-length env and gag nucleotide sequences 
The BLV full-length env (1,548bp) and gag (1,184bp) nucleotide sequences of the eight South 
African isolates were aligned with the BLV sequences obtained from the Basic Local Alignment 
Search Tool (BLAST) database [374] on CLC Main Workbench (QIAGEN Bioinformatics, 
Denmark) (Table S2.1). One hundred BLV nucleotide sequences from the BLAST dataset that 
shared the highest nucleotide sequence identity with the South African isolates were included 
in an initial sample pool. The BLV sequences with unknown genotypes were excluded 
whereas those with known genotypes that had not been included in the initial sample pool 
were manually included by obtaining the sequences from the GenBank nucleotide database. 
Pair-wise comparison of the sequences in this sample pool was performed to remove the 
sequences with the 100% nucleotide sequence identity from the same genotype and the same 
country.  
Subsequently, 29 BLV full-length env sequences representing 9 genotypes, 56 partial env 
sequences representing 10 genotypes and 20 BLV full-length gag sequences representing 6 
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genotypes obtained from BLAST database [374] and GenBank nucleotide database were 
aligned with the eight South African env and gag nucleotide sequences, using MUSCLE on 
MEGA7 [375]. The 444bp fragment of the BLV env gene from the South African isolates were 
aligned with those obtained from the BLAST database [374] and the GenBank nucleotide 
database using MUSCLE on MEGA7 [375]. The BLV full-length env, partial env and full-length 
gag nucleotide sequences were translated into amino acid sequences and aligned using 
MUSCLE on MEGA7 [375]. Model testing was performed using MEGA7 [375] to select the 
best evolutionary model based on the Bayesian information criterion (BIC) [376].  
Neighbour-joining (NJ) and Maximum-likelihood (ML) trees based on the BLV full-length and 
444bp partial env nucleotide sequences were constructed using the Tamura-Nei substitution 
model with the Gamma distribution (TN83 + G) [377] and the Kimura-2-parameter model with 
the Gamma distribution (K2 +G) [378], respectively, on MEGA7 [375].  
NJ and ML trees based on the BLV full-length gag nucleotide sequences were constructed 
using the TN83 + G [377] and the Hasegawa-Kishino-Yano substitution model with the 
Gamma distribution (HKY + G) [379], respectively on MEGA7 [375].  
The nonparametric bootstrap analysis with 1000 iterations [380] was used to evaluate the 
robustness of evolutionary relationships. 
 
2.2.5. Comparison of the BLV Env and Gag nucleotide and amino acid sequences of the 
South African and global isolates 
To evaluate the nucleotide and amino acid sequence percent identities and differences, pair-
wise comparison of the BLV env and gag sequences between the South African isolates and 
the global isolates selected in Section 2.2.4 was performed on CLC Main Workbench 7.9.3 
(QIAGEN Bioinformatics, Denmark).  
To estimate the mean intragenotype and intergenotype distances of the BLV Env and Gag 
nucleotide and amino acid sequences, 115 full-length Env and 56 full-length Gag sequences 
from the global isolates with 10 and 6 known genotypes, respectively were obtained from the 
BLAST database [374]. Five hundred full-length env nucleotide sequences and 250 full-length 
gag nucleotide sequences from the BLAST dataset that shared the highest nucleotide 
sequence identity with the South African isolates were included in the initial sample pool. The 
BLV sequences with unknown genotypes were excluded whereas those with known 
genotypes that had not been included in the initial sample pool were manually included by 
obtaining the sequences from the GenBank nucleotide database. The nucleotide sequences 
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were translated into amino acid sequences on MEGA7 [375] and their deduced amino acid 
sequences were confirmed with BLV sequences available on the NCBI [381].   
The mean intragenotype and intergenotype distances of BLV Env nucleotide and amino acid 
sequences were estimated using the Tamura-Nei substitution model with the Gamma 
distribution (TN83 + G) [377] and the Jones-Taylor-Thornton model with the Gamma 
distribution (JTT + G) [382], respectively, on MEGA7 [375]. The mean intragenotype and 
intergenotype distances of the BLV Gag nucleotide and amino acid sequences were estimated 
using the HKY + G [379] model on IQ-TREE [383] and the JTT + G model [382] on MEGA7 
[375], respectively. Nonparametric bootstrap analysis with 1000 iterations [380] was used to 
evaluate the robustness of evolutionary relationships. 
To identify genotype-specific amino acid substitutions as well as those unique to the South 
African isolates, the full-length Env and Gag amino acid sequences of the South African 
isolates were aligned with full-length and partial Env and Gag amino acid sequences obtained 
from the Basic Local Alignment Search Tool (BLAST) database [374] using MUSCLE on 
MEGA7 [375].  
 
2.3. RESULTS  
 
2.3.1. Phylogenetic analyses of the BLV env and gag nucleotide sequences 
Total bovine DNA was extracted from blood obtained from eight BLV-infected cattle and the 
full-length env and gag sequences were successfully amplified and sequenced from eight 
samples (designated as sample ID K1170, K1194, M1878, M2746, P591, P2152, P2677 and 
L3401). In the process of selecting BLV global sequences for the comparison with the South 
African sequences, as many BLV sequences with known genotypes from various countries as 
possible were included in the sample pool but the BLV sequences with the 100% sequence 
identity from the same genotype and the same country were excluded. Subsequently, the 
South African BLV full-length env (1,548bp), partial env (444bp) and full-length gag (1,184bp) 
nucleotide sequences were aligned with 29 full-length env sequences representing nine 
genotypes, 56 partial env sequences representing ten genotypes and 20 full-length gag 
sequences representing six genotypes, respectively, to perform phylogenetic analyses. 
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2.3.1.1. Phylogenetic analysis of BLV env nucleotide sequences 
2.3.1.1.1. Phylogenetic analysis of the South African isolates based on the full-length 
env nucleotide sequences 
To determine evolutionary relationships between the South African and global isolates, 
neighbour-joining (NJ) (Figure 2.1) and maximum-likelihood (ML) (Figure 2.2) trees based on 
the full-length env nucleotide sequences were constructed using the TN83 + G substitution 
model G [377]. Both phylogenetic trees showed congruent topologies with high bootstrap 
values. The NJ and ML trees showed that the seven South African isolates (K1170, K1194, 
M1878, P591, P2152, P2677 and L3401) are closely related to each other with 99% bootstrap 
value. These seven South African isolates appeared to belong to G4, clustering with the G4 
isolates with 99% bootstrap value (NJ and ML). Furthermore, these seven South African 
isolates appear to be most closely related to the G4 Russian isolate (JN695878) with 79% 
(NJ) and 81% (ML) bootstrap values.  
Interestingly, the NJ and ML trees also showed that one South African isolate (M2746) did not 
cluster with the seven other South African isolates but clustered within the G1 group with 94% 
(NJ and ML) bootstrap value. Furthermore, this M2746 isolate appeared to be most closely 
related to the G1 Saint Kitts and Nevis isolate (KX674369) with 90% (NJ) and 87% (ML) 
bootstrap values. Therefore, the eight South African isolates from a single herd appeared to 
contain two genotypes, G1 and G4.  
This phylogenetic analysis also indicates that the G4-like South African isolates were more 
divergent from the other G4 isolates whereas the G1-like South African isolate was less 
divergent from some of the closest G1 global isolates. The genetic distance between the G1-
like South African isolate and the Saint Kitts and Nevis isolate (KX674369) was estimated to 
be 0.003 nucleotide substitutions per site whereas the genetic distance between the G4-like 
South African isolates and the Russian isolate (JN695878) was estimated to be 0.013 
nucleotide substitutions per site.  
The Japanese AP018021 isolate which had been used to design the recombinant LSDV-BLV-
Env-Gag and LSDV-BLV-Env clustered with the South African M2746 isolate with low (39% 





Figure 2.1: Neighbour-joining phylogenetic tree based on the BLV full-length env nucleotide sequences 
from South Africa and other geographic regions worldwide. BLV strains identified in this study are indicated 
by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant LSDV-BLV-Env-
Gag and LSDV-BLV-Env is indicated by a filled square (■). Other strains are shown by genotype followed by 
GenBank accession number and country of origin. Numbers at the branches denote bootstrap support (1000 





Figure 2.2: Maximum-likelihood phylogenetic tree based on the BLV full-length env nucleotide 
sequences from South Africa and other geographic regions worldwide. BLV strains identified in this study 
are indicated by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant 
LSDV-BLV-Env-Gag and LSDV-BLV-Env is indicated by a filled square (■). Other strains are shown by genotype 
followed by GenBank accession number and country of origin. Numbers at the branches denote bootstrap 
support (1000 iterations). The bar at the bottom of the figure denotes genetic distance. 
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2.3.1.1.2. Phylogenetic analysis of the South African isolates based on the 444bp partial 
env nucleotide sequences 
The only African BLV sequence that had been sequence was a Zambian isolate with a partial 
env sequence [345]. Furthermore, since the 444bp partial env sequences have been used for 
the BLV genotyping in various studies [329, 336-338, 346, 356, 384], the 444bp partial env 
sequences are available from all 10 genotypes and from various geographic regions. To 
confirm the results obtained from the phylogenetic analyses based on the full-length env 
nucleotide sequences and to further investigate the phylogenetic relationships between the 
South African isolates with more diverse BLV isolates from different geographic regions, NJ 
(Figure S2.1) and ML (Figure 2.3) trees based on the 444bp partial env nucleotide sequences 
were constructed using the K2P + G model [378].  
Despite the low to moderate bootstrap values, this analysis was consistent with the analysis 
using the full-length env nucleotide sequences, showing that the seven South African isolates 
belong to G4 and one South African isolate (M2746) belongs to G1. The seven South African 
isolates clustered within the G4 group with 48% bootstrap value (NJ and ML) whilst one South 
African isolate (M2746) clustered with fourteen phylogenetically closest G1 isolates as well as 
the Japanese AP018021 isolate with 40% (NJ) and 39% (ML) bootstrap values. None of the 
G1 isolates shared moderate to high bootstrap values with the South African isolate (M2746) 
and the Japanese isolate AP018021 but the South African (M2746) and Japanese 
(AP018021) isolates were clustered with all other G1 isolates with 73% (NJ) and 74% (ML) 
bootstrap values, confirming that these two isolates belong to G1. This second analysis also 
showed that despite the low bootstrap values, these seven South African isolates are more 
closely related to the Zambian isolate (LC193462; a black arrow in Figure 2.3) than other G4 
isolates with 46% (NJ) and 50% (ML) bootstrap values. Furthermore, these sequences 
appeared significantly similar to each other, showing 0.002 nucleotide substitutions per site 





Figure 2.3: Maximum-likelihood phylogenetic tree based on the BLV partial env nucleotide sequences 
from South Africa and other geographic regions worldwide. BLV strains identified in this study are indicated 
by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant LSDV-BLV-Env-
Gag and LSDV-BLV-Env is indicated by a filled square (■). A black arrow indicates the Zamibain isolate which 
is most closely related to the seven South African isolates. Other strains are indicated by their genotype, 
GenBank accession number and country of origin. Numbers at the branches denote bootstrap support (1000 
iterations). The bar at the bottom of the figure denotes genetic distance. 
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2.3.1.2. Phylogenetic analysis of the BLV gag nucleotide sequences 
Although the BLV gag sequence has been rarely used for phylogenetic analyses, the BLV gag 
sequence was included in this study to add more insight into the genetic variabilities of the 
BLV isolates and to compare the results with the phylogenetic analyses of the BLV env 
nucleotide sequences. NJ (Figure S2.2) and ML (Figure 2.4) trees based on the BLV full-
length gag nucleotide sequences were constructed using the HKY + G [379] and the TN83 + 




Figure 2.4: Maximum-likelihood phylogenetic tree based on the BLV full-length gag nucleotide 
sequences from South Africa and other geographic regions worldwide. BLV strains identified in this study 
are indicated by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant 
LSDV-BLV-Env-Gag and LSDV-BLV-Env is indicated by a filled square (■). Other strains are shown by genotype 
followed by GenBank accession number and country of origin. Numbers at the branches denote bootstrap 
support (1000 iterations). The bar at the bottom of the figure denotes genetic distance. 
 
Despite the limited number of the available BLV full-length gag nucleotide sequences, the NJ 
and ML trees showed congruent topologies with the phylogenetic analyses of the BLV full-
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length and partial env nucleotide sequences. Furthermore, the phylogenetic analyses based 
on the full-length gag nucleotide sequences were supported by higher bootstrap values 
compared to those based on the env nucleotide sequences. Like the BLV env phylogenetic 
trees, the BLV gag trees showed that one South African isolate (M2746) belongs to G1 with 
100% bootstrap value (NJ and ML) whereas the seven South African isolates belong to G4 
with 93% (NJ) and 97% (ML) bootstrap values.  
The result showed that the G1-like South African isolate (M2746) was clustered with two G1 
Vietnamese isolates (MH170027 and MH170028) and a G1 Japanese isolate (LC005615) with 
83% (NJ) and 85% (ML) bootstrap values. The result also showed that the Japanese isolate 
AP018021 belongs to G1 as consistent with the phylogenetic analyses based on the full-length 
and partial env nucleotide sequences.   
Interestingly, there appeared to be more genetic variabilities in the BLV gag nucleotide 
sequences than the BLV env nucleotide sequences as evident from the tree topology. 
Consistent with the phylogenetic analyses based on the full-length and partial env sequences, 
the G4-like South African gag nucleotide sequences appeared more divergent from those of 
the other G4 isolates but the G1-like South African gag nucleotide sequence appeared less 
divergent from those of some of the closest G1 global isolates. The genetic distance between 
the seven G4-like South African and the G4 Belgian isolate (KT122858) was estimated to be 
0.02 nucleotide substitution per site, which is approximately 1.5 times higher than the 
nucleotide substitution rate between the G4-like South African and the G4 Russian isolate 
(JN695878) and ten times higher than the nucleotide substitution rate between the G4-like 
South African and the G4 Zambian isolate (LC193462). 
 
2.3.2. Pair-wise comparison of the BLV Env and Gag sequences  
To confirm the results obtained from the phylogenetic trees based on the full-length and partial 
env as well as full-length gag nucleotide sequences and to investigate the genetic variabilities 
of the BLV strains, pair-wise comparison of the nucleotide and amino acid sequences between 
South African and global isolates was performed.  
 
2.3.2.1. Pair-wise comparison of the BLV full-length Env sequences  
Pair-wise comparison of the BLV full-length Env nucleotide and amino acid sequences of the 
South African and global isolates was consistent with the phylogenetic analyses based on the 
NJ and ML trees. The results showed that one South African isolate (M2746) was most closely 
related to the G1 isolates and the seven remaining South African isolates were closely related 
42 
Chapter 2 
to each other and most closely related to the G4 isolates (Table 2.5, Figure 2.5 and Table 
S2.2 for the full data). 
 
Table 2.5: Nucleotide and amino acid differences in the BLV full-length Env sequences between 
South Africa isolates and global isolates representing nine genotypes 
 
Amino acid sequence differences are shown in brackets. 
Each cell in the table is highlighted according to amino acid 
differences.    
 
  
K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401
K1170 South Africa
K1194 South Africa 2 (1)
M1878 South Africa 2 (1) 2  (2)
M2746 South Africa 56 (15) 56 (15) 56 (16)
P591 South Africa 1 (0) 1 (1) 1 (1) 55 (15)
P2152 South Africa 2 (0) 2 (1) 2 (1) 56 (15) 1 (0)
P2677 South Africa 1 (0) 1 (1) 1 (1) 55  (15) 0  (0) 1  (0)
L3401 South Africa 4 (0) 4 (1) 4 (1) 58 (15) 3 (0) 4 (0) 3 (0)
AP018021 Japan 56 (14) 56 (15) 56 (15) 14 (1) 55 (14) 56 (14) 55 (14) 58 (14)
D00647 Australia 53 (14) 53 (15) 53 (15) 38 (9) 52 (14) 53 (14) 52 (14) 55 (14)
AF399703 Brazil 49 (14) 49 (15) 47 (13) 19 (7) 48 (14) 49 (14) 48 (14) 51 (14)
AY151262 Brazil 56 (16) 56 (17) 54 (15) 16 (3) 55 (16) 56 (16) 55 (16) 58 (16)
EF065637 Costa Rica 53 (16) 53 (17) 53 (17) 13 (3) 52 (16) 53 (16) 52 (16) 55 (16)
KX674372 Dominica 51 (15) 51 (16) 51 (16) 9 (2) 50 (15) 51 (15) 50 (15) 53 (15)
EF065646 Japan 50 (14) 50 (15) 50 (15) 10 (3) 49 (14) 50 (14) 49 (14) 52 (14)
LC080651 Paraguay 54 (16) 54 (17) 52 (15) 13 (3) 53 (16) 54 (16) 53 (16) 56 (16)
KX674369 St. Kitts and Nevis 52 (15) 52 (16) 52 (16) 6 (2) 51 (15) 52 (15) 51 (15) 54 (15)
HE967301 Uruguay 54 (15) 54 (16) 52 (14) 13 (2) 53 (15) 54 (15) 53 (15) 56 (15)
EF065641 USA 52 (14) 52  (15) 52 (15) 10 (1) 51 (14) 52 (14) 51 (14) 54 (14)
MH170027 Vietnam 53 (16) 53 (17) 53 (17) 11 (3) 52 (16) 53 (16) 52 (16) 55 (16)
MH170028 Vietnam 53 (15) 53 (16) 53 (16) 11 (2) 52 (15) 53 (15) 52 (15) 55 (15)
AF257515 Argentina 68 (29) 68 (30) 68 (30) 63 (25) 67 (29) 68 (29) 67 (29) 70 (29)
AF399704 Brazil 52 (13) 52 (14) 52 (14) 47 (11) 51 (13) 52 (13) 51 (13) 54 (13)
LC080655 Paraguay 49 (12) 49 (13) 49 (13) 44 (10) 48 (12) 49 (12) 48 (12) 51 (12)
LC080654 Peru 53 (14) 53 (15) 53 (15) 48 (13) 52 (14) 53 (14) 52 (14) 55 (14)
G3 EF065650 Japan 50 (13) 50 (14) 50 (14) 45 (11) 49 (13) 50 (13) 49 (13) 52 (13)
EF065647 USA 49 (13) 49 (14) 49 (14) 44 (11) 48 (13) 49 (13) 48 (13) 51 (13)
AF503581 Belgium 24 (7) 26 (8) 26 (8) 60 (14) 25 (7) 26 (7) 25 (7) 28 (7)
JN695878 Russia 21 (6) 21 (7) 21 (7) 59 (13) 20 (6) 21 (6) 20 (6) 23 (6)
AF033818 USA 20 (6) 20 (7) 20 (7) 54 (13) 19 (6) 20 (6) 19 (6) 22 (6)
G5 EF065635 Costa Rica 54 (17) 54 (18) 54 (18) 64 (18) 53 (17) 54 (17) 53 (17) 56 (17)
MF580991 China 59 (13) 59 (14) 59 (14) 65 (15) 58 (13) 59 (13) 58 (13) 61 (13)
AY185360 Brazil 60 (15) 60 (16) 60 (16) 64 (18) 59 (15) 60 (15) 59 (15) 62 (15)
LC080656 Paraguay 59 (12) 59 (13) 59 (13) 62 (15) 58 (12) 59 (12) 58 (12) 61 (12)
MH170030 Vietnam 58 (13) 58 (14) 58 (14) 64 (16) 57 (13) 58 (13) 57 (13) 60 (13)
KF801457 Moldova 48 (13) 48 (14) 48 (14) 56 (12) 47 (13) 48 (13) 47 (13) 48 (13)
JN695879 Russia 46 (13) 46 (14) 46 (14) 56 (13) 45 (13) 46 (13) 45 (13) 46 (13)
G9 LC080659 Bolivia 49 (14) 51 (15) 51 (15) 46 (12) 50 (14) 51 (14) 50 (14) 53 (14)
MF580994 China 54 (14) 54 (15) 54 (15) 65 (19) 53 (14) 54 (14) 53 (14) 54 (14)














A. Nucleotide sequence B. Amino acid sequence C 
 
Figure 2.5: Heat map showing percent identities and differences of nucleotide and amino acid sequences in the BLV full-length Env sequences from South Africa 
and other geographic regions worldwide. Percent identities (lower matrix) and differences (upper matrix) of BLV full-length Env (A) nucleotide and (B) amino acid sequences 
were compared between eight South African isolates (No. 1-8) and 32 sequences representing nine genotypes (G1-G7, G9 and G10) from other geographic regions worldwide 
(No. 9-40). (C) A table summarises sequence number, GenBank accession number and country of origin used in Figures A and B. SA, South Africa. 
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Furthermore, the full-length Env nucleotide and amino acid sequences of the G1-like South 
African isolate (M2746) shared high percent identities (>98.50%) and less sequence 
differences (< 20 nucleotides, < 5 amino acids) with the G1 sequences whereas those of the 
G-4 like South African isolates showed moderately high percent identities (98.00%-98.99%) 
and more sequence differences (<30 nucleotides, 5-29 amino acids) with the G4 sequences. 
However, intragenotype comparison showed that the full-length Env sequences of the G4-like 
South African isolates are more conserved than other genotypes. The pair-wise comparison 
of the full-length Env sequences amongst the seven G4-like South African isolates showed 
that they shared 99.74-100.00% nucleotide sequence identities and 99.61-100.00% amino 
acid sequence identities. In particular, the P591 and P2677 isolates had identical nucleotide 
sequences whereas despite some nucleotide sequence variabilities (99.74%- 99.94% or 1-4 
nucleotide differences) amongst the other five South African isolates (K1170, P591, P2152, 
P2677 and L3401), their amino acid sequences shared 100.00% identity, indicating that their 
nucleotide substitutions were synonymous mutations.  
Consistent with the phylogenetic analysis, the G-1like South African M2746 isolate was most 
closely related to the Saint Kitts and Nevis isolate (KX674369) with 99.61% nucleotide and 
amino acid identity (i.e., six nucleotide and two amino acid differences). Although their 
nucleotide sequences were slightly divergent, at the amino acid level, the South African M2746 
isolate was also closely related to the Japanese isolate (AP018021) and the G1 American 
isolate (EF065641) with 99.81% sequence identity and one amino acid difference.  
The seven G4-like South African isolates were most closely related to the G4 American isolate 
(AF033818) and the G4 Russian isolate (JN695878), sharing 98.51-98.71% nucleotide 
sequence identities (19-23 nucleotide differences) and 98.64-98.84% amino acid sequence 
identities (6-8 amino acid differences).  
 
2.3.2.2. Pair-wise comparison of the BLV partial Env sequences  
To further assess the genetic variabilities of the BLV Env sequences between the G1- and 
G4-like South African isolates and the G1 and G4 isolates from other geographic regions, pair-
wise comparison of the partial Env nucleotide and amino acid sequences was performed 
(Table 2.6 and Table S2.3 for the full data). This analysis was consistent with the phylogenetic 
analyses based on the partial env nucleotide sequences where one South African isolate 
belongs to G1 and the seven remaining South African isolates belong to G4 and they were 




Table 2.6: Nucleotide and amino acid differences in the BLV partial Env sequences between South Africa 
isolates and genotype-1 and genotype-4 isolates 
 
Amino acid sequence identities and differences are shown in brackets. 
Each cell in the table is highlighted according to amino acid differences.       
 
 
The NJ and ML trees based on the partial Env nucleotide sequences could not identify G1 
global isolate(s) that was most closely related to the G1-like South African isolate (M2746) as 
the G1-like South African isolate was closely related to fourteen G1 isolates with 39% 
K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401 
K1170 South Africa
K1194 South Africa 0 (0)
M1878 South Africa 1 (1) 1 (1)
M2746 South Africa 13 (4) 13 (4) 14 (5)
P591 South Africa 0 (0) 0 (0) 1 (1) 13 (4)
P2152 South Africa 0 (0) 0 (0) 1 (1) 13 (4) 0 (0)
P2677 South Africa 1 (0) 1 (0) 2 (1) 14 (4) 1 (0) 1 (0)
L3401 South Africa 1 (0) 1 (0) 2 (1) 14 (4) 1 (0) 1 (0) 2 (0)
AP018021 Japan 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
FJ808571 Argentina 12 (4) 12 (4) 13 (5) 3 (2) 12 (4) 12 (4) 13 (4) 13 (4)
D00647 Australia 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
LC075568 Bolivia 13 (3) 13 (3) 14 (4) 4 (1) 13 (3) 13 (3) 14 (3) 14 (3)
AF399703 Brazil 11 (4) 11 (4) 10 (3) 4 (2) 11 (4) 11 (4) 12 (4) 12 (4)
EF065637 Costa Rica 11 (3) 11 (3) 12 (4) 4 (1) 11 (3) 11 (3) 12 (3) 12 (3)
KX674372 Dominica 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
EU266061 Iran 13 (4) 13 (4) 14 (5) 4 (2) 13 (4) 13 (4) 14 (4) 14 (4)
EF065646 Japan 11 (3) 11 (3) 12 (4) 2 (1) 11 (3) 11 (3) 12 (3) 12 (3)
LC075558 Paraguay 11 (3) 11 (3) 12 (4) 2 (1) 11 (3) 11 (3) 12 (3) 12 (3)
LC075543 Peru 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
KX674369 St. Kitts and Nevis 11 (3) 11 (3) 12 (4) 2 (1) 11 (3) 11 (3) 12 (3) 12 (3)
KJ707242 South Korea 16 (5) 16 (5) 17 (6) 8 (3) 16 (5) 16 (5) 17 (5) 17 (5)
KU233528 Thailand 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
FM209468 Uruguay 13 (4) 13 (4) 12 (3) 5 (2) 13 (4) 13 (4) 14 (4) 14 (4)
EF065641 USA 13 (3) 13 (3) 14 (4) 4 (1) 13 (3) 13 (3) 14 (3) 14 (3)
MH170027 Vietnam 12 (3) 12 (3) 13 (4) 3 (1) 12 (3) 12 (3) 13 (3) 13 (3)
MH170028 Vietnam 13 (4) 13 (4) 14 (5) 4 (2) 13 (4) 13 (4) 14 (4) 14 (4)
HQ902258 Belarus 6 (3) 6 (3) 7 (4) 13 (3) 6 (3) 6 (3) 7 (3) 7 (3)
K02251 Belgium 4 (3) 4 (3) 5 (4) 13 (3) 4 (3) 4 (3) 5 (3) 5 (3)
AY515279 Chile 9 (5) 9 (5) 10 (6) 16 (5) 9 (5) 9 (5) 10 (5) 10 (5)
M35238 France 2 (1) 2 (1) 3 (2) 13 (3) 2 (1) 2 (1) 3 (1) 3 (1)
LC060792 Mongolia 3 (2) 3 (2) 4 (3) 10 (2) 3 (2) 3 (2) 4 (2) 4 (2)
AF067081 Poland 4 (2) 4 (2) 5 (3) 13 (2) 4 (2) 4 (2) 5 (2) 5 (2)
JN695878 Russia 5 (3) 5 (3) 6 (4) 14 (3) 5 (3) 5 (3) 6 (3) 6 (3)
JQ696091 Russia 6 (3) 6 (3) 7 (4) 15 (3) 6 (3) 6 (3) 7 (3) 7 (3)
AF033818 USA 4 (3) 4 (3) 5 (4) 13 (3) 4 (3) 4 (3) 5 (3) 5 (3)






bootstrap value. However, pair-wise comparison of the partial env nucleotide and amino acid 
sequences revealed that the G1-like South African isolate was most closely related to the 
Japanese (EF065646), Paraguayan (LC075558) and St Kitts and Nevis (KX674369) isolates, 
sharing 99.55% nucleotide sequence identity (two nucleotide differences) and 99.32% amino 
acid sequence identity (one amino acid difference).  
Three G4-like South African isolates (M1878, P2677 and L3401) and other four G4-like South 
African isolates (K1170, K1194, P591 and P2152) shared 99.55% (two nucleotide differences) 
and 99.77% nucleotide sequence identities (one nucleotide difference) with the Zambian 
isolate (LC193462), respectively but all seven G4-like South African isolates except the M1878 
isolate shared 100% amino acid sequence identity with the Zambian isolate. The M1878 
isolate shared 99.32% amino acid sequence identity with the Zambian isolate, which is only 
one amino acid difference between these isolates.  
 
2.3.2.3. Pair-wise comparison of the BLV Gag nucleotide and amino acid sequences 
between the South African and global isolates 
Consistent with the phylogenetic analyses based on the NJ and ML trees, pair-wise 
comparison of the BLV full-length Gag nucleotide and amino acid sequences revealed that 
the G-1 like South African isolate (M2746) was most closely related to the G1 Vietnamese 
isolate (MH170028) and the seven remaining South African isolates were most closely related 
to the G4 isolates (Table 2.7, Figure 2.6 and Table S2.4 for the full data). The gag sequences 
amongst the seven G4-like South African isolates appeared slightly more variable than the 
env sequences. Furthermore, as evident in heat maps, the Gag amino acid sequences are 
generally more conserved than the gag nucleotide sequences (Figure 2.6 A and B) as well as 
the Env amino acid sequences (Figure 2.5 B). 
Whilst the seven G4-like South African isolates showed up to four nucleotide and two amino 
acid differences in the env sequences with each other, their gag sequences had up to nine 
nucleotide and four amino acid differences with each other. Despite these some variabilities, 
the Gag sequences of the seven G4-like South African isolates still showed high sequence 
identities, sharing 99.24-99.92% nucleotide and 98.73-100.00% amino acid sequence 
identities with each other. The K1170 and P2677 isolates shared 100.00% amino acid 
sequence identity and the P2152 and L3401 isolates also shared 100.00% amino acid 





Table 2.7: Nucleotide and amino acid differences in the BLV full-length Gag sequences between South 
Africa isolates and global isolates representing nine genotypes 
 
Amino acid sequence identities and differences are shown in 
brackets. Each cell in the table is highlighted according to amino 
acid differences.      
 
 
Consistent with the results from the pair-wise comparison of the BLV Env sequences, the G1-
like South African isolate (M2746) had fewer sequence variabilities with G1 isolates than the 
sequence variabilities between the G4-like South African isolates and the G4 isolates. The 
G1-like South African isolate (M2746) shared more than 99.00% nucleotide and amino acid 
sequence identities (<10 nucleotide differences and <4 amino acid differences) with all other 
G1 isolates except the Australian isolate (D000647) (c.f., the Australian isolate has 3-
nucleotide deletion and is more divergent from other G1 sequences). The G1-like South 
African isolate shared the highest nucleotide sequence identity (99.66% identity or four 
nucleotide differences) and the highest amino acid identity (99.75% or one amino acid 
difference) with G1 Vietnamese isolate (MH170028). The G1-like South African isolate also 
shared with 99.75% amino acid identity and one amino acid difference with the Japanese 
isolate (AP018021). 
K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401 
K1170 South Africa
K1194 South Africa 5 (1)
M1878 South Africa 8 (3) 9 (3)
M2746 South Africa 46 (9) 45 (10) 47 (10)
P591 South Africa 4 (2) 5 (3) 10 (5) 44 (9)
P2152 South Africa 7 (2) 8 (2) 3 (1) 44 (9) 8 (3)
P2677 South Africa 2 (0) 3 (1) 8 (3) 44 (9) 1 (1) 7 (2)
L3401 South Africa 6 (2) 7 (2) 2 (1) 45 (9) 7 (3) 1 (0) 6 (2)
AP018021 Japan 44 (8) 43 (9) 45 (9) 5 (1) 43 (9) 43 (8) 42 (8) 43 (8)
D00647 Australia 51 (23) 50 (24) 54 (26) 66 (25) 50 (24) 52 (25) 49 (23) 52 (25)
AB934282 Japan 48 (9) 47 (10) 47 (8) 9 (2) 47 (10) 47 (9) 46 (9) 47 (9)
LC005615 Japan 50 (11) 51 (12) 51 (12) 7 (2) 51 (12) 49 (11) 50 (11) 49 (11)
LC080651 Paraguay 46 (9) 45 (10) 47 (10) 7 (2) 45 (10) 45 (9) 44 (9) 45 (9)
HE967301 Uruguay 47 (9) 46 (10) 48 (10) 8 (2) 46 (10) 46 (9) 45 (9) 46 (9)
EF600696 USA 46 (9) 45 (10) 47 (10) 7 (3) 45 (10) 45 (9) 44 (9) 45 (9)
MH170027 Vietnam 50 (11) 49 (12) 51 (12) 5 (2) 49 (12) 49 (11) 48 (11) 49 (11)
MH170028 Vietnam 49 (10) 48 (11) 50 (11) 4 (1) 48 (11) 48 (10) 47 (10) 48 (10)
FJ914764 Argentina 52 (11) 51 (12) 53 (12) 44 (8) 51 (12) 51 (11) 50 (11) 51 (11)
LC080655 Paraguay 50 (8) 49 (9) 51 (9) 40 (5) 49 (9) 49 (8) 48 (8) 49 (8)
LC080654 Peru 49 (8) 48 (9) 50 (9) 43 (5) 48 (9) 48 (8) 47 (8) 48 (8)
KT122858 Belgium 22 (6) 23 (7) 25 (9) 44 (9) 23 (7) 24 (8) 22 (6) 23 (8)
AF033818 USA 30 (6) 31 (7) 31 (7) 52 (8) 31 (7) 32 (8) 30 (6) 31 (8)
MF580991 China 53 (11) 50 (10) 54 (13) 63 (12) 54 (12) 54 (12) 53 (11) 54 (12)
LC080656 Paraguay 45 (6) 46 (7) 48 (9) 56 (7) 46 (7) 46 (8) 45 (6) 46 (8)
MH170030 Vietnam 49 (8) 48 (9) 50 (9) 60 (9) 48 (9) 50 (10) 47 (8) 50 (10)
G9 LC080659 Bolivia 43 (8) 44 (9) 44 (9) 37 (5) 44 (9) 42 (8) 43 (8) 42 (8)
MF580994 China 69 (21) 70 (22) 72 (23) 75 (20) 70 (22) 70 (23) 69 (21) 70 (23)









A. Nucleotide sequence B. Amino acid sequence C 
 
 
Figure 2.6: Heat map showing percent identities and differences of nucleotide and amino acid sequences in the BLV full-length Gag sequences from South Africa 
and other geographic regions worldwide. Percent identities (lower matrix) and differences (upper matrix) of BLV full-length Gag (A) nucleotide and (B) amino acid sequences 
were compared between eight South African isolates (No. 18) and 20 sequences representing six genotypes (G1, G2, G4, G6, G9 and G10) from other geographic regions 
worldwide (No. 9-28). (C) A table summarises sequence number, GenBank accession number and country of origin used in Figures A and B. 
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In contrast, the G4-like South African isolates shared only 97.29-98.14% nucleotide identities 
and 97.72-98.48% amino acid identities with the G4 Belgian isolates (KT122858) and 
American isolate (AF0033818), which corresponds to 22-32 nucleotide differences and 6-9 
amino acid differences.  
 
2.3.3. Genetic variabilities of the BLV Env and Gag sequences  
To assess genetic divergence of different BLV strains, mean intragenotype and intergenotype 
genetic distances were estimated amongst and between the South African sequences and 
115 full-length Env and 56 full-length Gag sequences from BLV isolates from various 
geographic regions obtained from the NCBI [381]. 
 
2.3.3.1. Genetic variabilities of the BLV Env sequences  
Using 115 full-length Env sequences with ten genotypes available from the NCBI [381] and 
the eight South African Env sequences, mean intragenotype and intergenotype nucleotide and 
amino acid distances were estimated (Table 2.8). This analysis was consistent with the results 
from the pair-wise comparison of the full-length env sequences showing that the Env 
sequences of the G4-like South African isolates themselves were more conserved than other 
genotypes. The analysis also confirmed that the seven G4-like South African isolates and one 
G1-like South African isolate belong to G4 and G1, showing the lowest mean intergenotype 
distances. The full-length Env sequences of the G1-like and G4-like South Africa isolates had 
mean nucleotide distances of 0.008 and 0.015 with the G1 and G4 global isolates, respectively 
whereas their mean amino acid distances were 0.006 and 0.014, respectively.  
Mean intragenotype distance of the G4-like South African Env sequences were 0.001 for both 
nucleotide and amino acid sequences, which was the lowest amongst all genotypes and 
indicates that the Env sequences of the G4-like South African sequences were less variable 
than other genotypes. Furthermore, the analysis revealed that whilst the mean intragenotype 
nucleotide distance of the G4 isolate (0.014) was twenty times higher than that of G1 (0.007), 
their amino acid distances of G1 and G4 isolates were comparable (0.007 and 0.009, 
respectively). This indicates that the full-length Env amino acid sequences of G1 and G4 
isolates including the G4-like South African isolates were conserved.  
In contrast, Env sequences of G6 and G10 isolates appeared to be more variable than other 
genotypes. The G6 and G10 Env sequences showed mean intragenotype nucleotide 
distances of 0.026 and 0.027, respectively, and mean intragenotype amino acid distances of 
0.022 and 0.032, respectively. Lastly, average genetic distances in the Env nucleotide and 
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amino acid sequences amongst all genotypes including South African isolates were calculated 
and they were 0.038 and 0.032, respectively.  
 
Table 2.8: Mean nucleotide and amino acid distances in the BLV full-length Env sequences within 
(intragenotype) and between (intergenotype) BLV strains from South Africa and other geographic 
regions worldwide 
 
Genetic distances in each column are shown with standard errors. Lower matrix (highlighted in blue) shows intergenotype 
nucleotide distance and the upper matrix (highlighted in yellow) shows intergenotype amino acid distance. Diagonal columns 
(highlighted in green) show intragenotype nucleotide (top) and amino acid (bottom) distances. Average nucleotide and amino 
acid intergenotype distance from all genotypes are shown in the bottom row and right column, respectively. Values in bold 
indicate minimum genetic divergence with the South African isolates. N/A, not applicable.   
 
2.3.3.2. Genetic variabilities of the BLV Gag sequences  
Using 56 full-length Gag sequences with six genotypes available from the NCBI [381] and the 
eight South African Gag sequences, mean intragenotype and intergenotype nucleotide and 
amino acid distances were estimated (Table 2.9). The analysis indicated that the G4-like South 
African Gag sequences were more variable than the G4-like South African Env sequences. 
Mean intragenotype nucleotide and amino acid distances of the G4-like South African Gag 
sequences were 0.005 for both sequences whilst the mean intragenotype nucleotide and 
amino acid distance of the G4-like South African Env sequences were 0.001 (Table 2.8).  
The average genetic distances in the Gag nucleotide and amino acid sequences amongst all 
genotypes were 0.043 and 0.029, respectively. This is consistent with the results from the pair-
wise comparison of the Gag sequences showing that the Gag amino acid sequences are more 
conserved than the gag nucleotide sequences. It appeared that the nucleotide changes in the 
gag gene did not dramatically change Gag amino acid sequences, which is reflected by the 
lower average amino acid distance (0.029) than the average nucleotide distance (0.043).  
Consistent with the genetic variabilities of the G4-like South African full-length Env sequences, 
mean nucleotide and amino acid distances between the G4-like South African isolates and 
the G4 isolates were lowest amongst all nine genotypes, showing 0.023 and 0.020, 








































0.044 ± 0.0070.045 ± 0.0080.033 ± 0.0060.018 ± 0.004
0.036 ± 0.005 
0.045 ± 0.0050.051 ± 0.0050.048 ± 0.0050.044 ± 0.005
0.039 ± 0.006
0.034 ± 0.0050.030 ± 0.005
0.035 ± 0.005
0.008 ± 0.002
0.032 ± 0.007 0.036 ± 0.007
0.033 ± 0.0040.038 ± 0.005 
0.049 ± 0.006
0.024 ± 0.0040.031 ± 0.005
0.032 ± 0.0050.030 ± 0.005
0.032 ± 0.006
0.025 ± 0.0040.029 ± 0.004
0.026 ± 0.007
0.041 ± 0.0070.012 ± 0.0050.027 ± 0.0070.036 ± 0.0070.037 ± 0.0080.024 ± 0.006
0.049 ± 0.007
0.044 ± 0.007
0.029 ± 0.0070.028 ± 0.0070.031 ± 0.006





0.038 ± 0.005 
0.035 ± 0.0040.039 ± 0.0050.037 ± 0.005
0.041 ± 0.0060.045 ± 0.0050.045 ± 0.0060.036 ± 0.0050.022 ± 0.0040.031 ± 0.005
0.033 ± 0.0080.039 ± 0.005
0.047 ± 0.0050.049 ± 0.0050.029 ± 0.0030.029 ± 0.005 0.045 ± 0.005
0.047 ±0.005
0.041 ± 0.005 0.045 ± 0.005
0.040 ± 0.005
0.043 ± 0.007 0.033 ± 0.008 0.038 ± 0.008
0.050 ± 0.005
0.040 ±0.005 0.046 ± 0.005 0.046 ± 0.005
0.050 ± 0.005
0.035 ± 0.005 0.040 ± 0.007
0.045 ± 0.0050.045 ± 0.0050.035 ± 0.0050.042 ± 0.0050.038 ± 0.005
0.030 ± 0.0050.037 ± 0.0070.033 ± 0.006
0.037 ± 0.006
0.037 ± 0.0060.028 ± 0.007
0.049 ± 0.0050.043 ± 0.004
0.039 ± 0.005
0.023 ± 0.0060.031 ± 0.007
0.036 ± 0.0070.028 ± 0.006
0.048 ± 0.007
0.033 ± 0.0070.014 ± 0.004




respectively, which were slightly more divergent than the mean nucleotide and amino acid 
sequence distances in the full-length Env sequences between the G4-like South African and 
G4 isolates (0.015 and 0.014, respectively).   
Mean nucleotide and amino acid distances between the G1-like South African isolates and 
the G1 isolates were 0.009 and 0.021, respectively. However, mean intergenotype amino acid 
distance between the G1-like South African isolate and G9 isolates showed 0.013, which was 
the lowest value amongst all nine genotypes, indicating that the G1-like South African isolate 
has a G9-like Gag amino acid sequence.  
 
Table 2.9: Mean nucleotide and amino acid distances in the BLV full-length Gag sequences within 
(intragenotype) and between (intergenotype) BLV strains  
 
Genetic distances in each column are shown with standard errors. Lower matrix (highlighted in blue) shows intergenotype 
nucleotide distance and the upper matrix (highlighted in yellow) shows intergenotype amino acid distance. Diagonal columns 
(highlighted in green) show intragenotype nucleotide (top) and amino acid (bottom) distances. Average nucleotide and amino 
acid intergenotype distance from all genotypes are shown in the bottom row and the right column, respectively. Values in bold 
indicate minimum genetic divergence with the South African isolates. N/A, not applicable.   
 
2.3.4. Alignment of the BLV Env and Gag amino acid sequences  
To assess whether nucleotide substitutions altered amino acid sequences in the South African 
isolates and to identify genotype-specific amino acid substitutions previously described [249, 
328-330] as well as amino acid substitutions unique to the South African isolates, the full-
length Env and Gag deduced amino acid sequences of the South African isolates were aligned 
with a total of 282 Env amino sequences and 211 Gag amino acid sequences available from 
the NCBI [381]. 
 
 




G1-like N/A 0.025 ± 0.007 0.021 ± 0.003 0.020 ± 0.006 0.023 ± 0.007 0.028 ± 0.007 0.013 ± 0.006 0.035 ± 0.008 
0.005 ± 0.001
0.005 ± 0.003
0.013 ± 0.002 
0.038 ± 0.005
0.005 ± 0.001 
0.011 ± 0.004 
0.015 ± 0.005 
0.011 ± 0.004 









0.043 ± 0.002  0.055 ± 0.0000.059 ± 0.002 0.053 ± 0.001 0.058 ± 0.001 0.059 ± 0.001 0.050 ± 0.001 
 0.027 ± 0.007 0.030 ± 0.006
0.034 ± 0.000 0.039 ± 0.001 0.035 ± 0.000 0.026 ± 0.000 0.038 ± 0.000 0.049 ± 0.000 0.033 ± 0.007
0.055 ± 0.002 0.046 ± 0.001 0.053 ± 0.001 0.055 ± 0.001 0.043 ± 0.001 
0.030 ± 0.008 0.019 ± 0.006 0.029 ± 0.007 
0.022 ± 0.006 0.034 ± 0.007 
0.038 ± 0.001 0.044 ± 0.000 0.039 ± 0.001 0.029 ± 0.007 0.031 ± 0.007 
0.042 ± 0.002 0.023 ± 0.001 0.023 ± 0.001 0.043 ± 0.001 0.024 ± 0.006










0.023 ± 0.007 0.039 ± 0.008
0.009 ± 0.003 0.041 ± 0.000 0.037 ± 0.007 0.038 ± 0.007 0.044 ± 0.007 0.030 ± 0.006 0.051 ± 0.008 
0.039 ± 0.000 0.041 ± 0.008
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2.3.4.1. Alignment of the BLV Env amino acid sequences  
Alignment of the Env amino acid sequences of the South African isolates with the 282 Env 
amino acid sequences obtained from the NCBI [381] confirmed the presence of the G1- and 
G4-specific amino acid substitutions in the M2746 isolate and the seven other South African 
isolates, respectively. Table 2.10 shows the alignment of Env amino acid sequences of the 
South African isolates with those of the 29 selected isolates representing ten genotypes. The 
analysis showed that the South African isolates contained G1-specific and G4-specific amino 
acid substitutions at 14 residues (at positions 29, 48, 56, 73, 74, 82, 121, 132, 134, 144, 254, 
479, 480 and 504) in their Env sequences. Furthermore, three amino acid substitutions in the 
Env sequences (at positions 59, 153 and 476) that were present exclusively in the South 
African sequences were detected. An isoleucine-to-leucine substitution at position 59 (I59L) 
and a histidine-to-glutamine substitution at position 153 (H153Q) were only present in the 
K1194 and M2746 isolates, respectively and thus, this could be a random mutation or 
sequencing errors. In contrast, an E476D substitution was consistently found in the seven G4-
like South African isolates and thus, this amino acid substitution appeared to be unique to the 
G4-like South African isolates. A D134N substitution was found only in the G4-like South 
African M1878 isolate and this appeared to be a G1-like substitution.  
 
2.3.4.2. Alignment of the BLV Gag amino acid sequences  
Alignment of the Gag amino acid sequences of the South African isolates with 212 Gag amino 
acid sequences available on the NCBI [381] also confirmed the presence of the G1- and G4-
specific amino acid substitutions in the M2746 isolate and the seven other South African 
isolates, respectively. Table 2.11 shows the alignment of Gag amino acid sequences of the 
South African isolates with those of the 16 selected isolates representing six genotypes. The 
analysis showed that the South African isolates contained G1-specific and G4-specific amino 
acid substitutions at four residues (at positions 63, 69, 88 and 365) in their Gag sequences.  
In this study, seven amino acid substitutions that had not been previously described were 
detected in the South African isolates and these were mainly found from the G4-like South 






Table 2.10: Amino acid substitutions in the BLV env gene of the South African sequences and 25 selected sequences   
 
a, amino acid substitutions described by Rodriguez et al. (2009) [328]; b, genotype-specific amino acid substitution described by Zhao and Buehring (2007) [249]; c, genotype-specific 
amino acid substitution previously described by Lee et al. (2016) [329]; d, genotype-specific amino acid substitutions described by Polat et al. (2016) [330]. SU, surface protein; TM, 
transmembrane protein; ND 2, neutralising domain 2; PXXP motif, proline-rich motif for the cell signalling; –, not available due to the partial env sequences. Amino acid substitutions 
that are previously not described are highlighted in blue. G1 and G4 sequences are highlighted in yellow for comparison. The country of origin is indicated by 2-letter codes. AR, Argentina; 
BE, Belgium; BO, Bolivia; BR, Brazil; HR, Croatia; IT, Italy; JP, Japan; KN, Saint Kitts and Nevis; MM, Myanmar; MD, Moldova; PE, Peru; PL, Poland; PY, Paraguay; RU, Russia; TH, Thailand; 
US, USA; UY, Uruguay; ZM, Zambia. 
Amino acid position 29 48 56 59 73 74 82 121 132 134 144 153 254 476 479 480 504
Reference d a,d a a,b a,d a,d a,c a a,d a,d a,d d d d
K1170 Q T F I P R F H R D T H L D F P T
K1194 Q T F L P R F H R D T H L D F P T
M1878 Q T F I P R F H R N T H L D F P T
M2746 R A S I A K S R Q D I Q S E L T V
P591 Q T F I P R F H R D T H L D F P T
P2152 Q T F I P R F H R D T H L D F P T
P2677 Q T F I P R F H R D T H L D F P T
L3401 Q T F I A R F H R D T H L D F P T
AP018021 JP R A S I A K S R Q D I H S E L T V
AF399703 BR Q A S I A K F R Q N I H S E F T V
KX674639 KN R A S I A K S R Q D I H S E L T V
EF065646 JP Q A S I A K S R Q D I H S E L T V
LC075558 PY - - - - - - - R Q D I H - - - - -
HE967301 UY R A S I A K S R Q N I H S E L T V
EF065641 US R A S I A K S R Q D I H S E L T V
AF257515 AR Q A S I A K F R Q D I H L E L A T
LC080655 PY Q A S I A K F R Q D I H L E F A T
LC080654 PE Q V S I A K F R Q D I H L E F A T
EF065650 JP Q A S I A K F R Q D I H L E F A T
EF065647 US Q A S I A K F R Q D I H L E F A T
M35238 FR Q T F I P R F H Q D T H L E F P T
AF067081 PL - - - - - - - H Q D I H - - - - -
JN695878 RU Q T S I P R F H Q D I H L E F P T
AF033818 US Q T S I P R F H Q D I H L E F P T
LC193462 ZM - - - - - - - H R D T H - - - - -
AF399702 BR - - - - - - - R R D I H - - - - -
EF065635 CR R T S I A R F R R D I H L E F T T
LC075571 BO - - - - - - - R Q D T H - - - - -
AY185360 BR Q T S I A R F R Q D T H L E F T T
MF580991 CN Q T S I A R F R Q D T Y L E F T T
KU233530 TH - - - - - - - R Q D T H - - - - -
KF801457 MD Q I S I A R F R Q D I H L E F T A
JN695879 RU Q T S I A R F R Q D I H L E F T A
S83530 IT - - - - - - - R Q D I H - - - - -
GU724606 HR - - - - - - - R Q D I H - - - - -
JF713455 RU - - - - - - - R Q D I H - - - - -
LC080659 BO Q A S I A K L R Q D I H L E F A T
LC080664 BO Q A S I A K F R Q D I H L E F A T
LC154848 MM Q T S I A R F R Q D T H L E F T T
KU233527 TH - - - - - - - H Q D T H - - - - -
gp51 SU gp30 TM













It appeared that four of these seven amino acid substitutions were unique to the South African 
sequences. The amino acid alignment showed that N29D, I278V and P343S substitutions 
were only found in the seven G4-like South African sequences, though the I278V substitution 
was also detected in an Iranian isolate (LC193727), which has not been genotyped. Although 
previously not described, our analysis indicates that the presence of methionine at position 
318 in the M2746 sequence and isoleucine at the same position in the seven G4-like South 
African sequences could be genotype-specific. A K341Q substitution was only found in the 
South African P591 isolate and it is uncertain whether this is a spontaneous mutation or a 
sequencing error.  
 
Table 2.11: Amino acid substitutions in the BLV Gag gene of the South African sequences and 16 
selected sequences  
 
* genotype-specific amino acid substitutions previously described by Polat et al. (2016) [330]. Amino acid substitutions that are 
previously not described are highlighted in blue. G1 and G4 sequences are highlighted in yellow for comparison. MA, matrix; CA, 
capsid; NC, nucleocapsid. The country of origin is indicated by 2-letter codes. AR, Argentina; AU, Australia; BE, Belgium; BO, 
Bolivia; CN, China; JP, Japan; MM, Myanmar; PE, Peru; PY, Paraguay; US, USA; UY, Uruguay; VN, Vietnam.    
 
A genotype-specific glycine-to-glutamic acid substitution at position 88 (G88E) was previously 
described [330] and in their study, the presence of the glycine residue at this position was 
identified as a G1-specific and the presence of the glutamic acid residue as G4-specific. 
However, in our study, the G4-like M1878, P2152 and L3401 isolates had the glycine residue 
at this position. This could be a mutation conserved amongst these G4-like South African 
isolates, random mutation or a sequencing error.  
Amino acid position 29 63* 69* 88* 107 108 278 318 341 343 365*
K1170 D A K E A V V I K S T
K1194 D A K E V V V I K S T
M1878 D A R G S I V I K S T
M2746 N T K G A V I M K P A
P591 D A K E A V V I Q S T
P2152 D A K G S V V I K S T
P2677 D A K E A V V I K S T
L3401 D A K G S V V I K S T
AP018021 N T R G A V I M K P A
D00647 AU N A K E A V I T K P T
AB934282 JP N T R G A I I M K P A
LC005615 JP N T R G A V I M K P A
LC080651 PY N T R G A V I M K P A
MH170027 VN N T R G A V I M K P A
MH170028 VN N T R G A V I M K P A
EF600696 US N T R G A V I V K P A
HE967301 UY N T R G A V I M K P A
FJ914764 AR N T R G A V I I K P T
LC080655 PY N T R G A V I I K P T
LC080654 PE N T R G A V I I K P T
KT122858 BE N A K E A V I I K P T
AF033818 US N A K E A I I V K P T
MF580991 CN N V K E V V I T K P T
LC080656 PY N V K E A V I T K P T
MH170030 VN N V K E A I I T K P T
LC080659 BO N T R G A V I I K P T
LC080664 BO N T R G A V I I K P T
MF580994 CN N V K E A D I V K P A








p24 CA p12 NC
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A V108I substitution was exclusively found in the M1878 sequence and this mutation can be 
G4-specific but AF033818-like change or a sequencing error. On the other hand, an A107V 
substitution in the K1194 isolate and an A107S substitution in the M1878, P2152 and L3401 
isolates could be either a sequencing error or a random mutation as these mutations did not 
appear to be genotype-specific.  
 
2.4. DISCUSSION 
In this study, full-length env and gag genes were sequenced for the first time from some South 
African BLV isolates and phylogenetic analyses revealed that at least two genotypes, 
genotype 1 and genotype 4, are present in South Africa. Pair-wise comparison of the full-
length and partial env sequences between the South African isolates and those from other 
geographic regions showed that the env sequences of the G4-like South African isolates were 
significantly similar to the Zambian sequence whereas the env sequence of the G1-like South 
African isolate was similar to the Japanese, Paraguayan and St Kitts and Nevis isolates. 
Furthermore, the analyses indicated that the G1-like South African isolate is more similar to 
the other global G1 isolates whereas the G4-like South African isolates are more divergent 
from the other global G4 isolates. Lastly, amino acid sequence alignment identified genotype-
specific as well as novel amino acid substitutions in the South African isolates.  
In our study, neighbour-joining (NJ) and maximum-likelihood (ML) methods were used to 
analyse the evolutionary relationships between the South Africa isolates and global isolates. 
The results from the NJ trees were confirmed by the results obtained from the ML trees. The 
NJ method is one of the simplest methods to assess evolutionary relationships, but this 
method does not assume each nucleotide position as a discrete character. In contrast, the ML 
method takes a substitution rate at each nucleotide position into account and thus, it is 
considered to be a more robust method. During our analysis using partial env sequences, we 
found that one Iranian isolate (EU266061) as well as three Iranian isolates (EU266060, 
EU266062 and EU266063), which had been previously grouped into G1 and G8, respectively, 
by Matsumura et al [385], were all grouped into G1 (data not shown). Our analysis was 
consistent with the studies conducted by Rodríguez et al. [328] and Rola-Łuszczak [151] using 
Bayesian and ML or NJ methods, where they also classified these Iranian isolates (EU266060 
to EU266063) as G1. The discrepancy in these results is that Matsumura et al [385] used the 
UPGMA method [386], which assumes a uniform substitution rate amongst different isolates 
and thus, is a less robust method. All our phylogenetic analyses based on the NJ and ML 
methods were thus, consistent with previous studies using the same or Bayesian models and 
supported by the similar bootstrap values. Similarly, all isolates used in our study were 
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correctly grouped as previous studies demonstrated [45, 151, 329, 330, 341-347]. In our study, 
phylogenetic analysis based on the partial env nucleotide sequences was supported by low to 
moderate bootstrap values, indicating that this analysis could be less reliable. However, 
phylogenetic analyses supported by low bootstrap values were also noted in previous studies 
[344, 347, 352] but these studies showed congruent tree topology amongst different studies 
and with our study. Furthermore, evolutionary relationships of BLV isolates using partial env 
nucleotide sequences were further assessed by pair-wise sequence comparison, whose 
results were in agreement with the phylogenetic analysis. Our analyses for the mean 
intergenotype and intragenotype genetic distances were also consistent with the previous 
studies [343, 346]. Lastly, our results reflect recent data as we included in our analyses not 
only the South Africa isolates but also isolates recently sequenced from China and Vietnam. 
This has allowed more comprehensive studies on the BLV genetic variants from diverse 
geographic regions. It should be noted that the collection dates are unknown for the majority 
of the isolates used in this study. Therefore, we could not perform the analysis and 
interpretation of the BLV evolutionary history for ten genotypes as well as G1- and G4-like 
South African isolates.   
Our phylogenetic analyses based on the env and gag nucleotide sequences as well as 
sequence comparison revealed that the G1-like South African isolate (M2746) was more 
similar to the G1 isolates from the other geographic regions whereas the G4-like South African 
isolates appeared more divergent from other G4 global isolates except for the Zambian isolate. 
Although G4 isolates themselves appeared less conserved compared to the G1 isolates, the 
Env and Gag sequences of the seven G4-like South African isolates were conserved amongst 
themselves. This is consistent with the previous studies showing that G1 is the most 
conserved amongst other genotypes [329, 343] and that sequences from the same geographic 
area tend to be conserved [249, 328].  
Since the only isolate sequenced from Africa (Zambia) belongs to G4, we predicted that the 
South African isolates might also belong to G4. We also speculated that the South African 
cattle might be infected with BLV with different genotype(s) as multiple genotypes are currently 
circulating in single countries or geographic areas worldwide (see Section 2.1) [151, 249, 330, 
339, 353]. As speculated, our analysis identified two genotypes, G1-like and G4-like strains, 
from the South African isolates. Furthermore, not surprisingly, the phylogenetic analysis based 
on the partial env nucleotide sequences and sequence comparison revealed that the seven 
G4-like South African isolates and the Zambian isolate are significantly close to each other, 
differing by only 0.002 nucleotide substitutions per site. Furthermore, six of these seven G4-
like South African isolates and the Zambian isolate showed the identical amino acid sequence 
and the one other G4-like South African isolate showed only one amino acid difference with 
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the Zambian isolate. Although the phylogenetic analyses and sequence comparison 
demonstrated with high bootstrap values and percent similarities that the G1-like South African 
isolate (M2746) is closely related to the G1Japanese, Paraguayan and St Kitts and Nevis 
isolates, this does not necessarily indicate that the cow infected with the M2746 isolate 
originates from these countries. However, South Africa and these countries may import cattle 
or semen/embryos from the same source. Furthermore, the coexistence of the G1 strain with 
the G4 strain in South Africa may indicate that cattle or semen/embryos have been imported 
from multiple countries [340, 357]. It is uncertain whether the G4 strain is already circulating 
extensively in South Africa and whether the presence of the G1 strain in South Africa is 
sporadic. However, our results highlight an urgent need for stringent disease management to 
prevent and control the BLV spread across the country.  
Our analyses further revealed that the Japanese isolate (AP018021) used to design the 
recombinant LSDV vaccines (see Chapter 4) was closely related to the G1-like South African 
isolate (M2746) with only one amino acid difference in its Env and Gag sequences. During our 
study, the genotype of the Japanese isolate (AP018021) was unknown. However, the paper 
that described this isolate later became available [347] and consistent with our analyses, their 
study identified this Japanese isolate as G1. Since there has not been any study on the cross-
protection between different BLV genotypes so far, it is unknown whether our recombinant 
LSDV vaccines could confer the cross-protection to animals infected with G4 strains. Yet, our 
results have provided valuable data for the future development of an efficacious BLV vaccine 
that is tailored to protect against local strains.      
The analyses of the BLV Gag sequences provided an additional finding. The G4-like gag 
nucleotide sequences appeared prone to mutations and more variable than their env 
nucleotide sequences, but their amino acid sequences were comparable. Whilst the gag 
nucleotide sequences of the G4-like South African isolates showed 22 to 32 nucleotide 
differences with the global G4 isolates, their env nucleotide sequences differ by 19 to 28 
nucleotides. However, both Gag and Env amino acid sequences differ by six to eight amino 
acids between the G4-like South African isolates and the global G4 isolates. This is in 
agreement with the analyses on the mean nucleotide and amino acid distances in the Env and 
Gag sequences. The mean intergenotype distances in the Gag sequences between the G4-
like South African isolates and the global G4 isolates were 0.023 and 0.019 for the nucleotide 
and amino acid sequences, respectively whereas those in the Env sequences were 0.015 and 
0.014 for the nucleotide and amino acid sequences, respectively. The same trend was also 
observed in Gag and Env sequences in general. The average nucleotide and amino acid 
distances in the Env sequences amongst all genotypes were 0.038 and 0.032, respectively 
whereas those in the Gag sequences were 0.043 and 0.029, respectively. Although gag 
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nucleotide sequences are generally more variable than env nucleotide sequences, these 
nucleotide changes in the gag gene did not cause significant changes in their amino acid 
sequences. These findings are consistent with a previous study [185] showing that the Gag 
sequences are subject to purifying selection. Mutagenesis studies on Gag variants have not 
been conducted and it remains unclear how BLV Gag mutations impact viral infectivity, fitness 
and persistence. However, a recent study identified two BLV haplotypes based on the gag 
sequences from 780 leukemic and aleukemic cows and demonstrated that the gag haplotypes 
are associated with the maintenance of high proviral load [387]. Furthermore, studies on the 
HIV Gag mutants demonstrated a correlation with drug resistance (e.g., protease inhibitors) 
[388-392], suggesting a role of retroviral Gag mutations in the viral persistence inside their 
hosts. Therefore, changes in Gag amino acid sequences could have a significant impact on 
viral infectivity and persistence and as a result, Gag amino acid sequences are less prone to 
mutations.  
Seventeen and eleven amino acid substitutions in the South African Env and Gag sequences, 
respectively were detected by the amino acid sequence alignment between the South African 
isolates and global isolates. These substitutions include genotype-specific substitutions as 
well as those unique to the South African isolates. The amino acid substitution at position 476 
in the Env sequences as well as the amino acid substitutions at positions 29, 278 and 343 in 
the Gag sequences were consistently detected from the seven G4-like South African isolates. 
These substitutions are absent in the global G4 isolates as well as any other global isolates. 
Importantly, these amino acid substitutions unique to the G4-like South African isolates appear 
to be conservative substitutions and thus, they are unlikely to cause functional changes to the 
proteins. No insertions and deletions were detected in the South African sequences. 
The genotype-specific amino acid substitutions in the Env sequence detected in this study 
include those at position 29 in the signal sequence, positions 48, 73, 74 and 82 in the G epitope, 
position 56 in the H epitope, positions 134 and 144 in the second neutralising domain (ND2), 
position 254 in the D epitope and position 504 in the PXXP motif. The Env mutations in the 
South African isolates appeared to be concentrated in the conformational epitopes (F, G and 
H) and the ND2. These results are consistent with previous studies showing that the G 
epitopes, particularly resides 48, 74 and 82, are under positive selection and most polymorphic 
sites [185, 249, 333, 334]. Homology modelling of the BLV Env protein has suggested that the 
conformational epitopes and the neutralising domains are located on the surface of the virus 
[236, 249]. Therefore, it is not surprising that these epitopes and domains are targets of NAbs 
[238, 240, 241, 246] and under the strong selection pressure [249], leading to the antigenic 
variations in these regions [241].  
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There are eight conformational epitopes (F, G and H) [239, 331, 332] on the Env gp51 surface 
protein and they are important for cell fusion and syncytium during viral dissemination [238]. 
In our study, four point mutations in the G epitopes and one point mutation in the H epitope 
were detected from the South African isolates. Since functional studies on the Env protein and 
Env mutants are scarce, functional consequences of the Env mutations found in our studies 
are unknown. However, non-conservative mutations in the conformational epitopes and the 
ND2 would affect the recognition of NAbs to these epitopes. A previous study which identified 
the S56F substitution in the H epitope showed that this substitution altered the recognition of 
a mAb to this epitope owing to the drastic changes from the small serine residue to the large 
hydrophobic phenylalanine residue [348]. This effect would also apply to the S82F substitution 
in the G epitope. Mutations in the conformational epitopes appear to benefit viral persistence 
through antigenic changes and immune escape. Previous studies demonstrated that BLV 
natural variants lacking one or two of the conformational epitopes were viable and appear to 
have evolved these mutations to evade host immune responses by altered antibody 
recognition [241, 348]. Yet, BLV mutants lacking all conformational epitopes have not been 
detected and these deletion mutants retained at least one of the three conformational epitopes 
[241, 348]. These observations indicate that the simultaneous loss of these epitopes would be 
deleterious and possibly lose infectivity [238].  
The BLV Env protein contains three neutralising domains (ND1 to ND3) [246] and these 
domains also play a role in viral infectivity (cell fusion and syncytium) as well as 
immunogenicity [237, 246, 353]. Previous studies demonstrated that the ND2 is particularly 
prone to multiple point mutations [328, 341] but it was also shown that the ND2 is under the 
purifying selection [249, 334], reflecting its functional significance. Rodríguez et al. [328] 
identified eleven point mutations within the ND2 from BLV strains from a variety of geographic 
regions. In contrast, interestingly, the ND1 and ND3 appear to be less prone to mutations [328, 
339]. Using homology modelling, Moratorio et al. [353] demonstrated that the D134N 
substitution changed net charge in a loop of the Env protein, possibly disturbing the 
immunogenicity and/or fusogenic properties of the ND2. One G4-like South African isolate 
(M1878) had the G1-like D134N substitution in this ND2. It is unclear whether this is a 
spontaneous mutation or a sequencing error. Although the chromatograms showed high-
quality trace data at this position (data not shown), to confirm whether this could be a 
spontaneous mutation or a sequencing error, the sequencing needs to be performed thrice.  
Eleven amino acid substitutions were found in the South African Gag sequences and the 
majority of the substitutions (six out of eleven substitutions) were concentrated in the p15 
matrix (MA) protein whereas only two amino acid substitutions were found in the p24 capsid 
(CA) protein. Since the CA protein is the second major target for the NAbs next to the gp51 
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surface protein [93], this protein can be under the selection pressure. Yet, it is possible that 
mutations in the CA can render fitness cost to the virus and cause deleterious effects to the 
viral replication. A genetic footprinting analysis on the Moloney murine leukemia virus 
demonstrated that the majority of the MA regions were tolerant of insertions whereas the N-
terminal region of the CA was susceptible to insertions [393]. They further demonstrated that 
although Gag mutants harbouring mutations in the MA and N-terminal region of the CA all 
produced virions, CA mutants produced an abundance of immature virions [393]. Furthermore, 
whilst the MA mutants showed reverse transcriptase (RT) and nuclear transport activities and 
appeared infectious, the RT and nuclear transport activities were not detected in the CA 
mutants, indicating the defect of uncoating or viral entry [393].  
Three amino acid substitutions were detected in the p12 nucleocapsid (NC) protein. The 
retroviral NC protein contains conserved zinc-finger motifs [259, 394-396] and basic residues 
[397-399] for RNA packaging and virion assembly [400, 401]. The K341Q substitution in the 
NC protein was only detected from the South African P591 isolate, not from any other South 
African nor global isolates. This mutation might be a spontaneous mutation or a sequencing 
error, which needs to be confirmed by re-sequencing. Yet, this amino acid change may cause 
functional changes in the virion assembly. Wang et al. [260] performed alanine-scanning 
mutagenesis study for the basic residues in the BLV NC and demonstrated that although the 
K341A substitution in the NC did not affect RNA packaging, the K341A mutant had two- to 
three-fold reduction in virion production. Although lysine can be substituted with other polar 
amino acids including glutamine, it is unknown whether the loss of charge may also affect 
virion production.   
This study served as the first phylogenetic analysis of the BLV env and gag complete 
sequences from some South African isolates and has contributed to a more comprehensive 
study on the global BLV genetic diversity. Furthermore, the detection of two genotypes (G1 
and G4) in South Africa highlights the urgent need for the disease management and 
development of an efficacious vaccine against local strains. Since the sample size in this study 
was small and only cattle from a single herd were assessed, further studies investigating BLV 
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Recombinant poxvirus vectors have been widely used as a next-generation vaccine platform 
for human and animal pathogens [402-410] and a therapeutic tool for various cancers [411-
414]. Recombinant poxvirus-vectored vaccines can express foreign antigens that induce 
immune responses. Several factors are essential in the design of recombinant poxvirus-
vectored vaccines such as types of poxviruses [415], host range of vector viruses [416] and 
poxvirus promoters used to drive transgene expression [417].  
Poxvirus promoters are particularly important in determining the strength and timing of antigen 
expression in recombinant poxvirus vaccines, thereby playing a role in the induction of desired 
immune responses. Linked to the stages of the viral life cycle, poxvirus promoters are 
classified into five temporal classes: immediate-early, early, early-late, intermediate and late 
promoters. Temporal gene expressions, switching from early to late gene expressions, are not 
unique to poxvirus but ubiquitous to all types of viruses, whether DNA or RNA viruses. 
However, poxvirus transcription is a cascading pathway in which gene expression is 
temporally regulated at levels of transcriptional initiation and by phase-specific transcription 
factors (TFs), which are products of the preceding gene expression (Figure 3.1) [418]. Early 
genes are expressed from early promoters by the control of early TFs that have been 
packaged in virion cores. Early genes encode proteins necessary for DNA replication and 
transcription of intermediate genes. Following the uncoating of viral cores, DNA replication 
initiates, which results in expression of intermediate genes from intermediate promoters and 
expression of proteins required for late gene expression and morphogenesis. Upon initiation 
of intermediate transcription, transcription of late genes commences from late promoters. 
One classic early-late poxvirus promoter is that of the 7.5 kilo Dalton (kDa) polypeptide gene 
(p7.5) of vaccinia virus (VACV) [419], which is the first poxvirus promoter sequenced [420] 
and has been used widely in recombinant poxvirus vectors [94, 327, 421-424]. In poxvirus-
infected cells, the p7.5 promoter is activated at the early stage of the viral life cycle and re-
activated in the later stage [425].  
Much focus has been on the selection of strong poxviruses promoters to enhance the level of 
antigen expression to improve immunogenicity of vaccines [426, 427]. However, accumulating 
evidence suggests that not only the strength of poxvirus promoter per se is critical for the 
immunogenicity but also the timing of antigen expression driven by different temporal classes 





Figure 3.1: Lifecycle of poxvirus. Replication cycle and transcription pathways of poxviruses are conserved 
amongst the Poxviridae family.  Infectious virions, extracellular enveloped virus (EEV) or intracellular mature 
virus (IMV) bind to cell surface proteins to fuse with the cell membrane, which results in the release of the viral 
core into the cytoplasm. Transcription of immediate-early and early genes leads to the uncoating of viral cores 
and DNA replication in viral factories (not shown in the figure). Transcription of intermediate and late genes 
follows DNA replication. In the viral factory, immature virions are assembled and form IMVs ((not shown in the 
figure). Some IMVs are transported to the Golgi apparatus, where they are wrapped with a double membrane 
to form intracellular enveloped viruses (IEVs). The IEVs are transported to the cell membrane, and thereby 
released as EEVs to initiate infection of uninfected cells. Taken from McFadden. G (2015) [416]. 
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It has been shown that early-activity of poxvirus promoters is important to induce cytotoxic T 
cell responses in vivo [428-431] whereas genes expressed from intermediate and/or late 
promoters induced both antibody and CD4+ T cell responses [432-434]. In particular, early 
expression of antigens relates to the induction of antigen-presenting dendritic cells [435] as 
well as the sustained production of memory CD4+ and CD8+ T cells, which play a crucial role 
in the secondary immune responses [428, 435-437] in vaccinated individuals.  
The aim of this chapter is to examine the activity of five selected poxvirus promoters in cells 
infected with LSDV by the detection of transient expression of an enhanced green fluorescent 
protein (eGFP) reporter gene driven by each poxvirus promoter from a reporter plasmid. The 
poxvirus promoters tested included a modified early fowlpox virus promoter (mFP) [438, 439], 
the p7.5 promoter [419], a synthetic early-late promoter of VACV (pS) [426], a modified early-
late promoter of the H5 gene of VACV (mH5) [440] and a synthetic early-late optimised 
promoter (LEO) of VACV [436], which all have either an early promoter element alone or an 
early-late promoter element.   
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Source of plasmids  
Plasmids pBLV-Env-Gag, pLSDV_K1L_eGFP (a generous gift from Ruzaiq Omar) and 
pSSPExSHIVgp150I-Pgag (a generous gift from Dr. Ros Chapman) (Figure 3.2) were used to 
construct the reporter plasmid vectors that contained one of the five poxvirus promoters 
upstream of the eGFP gene.  
 
3.2.2. Source of poxvirus promoters 
Sequences of the p7.5, pS, mH5 and LEO promoters were taken from original studies that 
characterised these promoters [419, 426, 436, 440]. The early mFP promoter was designed 
by Ruzaiq Omar [438] from a native early-late fowlpox virus promoter [439] by replacing the 
late promoter element with an antisense poxvirus terminator sequence (AGAAAAA).  
 
3.2.3. Source of LSDV  
A recombinant Neethling lumpy skin disease virus, nLSDVSODis-UCT [441] was used for the 














Figure 3.2: Plasmid maps of the source and intermediate plasmids used to construct the five poxvirus 
promoter plasmid vectors containing different promoters. (A) pBLV-Env-Gag plasmid. (B) 
pLSDV_K1L_eGFP plasmid. (C) pSSPExSHIVgp150I-Pgag-1. (D) pBLV-Gag-eGFP is an intermediate plasmid 
vector constructed by excision of the mFP promoter and BLV env gene from the pBLV-Env-Gag plasmid. This 
intermediate plasmid was used to construct the pmH5-eGFP and pLEO-eGFP plasmids. Nucleotide positions 
of restriction sites are shown in brackets. Arrows, arrowheads and boxes indicate genes. mFP, modified early 
fowlpox virus promoter; p7.5, promoter for the 7.5 kDa polypeptide gene of vaccinia virus (VACV); pS, synthetic 
early-late promoter of VACV; mH5, a modified promoter of the H5 gene of VACV; LEO, synthetic early-late 
optimised promoter of VACV, 49 flank, 356bp of the 3’ end of 049 ORF from Neethling lumpy skin disease virus; 
50 flank, 440bp of the 3’ end of 050 ORF from Neethling lumpy skin disease virus; BLV env, envelope gene of 
bovine leukaemia virus (BLV); BLV gag, gag gene of BLV; eGFP, gene of enhanced green fluorescent protein; 
K1L, K1L gene of VACV; I8R, 3’ portion of I8R gene of VACV; G1L, 3’ portion of G1L gene of VACV; PEPV DR, 
penguin poxvirus direct repeat; tPA, leader sequence of a human tissue-type plasminogen activator gene; SHIV 
gp120, env gp120 gene of human immunodeficiency virus (HIV); SHIV gp41, env gp41 gene of HIV; SIV gag, 
gag gene of simian immunodeficiency virus; bla (AmpR), beta-lactamse (bla) gene; CmpR, chloramphenicol 




The Neethling vaccine strain was modified such that ORF 131, a truncated superoxide 
dismutase (SOD) was deleted and replaced with a modified SOD homologue gene which 
resembled that of Herbivac LS, a vaccine strain of LSDV derived from Neethling 
(manufactured by Deltamune, Pretoria, South Africa) [442]. The resultant nLSDVSODis-UCT 
had a stable 131 gene which encoded a protein with the identical amino acid sequence to that 
of the Herbivac LS SOD homologue. The nLSDVSODis-UCT (“is” referring improved stability) 
recombinant was designed such that it would be unlikely to mutate in a region of dinucleotide 
repeats and therefore be more stable. There are no selection and/or marker gene(s) present 
in nLSDVSODis-UCT.  
 
3.2.4. Cell culture 
3.2.4.1. Sources of cells 
The baby hamster kidney (BHK-21) adherent cell line (CCL-10) was obtained from the 
American Type Culture Collection (ATCC).  
 
3.2.4.2. Thawing and recovery of cell lines from deep-frozen stocks 
A cryovial containing 4.0x106 BHK-21 cells was removed from the -80°C freezer and 
immediately placed in the 37°C water bath. The cells were thawed by agitating the vial gently 
in the water bath for up to 1 minute. Then, the cells were re-suspended in 5ml of pre-warmed 
complete Dulbecco’s Modified Eagle Medium (cDMEM) (Appendix A) contained in a 15ml 
conical centrifuge tube to dilute the dimethyl sulfoxide (DMSO) (Lonza, USA). After the cell 
suspension was centrifuged briefly for 3 minutes at low speed (< 500g), the supernatant was 
removed, and the cell pellet was resuspended using the residual cell medium. Lastly, 5ml of 
cDMEM (Appendix A) was added and the cell suspension was transferred into a 25cm2 cell 
culture flask (T-25). Cell viability was examined using the trypan blue staining method as 
described in Section 3.2.4.4. If excessive dead cells were observed, they were removed 
carefully once the majority of the viable cells settled. Then, the T-25 flask was incubated for 2 
to 3 days in a CO2 incubator set at 37°C, 70% relative humidity and 5% CO2 (standard growth 
conditions) to stabilise the cells before transferring the cells into a 75cm2 tissue culture (T-75)  
 
3.2.4.3. Growth and maintenance of adherent cell line 
The method was adapted from Phelan (2007) [443] and Cotter et al. (2015) [444]. The BHK-
21 cells were sub-cultured regularly or when the cells formed a confluent monolayer. The 
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whole volume of culture medium was aspirated, and cells were washed with 10ml of 1x 
phosphate-buffered saline (PBS) (Thermo Fisher Scientific, USA). The PBS was discarded, 
and the cells were overlaid with 2ml of 1x trypsin-EDTA (0.25%) (Thermo Fisher Scientific, 
USA). After a 3-minute incubation in the CO2 incubator to enhance the dissociation of cells, 
the dissociation of the adherent cells was further facilitated by tapping the flask gently several 
times. Then, 8ml of cDMEM (Appendix A) was added to the trypsinised cells and the cell 
suspension was mixed thoroughly by pipetting up and down several times to dissociate cell 
clumps. Lastly, the cell suspension was diluted with cDMEM at a ratio of 1:5 and incubated in 
the CO2 incubator under standard growth conditions until the next sub-culturing. Cell growth 
and viability was monitored daily by examining the cells with an optical microscope under 
brightfield illumination (Olympus, Japan) and the colour change of the culture media.  
 
3.2.4.4. Cell counting 
Cell count of viable cells was performed by a trypan blue staining method [443, 445]. When 
the cells formed a confluent monolayer, cells were washed with 1x PBS and trypsinised (See 
Section 3.2.4.3) Then, the cell suspension and Trypan Blue Stain (0.4%) (Thermo Fisher 
Scientific, USA) were mixed thoroughly in a ratio of 1:10 in a 1.5ml Eppendorf tube and 10μl 
of the mixture was loaded on a Neubauer Chamber with coverslip in place (Marienfeld, 
Germany). Transparent, viable cells on 1mm2 grids at the four corners were counted under 
the optical microscope at 100x magnification (Olympus, Japan). The following equation was 
used to obtain total cells per ml: 
Total cells/ml = The average number of cells obtained from the Neubauer Chamber x 104 x 
Dilution factor (i.e., 10)  
 
3.2.5. Construction of pmFP-eGFP, p7.5-eGFP, pmH5-eGFP, pS-eGFP and pLEO-eGFP 
reporter plasmids 
3.2.5.1. Construction of plasmid pmFP-eGFP 
pBLV-Env-Gag plasmid DNA was digested with restriction endonuclease NcoI, and a 4,327bp 
fragment containing the vector backbone, the 49 flank, mFP promoter, eGFP gene and 50 
flank was gel purified as described in Appendix B1.1. One hundred nanograms of the gel-
purified plasmid DNA was then re-ligated and transformed into E. coli competent cells (see 
Appendix B1.3 and B1.4). Twenty single colonies were picked from the plates for small scale 
plasmid DNA isolation (see Appendix B1.5). The plasmid DNA was then digested with 
restriction endonucleases FastDigest HindIII and FastDigest KpnI (Thermo Fisher Scientific, 
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USA), as described in Appendix B1.1 and was subject to ethidium-bromide (0.5μg/ml) stained 
0.8% agarose gel electrophoresis in 1xTBE at 100V for 1 hour. The desired plasmid was 
amplified as described in Appendix B1.6. Preliminary confirmation of the correct plasmid 
construct was made by restriction endonuclease mapping of the plasmid DNA and final 
confirmation by Sanger sequencing using M13F and M13R universal primers (Table 3.1). 
 
Table 3.1: A set of primers used to sequence the five reporter plasmid vectors 
Primer Orientation Primer sequence Binding site 
M13F Forward 5’- GTTTTCCCAGTCACGAC - 3’ Lac Z outside the 49 flank 
M13R Reverse 5’- CAGGAAACAGCTATGAC - 3’ Lac Z outside the 50 flank 
 
3.2.5.2. Construction of plasmid p7.5-eGFP 
pBLV-Env-Gag plasmid DNA was digested with restriction endonucleases ApaI and XhoI 
(Thermo Fisher Scientific USA), and a 4,387bp fragment containing the vector backbone, the 
49 flank, p7.5 promoter, eGFP gene and 50 flank was gel purified as described in Appendix 
B1.1. Approximately 1,140ng of the gel-purified plasmid DNA was blunted and re-ligated (see 
Appendix B1.2 and B1.3). For the ligation reaction, two reaction mixtures were prepared. One 
reaction mixture contained five times more plasmid DNA than the manufacturer’s 
recommendation whereas the other contained two times more T4 DNA ligase than the 
manufacturer’s recommendation. Then, re-ligated plasmids were transformed into E. coli 
competent cells (see Appendix B1.4). Sixteen single colonies were picked from the plates for 
small scale plasmid DNA isolation (see Appendix B1.5). The plasmid DNA was then digested 
with restriction endonuclease FastDigest NcoI (Thermo Fisher Scientific, USA), as described 
in Appendix B1.1 and was subject to ethidium-bromide (0.5μg/ml) stained 0.8% agarose gel 
electrophoresis in 1xTBE at 100V for 1 hour. The desired plasmid was amplified as described 
in Appendix B1.6. Preliminary confirmation of the correct plasmid construct was made by 
restriction endonuclease mapping of the plasmid DNA and final confirmation by Sanger 
sequencing using M13F and M13R universal primers (Table 3.1). 
 
3.2.5.3. Construction of plasmid pS-eGFP  
pLSDV_K1L_eGFP plasmid DNA was digested with endonuclease SpeI (New England 
Biolabs, USA) and a 5,326bp fragment containing the vector backbone, the 49 flank, pS 
promoter, eGFP gene and 50 flank was gel purified as described in Appendix B1.1. 
Approximately 50ng of the gel-purified plasmid DNA was then re-ligated and transformed into 
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E. coli competent cells (see Appendix B1.3 and B1.4). For the ligation reaction, two reaction 
mixtures were prepared. One reaction mixture was prepared as per the manufacturer’s 
recommendation whereas the other contained five times more plasmid DNA than the 
manufacturer’s recommendation. Then, re-ligated plasmids were transformed into E. coli 
competent cells (see Appendix B1.4). Sixteen single colonies were picked from the plates for 
small scale plasmid DNA isolation (see Appendix B1.5). The plasmid DNA was then digested 
with restriction endonucleases FastDigest XhoI and FastDigest BamHI (Thermo Fisher 
Scientific, USA), as described in Appendix B1.1 and was subject to ethidium-bromide 
(0.5μg/ml) stained 0.8% agarose gel electrophoresis in 1xTBE at 100V for 1 hour. The desired 
plasmid was amplified as described in Appendix B1.6. Preliminary confirmation of the correct 
plasmid construct was made by restriction endonuclease mapping of the plasmid DNA and 
final confirmation by Sanger sequencing using M13F and M13R universal primers (Table 3.1). 
 
3.2.5.4. Construction of the pBLV-Gag-eGFP intermediate plasmid  
pBLV-Env-Gag plasmid DNA was digested with restriction endonucleases ApaI and XbaI 
(Thermo Fisher Scientific USA), and a 5,679bp fragment containing the vector backbone, the 
49 flank, mH5 promoter, BLV gag gene, p7.5 promoter, eGFP gene and 50 flank was gel 
purified as described in Appendix B1.1. Approximately 30ng of the gel-purified plasmid DNA 
was blunted and re-ligated. (see Appendix B1.2 and B1.3) Two ligation mixtures were 
prepared as described in Section 3.2.5.2. Then, re-ligated plasmids were transformed into E. 
coli competent cells (see Appendix B1.4). Sixteen single colonies were picked from the plates 
for small scale plasmid DNA isolation (see Appendix B1.5). The plasmid DNA was then 
digested with restriction endonuclease FastDigest NcoI (Thermo Fisher Scientific, USA), as 
described in Appendix B1.1 and was subject to ethidium-bromide (0.5μg/ml) stained 0.8% 
agarose gel electrophoresis in 1xTBE at 100V for 1 hour. The desired plasmid was amplified 
as described in Appendix B1.6. Preliminary confirmation of the correct plasmid construct was 
made by restriction endonuclease mapping of the plasmid DNA.  
 
3.2.5.5. Construction of plasmid pmH5-eGFP  
pBLV-Gag-eGFP intermediate plasmid DNA was digested with restriction endonuclease NcoI 
(Thermo Fisher Scientific USA), and a 4,368bp fragment containing the vector backbone, the 
49 flank, mH5 promoter, eGFP gene and 50 flank was gel purified as described in Appendix 
B1.1. Approximately 41.5ng of the gel-purified plasmid DNA was re-ligated and transformed 
into E. coli competent cells (see Appendix B1.3 and B1.4). Two ligation mixtures were 
prepared as described in Section 3.2.5.2. Sixteen single colonies were picked from the plates 
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for small scale plasmid DNA isolation (see Appendix B1.5). The plasmid DNA was then 
digested with restriction endonucleases SmaI and SalI (New England Biolabs, USA), as 
described in Appendix B1.1 and was subject to ethidium-bromide (0.5μg/ml) stained 0.8% 
agarose gel electrophoresis in 1xTBE at 100V for 1 hour. The desired plasmid was amplified 
as described in Appendix B1.6. Preliminary confirmation of the correct plasmid construct was 
made by restriction endonuclease mapping of the plasmid DNA and final confirmation by 
Sanger sequencing using M13F and M13R universal primers (Table 3.1). 
 
3.2.5.6. Construction of plasmid pLEO-eGFP 
Since the LEO promoter sequence is only 82bp, it was decided it would be difficult to purify 
the 82bp fragment from an agarose gel. Therefore, ligation of the LEO promoter DNA fragment 
into the reporter plasmid backbone was conducted by “shot-gun cloning”.  
Five micrograms of plasmid pSSPExSHIVgp150I-Pgag were digested with 1µl of NgoMIV, 
NcoI and XhoI restriction endonucleases (New England BioLabs, USA) (see Appendix B1.1). 
Following the incubation at 37°C for 1 hour, the reaction was heat-inactivated at 80°C for 20 
minutes as per the manufacturer’s recommendations. To generate the vector backbone for 
the cloning, 1.4µg of the pBLV-Gag-eGFP intermediate plasmid was digested with 1µl of NcoI 
and XhoI (Thermo Fisher Scientific, USA). For both reactions, reaction mixtures without the 
restriction endonucleases were also prepared as a negative control. Following a 1-hour 
incubation at 37°C, the pBLV-Gag-eGFP intermediate plasmid DNA digested with the NcoI 
and XhoI restriction endonucleases was subject to ethidium-bromide (0.5μg/ml) stained 0.8% 
agarose gel electrophoresis in 1x TBE buffer (Appendix A) at 100V for 1 hour. A 4,277bp 
fragment containing the vector backbone, the 49 flank, eGFP gene and 50 flank was gel 
purified as described in Appendix B1.1. 
For the “shot-gun cloning,” two experimental reactions and two controls were prepared. The 
two experimental reaction mixtures consisted of 20µl and 40µl. The insert 
(pSSPExSHIVgp150I-Pgag plasmid DNA digested with NgoMIV, NcoI and XhoI) was ligated 
with the gel-purified plasmid backbone using T4 DNA Ligase as described in Appendix B1.3. 
For the controls, one reaction mixture without the insert plasmid DNA and one without both 
the insert plasmid DNA and T4 DNA ligase were prepared. The first control was included to 
determine the levels of singly-cut or undigested plasmid DNA and the second control was 
included to detect the quantity of undigested vector. See Appendix B1.3 for the detailed 
method of ligation. Following the incubation of the reaction mixtures at room temperature 
overnight, the transformation of the chemically competent E. coli cells was conducted (see 
Appendix B1.4). Eighteen bacterial colonies were selected from the agar plates and inoculated 
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into an LB-broth (Appendix A) containing carbenicillin (50µg/ml) (Thermo Fisher Scientific, 
USA) for colony PCR. These 18 bacterial cultures were incubated overnight on at 37°C 
shaking incubator at 250 rpm. 
 
3.2.5.6.1. Colony PCR 
Colony PCR was used to identify the recombinants containing the LEO promoter. Colony PCR 
was performed using 1µl of each of the overnight bacterial culture, 1.25µl of the LEO fwd 4 
and eGFP rev 5 primers (Table 3.2) and 12.5µl of KAPA 2G Robust HotStart ReadyMix PCR 
Kit (KAPA BIOSYSTEMS, USA) in 25µl reaction mixtures as per manufacturer’s protocol. A 
reaction mixture without bacterial culture was included as a PCR control. The reaction 
conditions were as follows: initial denaturation at 95°C for 5 minutes followed by 30 cycles of 
denaturation at 95°C for 15 seconds, annealing at 52°C for 15 seconds and extension at 72°C 
for 15 seconds. 
 
Table 3.2: Primers used for the colony PCR 
Primer Orientation Primer sequence Binding site 
LEO fwd 4 Forward 5’- AGACGCTAGACTAGTACC -3’ LEO promoter 
eGFP rev 5 Reverse 5’- GCGGATCTTGAAGTTCAC -3’ 5’ end of eGFP gene 
 
A large-scale plasmid DNA isolation was carried out using one of the recombinants found to 
contain the LEO promoter (see Appendix B1.6). Preliminary confirmation of the correct 
plasmid construct was made by restriction endonuclease mapping of the plasmid DNA and 
final confirmation by Sanger sequencing using M13F and M13R universal primers (Table 3.1). 
 
3.2.6. Fluorescence microscopy analysis of transient eGFP expression in baby hamster 
kidney (BHK-21) cells infected with LSDV and transfected with a reporter plasmid 
A 12-well tissue culture plate was seeded with 1ml of BHK-21 cells at a concentration of 
1.0x105 cells/ml and incubated overnight under standard growth conditions. On the following 
day, a 70% confluent monolayer of the cells was infected with 5µl of the recombinant Neethling 
lumpy skin disease virus nLSDVSODis-UCT (1.0x107.25 TCID50/ml) at a multiplicity of infection 
(MOI) of 0.5 and incubated for 2 hours under standard growth conditions. Following a 2-hour 
incubation, the culture media was aspirated from wells and the cells were transfected with a 
transfection mixture containing 500µl of DMEM (Thermo Fisher Scientific, USA), 1µl of X-







Figure 3.3: Layout of a 12-well plate for the infection and transfection of BHK-21 cells 
with LSDV and poxvirus promoter plasmid DNA. A schematic diagram shows seven control 
wells and five experimental wells. One well was left uninfected and untransfected (Cells only). 
In another control well, BHK-21 cells were only infected with LSDV. The remaining five control 
wells were only transfected with one of the five poxvirus reporter plasmids. In the experimental 
wells, BHK-21 cells were infected and transfected with LSDV and each of the poxvirus promoter 
plasmid DNA. Wells where cells were infected with the LSDV are shown in pink semicircles, 
those transfected with the poxvirus promoter plasmid DNA are shown in blue semicircles and 
uninfected and/or untransfected wells are shown in white semicircles. 
 
One experimental control well of uninfected and untransfected cells, one infection control well 
of the LSDV-infected cells only and five plasmid control wells of the transfected cells only were 
also prepared (Figure 3.3). eGFP expression was monitored daily for 72 hours post-
infection/transfection using an epifluorescent inverted microscope (Zeiss, Germany). 
 
3.3. RESULTS 
In this study, five reporter plasmid vectors that contained each of the selected poxvirus 
promoters were constructed. To assess whether these promoters were expressed in the 
LSDV-infected cells, BHK-21 cells were infected with LSDV and transfected with each of the 
reporter plasmid vectors. eGFP was transiently expressed from all poxvirus promoter plasmid 
vectors over the 72-hour study period. Figure 3.4 outlines the experimental procedure and a 
mechanism for transient eGFP expression driven by the poxvirus promoter and viral 











Figure 3.4: Flow diagram of the experimental procedure and schematic diagram of a mechanism for 
transient eGFP expression in LSDV infected and transfected BHK-21 cells. (A) Five reporter plasmid 
vectors were constructed, and BHK-cells were infected with LSDVT and transfected with one of the reporter 
plasmids. eGFP expression was examined using an epifluorescent inverted microscope. (B) In BHK-21 cells 
that were infected with LSDV and transfected with a reporter plasmid DNA, the LSDV expresses a viral 
transcription complex that binds to the poxvirus promoter of the reporter plasmid DNA, driving transient 
expression of eGFP.  
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3.3.1. Construction of the poxvirus promoter-eGFP plasmid vectors 
3.3.1.1. Enzymatic manipulation of the plasmids 
Five reporter plasmid vectors were constructed as described in the Methods and shown in 
Table 3.3 and the schematic diagrams in Figure 3.5. The resultant plasmids each contained 
one of the poxvirus promoters immediately upstream of the eGFP gene. Table 3.4 outlines the 
promoter sequences used in this study. 
 
Table 3.3: Table showing the details of the plasmids and restriction endonucleases used to construct the 
five reporter plasmids 
Promoter Source plasmid  Restriction enzyme Resultant plasmid  
mFP pBLV-Env-Gag NcoI pmFP-eGFP 
p7.5 pBLV-Env-Gag ApaI and XhoI p7.5-eGFP 
mH5 pBLV-Env-Gag ApaI and XbaI pBLV-Gag-eGFP 
 pBLV-Gag-eGFP NcoI  pmH5-eGFP 
pS pLSDV_K1L_eGFP SpeI pS-eGFP 
LEO pSSPExSHIVgp150I-Pgag XhoI, NcoI and NgoMIV pLEO-eGFP 
 pBLV-Gag-eGFP XhoI and NcoI 
  
Table 3.4: Sequences of the five poxvirus promoters used in this study   

















Figure 3.5: Construction of the five poxvirus reporter plasmids. (A) pmFP-eGFP (B) p7.5-eGFP (C) pS-
eGFP (D) pmH5-eGFP (E) pLEO-eGFP plasmids. Poxvirus promoter sequences are represented by triangles 
and arrows indicate ORFs. The bla and lacz genes and Ori derived from the pUC57 simple plasmid cloning 
vector and 49 and 50 flanks are omitted from the plasmid maps.  
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3.3.1.2. Confirmation of the integrity of the poxvirus reporter plasmids 
Restriction endonuclease mapping was used to confirm the integrity of plasmids pmFP-eGFP, 
p7.5-eGFP, pS-eGFP, pBLV-Gag-eGFP and pmH5-eGFP. Table 3.5 summarises the 
restriction endonucleases used for the restriction endonuclease mapping and the expected 
sizes of the fragments generated. 
 
Table 3.5: Restriction endonucleases used to confirm the integrity of the poxvirus reporter plasmids 
Plasmid construct Restriction enzyme Size of restriction fragments 
pmFP-eGFP  ApaI and KpnI 3,079bp and 1,248bp 
p7.5-eGFP NcoI and KpnI 3,195bp and 1,192bp 
pS-eGFP XhoI and BamHI 2,742bp and 1,693bp 
pBLV-Gag-eGFP   NcoI 4,368bp and 1,307bp 
pmH5-eGFP NcoI and SalI 3,599bp and 773bp 
 
Restriction endonuclease digestion of plasmids pmFP-eGFP, p7.5-eGFP, pS-eGFP, pBLV-
Gag-eGFP and pmH5-eGFP yielded DNA fragments of the correct sizes (Figure 3.6 A-E). 
Amplification of a 525bp fragment using LEO fwd 4 and eGFP rev 5 primers from the pLEO-
eGFP plasmid and not from the pBLV-Gag-eGFP intermediate plasmid or the pmH5-eGFP 
plasmid (which were included as negative controls) provided preliminary confirmation that the 
correct pLEO-eGFP plasmid was constructed (Figure 3.6 F).  
The integrity of all plasmids was also confirmed by Sanger sequencing using M13F and M13R 
universal primers (Table 3.1). 
 
3.3.2. Analysis of transient eGFP expression in BHK-21 cells infected with LSDV and 
transfected with the different reporter plasmids 
To confirm that all five poxvirus promoters were active in LSDV, BHK-21 cells were infected 
with nLDSVSODis-UCT (LSDV) and transfected with each of the reporter plasmids, and 
expression of the eGFP was monitored using an epifluorescent inverted microscope. All five 
poxvirus promoters appeared to be functional in LSDV-infected cells as eGFP expression was 
consistently detectable throughout the 72-hour study period (Figure 3.8 to Figure 3.11). 
No eGFP expression was detected from any of the experimental controls over the 72-hour 
study period (Figure 3.7). The BHK cells that were not infected and transfected remained 





Figure 3.6: Preliminary confirmation of the integrity of the five poxvirus reporter plasmids. Plasmids (A) pmFP-eGFP, (B) p7.5-eGFP, (C) pS-eGFP, (D) pBLV-Gag-
eGFP and (E) pmH5-eGFP were digested with restriction endonucleases (lane 1) or without restriction endonucleases (lane 2) and analysed by 0.8% agarose gel 
electrophoresis with ethidium-bromide staining (0.5μg/ml). M, 1kb DNA ladder (Thermo Scientific, USA). A 525bp fragment was amplified from (F) pLEO-eGFP plasmid using 
LEO fwd 4 and eGFP rev 5 primers. 1, PCR control without template DNA; 2, pLEO-eGFP plasmid DNA as a template; 3, pBLV-Gag-eGFP plasmid DNA as a template; 4, 
pmH5-eGFP plasmid DNA as a template. Restriction sites are shown on the plasmid maps with their nucleotide positions shown in brackets. Binding sites of LEO fwd 4 and 
eGFP rev 5 primer (yellow arrows) are indicated on the pLEO-eGFP plasmid map. Black arrowheads in the images of agarose gels indicate the sizes of DNA fragments 
digested with restriction endonucleases. 
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The BHK cells that were infected with LSDV at an MOI of 0.5 were heavily infected and 
numerous cells were rounded up at 72 hours post-infection/transfection. At 72 hours post-
transfection, the BHK cells in all transfection control wells were sparser and less viable than 
the infection control and uninfected cells due to the toxicity of a transfection reagent to the 
cells.  
The eGFP expression from the LSDV-infected cells that were transfected with each of the five 
poxvirus promoter plasmids was first monitored at 3 hours post-infection/transfection and no 
eGFP was detectable from any of the reporter plasmids. However, at 6 hours post-
infection/transfection, weak eGFP expression was detected from some cells transfected with 
the pmH5-eGFP reporter plasmid (Figure 3.8).  
At 9 hours post-infection/transfection, slightly more cells transfected with the pmH5-eGFP 
plasmid showed eGFP expression but no eGFP expression was detected from the other four 
reporter plasmids (data not shown).  
At 24 hours post-infection/transfection, eGFP expression was also detected from the other 
four poxvirus promoter plasmids (Figure 3.9) but their eGFP expression was still weaker than 
the eGFP expression driven by the pmH5-eGFP reporter plasmid. Despite the weaker eGFP 
expression from the other four reporter plasmids, most cells were transfected and expressing 
eGFP.  Interestingly, although eGFP expression from the p7.5-eGFP reporter plasmid was 
also only first detectable at 24 hours post-infection/transfection, its eGFP expression appeared 
stronger than the pS-eGFP, pLEO-eGFP and pmFP-eGFP reporter plasmids. Furthermore, 
eGFP expression from the mFP-eGFP reporter plasmid appeared much weaker than the other 
four reporter plasmids.   
At 48 hours post-infection/transfection, strong eGFP expression was observed from the pS-
eGFP, pLEO-eGFP and p7.5-eGFP reporter plasmids (Figure 3.10) and almost all cells 
appeared to be expressing eGFP in all experimental wells. In particular, a large amount of the 
eGFP product appeared to be accumulating in the LSDV-infected cells that were transfected 
with the p7.5-eGFP and pmH5-eGFP reporter plasmids, resulting in brighter eGFP expression 
than other reporter plasmids. In contrast, eGFP expression from the pmFP-eGFP reporter 
plasmid remained low even at 48 hours post-infection/transfection.   
At 72 hours post-infection/transfection, more eGFP appeared to be accumulating in all 
experimental wells but eGFP expression from the pmFP-eGFP reporter plasmid was still much 
lower than the other four reporter plasmids (Figure 3.11). Nonetheless, stable eGFP 






Figure 3.7: Fluorescent images of the experimental, infection and transfection controls. Cells only: Baby 
hamster kidney (BHK-21) cells were not infected or transfected; Infection only: BHK-21 cells were infected with 
LSDV at an MOI of 0.5; Transfection only: BHK-21 cells were transfected with 2µg of pS-eGFP, pLEO-eGFP, 
pmFP-eGFP, p7.5-eGFP or pmH5-eGFP plasmid DNA. All images were taken at 6 hours post-






Figure 3.8: Transient eGFP expression in BHK-21 cells infected with LSDV and transfected with a 
reporter plasmid at 6 hours post-infection/transfection. Baby hamster kidney (BHK-21) cells (2.0x105 cells 
per well) were infected with LSDV at an MOI of 0.5 and transfected with 2µg of pS-eGFP, pLEO-eGFP, pmFP-
eGFP, p7.5-eGFP or pmH5-eGFP plasmid DNA. All images were taken at 6 hours post-infection/transfection 





Figure 3.9: Transient eGFP expression in BHK-21 cells infected with LSDV and transfected with a 
reporter plasmid at 24 hours post-infection/transfection.  Baby hamster kidney (BHK-21) cells (2.0x105 cells 
per well) were infected with LSDV at an MOI of 0.5 and transfected with 2µg of pS-eGFP, pLEO-eGFP, pmFP-
eGFP, p7.5-eGFP or pmH5-eGFP plasmid DNA. All images were taken at 24 hours post-infection/transfection 





Figure 3.10: Transient eGFP expression in BHK-21 cells infected with LSDV and transfected with a 
reporter plasmid at 48 hours post-infection/transfection. Baby hamster kidney (BHK-21) cells (1.0x105 cells 
per well) were infected with LSDV at an MOI of 0.5 and transfected with 2µg of pS-eGFP, pLEO-eGFP, pmFP-
eGFP, p7.5-eGFP or pmH5-eGFP plasmid DNA. All images were taken at 48 hours post-infection/transfection 





Figure 3.11: Transient eGFP expression in BHK-21 cells infected with LSDV and transfected with a 
reporter plasmid at 72 hours post-infection/transfection. Baby hamster kidney (BHK-21) cells (1.0x105 cells 
per well) were infected with LSDV at an MOI of 0.5 and transfected with 2µg of pS-eGFP, pLEO-eGFP, pmFP-
eGFP, p7.5-eGFP or pmH5-eGFP plasmid DNA. All images were taken at 72 hours post-infection/transfection 
using a Zeiss Axiovert 200M fluorescence inverted microscope at 100x magnification. 
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3.4. DISCUSSION  
In this study, the activity of five poxvirus promoters (mFP, pS, LEO, p7.5 and mH5 promoters) 
was examined by the detection of the transient eGFP expression driven by each of the five 
poxvirus promoters to assess whether the five selected poxvirus promoters were functional in 
the LSDV-infected cells. We demonstrated that all poxvirus promoters tested in this study were 
functional in the LSDV-infected cells.   
The five poxvirus promoters selected in this study all contained an early promoter element and 
four of the promoters also contained a late promoter element (pS, LEO, p7.5 and mH5). As 
early promoter expression is considered to occur immediately following infection and prior to 
DNA replication, eGFP expression was monitored first at 3 hours and at 6 hours post-
infection/transfection as poxviral DNA replication communes within 2 hours post-infection and 
terminates at approximately 8 hours post-infection [428, 437]. At 3 hours post-
infection/transfection, no eGFP was detected from any of the five reporter plasmids. At 6 hours 
post-infection/transfection, low levels of eGFP expression were detected from the pmH5-
eGFP reporter plasmid and at 9 hours post-infection/transfection, eGFP expression was still 
undetectable from the four remaining reporter plasmids. It should be noted that the monitoring 
of the activity of the poxvirus promoters relied solely on the visible detection of eGFP and the 
detection of eGFP is only possible when the amount of the eGFP produced reaches a 
detectable level. Therefore, the absence of the eGFP expression from all reporter plasmids at 
3 hours post-infection/transfection and from the pmFP-eGFP, pS-eGFP, pLEO-eGFP and 
p7.5-eGFP reporter plasmids at 6 hours does not necessarily indicate that all promoters 
commenced transcription later than 3 hours post-infection/transfection. It could be simply 
because the amount of the eGFP was below the detectable levels using fluorescent 
microscopy.  
By 24 hours post-infection/transfection, eGFP was detected from the other four promoters and 
most cells were fluorescing in all experimental wells. At 48 hours post-infection/transfection, 
almost all cells were fluorescing in all experimental wells and eGFP expression from all 
reporter plasmids except for the pmFP-eGFP reporter plasmid appeared brighter than the 
eGFP observed at 24 hours post-infection/transfection. At 72 hours post-infection/transfection, 
a further increase in the eGFP intensity was observed in the infected/transfected cells, except 
for cells transfected with the pmFP-eGFP reporter plasmid, whose eGFP expression remained 
weak at 72 hours post-infection/transfection. Since almost all cells were transfected and 
fluorescing, this weak eGFP expression is likely due to the weak activity of the mFP promoter. 
These results together demonstrated that five poxvirus promoters were able to drive the stable 
expression of eGFP during the study period.  
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A previous study conducted by Baur et al. [429] with MVA demonstrated that similar to the 
earlier expression of the mH5 promoter observed in our study, their strong hybrid early-late 
promoter (pHyb) showed detectable eGFP expression as early as 30 minutes post-
infection/transfection whereas mean fluorescence intensity of eGFP driven by p7.5 and pS 
promoters only reached an equivalent expression level at 6 hours post-infection. Furthermore, 
they observed slightly earlier eGFP expression driven by the p7.5 promoter than the pS 
promoter [429]. However, these expression levels were not significantly different.  
The modified early fowlpox (mFP) promoter was designed from the native early-late fowlpox 
promoter [439] at our laboratory to retain the early promoter element by replacing the late 
promoter element with the poxvirus terminator sequence [438]. The mFP promoter was 
previously utilised in our recombinant LSDV vaccine to drive the expression of the Rift Valley 
fever virus (RVFV) nucleocapsid (NC) gene [438]. The expression of the NC protein from this 
recombinant LSDV was confirmed by Western blotting and immunofluorescence assay [438]. 
In our study, eGFP expression driven by the mFP promoter appeared to be lower than the 
other four promoters even at 72 hours post-infection/transfection. It should be noted that there 
was no internal control to determine if the lower expression level was due to low transfection 
efficiency. However, it is possible that the removal of the late promoter element had an impact 
on the overall promoter activity, thereby leading to lower eGFP expression. A previous study 
demonstrated that a substitution of a G residue to an A, C or T residue in the late promoter 
initiation sequence (TAAATG) resulted in a significant decrease in promoter activity with 
approximately 80-90% reduction of the reporter gene expression [446]. Since the late 
promoter initiation sequence is absent in the mFP promoter, this could explain the low eGFP 
expression observed in our study. It is also possible that since the mFP promoter has early 
promoter activity only, the eGFP production terminates after DNA replication, i.e., ~8 hours 
post-infection, which may lead to a smaller amount of eGFP production compared to the other 
four promoters. The other four poxvirus promoters contain a late promoter element, and this 
may drive sustained transcription after DNA replication. It should be noted that strong 
promoters are not necessarily advantageous. Wyatt et al. [440] observed that irrespective of 
types of recombinant viruses, cell lines, the number of transgenes and insertion sites, the use 
of the pS promoter in recombinant vaccinia viruses to express parainfluenza virus type 3 
antigen(s) resulted in the inhibition of replication of the recombinant vaccinia viruses with titres 
ranging from 6x100 to 6x104 pfu/ml after four or five passages. Whereas recombinants 
constructed using the same VACV vector expressing the same transgenes inserted at the 
same locus but under the control of the p7.5 promoter replicated to higher titres and were 
immunogenic in vaccinated animals [447]. They reasoned that the overexpression of the 
transgene(s) by the pS promoter was too toxic for the recombinant vaccinia viruses to 
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propagate efficiently [440]. Therefore, the possibly weaker mFP promoter might be useful to 
drive expression of genes that could be toxic.  
It may be possible to enhance early promoter activity of the mFP promoter to an appropriate 
level by introducing tandem repeats of an early promoter sequence [429, 448, 449]. However, 
caution must be taken as tandem repeats are prone to induce mutations and inter- and 
intramolecular homologous recombination [450-452]. In addition, a previous study [453] 
showed that the overexpression of a transgene driven by a strong promoter harbouring 
tandem repeats of the early element of the p7.5 promoter in the replication-competent vaccinia 
virus LC16m8Δ resulted in the increased neurovirulence of the vaccinia virus. Apart from the 
modification and optimisation of the promoter sequence itself, it has been reported that a 
spacer length between a promoter and a gene of interest could enhance antigen expression 
and immunogenicity [437, 448].  
The synthetic early-late optimised promoter (LEO) of VACV is a new synthetic vaccinia virus 
promoter designed by Pilato et at. [436, 437] to improve early gene expression and antigen-
specific T cell responses by using a late promoter element of the pS promoter and an early 
promoter consensus sequence identified from the alignment of 45 genes belonging to the 
immediate-early and E1.1 classes. To characterise the LEO promoter activity, they 
constructed recombinant MVA containing the eGFP or a Leishmania LACK protein under the 
control of LEO, pS or mH5 promoters [436, 437]. They demonstrated that in vitro and in vivo 
expression of the eGFP and the LACK protein driven by the LEO promoter was higher at 4 
hours post-infection than the expression driven by the pS and mH5 promoters, which 
correlated to the enhanced expression of antigen-specific multifunctional memory CD4+ and 
CD8+ T cells [436, 437]. Our results demonstrated that the LEO promoter was functional in 
the LSDV-infected cells and indicate that the LEO promoter will be functional in recombinant 
LSDV.  
In the present study, to remove possible confounding factors, monitoring of the promoter 
activity was conducted under the same molecular, biological and technical contexts where 
possible. Firstly, the five reporter plasmids were constructed to have a similar size (4,327bp -
4,435bp) and the same plasmid backbone. All reporter plasmids also contained the same egfp 
gene optimised for bovine cells. Secondly, to equalise the amount of plasmid DNA used for 
the transfection, the concentrations of the five plasmid DNA were more accurately estimated 
based on the absolute density of the plasmid DNA resolved on an agarose gel, which enables 
the separation of the plasmid DNA and RNA contained in each sample. Thirdly, the same 
recombinant LSDV at the same MOI was used to infect the same batch of BHK-21 cells at a 
concentration of 1.0x105 cells/ml. Fourthly, to detect expression of the eGFP driven by each 
of the reporter plasmids, the same area of the cells was monitored during the 72-hour study 
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and all fluorescence images were taken by normalising the exposure time based on the 
exposure time used to take images of the cells transfected with the p7.5-eGFP reporter 
plasmid. This allowed us to monitor the activity of the five poxvirus promoters under as similar 
contexts as possible. However, the use of plasmid DNA and a virus in this reporter system 
essentially introduces experimental variables both from the plasmid and the virus.  
It should be noted that the results of this experiment are qualitative and not quantitative. The 
aim was to determine whether the promoters would be recognised by LSDV or not. Promoter 
activity was not quantified. In order to quantitate expression, one would require an internal 
transfection control. The use of an internal control would allow for measuring of timing and 
strength of the five poxvirus promoters relative to this internal control. In addition, transfection 
efficiency, which is another experimental variable, was not evaluated in this study. In our study, 
no comparison of the strength of promoter activities was made to avoid misinterpretation.   
Another possible limitation in this study is the use of eGFP as a reporter gene. The use of 
fluorescent proteins (FPs) in reporter gene systems is a well-established method and myriads 
of mutant FPs with improved photochemical properties have been engineered, allowing them 
for multiple labelling and wide use in various applications. As opposed to enzyme-based 
assays, the use of FPs allows direct monitoring of live cells noninvasively (i.e., no fixation, 
permeabilization and lysis of cells) without the need for cofactors and substrates. However, it 
is important to take into account their limitations. It is also important to understand biochemical 
properties of FP to make correct interpretations of experimental results.  
eGFP is one of the mutant variants and was engineered from the wild-type Aequorea GFP by 
introducing two point mutations (S65T and F64L) [454]. The resultant eGFP is well recognised 
for its increased brightness [454], which is one of the reasons for its popularity amongst 
researchers. In addition, eGFP is superior to the wild-type Aequorea eGFP due to its 
thermostability [455] and pH resistance [456]. eGFP also exhibits faster maturation time, 
improved sensitivity of detection and slower photobleaching rates [456-458].  Since eGFP is 
more tolerant of photobleaching, this feature is useful for time-lapse imaging [459]. Yet, 
consideration should also be given to the fact that intensive illumination can result in cell 
damage and cell death [460]. 
Since one eGFP molecule emits one photon, the signal cannot be amplified. This means that 
detection of eGFP expression largely relies on the amount of eGFP produced above threshold 
levels. Approximately 104 to 106 eGFP molecules per cell are generally required for detection 
[456]. To achieve these copy numbers, one of the simplest ways is the use of strong or 
constitutive promoters or transcription regulators. In addition to the threshold, eGFP intensity 
should exceed that of cellular autofluorescence [461].  
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The use of the FPs is useful for an “all-or-none” type of reporter assays, which was utilised in 
our study. There are several methods to estimate the strength and timing of the promoter 
activity. For example, the number of eGFP positive cells and fluorescence intensity of the 
eGFP positive cells could be measured using flow cytometry [429, 436, 437] at various time 
points up to 8 hours post-infection to monitor the activity of the early promoters. Alternatively, 
a luciferase assay [462] or quantification of the eGFP mRNA by real-time PCR [437] would be 
more sensitive. There are some advantages to the use of luciferase as a reporter over FPs. 
FPs are stable proteins and thus, tend to accumulate in cells [455] whereas the low stability 
of luciferases [463] means less accumulation in cells and so small changes in expression 
levels are more easily detected. In addition, only viable cells expressing luciferase can be 
bioluminescent and dead cells do not contribute any signal. This is due to the inherent 
properties of the enzymatic reaction where luciferases require cellular ATP from viable cells 
[464, 465]. Luciferase assays are free from autofluorescence and provide a better signal to 
noise ratio [466]. Lastly, posttranslational modifications (i.e., protein maturation) and 
photobleaching are absent in luciferase assays [464]. These features also enable 
instantaneous measurement of gene expression as well as detection of a wide range of 
expression levels.  
In conclusion, stable and sustained activity of the five selected poxvirus promoters that contain 
early and late promoter elements were confirmed in the LSDV-infected cells under the 
transient expression system. Our results indicate that the five poxvirus promoters will be 
functional to drive the expression of transgenes in recombinant LSDV. Further study will be 
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Poxviruses are one of the most well-studied and extensively-utilised viruses in the history of 
vaccination: from the classical use of cowpox virus by Benjamin Jesty and Edward Jenner to 
protect from smallpox in the 18th century [467, 468] to the use of vaccinia virus to eradicate 
smallpox in the 20th century and to the current use of recombinant poxviruses in various 
vaccines against animal and human diseases [402-406, 408-410, 469]. Poxviruses harbour a 
large genome, up to 370kb [470], and replicate in the cytoplasm of the host cell [471], enabling 
them to accommodate large transgene(s) [472, 473] without an issue of integration of 
transgenes into the host genome. The poxvirus genome contains numerous non-essential 
genes for its replication [474-476] as well as regions which have acquired deletions which 
resulted from successive and intensive passages [477-479]. These regions of the genome 
have been traditionally utilised as sites for transgenes in expression systems. Intergenic 
regions have also been recently utilised as insertion sites [480, 481]. Furthermore, it is 
possible to insert multiple transgenes at a single insertion site [29, 30, 482] or multiple insertion 
sites [479, 483, 484]. Most poxviruses have a similar genomic arrangement [485] and share 
the same transcriptional pathways [418]. Previous studies have shown that transcription 
factors and promoter functions are conserved across the Poxviridae family [486, 487]. These 
features make recombinant poxviruses useful as an expression vector as heterologous 
poxvirus promoters can be used in a recombinant poxvirus, and several different poxvirus 
promoters can be incorporated into a single recombinant poxvirus vector. It is also possible to 
fine-tune the timing and strength of transgene expression by placing these genes under the 
control of different poxvirus promoters [419, 426, 440, 488]. Host tropism of poxviruses is 
another useful feature that can be utilised in generating safe poxvirus-vectored vaccines. 
Poxvirus host tropism [416] is unique in that unlike other families of viruses, poxvirus host 
range is not determined by their binding to host cell receptors but regulated by host range 
genes [489, 490] and immunomodulatory genes [491]. For example, a poxvirus with a specific 
host range can infect and express its genes in restrictive cells but the replication is abortive at 
a later stage of the replication cycle (i.e., after protein synthesis) [492]. Therefore, the spill-
over of host-restricted vaccine viruses to non-host animals is unlikely. Lastly, genetic 
engineering of recombinant poxviruses has enabled the generation of further versatile 
poxvirus vectors such as attenuated recombinant viruses [493-501], inducible recombinant 
vaccinia virus expression system [502, 503] and modified recombinant poxvirus vectors that 
contain genetic adjuvant(s) to enhance immunogenicity [504-506].  
As homologous recombination (HR) naturally occurs between replicating poxviruses during 
viral replication, one of the conventional methods to generate recombinant poxviruses utilises 
this process to insert transgene(s) into the poxvirus genome [507-511] at a specific site (Figure 
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4.1). In this method, a transfer vector is designed to contain transgene(s) under the control of 
poxvirus promoter(s), homologous sequences to the poxvirus genome at the site of insertion 
(left and right flanks) and marker and/or selectable genes. Nowadays, genes expressing 
fluorescent proteins are frequently utilised as marker genes to identify recombinant viruses. 
Transgenes are placed between the left and right flanks so that these flanks guide the 
exchange of genomic sequences between the poxvirus genome and the flanking regions of 
the transfer vector through HR. This results in the site-directed insertion of the transgene(s) 




Figure 4.1: Schematic diagram of the generation of a recombinant poxvirus by homologous 
recombination. The diagram describes a method to generate a recombinant virus from parental virus and a 
transfer vector containing two antigen genes (purple arrows), an egfp gene as a marker gene (green arrow) as 
well as left and right flanks (49 and 50 flanks, respectively; blue arrows). 49, left flank of the transfer vector, 
±300bp of the 3’ end of 049 ORF of the LSDV genome; 50, right flank of the transfer vector, ±300bp of the 3’ 
end of 050 ORF of the LSDV genome; egfp, green-fluorescent protein gene.  
 
The overall aim of this chapter was to construct and characterise a recombinant LSDV 
expressing BLV Env and Gag and another recombinant LSDV expressing BLV Env alone 
(collectively, recombinant LSDVs). BLV env gene was selected as an antigen based on 
previous studies that showed induction of humoral and cellular responses from recombinant 
vaccinia virus containing BLV env gene [90-95, 97, 326, 327]. BLV gag gene was selected as 
a second antigen as BLV Gag forms virus-like particles (VLPs) [264, 512-514], which are 
immunogenic  [274, 277-279] and could serve as a platform to present the BLV Env proteins 




The objectives included: 
• to select BLV Env and Gag sequences for the BLV expression cassette based on the 
sequence alignment of BLV natural isolates.  
• to determine whether the human tissue plasminogen activator (tPA) signal sequence 
is functional in bovine cells. 
• to design and construct BLV transfer vectors to generate the recombinant LSDVs. 
• to confirm the presence of BLV env and gag genes in the recombinant LSDVs by PCR 
and to confirm the integrity of these genes by sequencing.  
• to confirm expression of BLV Env protein by immunofluorescence and BLV Gag protein 
by Western blotting.    
 
4.2 MATERIALS AND METHODS 
 
4.2.1. Design of the BLV transfer vectors 
4.2.1.1. Selection of a BLV natural isolate to design the BLV env and gag sequences of 
the BLV expression cassette 
To design antigen sequences for the BLV expression cassette in the pBLV-Env-Gag and 
pBLV-Env transfer vectors (collectively BLV transfer vectors), full-length env and gag 
nucleotide sequences of a natural BLV isolate were selected as follows. Firstly, BLV complete 
genomic sequences from BLV natural isolates representing six genotypes were obtained from 
the GenBank nucleotide sequence database (Table S4.1). BLV complete genomic sequences 
with unknown genotype were also included to add sequence variations. The nucleotide 
sequences were then, translated into amino acid sequences using CLC Main Workbench 
(QIAGEN Bioinformatics, Denmark). These nucleotide and amino acid sequences were 
aligned to obtain consensus Env and Gag (Cons-Env and Cons-Gag, respectively) nucleotide 
and amino acid sequences, respectively, (Table S4.2 and Table S4.3). Then, nucleotide and 
amino acid sequences of the Cons-Env and Cons-Gag were aligned to those of BLV natural 
isolates available in the Basic Local Alignment Search Tool (BLAST) database [374]. Full-
length Env and Gag nucleotide and amino acid sequences of candidate natural isolates were 
selected using 90% nucleotide and amino acid sequence identity as a cut-off and excluding 
isolates whose partial Env and Gag nucleotide and amino acid sequences had high identity 
with those of the Cons-Env and Cons-Gag. Env and Gag amino acid sequences of candidate 
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natural isolates were aligned back to the Cons-Env and Cons-Gag amino acid sequences 
using pair-wise alignment of EMBOSS Needle protein [515] for final confirmation.  
 
4.2.1.2. Assessment of functionality of the signal sequence of the human tissue 
plasminogen activator gene (tPA) in a bovine cell line  
To assess whether the signal sequence of the BLV env gene in the BLV transfer vectors could 
be replaced with the signal sequence of the human tPA, amino acid sequences of the signal 
sequences of the human and bovine tPA were compared.  
 
4.2.1.2.1. Amino acid sequence comparison of the signal sequences of the human and 
bovine tPA  
Amino acid sequences of the signal sequences of the human and bovine tPA were obtained 
from the UniProtKB database and the comparison of their amino acid sequences was 
performed using pair-wise alignment of EMBOSS Needle protein [515]. EBLOSUM62 with 
10,0 value as gap penalty and 0.5 value as extend penalty were used.  
 
4.2.1.2.2. Assessment of the in vitro activity of the human tPA by Western blotting 
4.2.1.2.2.1. Source of an adherent cell line 
A Madin-Darby bovine kidney (MDBK) adherent cell line (CCL-22) was obtained from the 
American Type Culture Collection (ATCC).  
For the detailed methods of recovery of cell lines from deep-frozen stocks, maintenance of 
cell lines and cell counting, see Section 3.2.4.  
 
4.2.1.2.2.2. Source of a virus 
Recombinant modified vaccinia virus Ankara (MVA) containing HIV-1 type C env and gag 
genes (MVA-GC5SS) was obtained from Shireen Galant (a member of our research group). 





4.2.1.2.2.3. Crude extraction of total proteins from MDBK cells infected with MVA-
GC5SS  
One millilitre of MDBK cells at a concentration of 2.0x105 cells/ml were infected with MVA-
GC5SS at a multiplicity of infection (MOI) of 1, 2 or 5 in 12-well tissue culture plates and the 
plates were incubated under standard growth conditions (37°C, 70% relative humidity and 5% 
CO2) for 3 days with daily monitoring of the infected cells using an epifluorescent inverted 
microscope (Zeiss, Germany). At 72 hours post-infection, crude extraction of total proteins 
from the MVA-GC5SS infected cells was conducted as outlined in Appendix B2.1. The total 
proteins contained in the culture media and cell lysate were resolved by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and the resolved proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes as described in Appendix B2.2 
and B2.3, respectively. Subsequently, HIV-1 Env glycoprotein was detected with a goat anti-
HIV-1 Env polyclonal antibody (BioRad, USA) at a dilution of 1:1,000 followed by an anti-
goat/sheep IgG monoclonal antibody conjugated with alkaline phosphatase (Sigma-Aldrich, 
USA) at a dilution of 1:10,000 as outlined in Appendix B2.3.  
 
4.2.2. Construction of the BLV transfer vectors 
4.2.2.1. Insertion site, maker gene and promoters 
An insertion site of the BLV expression cassette in the LSDV was determined based on the 
following criteria. Firstly, an insertion site should be genetically stable such that BLV env and 
gag genes and egfp gene would not be deleted and/or mutated. Secondly, an insertion site 
was selected so as not to disturb promoter regions and expression of adjacent genes.  
Homologous sequences to the LSDV genome at the site of insertion (left and right flanks or 
flanking sequences) were included at the 5’ and 3’ ends of the BLV expression cassette to 
facilitate HR and correct insertion of the BLV expression cassette at a given viral genome.  
An egfp gene was selected as a marker gene and obtained from Ruzaiq Omar’s 
pBEFV_K1L_eGFP transfer vector. 
Three heterologous poxvirus promoters were selected to control the expression of the BLV 
env, gag and egfp genes.  
 
4.2.2.2. Modification and optimisation of the sequences of the BLV expression cassette 
Two modifications were made in the BLV env gene of a BLV natural isolate obtained in Section 
4.2.1.1. The signal sequence of the BLV env gene (see Section 4.2.1.2) was replaced with the 
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signal sequence of the human tPA and the subtilisin/kesin-like convertase cleavage sequence 
(RVRR) located between BLV Env gp51 and gp30 sequences was replaced with a flexible 
linker (GGGGS)2. 
Another modification was the introduction of Mfel and EcoRI restriction sites to allow the 
removal of the BLV gag gene from the BLV expression cassette (see Section 4.2.2.5).  
Lastly, the env and gag nucleotide sequences of the BLV natural isolate selected in Section 
4.2.1.1 were codon-optimised for the use in cattle prior to their inclusion into the pBLV-Env-
Gag transfer vector. 
 
4.2.2.3. Preparation of the pBLV-Env-Gag transfer vector plasmid DNA 
The pBLV-Env-Gag transfer vector was manufactured by GenScript and received as 
lyophilised plasmid DNA. The lyophilised pBLV-Env-Gag plasmid DNA was suspended in 20µl 
of high-performance liquid chromatography (HPLC) grade water (Merck, USA) and the 
solution was heated in a heating block at 50°C for 15 minutes to completely dissolve the 
plasmid DNA. The plasmid DNA concentration was adjusted to 2ng/µl using HPLC grade water 
prior to the transformation of chemically competent E. coli cells.  One microliter of the plasmid 
DNA (2ng) was used for the transformation of E. cloni 10G chemically competent cells 
(Lucigen, USA). See Appendix B1.4 for the detailed method of transformation. Expression 
mixes from the transformation were plated on LB agar (Appendix A) containing 50µg/ml 
carbenicillin (Thermo Fisher Scientific, USA) and incubated at 37°C overnight. Two single 
bacterial colonies were picked from the LB-agar plates for medium-scale plasmid DNA 
isolation, which was conducted using ZymoPURE II Plasmid Midiprep Kit (Zymo Research, 
USA) as per the manufacturer’s instructions. Concentration and purity of the extracted 
plasmids were measured using Nanodrop®1000 (Thermo Fisher Scientific, USA). The 
extracted plasmids were stored at -20°C until needed.  
 
4.2.2.4. Confirmation of the integrity of the pBLV-Env-Gag transfer vector  
Restriction endonuclease mapping was used to make a preliminary confirmation of the 
integrity of the pBLV-Env-Gag transfer vector plasmid. Approximately, 280ng to 355ng of the 
pBLV-Env-Gag plasmids were digested with restriction endonuclease FastDigest NcoI 
(Thermo Fisher Scientific, USA) as described in Appendix B1.1 and subject to ethidium-
bromide (0.5μg/ml) stained 0.8% agarose gel electrophoresis in 1xTBE at 100V for 1 hour. 
Final confirmation was made by Sanger sequencing using sequencing primers outlined in 
Table 4.1 (also see Table S4.4 and Figure S4.1). 
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Table 4.1: Primers used to sequence the pBLV-Env-Gag plasmid vector 
Primer Orientation Primer sequence Binding site 
M13F Forward 5’- GTTTTCCCAGTCACGAC - 3’ Lac Z  
49 fwd Forward 5’- TGGAAACGATGCATGTGCG - 3’ 49 flank 
Env fwd 6 Forward 5’- TCCTTTAATACCACACAG - 3’ Env gp51  
Env fwd 7 Forward 5’- CCTGGAATTGGGATCTGG - 3’ Env gp30 
Gag fwd 1 Forward 5’- GACTTCACCGATCTGAAG - 3’ Gag 
eGFP rev 5 Reverse 5’- GCGGATCTTGAAGTTCAC - 3’ eGFP  
M13R Reverse 5’- CAGGAAACAGCTATGAC - 3’ Lac Z 
 
4.2.2.5. Construction of the pBVL-Env transfer vector  
To construct the pBLV-Env transfer vector, the pBLV-Env-Gag transfer vector plasmid was 
enzymatically manipulated to remove the mH5 promoter and BLV gag gene. One microgram 
of the pBLV-Env-Gag plasmid was digested with restriction endonucleases Mfel and EcoRI 
(New England Biolab, USA) as described in Appendix B1.1 and a 5,995bp fragment containing 
the vector backbone, the 49 flank, mFP promoter, BLV env, p7.5 promoter, eGFP gene and 
50 flank was gel purified using the Zymoclean Gel DNA Recovery Kit (Zymo Research, USA) 
as per the manufacturer’s protocol. Self-circularisation of the linearised DNA was performed 
using two ligation reaction mixtures (both in 20µl). The first reaction mixture contained 1µl 
(approx. 871.5ng) of the linearised plasmid DNA, 1µl of Quick T4 DNA Ligase (New England 
BioLabs, USA), 2µl of 10x T4 Ligase Reaction Buffer (New England BioLabs, USA) and HPLC 
water as per the manufacturer’s recommendation. The second reaction mixture contained 5µl 
(approx. 4.35µg) of the linearised plasmid DNA (five times more plasmid DNA than the 
manufacturer’s recommendation), 1µl of T4 DNA Ligase (New England BioLabs, USA), 2µl of 
10x T4 Ligase Reaction Buffer (New England BioLabs, USA) and HPLC water. A reaction 
mixture without T4 DNA Ligase was included as a negative control. The reaction mixtures 
were then incubated at room temperature (20°C to 25°C) as described in Appendix B1.3. 
Aliquots of 1.5µl of the ligation mixtures were used for the transformation of E.cloni 10G 
chemically competent cells (Lucigen, USA) (Appendix B1.4). Expression mixtures from the 
transformation were plated on LB agar (Appendix A) containing 100μg/ml ampicillin (VWR Life 
Science, USA) and incubated at 37°C overnight. Sixteen single colonies were picked from the 
plates for small scale plasmid DNA isolation (Appendix B1.5). The plasmid DNA was then 
digested with restriction endonucleases FastDigest HindIII and FastDigest SalI (Thermo 
Fisher Scientific, USA), as described in Appendix B1.1 and subject to ethidium-bromide 
(0.5μg/ml) stained 0.8% agarose gel electrophoresis in 1xTBE at 100V for 1 hour. One millilitre 
of bacteria culture containing the correct E. coli recombinant (identified from the restriction 
endonuclease mapping) was used to prepare a 1.5ml starter culture for large scale plasmid 
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DNA isolation (see Appendix B1.6). Preliminary confirmation of the correct plasmid construct 
was made by restriction endonuclease mapping of the plasmid DNA and final confirmation by 
Sanger sequencing using M13F and M13R universal primers, 49 fwd, Env fwd 6 and Env fwd 
7 primers (Table 4.1). 
 
4.2.3. Construction of recombinant LDSV-BLV-Env-Gag and LSDV-BLV-Env  
4.2.3.1. Source of an adherent cell line 
Primary foetal bovine testes (FBT) adherent cells were used for the initial transfection of the 
transfer vectors and infection of the LSDV to generate the recombinant LSDV and Madin-
Darby bovine kidney (MDBK) adherent cells were used for further purification of the 
recombinant LSDV. 
Primary FBT adherent cells were obtained from Ruzaiq Omar (a member of our research 
group) at the University of Cape Town, who prepared the cells from foetal bovine testes that 
had been obtained from the Paarl Abattoir in Cape Town, South Africa.   
An MDBK adherent cell line (NBL-1) (CCL-22™) was obtained from the American Type 
Culture Collection (ATCC, USA).  
For the detailed methods of recovery of cell lines from deep-frozen stocks, maintenance of 
cell lines and cell counting, see Section 3.2.4. As a minor modification, the primary FBT cells 
were specifically treated with cDMEM containing a 0.1% antifungal agent (10mg/ml) 
(InvivoGen, USA) (Appendix A).  
  
4.2.3.2. Source of parental LSDV viruses  
Two recombinant Neethling lumpy skin disease virus (nLSDV) vectors generated by Henry 
Munyanduki were used in this study [441]; nLSDVSODis-M was used for the construction of 
LSDV-BLV-Env-Gag; and nLSDVSODis-UCT (see Section 3.2.3) was used for the 
construction of LSDV-BLV-Env. The nLSDVSODis-M has the same sequence as the 
nLSDVSODis-UCT except that it contains an Escherichia coli xanthine 
phosphoribosyltransferase (Ecogpt) selection gene and mCherry red fluorescent protein 




4.2.3.3. Generation of the recombinant LSDV-BLV-Env-Gag and LSDV-BLV-Env in 
primary foetal bovine testes (FBT) cells  
To generate recombinant LSDV expressing the BLV Env and Gag antigens, a 12-well tissue 
culture plate was seeded with 1ml of primary FBT cells at a concentration of 2.0x105 cells/ml 
and incubated overnight under the standard growth conditions. A 70% confluent monolayer of 
the cells was infected with the nLSDVSODis-M (1.0x106 TCID50/ml) at an MOI of 0.01 or 0.1 
and incubated for 2 hours under the standard growth conditions. Following a 2-hour incubation, 
the culture media was aspirated from wells and the cells were washed with DMEM (Thermo 
Fisher Scientific, USA). Then, the cells were transfected with a transfection mixture containing 
500µl of DMEM (Thermo Fisher Scientific, USA), 2µl of X-tremeGene (Roche, Switzerland) 
and 6µg of the pBLV-Env-Gag transfer vector plasmid DNA. One experimental control well 
(cells only) of uninfected and untransfected cells, two infection control wells (nLSDVSODis-M 
only) where cells were infected with nLSDVSODis-M at an MOI of 0.1 or 0.01, and one plasmid 
control well (pBLV-Env-Gag only) of the transfected cells only were also prepared (Figure 4.2). 
eGFP and mCherry expressions were monitored daily using an epifluorescent inverted 
microscope (Zeiss, Germany). Figure 4.3 outlines a procedure used to generate the 




Figure 4.2: Layout of a 12-well plate for the infection and transfection of primary FBT 
cells with nLSDVSODis-M and pBLV-Env-Gag transfer vector plasmid DNA to generate 
recombinant LSDV-BLV-Env-Gag. The schematic diagram shows two experimental wells and 
four control wells. In experimental wells, primary FBT cells were transfected with the pBLV-Env-
Gag transfer vector plasmid DNA and infected with the nLSDVSODis-M at an MOI of 0.1 or 
0.01. In a control well (Cells only), cells were not infected or transfected. In a transfection control 
well (pBLV-Env-Gag only), cells were only transfected with the pBLV-Env-Gag transfer vector 
plasmid. For infection controls, cells were only infected with the nLSDVSODis-M at an MOI of 
0.1 or 0.01. Wells where cells were transfected with the pBLV-Env-Gag transfer vector plasmid 
DNA are shown in blue semicircles, those infected with the nLSDVSODis-M are shown in pink 






Figure 4.3: Schematic outline of the generation of recombinant viruses in primary FBT cells. The primary 
FBT cells were infected with the parental virus and transfected with the transfer vector. Following the incubation 
of the cells at several days, recombinant viruses resulted from the HR between the transfer vector and parental 
virus are detected as green and red fluorescing cells under the microscope whereas parental viruses are 
detected as red fluorescing cells.  
 
A similar method was used to construct recombinant LSDV expressing the BLV Env antigen 
only with the following minor modifications. A 12-well tissue culture plate was seeded with 1ml 
of primary FBT cells at a concentration of 1.0x105 cells/ml and incubated overnight under 
standard growth conditions. Then, 70% confluent monolayer cells were infected with 
nLSDVSODis-UCT (1.0x107.25 TCID50/ml) at a MOI of 0.01, 0.05, 0.1 or 0.5 (Figure 4.4). 
Following a 2-hour incubation, transfection of the nLSDV-infected cells was performed using 
a transfection mixture containing 500µl of DMEM (Thermo Fisher Scientific, USA), 2µl of X-
tremeGene (Roche, Switzerland) and 6µg of the pBLV-Env transfer vector plasmid DNA as 
described above. Seven control wells were also prepared. In an experimental control well 
(cells only), cells were not infected or transfected. In four infection control wells, cells were 
only infected with nLSDVSODis-UCT at an MOI of 0.01, 0.05, 0.1 or 0.5. In two plasmid control 
wells, cells were transfected with 6µg of the pBLV-Env transfer and 2µl of X-tremeGene 
(Roche, Switzerland), or 3µg of the pBLV-Env transfer and 1µl of X-tremeGene. eGFP 







Figure 4.4: Layout of a 12-well plate for the infection and transfection of primary FBT 
cells with nLSDVSODis-UCT and pBLV-Env transfer vector plasmid DNA to generate 
recombinant LSDV-BLV-Env. The schematic diagram shows four experimental wells and 
seven control wells. In experimental wells, primary FBT cells were transfected with the pBLV-
Env transfer vector plasmid DNA and infected with the nLSDVSODis-UCT at an MOI of 0.5, 
0.1, 0.05 or 0.01. In a control well (Cells only), cells were not infected or transfected. In 
transfection control wells, cells were only transfected with 6µg or 3µg of the pBLV-Env transfer 
vector plasmid. In four infection control wells, cells were only infected with the nLSDVSODis-
UCT at an MOI of 0.5, 0.1, 0.05 or 0.01. Wells where cells were transfected with the pBLV-
Env transfer vector plasmid DNA are shown in blue semicircles, those infected with the 
nLSDVSODis-UCT are shown in pink semicircles and uninfected and/or non-transfected wells 
are shown in white semicircles. 
 
4.2.4. Purification of the recombinant LSDV-BLV-Env-Gag and LSDV-BLV-Env in MDBK 
cells 
Purification of the recombinant LSDV-BLV-Env-Gag and LSDV-BLV-Env was conducted by 
sequential passages of progeny viruses in MDBK cells. To release the virus from the cells, the 
plate containing the infected and transfected primary FBT cells were subjected to three cycles 
of freezing at - 80°C and thawing at 37°C. The crude cell lysate was then aspirated from the 
plates and transferred into 1.5ml Eppendorf tubes and either stored at -20°C until needed or 
vortexed briefly prior to the infection of MDBK cells.  
One to two hundred microliters of the cell lysates were used to infect MDBK cells at a 
concentration of 2.0x105 cells/ml in 12-well or 24-well tissue culture plates. The plates were 
incubated under standard cell growth conditions for several days to allow the virus to 
propagate. The infected MDBK cells were monitored daily using an epifluorescent inverted 
microscope (Zeiss, Germany) until mature foci were detected. 
For the next round of infection (passage 2), either cell lysates or picked green fluorescent foci 
were used. To isolate an individual focus, culture media was aspirated from wells and cells 
were washed 3 to 5 times with 500µl to 1ml of 1x PBS (Thermo Fisher Scientific, USA). Then, 
the position of the green fluorescent focus was marked underneath the plate and a P10 pipette 
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tip was used to transfer the focus into a 1.5ml Eppendorf tube containing 50µl or 100µl of 
DMEM (Thermo Fisher Scientific, USA), which was then, frozen and thawed thrice at - 80°C 
and 37°C, respectively as described above to release the virus from the cells. Prior to the 
infection of MDBK cells, viral suspensions of picked foci were vortexed and centrifuged briefly 
at 12,100g. A volume of 5µl to 50µl of the viral suspensions of picked foci or 5µl to 200µl of 
cell lysates were used to infect MDBK cells (2.0x105 cells/ml) in 12-well or 24-well tissue 
culture plates. 
Several more rounds of infection of MDBK cells with recombinant progeny viruses and 
propagation and isolation of recombinant viruses were performed using 6-well, 12-well, 24-
well or 96-well tissue culture plates with different amounts and dilutions (10-1 to 10-9 dilutions 
that varied depending on each passage and tissue culture plate used) of cell lysate or viral 
suspension of picked foci. Figure 4.5 outlines a general procedure used to passage the 




Figure 4.5: Schematic outline of the purification of recombinant viruses by serial passages 
in MDBK cells.  To purify recombinant viruses, serial passages of the progeny viruses were 
performed by infecting the MDBK cells with cell lysate or picked foci. To release the viruses and 
infect the cells with the progeny viruses, the infected cells were subjected to three cycles of freezing 




4.2.5. Characterisation of the recombinant LSDV-BLV-Env-Gag 
 
4.2.5.1. Confirmation of the presence of BLV env and gag genes by polymerase chain 
reaction (PCR) 
4.2.5.1.1. Confirmation of the presence of BLV env and gag genes in recombinant LSDV-
BLV-Env-Gag by PCR 
To determine whether the recombinant LSDV-BLV-Env-Gag contained the BLV env and gag 
genes at the correct insertion site and whether an intermediate recombinant containing the 
entire transfer vector or the final recombinant only containing the BLV env and gag genes and 
egfp gene had been obtained, PCR was performed at various passages using various sets of 
PCR primers (Table 4.2). See Appendix B3.1 for the detailed method of extraction of total DNA 
from infected MDBK cells and Appendix B3.3 for the preparation of PCR reaction mixtures. 
The presence of a final recombinant or an intermediate recombinant was assessed using 
primer sets 1 and 2 (or 2B). The primer set 1 consisted of a primer that bound upstream of the 
49 flank of the transfer vector in the 049 ORF of LSDV (57 fwd) and a BLV env-specific primer 
(gp51 rev). The primer set 2 or 2B consisted of a primer specific to egfp (eGFP fwd 2 or 3 fwd) 
and one which bound downstream of the 50 flank of the transfer vector in the 050 ORF of 
LSDV (94 rev). Primer set 3 (57 fwd and 94 rev) was used to determine the presence of the 
correct, final LSDV-BLV-Env-Gag recombinant, and to determine whether the final LSDV-
BLV-Env-Gag stock contained the parental virus.  
To determine whether the final stock of the LSDV-BLV-Env-Gag contained an intermediate 
recombinant virus containing the entire transfer vector, two sets of primers were used. A 
primer set 4 was used to determine whether the viral stock contained an intermediate LSDV-
BLV-Env-Gag whereby recombination had only occurred in the 049 ORF. Primer set 5 was 
utilised to determine the presence or absence of an intermediate recombinant virus whereby 
recombination had only occurred in the 050 ORF. 
 
4.2.5.2. Confirmation of the BLV Env and Gag protein expression by Western blotting 
To confirm the expression of the BLV Env and Gag proteins, Western blotting was performed. 
Total crude proteins were extracted from MDBK cells infected with 100μl of a viral stock of the 
recombinant LSDV-BLV-Env-Gag at 72 hours post-infection. At 24 hours, 48 hours and 72 
hours post-infection, 500 μl of the culture media were transferred into 1.5ml Eppendorf tubes, 
and crude cell lysates were extracted as outlined in Appendix B2.1. Total proteins in the culture 
media and cell lysates were resolved by SDS-PAGE as described in Appendix B2.2 and 
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Western blotting was performed as outlined in Appendix B2.3, using mouse anti-BLV Env 
gp51 monoclonal antibody (Veterinary Medical Research and Development, USA) at a dilution 
of 1:5,000 and anti-BLV Gag p24 monoclonal antibody (Veterinary Medical Research and 
Development, USA) at a dilution of 1:5,000. Goat anti-mouse IgG H and L polyclonal antibody 
conjugated with alkaline phosphatase (Abcam, UK) at a dilution of 1:10,000 was used for the 
detection of BLV Env protein and the same secondary antibody at a dilution of 1:5,000 was 
used to detect BLV Gag. 
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Table 4.2: Primer sets used to confirm the presence of the recombinant LSDV-BLV-Env-Gag  
Set Primera Primer sequence Binding site PCR thermocycling conditionb Passage 
number  
Detection of target virus 
and product size 
1 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 
30 x {94°C (30 sec), 55°C (30 sec), 
68°C (1 min)}, 68°C (5 min)* 
7 
Final and intermediate 
recombinant virus 
744bp 
    35 x {95°C (15 sec), 54°C (15 sec), 
72°C (15 sec)}, 72°C (1 min) † 
14 
 gp51 rev 1 5’-TCGATGGAGATGCTGAAC -3’ BLV env gene 35 x {95°C (15 sec), 54°C (15 sec), 
72°C (1 min)}, 72°C (1 min) 
18 
2 eGFP fwd 2 5’- AACCACTACCTGAGCACC -3’ egfp gene 30 x {94°C (30 sec), 52°C (30 sec), 
68°C (1 min)}, 68°C (5 min)* 




 94 rev 5’- ATCTGGAAACTATGTGGC -3’ 050 ORF (upstream of 50 
flank) 
30 x {95°C (15 sec), 54°C (15 sec), 
72°C (15 sec)}, 72°C (1 min) † 
14 
2B 3 fwd 5’- GACGAGCTGTACAAGTAA -3’ egfp gene 
30 x {95°C (15 sec), 55°C (15 sec), 
72°C (1 min)}, 72°C (1 min) † 
18 




94 rev 5’- ATCTGGAAACTATGTGGC -3’ 
050 ORF (upstream of 50 
flank) 
3 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 
30 x {94°C (30 sec), 52°C (30 sec), 
68°C (5 min)}, 68°C (5 min)* 
7 
Final recombinant virus 
and/or parental virus 
 
5,084bp and/or 1,340bp 
   35 x {95°C (15 sec), 50°C (15 sec), 
72°C (3 min)}, 72°C (5 min) † 
14 
94 rev 5’- ATCTGGAAACTATGTGGC -3’ 050 ORF ORF (upstream of 
50 flank) 
35 x {95°C (15 sec), 54°C (15 sec), 
72°C (5 min)}, 72°C (7 min) † 
18 
4 Lacz F 5’- ATTGGAGATCGGTACTTCGC - 3’ lacZ within pUC57 region of 
transfer vector backbone 
30 x {95°C (15 sec), 60°C (15 sec), 
72°C (1.5 min)}, 72°C (1.5 min) † 
17,18 
Intermediate recombinant 




50R 5’- GCATCTGGAAACTATGTGGC - 3’ 050 ORF (upstream of 50 
flank) 
5 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 
30 x {95°C (15 sec), 54°C (15 sec), 
72°C (1 min)}, 72°C (1 min)† 
17,18 
Intermediate recombinant 




M13 R2 5’- CAGGAAACAGCTATGACC -3’ M13 primer binding site 
within pUC57 region of the 
transfer vector backbone 
a, fwd and F denote forward primers whereas rev and R denote reverse primers. b, the number of cycles, thermocycling conditions for denaturation, annealing, extension per cycle and final extension 
are shown. Note that thermocycling conditions with an asterisk (*) are specific to OneTaq DNA polymerase (New England BioLabs, USA) and those with dagger symbol (†) are specific to KAPA 2G 
HotStart DNA polymerase (KAPA BIOSYSTEMS, USA). PCR with OneTaq DNA polymerase initiated with denaturation at 94°C for 30 seconds and PCR with KAPA 2G HotStart DNA polymerase 
initiated with denaturation at 95°C for 3 minutes.
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4.2.6. Characterisation of the recombinant LSDV-BLV-Env 
4.2.6.1. PCR screening of the presence of the possible final recombinant LSDV-BLV-
Env  
To perform PCR screening of the recombinant LSDV-BLV-Env at passage 15, the MDBK cells 
at a concentration of 2x105 cells/ml were infected with 10µl of the cell lysate and incubated 
under the standard growth conditions until as many foci as possible were obtained. Once 
enough mature foci were obtained, all foci were picked and an individual focus was used to 
infect each well of a 24-well tissue culture plate which was seeded with the MDBK cells at a 
concentration of 2x105 cells/ml. The plate was incubated under standard growth conditions for 
several days. When enough foci were obtained, total DNA was extracted as outlined in 
Appendix B3.2. PCR reaction mixtures were prepared as described in Appendix B3.3. PCR 
was performed using three sets of PCR primers (primer set 1, 2B and 3) (Table 4.3).  
 
4.2.6.2. Confirmation of the presence of the BLV env gene of the recombinant LSDV-
BLV-Env by PCR 
To determine whether the recombinant LSDV-BLV-Env contained the BLV env gene at the 
correct insertion site and whether an intermediate recombinant containing the entire transfer 
vector or the final recombinant only containing the BLV env gene and egfp gene had been 
obtained, PCR was performed at various passages using various sets of PCR primers (Table 
4.3).  
To determine whether the final stock of the LSDV-BLV-Env contained an intermediate 
recombinant virus containing the entire transfer vector, primer sets 4 and 5 (Table 4.2) and 
the same PCR conditions outlined in Section 4.2.5.1.1. Confirmation of the presence of BLV 
env and gag genes in recombinant LSDV-BLV-Env-Gag by PCR were used. 
 
4.2.6.3. Confirmation of the integrity of the recombinant LSDV-BLV-Env by Sanger 
sequencing 
To confirm genetic integrity of the BLV env gene of the recombinant LSDV-BLV-Env, Sanger 
sequencing of a 2,244bp fragment containing a 260bp end of the 49 flank, an entire BLV env 
gene and a 365bp region of the beginning of the egfp gene was performed. Total crude DNA 
was extracted from MDBK cells infected with the recombinant LSDV-BLV-Env (see Appendix 
B3.1). To amplify a 2,244 bp fragment of the LSDV-BLV-Env, 49 fwd and eGFP rev 7 primers 
(Table 4.4) were utilised. 
109 
Chapter 4 
Table 4.3: Primer sets used to confirm the presence of the recombinant LSDV-BLV-Env 
Set Primera Primer sequence Binding site PCR thermocycling conditionb Passage 
number  
Detection of target virus 
and product size 
1 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 30 x {94°C (30 sec), 49°C (30 sec), 




Final and intermediate 
recombinant virus 
744bp gp51 rev 1 5’-TCGATGGAGATGCTGAAC -3’ BLV env gene 
2A eGFP F3 5’- CAACCACTACCTGAGCACC -3’ egfp gene 
30 x {95°C (15 sec), 60°C (15 sec), 
72°C (1 min)}, 72°C (1 min) † 
9 




50 R 5’- GCATCTGGAAACTATGTGGC - 3’ 050 ORF (upstream of 50 
flank) 
2B 3 fwd 5’- GACGAGCTGTACAAGTAA -3’ egfp gene 
30 x {95°C (15 sec), 57°C (15 sec), 
72°C (1 min)}, 72°C (1 min) † 
13, 15 
Final and intermediate 
recombinant virus 
834bp 
94 rev 5’- ATCTGGAAACTATGTGGC -3’ 050 ORF (upstream of 50 
flank) 
2C 3 fwd 5’- GACGAGCTGTACAAGTAA -3’ egfp gene 
30 x {94°C (30 sec), 46°C (30 sec), 
68°C (1 min)}, 68°C (5 min)* 
17,18 
Final and intermediate 
recombinant virus 
720bp 
39 rev 5’- GATGGTGTGCAAATAAATCATC -3’ 050 ORF (upstream of 50 
flank) 
3 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 
35 x {94°C (30 sec), 47°C (30 sec), 
68°C (4 min)}, 68°C (5 min)* 9 
Final recombinant virus 
and/or parental virus 
3,799bp and/or 1,340bp 94 rev 5’- ATCTGGAAACTATGTGGC -3’ 050 ORF ORF (upstream of 
50 flank) 
35 x {94°C (30 sec), 49°C (30 sec), 
68°C (4 min)}, 68°C (6 min)* 
13, 15 
3B 57 fwd 5’- GAGTGAAGCCTGGAACAT -3’ 049 ORF (upstream of 49 
flank) 35 x {94°C (30 sec), 47°C (30 sec), 
68°C (4 min)}, 68°C (5 min)* 
17, 18 
Final recombinant virus 
and/or parental virus 
3,537bp and/or 1,078bp 
39 rev 5’- GATGGTGTGCAAATAAATCATC -3’ 050 ORF ORF (upstream of 
50 flank) 
a, fwd denotes forward primers whereas rev denotes reverse primers. b, the number of cycles, thermocycling conditions for denaturation, annealing, extension per cycle and final extension are shown. 
Note that thermocycling conditions with an asterisk (*) are specific to OneTaq DNA polymerase (New England BioLabs, USA) and those with dagger symbol (†) are specific to KAPA 2G HotStart DNA 
polymerase (KAPA BIOSYSTEMS, USA). PCR with OneTaq DNA polymerase initiated with denaturation at 94°C for 30 seconds and PCR with KAPA 2G HotStart DNA polymerase initiated with 
denaturation at 95°C for 3 minutes.
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Sanger sequencing of the 2,244bp fragment of the LSDV-BLV-Env was conducted using 
sequencing primers outlined in Table 4.4 by Central Analytical Facilities at the University of 
Stellenbosch (South Africa). 
 
Table 4.4: Primers used to amplify and sequence a 2,244bp fragment of the LSDV-BLV-Env genome 
Primers Orientation Binding site Purposes 
49 fwd Forward 049 ORF 
Amplification of a 2,244bp fragment 
eGFP rev 7 Reverse  egfp 
Env rev 1 Reverse  Env gp51 
Sequencing of the 2,244bp PCR product 
Env fwd 2 Forward Env gp51 
Env fwd 6 Forward Env gp51 
Env fwd 7 Forward  Env gp30 
 
4.2.6.4. Confirmation of in vitro expression of the BLV Env protein by the recombinant 
LSDV-BLV-Env using immunofluorescence assay (IFA)  
To confirm the in vitro expression of the BLV Env protein expressed by the recombinant LSDV-
BLV-Env, an immunofluorescence assay (IFA) was conducted by live-cell staining of the 
MDBK cells infected with the recombinant LSDV-BLV-Env using the mouse anti-Env 
monoclonal antibody (anti-Env mAb) as outlined in Appendix B4. As a technical control for a 
donkey-anti-mouse IgG conjugated with Cy3 (anti-mouse IgG-Cy3), uninfected cells, cells 
infected with the parental nLSDVSODis-UCT virus and those infected with the recombinant 
LSDV-BLV-Env were incubated with anti-mouse IgG-Cy3 only. As an experimental control, 
uninfected cells and cells infected with the parental nLSDVSODis-UCT virus were incubated 
with anti-Env mAb at a dilution of 1:50 or 1:100 and anti-mouse IgG-Cy3 at a dilution of 1:5,000. 
Figure 4.6 outlines the layout of a 24-well plate used to perform the IFA.  
 
 
Figure 4.6: Layout of a 24-well plate 
used for immunofluorescence assay 
of BLV Env expression from 
recombinant LSDV-BLV-Env. MDBK 
cells were either not infected (NC; in the 
first column of the plate), infected with 
the parental LSDV virus (WT; the 
second column) or infected with 3µl or 
5µl of the passage 16 viral stock of the 
recombinant LSDV-BLV-Env (fourth 
and fifth columns, respectively) Wells 
where cells were immunostained with 
the anti-Env mAb (1° Ab) are indicated 
by green semicircles and those 
immunostained with anti-mouse IgG-







4.3.1. Design of BLV transfer vectors 
4.3.1.1. Selection of BLV env and gag sequences  
To design the BLV env and gag sequences of the BLV expression cassette, BLV env and gag 
sequences of a BLV natural isolate were selected as follows. Firstly, the nucleotide and amino 
acid sequences of consensus env and gag sequences (Cons-Env and Cons-Gag, 
respectively) were obtained by the alignment of BLV env and gag sequences of 62 BLV natural 
isolates representing six genotypes available in GenBank nucleotide database. Seven 
candidate BLV natural isolates whose BLV env and gag nucleotide and amino acid sequences 
were closest to those of the Cons-Env and Cons-Gag were selected from the BLAST database 
(Table 4.5), and their amino acid sequences were aligned back to those of the Cons-Env and 
Cons-Gag for the final confirmation. Consequently, a BLV natural isolate pvAK006 (GenBank 
accession number AP018021) was selected as its env and gag nucleotide sequences shared 
99.5% and 99.8% identity, respectively, with those of the Cons-Env and Cons-Gag and they 
shared 100% identity of the Env and Gag amino acid sequences. This process is described in 




Figure 4.7: Flow diagram outlining the selection of BLV Env and Gag amino acid sequences used to 
make LSDV recombinants.  
112 
Chapter 4 
Table 4.5: Summary of BLAST and EMBOSS results of the nucleotide and amino acid sequence alignment using the Cons-Env and Cons-Gag as a query sequence  
  Cons-Env Cons-Gag  
GenBank 
accession number  
Protein ID Nucleotide sequence Amino acid sequence Nucleotide sequence Amino acid sequence Strain 
LC164083.1 BAV17954.1 99.8%  
(1545/1548bp) 
Identity: 99.8% (514/515 aa) 
 
Similarity: 100% (515/515 aa) 
99.8%  
(1180/1182bp) 








Identity: 100% (515/515 aa) 
 
Similarity: 100% (515/515 aa) 
99.8%  
(1180/1182bp) 








Identity: 99.4% (512/515 aa) 
 
Similarity: 99.6% (513/515 aa) 
99.6%  
(1178/1182bp) 
Identity: 99.7% (392/393 aa) 
 







99. 8%  
(1546/1548bp) 
Identity: 99.8% (514/515 aa) 
 
Similarity: 100% (515/515 aa) 
99.6%  
(1178/1182bp) 
Identity: 99.2% (390/393 aa) 
 








Identity: 99.8% (514/515 aa) 
 
Similarity 100% (515/515 aa) 
99.5%  
(1177/1182bp) 
Identity: 99.7% (392/393 aa) 
 








99. 6%  
(1542/1548bp) 
Identity: 99.6% (513/515 aa) 
 
Similarity: 99.8% (514/515 aa) 
99.4%  
(1176/1182bp) 
Identity: 99.7% (392/393 aa) 
 








Identity: 99.2% (511/515 aa) 
 
Similarity: 99.8% (514/515 aa) 
99.4%  
(1176/1182bp) 
Identity: 99.7% (392/393 aa) 
 
Similarity: 100% (393/393 aa) 
pvAF245 
 
For the BLSAT results of the nucleotide sequences, sequence identities are shown. The number of nucleotides (bp) and amino acid (aa) matches between two sequences are shown in brackets. 
Each strain identifier (e.g., pvAN015, pvAK006) corresponds to a cow number (cow AN015 and AK009) from which the BLV was isolated.   
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4.3.1.2. Assessment of functionality of the signal sequence of the human tissue 
plasminogen activator in bovine cells 
Enhancement of antigen presentation on the cell membrane is important in the induction and 
improvement of immune responses in vaccines. One strategy that has been widely utilised in 
various expression systems [516-518] and vaccine modalities [519-523] is the modification of 
the signal sequence (also called signal peptide or leader sequence) of secretory and 
membrane proteins. Various studies have shown that the optimisation of the native signal 
sequence, particularly when the native signal sequence does not export proteins efficiently 
[524, 525], or the replacement of the native signal sequence with a heterologous signal 
sequence such as human tissue plasminogen activator (tPA) lead to efficient protein export 
and expression as well as enhancement of immunogenicity [517, 518, 522, 523, 526-529]. In 
our lab, the signal sequence of the human tPA has been utilised in our protein [530] and 
recombinant MVA-vectored [531] HIV-1 vaccines. However, the use of this signal sequence 
in bovine cells had not been tested. Therefore, the functionality of the human tPA signal 
sequence in bovine cells was assessed prior to its inclusion in the recombinant LSDV vaccines.   
 
4.3.1.2.1. Amino acid sequence comparison of the human and bovine tPA signal 
sequences  
To determine whether the signal sequence of the BLV env gene could be replaced with the 
signal sequence of the human tPA, amino acid sequences of the human and bovine tPA signal 
sequences were compared.  
Both the human and bovine tPA signal sequences are 21 amino acids in length and share a 
71.4% identity (Figure 4.8).  
 
Human tPA  
 
M D A M K R G L C C V L L L C C A V F V S 
  |  | | |     | | | | | | | | | | |  
Bovine tPA  M M S A M K T E F L C V L L L C C A V V T  
 
Figure 4.8: Amino acid sequence alignment of human tPA signal sequence (protein ID; P00750) and 
bovine tPA signal sequence (protein ID; Q29819). 
 
4.3.1.2.2. In vitro activity of the human tPA signal sequence in bovine cells 
It was difficult to determine from the amino acid sequence comparison of the human and 
bovine tPA signal sequences whether the human tPA signal sequence would be functional in 
bovine cells and could be used in the BLV transfer vector. Therefore, to address these 
questions, extracellular expression of an HIV-1 Env glycoprotein from MVA-GC5SS, which 
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contains the HIV env gene with the human tPA signal sequence, was assessed by Western 
blotting. Extracellular expression of the HIV1 Env glycoprotein (Figure 4.9 A) was detected 
from Madin-Darby bovine kidney (MDBK) cells infected with MVA-GC5SS at a MOI of 5 and 
its intracellular expression from the cells infected with MVA-GC5SS at MOIs of 2 and 5 (Figure 
4.9 B), indicating that the glycoprotein was successfully exported from the infected cells and 
that the human tPA signal sequence was functional in bovine cells. It should be noted that 
since the soluble Env protein (E) does not contain the transmembrane region and cytoplasmic 





Figure 4.9: Extracellular and intracellular expression of HIV-1 Env glycoprotein containing the human 
tPA signal sequence in bovine cells. A confluent monolayer of MDBK cells at a concentration of 2.0x105 
cells/ml was infected with MVA-rGC5SS at an MOI of 1,2 or 5 and total protein was extracted at 72 hours post-
infection from the culture media and cell lysate. The HIV-1 Env glycoprotein was detected with a goat anti-HIV-
1 Env polyclonal antibody (BioRad, USA) followed by anti-goat/sheep IgG monoclonal antibody conjugated with 
alkaline phosphatase (Sigma-Aldrich, USA). (A) Extracellular expression of HIV-1 Env glycoprotein (arrowhead) 
extracted from the culture media from the MDBK cells infected with MVA-GC5SS at different MOIs. (B) 
Intracellular expression of HIV-1 Env glycoprotein (arrowhead) extracted from the cell from the MDBK cells 
infected with MVA-GC5SS at different MOIs. M, protein molecular weight ladder (11-245 kDa) (Thermo Fisher 
Scientific, USA); E, soluble HIV-1 Env protein; NC, protein extracted from uninfected cells.  
 
4.3.1.3. Insertion site, marker gene and promoters 
An intergenic region between open reading frames (ORFs) 049 and 050 in the central coding 
region of the LSDV genome (Figure 4.10) was selected as the site of insertion by Dr. Nicola 
Douglass based on the following reasons. Firstly, the central coding region of the LSDV 
genome is evolutionally conserved [532], and there is no intergenic region between ORFs 049 
and 050. Therefore, inserted genes in this region are less likely to be mutated and/or deleted. 
Secondly, insertion of genes in this region is unlikely to disrupt the expression of ORFs 049 
and 050 as the two ORFs are convergent (i.e., one is transcribed in a sense direction and the 
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other in an antisense direction) and thus, promoter regions are unlikely to be disrupted by the 
insertion.  
The same insertion site was used for both recombinant LSDV-BLV-Env-Gag and LSDV-BLV-
Env, and 356bp and 440bp of the 3’ ends of the 049 and 050 ORFs, respectively were included 
as flanking sequences (49 and 50 flanks, respectively) in the BLV transfer vectors. The 49 and 
50 flanks correspond to positions 44542-44891 and 44887-45327 of the Neethling vaccine LW 
1959 strain (GenBank accession number AF409138).    
To differentiate the recombinant LSDV containing the BLV expression cassette from the 




Figure 4.10: A linear genomic map of an nLSDV NI-2490 isolate from Kenya (GenBank accession number 
AF325528). LSDV genome consists of the central coding region, flanked by two identical inverted terminal repeat 
(ITR) regions. ITRs are shown as black bars with one below ORFs 01 and 04 and the other below ORFs 154 to 
156. ORFs of LSDV genome are numbered from left to right along the genome. The ORFs on the sense strand, 
transcribed from left to right are shown above the horizontal line whereas those on the antisense strand, 
transcribed from right to left are shown below the horizontal line. Genes with similar functions are grouped and 
coloured in five groups and those within the same gene families are shown with one of three patterns. Taken 
from Tulman et al. (2001) [532].  
 
The modified early fowlpox virus promoter (mFP) [438, 439], modified early-late promoter of 
the H5 gene of VACV (mH5) [440] and early-late promoter of the 7.5 kilodalton (kDa) 
polypeptide gene (p7.5) of vaccinia virus (VACV) [419] were selected to drive expression of 
the BLV env, gag and egfp genes, respectively. Since the assessment of the activity of the 
five poxvirus promoters including these three poxvirus promoters (see Chapter 3) was 
performed in parallel with this current study of the construction and characterisation of the 
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recombinant LSDVs, these three promoters were selected based on previous studies 
conducted in our lab as well as published data.  
 
4.3.1.4. Modification and optimisation of the BLV expression cassette sequences 
Prior to the inclusion of the env and gag sequences of the BLV natural isolate pvAK006 
(GenBank accession number AP018021.1) into the BLV expression cassette, these 
sequences were modified, and codon optimised for the optimal expression of the BLV env and 
gag genes under poxvirus gene expression systems and in cattle.  
A few modifications were also made to the BLV env gene. The signal sequence of the BLV 
env gene was replaced with that of the human tissue plasminogen activator (tPA) for the 
efficient transport of the BLV Env protein to the cell membrane of infected cells and the 
sequence encoding the subtilisin/kesin-like convertase cleavage site (RVRR) located between 
the gp51 and gp30 subunits was replaced with a flexible linker sequence, (GGGGS)2. This 
was done to avoid poor subtilisin/kesin-like convertase cleavage which could impair the 
structure of the protein. The linker could also possibly stabilise the gp51 and gp30 glycoprotein 
complex.  
A Kozak sequence was introduced at translation initiation sites of the BLV env and gag 
sequences as well as the egfp sequence. Poxvirus early terminator sequences (TTTTTNT 
with N being any nucleotide) were included after the stop codons of all the genes, including 
the 49 and 50 flanks. Poxvirus termination signals were removed from all ORFs to prevent 




Figure 4.11: Plasmid map of the 
pBLV-Env-Gag transfer vector. 49 
flank, 356bp 3’ end of 049 ORF from 
Neethling lumpy skin disease virus; 50 
flank, 440bp 3’ end of 050 ORF from 
Neethling lumpy skin disease virus; 
mFP, modified early fowlpox virus 
promoter; mH5, a modified promoter of 
the H5 gene of VACV; p7.5, promoter 
for the 7.5 kDa polypeptide gene of 
vaccinia virus (VACV); BLV env, 
envelope gene of bovine leukaemia 
virus (BLV); BLV gag, BLV gag gene 
eGFP, enhanced green-florescent 
protein gene; tPA, human tissue 
plasminogen activator signal 
sequence; LacZ, LacZ alpha fragment 
of beta-galactosidase gene; bla 
(AmpR), beta-lactamase (bla) gene; 




4.2.1.5. Confirmation of the integrity of the pBLV-Env-Gag transfer vector  
Prior to the enzymatic manipulation of the pBLV-Env-Gag plasmid to generate the pBLV-Env 
and its use to generate the recombinant LSDV-BLV-Env-Gag, the integrity of the pBLV-Env-
Gag plasmid was confirmed by restriction endonuclease mapping and Sanger sequencing.  
E. coli competent cells were transformed with the pBLV-Env-Gag plasmid from GanScript, and 
medium-scale plasmid DNA isolation was carried out with two of the transformants, C1 and 
C2. Restriction endonuclease digestion of these plasmids with NcoI yielded DNA fragments 
of the correct sizes (Figure 4.12). The C1 plasmid contained more supercoiled plasmid DNA 
than the C2 plasmid DNA, and therefore, the C1 plasmid was selected for the downstream 
experiments. The integrity of the C1 plasmid DNA was also confirmed by Sanger sequencing 





Figure 4.12: Preliminary confirmation of the integrity of the pBLV-Env-Gag plasmids. The pBLV-Env-Gag 
plasmid DNA was digested with restriction endonuclease NcoI and separated on 0.8% agarose TBE gel stained 
with ethidium bromide (0.5 μg/ml). M, 1 kb DNA ladder (Thermo Scientific, USA); 1, the C1 plasmid digested 
with NcoI; 2, the C2 plasmid digested with NcoI; 3, uncut C1 plasmid; 4, uncut C2 plasmid. 
 
4.3.1.6. Construction of pBLV-Env transfer vector by enzymatic modification of the 
pBLV-Env-Gag plasmid 
To construct the pBLV-Env transfer vector, the pBLV-Env-Gag plasmid was digested with MfeI 
and EcoRI to remove the mH5 promoter and BLV gag gene (Figure 4.13). The integrity of the 
resultant plasmid was confirmed by restriction endonuclease mapping of the pBLV-Env with 
BamHI and SalI, yielding DNA fragments of the correct sizes (Figure 4.14). Final confirmation 
of the integrity of the pBLV-Env plasmid DNA was made by Sanger sequencing using M13F 







Figure 4.13: Construction of the pBLV-Env transfer vector. Restriction endonuclease digestion of the pBLV-






Figure 4.14: Preliminary confirmation of the integrity of the pBLV-Env plasmid. The pBLV-Env plasmid 
DNA was digested with restriction endonucleases BamHI and SalI and separated on 0.8% agarose TBE gel 
stained with ethidium bromide (0.5 μg/ml). M, 1 kb DNA ladder (Thermo Scientific, USA); 1, pBLV-Env plasmid 
digested with BamHI and SalI; 2, uncut pBLV-Env.  
 
4.3.2. Construction and purification of the recombinant LSDV-BLV-Env-Gag  
The recombinant LSDV harbouring the BLV env and gag genes as well as the egfp gene 
(LSDV-BLV-Env-Gag) was constructed by infecting and transfecting primary foetal bovine 
testes (FBT) cells with the nLSDVSODis-M and the pBLV-Env-Gag transfer vector, 
respectively. Although Madin-Derby bovine kidney (MDBK) cells are permissive for LSDV, 
transfection is inefficient in this cell line. Therefore, primary FBT cells were utilised to construct 
the recombinant LSDV-BLV-Env-Gag. The progeny viruses were then, isolated from the 
primary FBT cells and subjected to serial passages in MDBK cells to allow viral propagation 
and isolation. The parental nLSDVSODis-M contained a mCherry reporter gene and was 
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identified as red fluorescing cells by fluorescent microscopy whereas the recombinant LSDV-
BLV-Env-Gag contained both red and green reporter genes and thus appeared yellow.  
 
4.3.2.1. Construction of the recombinant LSDV-BLV-Env-Gag in primary foetal bovine 
testes (FBT) cells 
In the control wells, the primary FBT cells that were not infected or transfected (Figure 4.15 A) 
were slightly sparse at 48 hours post-infection but appeared to be viable enough. The primary 
FBT cells that were transfected only (Figure 4.15 B) appeared to be more sparse than the 
primary FBT cells that were not infected or transfected, due to the toxicity of the transfection 
reagent. Red fluorescing cells were observed from the primary FBT cells that were infected 
with the parental nLSDVSODis-M virus at a MOI of 0.1 (Figure 4.15 D) whereas such cells 
were not detected from those infected with the parental virus at an MOI of 0.01 (Figure 4.15 
C) but several cells were rounded up and showed cytopathic effects (CPEs), indicating that 
the cells were infected by the parental virus.  
At 48 hours post-infection, small green and red fluorescing cells were detected in the primary 
FBT cells that were transfected and infected with the transfer vector plasmid DNA and the 
parental nLSDVSODis-M virus at a MO of 0.1 and 0.01 (Figure 4.16). The cells were incubated 
further to obtain more and larger foci.  
At 120 hours post-infection, in the experimental cells infected with the nLSDVSODis-M at 
MOIs of 0.01 and 0.1, more and larger foci were detected compared to those observed at 48 
hours post-infection. Whilst some of the foci were fluorescing green and red from the entire 
foci (Figure 4.17 A), other foci were only partially fluorescing green (Figure 4.17 B) As a result 
of the extensive infection, the cells in the experimental wells had started to round up and die, 
indicating that further viral propagation was not possible. Therefore, at 120 hours post-
infection, the cells were subjected to three cycles of freezing at -80°C and thawing at 37°C to 
release the viruses and cell lysates containing the released viruses were passaged in MDBK 








Figure 4.15: Fluorescent images of the experimental, infection and transfection controls for the 
generation of recombinant  LSDV-BLV-Env-Gag in primary foetal bovine testes (FBT) cells. (A) Cells 
only: the primary FBT cells were not infected or transfected. (B) Transfection control: primary FBT cells 
were transfected with 6µg of the pBLV-Env-Gag plasmid DNA; (C) Infection control 1, primary FBT cells 
were infected with nLSDVSODis-M at an MOI of 0.01. (D) Infection control 2: primary FBT cells were 
infected with nLSDVSODis-M at an MOI of 0.1. Primary FBT cells infected with the parental nLSDVSODis-
M were visualized by their mCherry expression (red). All images were taken at 48 hours post-infection using 
a Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, Germany) at 50x magnification. Scale bars 
represent 200µm. 
Figure 4.16: Fluorescent images of primary FBT cells 
transfected with the pBLV-Env-Gag plasmid DNA and 
infected with the nLSDVSODis-M at 48 hours post-
infection. Cell morphology of the primary FBT cells at 48 
hours post-infection that were transfected with the pBLV-Env-
Gag plasmid DNA and infected with the nLSDVSODis-M at an 
MOI of (A) 0.01 and (B) 0.1. Primary FBT cells infected with 
the recombinant LSDV-BLV-Env-Gag were visualized by their 
eGFP (green) and mCherry expression (red). MDBK cells 
infected with the parental nLSDVSODis-M were visualized by 
their mCherry expression (red). All images were taken using a 
Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, 








Figure 4.17: Fluorescent images of primary FBT cells transfected with the pBLV-Env-Gag plasmid 
DNA and infected with the nLSDVSODis-M at 120 hours post-infection. (A) Cell morphology of the 
primary FBT cells at 120 hours post-infection that were transfected with the pBLV-Env-Gag plasmid DNA 
and infected with the nLSDVSODis-M at an MOI of 0.01. (B) Cell morphology of the primary FBT cells at 
120 hours post-infection that were transfected with the pBLV-Env-Gag plasmid DNA and infected with the 
nLSDVSODis-M at an MOI of 0.1. Primary FBT cells infected with the recombinant LSDV-BLV-Env-Gag 
were visualized by their eGFP (green) and mCherry expression (red). Primary FBT cells infected with the 
parental nLSDVSODis-M were visualized by their mCherry expression (red). All images were taken at 120 
hours post-infection using a Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, Germany)) at 
100x magnification. Scale bars represent 100µm. 
 
4.3.2.2. Purification of the recombinant LDSV-BLV-Env-Gag by serial passages in 
Madin-Darby bovine kidney (MDBK) cells  
To purify recombinant viruses away from parental viruses and allow them to propagate further, 
recombinant progeny viruses isolated in the primary FBT cells were sequentially passaged in 
MDBK cells. This process is to ensure that the recombinant progeny virus was a correct 
recombinant virus containing the BLV expression cassette between the 049 and 050 ORFs as 
the transfer vector may be transiently expressed in early passages. Figure 4.18 outlines tissue 





Figure 4.18: Flow diagram outlining the purification of the recombinant LSDV-BLV-Env-Gag in MDBK 
cells. The flow diagram outlines the tissue culture plates used at each passage and focus (yellow arrow) or 
cell lysate (pink arrow) isolated for the next passage. The viral stocks used to perform PCR and Western 
blotting (WB) are also indicated in this figure.   
 
Cell lysates were isolated from the primary FBT cells and varying amounts of the cell lysates 
(5 to 200µl) were used to infect MDBK cells for the optimal growth and purification at passage 
1. Cell lysate isolated from the transfected-primary FBT cells that were infected with the 
nLSDVSODis-M at an MOI of 0.01 in the initial plate did not produce any green and red 
fluorescing foci. In contrast, cell lysate isolated from the transfected-primary FBT cells that 
were infected with the nLSDVSODis-M at an MOI of 0.1 in the initial plate produced several 
green and red fluorescing foci at 96 hours post-infection. There were still a large number of 
red fluorescing foci (parental nLSDVSODis-M viruses) present. To isolate recombinant viruses 
away from the parental viruses, six large foci fluorescing both green and red were picked for 
the next passage. Of these six foci, five foci (Figure 4.19 A-E) did not grow in MDBK cells and 
only one focus (Figure 4.19 F) successfully grew and propagated extensively to produce 17 
foci at passage 2. 
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From passages 2 to 5, picked foci were used to infect MDBK cells to further isolate 
recombinant progeny viruses out of populations of parental viruses. At passage 5, 96-well 
tissue culture plates were used to remove the parental viruses further and to purify 
recombinant progeny viruses specifically as a single focus without the presence of parental 
viruses in the same well. Following a 72-hour incubation, four single foci that were fluorescing 
both green and red were obtained from four different wells without parental viruses present in 
the same wells (Figure 4.20 A-D). 
 
4.3.2.2.1. PCR analysis of the presence of the recombinant LSDV-BLV-Env-Gag at 
passage 7 
PCR was performed to determine whether the purification of the recombinant LSDV-BLV-Env-
Gag was successful at passage 7 (Figure 4.21 A). Using primer sets 1 and 2, 744bp and 
937bp fragments (Figure 4.21 C and D) were amplified from two samples (lanes 2 and 3) from 
the recombinant LSDV-BLV-Env-Gag. Since a sample in lane 4 was obtained from infected 
cells where only red fluorescing foci were detected, 744bp and 937bp fragments were not 
amplified. This result confirmed that the primer sets 1 and 2 were specific to the recombinant 
LSDV-BLV-Env-Gag genome.  
Since 744bp and 937bp fragments were amplified from the 5’-end and 3’-end of the BLV 
expression cassette, their amplification indicates that the recombinant virus contained the BLV 
env and egfp genes at the correct insertion site, between the 049 and 050 genes of the LSDV-
BLV-Env-Gag genome, but this could have resulted from a single crossover into 049 ORF only 
or 050 ORF only. Therefore, to determine the presence of a final recombinant virus that 
contained the entire BLV expression cassette in the insertion site by HR into both 049 and 050 
ORFs, another PCR was performed using primer set 3. Amplification of a 5,084bp fragment 
covering the entire BLV expression cassette between the 049 and 050 genes of the LSDV-
BLV-Env-Gag genome was not successful (Figure 4.21 E). This may have been due to the 
inefficient amplification of this large fragment. Using the same primer set 3, a 1,340bp 
fragment covering the 049 and 050 genes of the parental viral genome was amplified from 
recombinant LSDV-BLV-Env-Gag (Figure 4.21 E; lanes 2, 3 and 4), indicating the presence 
of the parental virus in the passage 7 viral stock.   
It should be noted that since this was the first PCR conducted for the recombinant LSDV, 
primers and PCR results appeared to be suboptimal, showing faint 744bp and 937bp bands 
on the agarose gels. Therefore, modified versions of primers as well as different DNA 





Figure 4.19: Six green and red fluorescing foci of MDBK cells infected with 
putative recombinant LSDV-BLV-Env-Gag at passage 1. (A-F) Green and red 
fluorescing foci isolated from a 24-well plate at passage 1. MDBK cells infected with 
the recombinant LSDV-BLV-Env-Gag were visualized by their eGFP (green) and 
mCherry expression (red). MDBK cells infected with the parental nLSDVSODis-M 
were visualized by their mCherry expression (red). All images were taken at 96 hours 
post-infection using a Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, 
Germany) at 400x magnification. Scale bars represent 20µm. 
Figure 4.20: Single green and red fluorescing foci of MDBK cells infected with 
recombinant LSDV-BLV-Env-Gag at passage 5.  (A-D) Single foci isolated from 
four wells of a 96-well plate at passage 5. MDBK cells infected with the recombinant 
LSDV-BLV-Env-Gag were visualized by their eGFP (green) and mCherry expression 
(red). MDBK cells infected with the parental nLSDVSODis-M were visualized by their 
mCherry expression (red). All images were taken at 72 hours post-infection using 
Zeiss Axiovert 200M fluorescent inverted microscope (Zeiss, Germany) at 400x 








C  Primer set 1 D Primer set 2 E Primer set 3 
 
Figure 4.21: Preliminary confirmation of the presence of the LSDV-BLV-Env-Gag at passage 7. Schematic diagrams showing (A) binding sites of primer set 1 (purple 
arrows) and primer set 2 (blue arrows) on the LSDV-BLV-Env-Gag gnome and (B) binding sites of primer set 3 (purple and blue arrows) on the LSDV-BLV-Env-Gag gnome 
and parental nLSDVSODis-M genome. PCR products are shown as a line with expected product size. 49, left flank; 50, right flank; 049 and 050, 049 and 050 ORFs of the 
LSDV genome; mFP, modified early fowlpox virus promoter; mH5, a modified promoter of the H5 gene of VACV; p7.5, promoter for the 7.5 kDa polypeptide gene of vaccinia 
virus (VACV); BLV env, envelope gene of bovine leukaemia virus (BLV); BLV gag, BLV gag gene; eGFP, green-florescent protein gene; tPA, human tissue plasminogen 
activator signal sequence. (C) Agarose gel showing a 744bp product amplified with primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-
Env-Gag into 049 ORF. Agarose gel. (D) Agarose gel showing a 937bp product amplified with primer set 2 to detect the presence of a final and intermediate recombinant 
LSDV-BLV-Env-Gag into 050 ORF. (E) Agarose gel showing a 1,340bp product amplified with primer set 3 which detects the presence of a final recombinant LSDV-BLV-Env-
Gag and/or parental nLSDVSODis-M. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, total DNA from uninfected cells; 2, 3 and 4, total DNA from the passage 7 viral stock 
of recombinant LSDV-BLV-Env-Gag; 5, parental viral DNA; 6, PCR control without template DNA. 
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As expected from the PCR results, at passage 8, parental viruses were detected in all except 
one well of a tissue culture plate. Most of the parental viruses grew faster than recombinant 
viruses. In some wells, parental viruses outnumbered recombinant viruses. However, for 
unknown reasons, some parental viruses were only detected at 120 hours post-infection.  
Careful monitoring of the viral growth revealed that some recombinant viruses were 
expressing eGFP only partially (Figure 4.22 A) and some of them appeared to have lost their 
eGFP expression almost entirely (Figure 4.22 B). These recombinant viruses could be 
intermediate recombinant viruses containing the entire transfer vector as a result of a single 
recombination event into 049 ORF or 050 ORF only. A second recombination event could then 
have resulted in the loss of the entire transfer vector and expression cassette, resulting in the 






Figure 4.22: Green and red fluorescing foci of MDBK cells infected with recombinant LSDV-BLV-Env-
Gag that partially or almost entirely lost eGFP expression at passage 8. (A) A representative image 
showing a recombinant virus showing the partial expression of eGFP. (B) A representative image showing 
recombinant virus that appeared to have lost its eGFP expression almost entirely. MDBK cells infected with 
the recombinant LSDV-BLV-Env-Gag were visualized by their eGFP (green) and mCherry expression (red). 
MDBK cells infected with the parental nLSDVSODis-M were visualized by their mCherry expression (red). All 
images were taken at 120 hours post-infection using Zeiss Axiovert 200M fluorescent inverted microscope 
(Zeiss, Germany) at 400x magnification. Scale bars represent 20µm. 
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4.3.2.2.2. PCR analysis of the presence of the recombinant LSDV-BLV-Env-Gag at 
passage 14 
Parental and recombinant viruses expressing partial eGFP expression persisted from passage 
9 through to passage 11. Therefore, at passage 12, foci were once again picked from a 12-
well tissue culture plate to specifically isolate recombinant viruses and to remove as many 
non-recombinant viruses as possible. Consequently, the number of parental viruses remained 
low up to passage 15. Since the presence of a possible final recombinant LSDV-BLV-Env-
Gag had not been confirmed at passage 7, PCR was once again performed at passage 14 
using the same primer sets 1, 2 and 3 but using different DNA polymerase and PCR conditions 
(Figure 4.23 A and B). Amplification of a 744bp fragment and no amplification of a 937bp 
fragment indicate the presence of a possible intermediate recombinant LSDV-BLV-Env-Gag 
into the 049 ORF only (Figure 4.23 C and D), though the latter result might have been due to 
the inefficient PCR using primer set 2. Using primer set 3, once again the presence of parental 
virus was confirmed by amplification of a 1,340bp fragment whereas a 5,084bp fragment 
indicating the presence of the final recombinant LSDV-BLV-Env-Gag was not amplified 
(Figure 4.23 E). 
 
4.3.2.2.3. Characterisation of the BLV Env and Gag in the recombinant LSDV-BLV-Env-
Gag in the final viral stock 
At passage 16, partial eGFP expression was still detected in foci. This recombinant virus was 
passaged twice to scale up the viral stock for downstream analyses of PCR (Section 
4.3.2.2.3.1) and Western blotting (Section 4.3.2.2.3.2). 
 
4.3.2.2.3.1. Confirmation of the presence of the BLV env and gag genes in recombinant 
LSDV-BLV-Env-Gag at passage 18  
Using primer sets 1 and 2B, 744bp and 843bp fragments (Figure 4.24 C and D) were amplified, 
indicating the presence of a possible final or intermediate recombinant LSDV-BLV-Env-Gag 
whereby HR occurred into 049 ORF only (primer set 1) and 050 ORF only (primer set 2B) in 
the passage 18 viral stock. Once again, using primer set 3, only a 1,340bp fragment was 
amplified from the recombinant LSDV-BLV-Env-Gag, indicating the presence of the parental 
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Figure 4.23: PCR analysis of the putative LSDV-BLV-Env-Gag at passage 14. Schematic diagrams showing (A) binding sites of primer set 1 (purple arrows) and primer 
set 2 (blue arrows) on the LSDV-BLV-Env-Gag gnome and (B) binding sites of primer set 3 (purple and blue arrows) on the LSDV-BLV-Env-Gag gnome and parental 
nLSDVSODis-M genome. PCR products are shown as a line with expected product size. See Figure 4.21 for the sequence annotation. (C) Agarose gel showing a 744bp 
product amplified with primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-Env-Gag into 049 ORF. (D) Agarose gel showing no amplification 
of a 937bp product with primer set 2 which detects the presence of a final and intermediate recombinant LSDV-BLV-Env-Gag into 050 ORF. (E) Agarose gel showing a 
1,340bp product amplified with primer set 3 which detects the presence of a final recombinant LSDV-BLV-Env-Gag and/or parental nLSDVSODis-M. M, 1 kb DNA ladder 
(Thermo Scientific, USA); 1, total DNA from uninfected cells; 2 and 3, total DNA from the passage 14 viral stock of recombinant LSDV-BLV-Env-Gag; 4, parental viral DNA; 
5, PCR control without template DNA.  
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Figure 4.24: PCR analysis of the putative LSDV-BLV-Env-Gag at passage 18. Schematic diagrams showing (A) binding sites of primer set 1 (purple arrows) and primer 
set 2 (blue arrows) on the LSDV-BLV-Env-Gag gnome and (B) binding sites of primer set 3 (purple and blue arrows) on the LSDV-BLV-Env-Gag gnome and parental 
nLSDVSODis-M genome. PCR products are shown as a line with expected product size. See Figure 4.21 for the sequence annotation. (C) Agarose gel showing a 744bp 
product amplified with primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-Env-Gag into 049 ORF. (D) Agarose gel showing an 834bp 
product amplified with primer set 2B to detect the presence of a final and intermediate recombinant LSDV-BLV-Env-Gag into 059 ORF. (E) Agarose gel showing a 1,340bp 
product amplified with primer set 3 which detects the presence of a final recombinant LSDV-BLV-Env-Gag and/or parental nLSDVSODis-M. M, 1 kb DNA ladder (Thermo 
Scientific, USA); 1, total DNA from uninfected cells; 2 and 3 total DNA from the passage 18 viral stock of recombinant LSDV-BLV-Env-Gag; 4, parental viral DNA; 5, PCR 
control without template DNA.  
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As foci that were partially fluorescing green were persistently detected during some passages, 
PCR confirmation of the presence or absence of an intermediate recombinant LSDV-BLV-
Env-Gag virus in the passage 18 viral stock was performed using two sets of primers. 
Recombination into the 050 ORF only was confirmed by amplification of a 1,051bp fragment 
using primer set 5 (Figure 4.25 A and C). A 1,420bp fragment was not amplified using primer 
set 4 (Figure 4.25 A and B). This shows that a single crossover event took place such that the 
entire transfer vector was inserted into the 050 ORF. Because of the repeated flanking 050 
sequence, the insert could either be excised in its entirety and the recombinant viruses reverts 
to the original parental virus, or a second crossover at the 049 ORF could result in the desired 
recombinant virus. In order to isolate the desired recombinant virus, extensive picking and 
screening of fluorescing foci are required. Due to time constraints, this could not be done. 
 
4.3.2.2.3.2. Confirmation of BLV Gag protein expression by Western blotting 
To confirm that the recombinant LSDV-BLV-Env-Gag expressed BLV Gag protein, Western 
blotting was performed using total crude protein extracted at 24, 48 and 72 hours post-infection 
from MDBK cells infected with the recombinant LSDV-BLV-Env-Gag from the passage 18 viral 
stock. Crude total protein was also extracted from infected cells from three wells of a 6-well 
tissue culture plate at 72 hours post-infection and the protein from these wells was combined 
as a Bulk sample (72B in Figure 4.26 B). Figure 4.26 A shows MDBK cells from which the 
crude protein was extracted. 
BLV Gag expression was detected at all time points both from the cell lysate and the culture 
media, indicating that the BLV Gag proteins were expressed intracellularly and extracellularly. 
Extracellular expression of the BLV Gag protein was detected even at 24 hours post-infection. 
Unexpectedly, the intensity of the BLV Gag band from the Bulk sample was not significantly 
different from those from proteins extracted at 48 and 72 hours post-infection.  
Expression of the BLV Env protein from the recombinant LSDV-BLV-Env-Gag was not 
detected using Western blotting as the anti-BLV Env antibody available from Veterinary 
Medical Research and Development (USA) recognises a conformational epitope present on 
BLV Env and does not bind to the denatured protein separated by SDS-PAGE. It is, however, 
possible to detect BLV Env expression using immunofluorescence assay (IFA) by live-cell 
staining of the infected-cells. This assay was not done due to time constraints.  
Table 4.6 summaries the findings in terms of fluorescing foci detected, PCR analysis and 









Figure 4.25: PCR analysis of the putative intermediate LSDV-BLV-Env-Gag in the passage 18 viral stock. (A) Schematic diagrams showing binding sites of primer set 
4 (yellow arrows) and primer set 5 (red arrows) on the genome of a possible intermediate recombinant virus that recombined into the 049 ORF only (top) or into 050 ORF 
only (bottom). PCR products are shown as a line with expected product size. A fragment containing the pUC57 vector backbone is shown as a dark blue arrow box in this 
figure. LacZ, LacZ alpha fragment of the beta-galactosidase gene; bla (AmpR), beta-lactamase (bla) gene; Ori, ColE1 origin of replication. (B) Agarose gel showing no 
amplification of a 1,420bp product with primer set 4 which detects the presence of intermediate recombinant LSDV-BLV-Env-Gag into 049 ORF only. (C) Agarose gel showing 
a 1,051bp product amplified with primer set 5 which detects the presence of intermediate recombinant LSDV-BLV-Env-Gag into 050 ORF only. M, 1 kb DNA ladder (Thermo 
Scientific, USA); 1, total DNA from uninfected cells; 2 and 3, total DNA from passage 18 viral stock of recombinant LSDV-BLV-Env-Gag; 4, parental viral DNA; 5, PCR control 








Figure 4.26: Detection of in vitro expression of the BLV Gag proteins from the passage 18 viral stock of 
the recombinant LSDV-BLV-Env-Gag. (A) Fluorescent images showing cell morphologies of the MDBK cells 
infected with the recombinant LSDV-BLV-Env-Gag at 24, 48 and 72 hours post-infection (hpi). MDBK cells 
infected with the recombinant LSDV-BLV-Env-Gag were visualized by their eGFP (green) and mCherry 
expression (red). MDBK cells infected with the parental nLSDVSODis-M were visualized by their mCherry 
expression (red). All images were taken using a Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, 
Germany) at 50x magnification at 24, 48 and 72 hours post-infection. Scale bars represent 200µm. (B) Western 
blotting showing extracellular and intracellular expression of the BLV Gag protein. NC, total protein extracted 
from uninfected cells; 24, 48 and 72, total protein extracted at 24, 48 and 72 hours post-infection, respectively; 
72B, total proteins were extracted from three wells of a 6-well tissue culture plate at 72 hours post-infection which 
were combined as a “Bulk” sample. Cell lysate at 24 hours post-infection is not available. BLV Gag protein with 
the expected size of 45 kDa is indicated by a black arrowhead.  
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Table 4.6: Table summarising results from passaging potential recombinant LSDV-BLV-Env-Gag and assays to characterise BLV Env and Gag antigens 
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15-16 ✓ ++        


















a, Checkmark (✓) indicates the presence of possible recombinant LSDV-BLV-Env-Gag. b, the relative number of the parental virus was shown by a plus sign (+, ++ and +++) and the minus 
sign (-) indicates no detection of the parental virus in any wells. c, Checkmark represents amplification of expected PCR products which confirm the presence of a possible final or 
intermediate recombinant virus or parental virus and cross () indicates no amplification of expected PCR products. d, Checkmark indicates the confirmation of the BLV Gag protein 
expression by Western blotting (WB). HR, homologous recombination; ORF, open reading frame.
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4.3.3. Construction and purification of the recombinant LSDV-BLV-Env  
Recombinant LSDV harbouring the BLV env and gag genes as well as the egfp gene (LSDV-
BLV-Env-Gag) was constructed as shown in Section 4.3.2. However, the parental virus 
persisted and eventually outgrew the recombinant virus after 18 passages. In addition, an 
intermediate recombinant virus was detected in the final viral stock at passage 18. Therefore, 
to assess whether the expression of BLV Gag might have inhibited the growth of recombinant 
LSDV-BLV-Env-Gag, recombinant LSDV harbouring the BLV env gene and the egfp gene 
(LSDV-BLV-Env) was constructed. For the generation of this recombinant LSDV, 
nLSDVSODis-UCT was used as a parental virus. This parental virus does not contain an 
Escherichia coli xanthine phosphoribosyltransferase (Ecogpt) selection gene or mCherry 
fluorescent protein marker gene. Since the presence of Ecogpt gene is not desirable in 
vaccines, this nLSDVSODisUCT was selected to construct the recombinant LSDV-BLV-Env.   
 
4.3.3.1. Construction of the recombinant LDSV-BLV-Env in primary foetal bovine testes 
(FBT) cells 
To generate the recombinant LSDV-BLV-Env, primary foetal bovine testes (FBT) cells were 
transfected with the pBLV-Env transfer vector plasmid and infected with the parental 
nLSDVSODis-UCT virus at an MOI of 0.01, 0.05, 0.1 or 0.5.  
Green fluorescing cells were detected from all experimental wells at 48 hours post-infection 
(Figure 4.27) and a great number of green fluorescing cells were detected from the 
transfected-cells that were infected with the nLSDVSODis-UCT at MOIs of 0.05, 0.1 and 0.5. 
Some of the green fluorescing cells showed characteristic cytopathic effects (CPEs), forming 
large distinctive foci at 48 hours post-infection. 
 
4.3.3.2. Purification of the recombinant LDSV-BLV-Env by serial passages in Madin-
Darby bovine kidney (MDBK) cells 
For the purification of the recombinant LSDV-BLV-Env-Gag, one of the problems was the 
presence of a great number of parental viruses at most passages. To address this issue, 
individual green fluorescent foci of the recombinant LSDV-BLV-Env were picked and used to 
infect MDBK cells in 6-well, 12-well or 24-well tissue culture plates and when the number of 
the parental virus started decreasing significantly from the viral stock, cell lysates were used 
to infect cells in a 96-well plate to dilute out parental viruses. Figure 4.28 outlines tissue culture 






Figure 4.27: Fluorescent images of primary FBT cells transfected with the pBLV-Env plasmid DNA and infected with nLSDVSODis-UCT. Primary FBT cells were 
infected with the nLSDVSODis-UCT at MOIs of (A) 0.01, (B) 0.05, (C) 0.1 or (D) 0.5 and transfected with 6µg of pBLV-Env-Gag plasmid. Primary FBT cells infected with 
the recombinant LSDV-BLV-Env were visualized by their eGFP expression (green). All images were taken at 48 hours post-infection using a Zeiss Axiovert 200M 
fluorescence inverted microscope (Zeiss, Germany) at 50x for the left panel and at 100x for the right panel. Scale bars represent 200µm for the images on the left panel 





Figure 4.28: Flow diagram outlining the purification of the recombinant LSDV-BLV-Env in MDBK cells. 
Flow diagram outlines the tissue culture plates used at each passage and focus (yellow arrow) or cell lysate 
(pink arrow) isolated for the next passage. Detection of parental viruses as a whole is indicated as plus signs 
and their relative numbers are represented by + to +++. ND indicates no detection of the parental virus in any 
wells. Passages at which PCR, sequencing and immunofluorescence (IF) analyses were performed are 
indicated in this figure.   
 
4.3.3.2.1. Plaque purification of the LSDV-BLV-Env in MDBK cells from passage 1 to 
passage 3  
Cell lysates were isolated from the primary FBT cells from the initial plate to infect MDBK cells 
at passage 1. At 48 hours post-infection, some of the green fluorescing foci observed at 24 
hours post-infection disappeared, indicating that they were expressing eGFP transiently or 
they were still unstable. No green fluorescing foci were detected from some other wells after 
a 120-hour incubation, indicating that they were also expressing eGFP transiently or they were 
too unstable to grow. 
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Green fluorescing foci that did not have non-fluorescing foci (parental viruses) in their proximity 
were carefully picked used to infect MDBK cells consecutively at passages 1, 2 and 3 (Figure 
4.29 A-C). Whilst some foci also resulted in no growth at passages 2 and 3, other foci were 
small, and others were large or appeared to be spreading and infecting adjacent cells. At 
passage 3, less parental viruses were detected and two wells appeared to contain a single 
green fluorescing focus without the presence of parental viruses (Figure 4.29 C), indicating 





Figure 4.29: Green fluorescing foci of MDBK cells infected with recombinant LSDV-BLV-Env at 
passages 1, 2 and 3. A single focus from (A) passage 1 (images taken at 72 hours post-infection), (B) 
passage 2 (images taken at 96 hours post-infection) and (C) passage 3 (images taken at 96 hours post-
infection). MDBK cells infected with the recombinant LSDV-BLV-Env were visualized by their eGFP 
expression (green). All images were taken using a Zeiss Axiovert 200M fluorescence inverted microscope 
(Zeiss, Germany) at 100x magnification. Scale bars represent 100µm. 
 
4.3.3.2.2. Purification of the LSDV-BLV-Env in MDBK cells using serial dilutions of cell 
lysates from passage 4 to passage 9 
Although non-fluorescing foci formed by parental viruses were not present in two wells at 
passage 3, parental viruses could be present in the culture media as an extracellular 
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enveloped virus (EEV), which exists in the extracellular space after budding out of the infected 
cells [533]. EEV is not visually detectable and detection of the parental viruses are only 
possible when parental viruses infect cells and form non-fluorescing foci, Therefore, from 
passage 4 to passage 9, MDBK cells were infected in a 96-well plate using serial dilutions of 
cell lysates to dilute out undetectable parental viruses and to isolate a single focus per well.  
Careful monitoring of the infected cells at passage 4 revealed that for unknown reasons, some 
non-fluorescing foci were only detected after an extended period of incubation (~6 days) and 
thus the presence of the parental nLSDVSODis-UCT virus could be missed out if the 




Figure 4.30: Detection of parental nLSDVSODis-UCT, recombinant LSDV-BLV-Env as well as 
recombinant LSDV-BLV-Env that partially lost eGFP expression at passage 9. (A) A representative 
image showing non-fluorescing parental viruses. (B) A representative image showing green fluorescing foci 
detected in a well where parental virus appeared to be absent. (C) A representative image showing green 
fluorescing foci that partially lost eGFP expression. MDBK cells infected with the recombinant LSDV-BLV-Env 
were visualized by their eGFP expression (green). All images were taken at 96 hours post-infection using a 
Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, Germany) at 50x magnification. Scale bars 
represent 200µm. 
 
At passage 9, following the five consecutive passages in 96-well plates, whilst numerous 
parental viruses were still detected in many other wells (Figure 4.30 A), no parental viruses 
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were detected in several wells after the isolation of green fluorescing foci at 96 hours post-
infection (Figure 4.30 B). However, in another tissue culture plate prepared at passage 9, 
green fluorescent foci that had partially lost eGFP expression was detected in some wells 
(Figure 4.30 C), indicating the presence of possible intermediate recombinant LSDV-BLV-Env 
whereby HR occurred into 049 ORF only or 050 ORF only.  
 
4.3.3.2.2.1. PCR analysis of the presence of the recombinant LSDV-BLV-Env at passage 
9  
Due to the presence of possible final and intermediate recombinant LSDV-BLV-Env as well 
as parental viruses at passage 9, PCR was performed to assess whether the final recombinant 
LSDV-BLV-Env was present at passage 9 (Figure 4.31). Amplification of a 744bp fragment 
using primer set 1 indicates that HR occurred into both 049 and 050 ORFs or into 049 ORF 
only whereas no amplification of a 945bp fragment using primer set 2A suggests either 
inefficient PCR or the absence of HR into 050 ORF (Figure 4.31 C and D). As these results 
were inconclusive to determine the presence of the final recombinant LSDV-BLV-Env, another 
PCR was performed to aim at amplification of a 3,799bp fragment across the BLV expression 
cassette using primer set 3 (Figure 4.31E). However, an expected 3,799bp fragment was not 
amplified. Instead, a 1,340bp fragment indicating the presence of the parental nLSDVSODis-
UCT was amplified using the same primer set 3 (Figure 4.31E).  
Since the amplification of a 744bp fragment using primer set 1 and no amplification of a 945bp 
fragment using primer set 2 from the 5’-end and 3’-end of the BLV expression cassette, 
respectively, only suggest, but cannot conclusively show, the possible presence of an 
intermediate recombinant virus whereby HR occurred into 049 ORF only, to confirm these 
results, primer sets 4 and 5 were used (Figure 4.32 A). The presence of a possible 
intermediate recombinant virus whereby HR occurred into 050 ORF only and not into 049 ORF 
was confirmed by amplification of a 1,051bp using primer set 5 (Figure 4.32 A and C). A 
1,420bp fragment was not amplified using primer set 4 (Figure 4.32 A and B), indicating either 
the absence of a possible intermediate recombinant LSDV-BLV-Env whereby HR occurred 





                              
 
 





Figure 4.31: Preliminary confirmation of the presence of the LSDV-BLV-Env at passage 9. Schematic diagrams showing (A) binding sites of primer set 1 (purple arrows) 
and primer set 2 (blue arrows) on the LSDV-BLV-Env gnome and (B) binding sites of primer set 3 (purple and blue arrows) on the LSDV-BLV-Env gnome and parental 
nLSDVSODis-UCT genome. PCR products are shown as a line with expected product size. See Figure 4.21 for the sequence annotation. (C) Agarose gel showing a 744bp 
product amplified with primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-Env into 049 ORF. (D) Agarose gel showing no amplification of 
a 945bp product with primer set 2A which detects the presence of a final and intermediate recombinant LSDV-BLV-Env into 050 ORF. (E) Agarose gel showing a 1,340bp 
product amplified with primer set 3 which detects the presence of a final recombinant LSDV-BLV-Env- and/or parental nLSDVSODis-UCT.  M, 1 kb DNA ladder (Thermo 
Scientific, USA); 1, total DNA from uninfected cells; 2 and 3, total DNA from the passage 9 viral stock of recombinant LSDV-BLV-Env; 4, parental viral DNA; 5, PCR control 
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Figure 4.32: Preliminary confirmation of the presence of an intermediate LSDV-BLV-Env at passage 9. 
(A) Schematic diagrams showing binding sites of primer set 4 (yellow arrows) and primer set 5 (red arrows) on 
genome of possible intermediate recombinant virus that recombined into the 049 ORF only (top) or into 050 ORF 
only (bottom). PCR products are shown as a line with expected product size. See Figure 4.25 A for the sequence 
annotation. (B) Agarose gel showing no amplification of a 1,420bp product with primer set 4 which detects the 
presence of intermediate recombinant LSDV-BLV-Env into 049 ORF only. (C) Agarose gel showing a 1,051bp 
product amplified with primer set 5 which detects the presence of intermediate recombinant LSDV-BLV-Env into 
050 ORF only. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, total DNA from uninfected cells; 2 and 3, total 
DNA from passage 9 viral stock of recombinant LSDV-BLV-Env; 4, parental viral DNA; 5, PCR control without 
template DNA. 
 
4.3.3.2.3. Plaque purification of the LSDV-BLV-Env in MDBK cells from passage 10 to 
passage 15 
Cell lysates were isolated from the passage 9 plate where no parental viruses were detected 
and used to infect MDBK cells to allow the recombinant LSDV-BLV-Env to propagate further 
without the presence of the parental virus. The passaging of the recombinant viruses 
continued by infecting picked foci at passages 10, 11 and 12. At passage 13, only a single 
parental virus was detected in one well of a tissue culture plate, suggesting that the passaging 
of picked foci after the consecutive passages of serial dilutions of cell lysates in a 96-well 




4.3.3.2.3.1. PCR analysis of the presence of the recombinant LSDV-BLV-Env at passage 
13  
Since the purification of the recombinant LSDV-BLV-Env had appeared to be successful, the 
presence of a possible final recombinant LSDV-BLV-Env at passage 13 was once again 
assessed by PCR. Amplification of 744bp, 834bp and 1,340bp fragments using primer sets 1, 
2B and 3, respectively indicates the presence of the parental virus but this time again, the 
presence of a final recombinant LSDV-BLV-Env was not confirmed (Figure 4.33 C-E). Since 
the presence of a possible intermediate recombinant LSDV-BLV-Env whereby HR occurred 
into 050 ORF was detected at passage 9, the presence of this type of intermediate 
recombinant virus was assessed at passage 13 using primer set 5. The absence of this 
intermediate recombinant virus was noted for no amplification of a 1,051bp fragment (Figure 
4.34 B).  
At passage 14, some parental viruses were detected. Nevertheless, a total of twenty green 
fluorescing foci were picked and each focus was used to infect MDBK cells in each well of a 
tissue culture plate. This passage 15 served as a preparation for the PCR screening of the 
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Figure 4.33: PCR analysis of the putative LSDV-BLV-Env at passage 13. Schematic diagrams showing (A) binding sites of primer set 1 (purple arrows) and primer set 2B 
(blue arrows) on the LSDV-BLV-Env gnome and (B) binding sites of primer set 3 (purple and blue arrows) on the LSDV-BLV-Env gnome and parental nLSDVSODis-UCT 
genome. PCR products are shown as a line with expected product size. See Figure 4.21 for the sequence annotation. (C) Agarose gel showing a 744bp product amplified with 
primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-Env into 049 ORF. (D) Agarose gel showing an 834bp product amplified with primer 
set 2B to detect the presence of a final and intermediate recombinant LSDV-BLV-Env into 050 ORF. (E) Agarose gel showing a 1,340bp product amplified with primer set 3 
which detects the presence of a final recombinant LSDV-BLV-Env- and/or parental nLSDVSODis-UCT. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, total DNA from 








Figure 4.34: Preliminary confirmation of the absence of an intermediate LSDV-BLV-Env that recombined 
into 050 ORF only at passage 13. (A) A schematic diagram showing binding sites of primer set 4 (yellow 
arrows) and primer set 5 (red arrows) on genome of possible intermediate recombinant virus that recombined 
into the 049 ORF only (top) or into 050 ORF only (bottom). PCR products are shown as a line with expected 
product size. See Figure 4.25 A for the sequence annotation. (B) Agarose gel showing no amplification of a 
1,051bp fragment with primer set 5 which detects the presence of an intermediate LSDV-BLV-Env that 
recombined into the 050 ORF only. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, total DNA from uninfected 
cells; 2 and 3, total DNA from passage 13 viral stock of the LSDV-BLV-Env; 4, parental viral DNA; 5, PCR 
control without template DNA. 
 
4.3.3.2.3.2. PCR screening of the presence of the final recombinant LSDV-BLV-Env at 
passage 15 
PCR screening of the many possible recombinant viruses was conducted in order to isolate 
those with no parental viruses in the same well. To do this, twenty foci that did not have 
parental viruses in their proximity were isolated from a 6-well tissue culture at passage 14 and 
the individual foci were used to infect MDBK cells in each well of a 24-well tissue culture plate. 
Some foci (Figure 4.35) propagated extensively forming large foci at 96 hours post-infection 
but parental viruses were detected in all wells. Ten out of twenty wells that contained more 
recombinant viruses and less parental viruses were selected to perform PCR screening using 
the primer sets outlined in Table 4.3. 
Using primer set 1, a 744bp fragment was amplified from all ten samples (Figure 4.36 B), 
indicating recombination into the 049 ORF had occurred. An 834bp fragment using primer set 
2B was amplified only from samples 2, 6, 8 and 9 (Figure 4.36 C), indicating that recombination 





Figure 4.35: Fluorescent images showing the presence of parental nLSDVSODis-UCT and recombinant LSDV-BLV-Env in ten wells selected for the PCR screening 
of recombinant LSDV-BLV-Env at passage 15. (1-10) Fluorescent images showing ten wells of the passage 15 plate, from which total crude DNA was extracted at 96 hours 
post-infection. Note that foci detected in each well originated from single foci from the passage 14 plate. MDBK cells infected with the recombinant LSDV-BLV-Env were 
visualized by their eGFP expression (green). All images were taken at 96 hours post-infection using a Zeiss Axiovert 200M fluorescence inverted microscope (Zeiss, Germany) 
at 50x magnification. Scale bars represent 200µm. Uninfected, uninfected cells. 
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Although an 834bp fragment was not amplified from other samples, this does not mean that 
those samples did not contain the recombinant viruses. It possible that the primer set 2 did 
not amplify as efficiently and thus may not have detected low levels of recombinants in this 
region. Using primer set 3, a 1,340bp fragment was amplified from all samples, indicating the 
presence of the parental virus in all the well (Figure 4.36 D). No 3,799bp fragment indicating 
the presence of the recombinant LSDV-BLV-Env was amplified in any of the samples (Figure 
4.36 D). This may have been due to the inefficient amplification of this large fragment. 
Well number 2 was selected for the downstream analyses as amplification of the 834bp 
fragment using both primer sets 1 and 2 was successful (Figure 4.36 C lane 2).  
Although the parental virus was still detected, cell lysate was further passaged into a 6-well 
tissue culture plate and then into a 75 cm2 tissue culture (T-75) flask to perform a PCR analysis 
to assess the presence of the final recombinant virus and IFA to confirm the expression of the 
BLV Env protein from the recombinant LSDV-BLV-Env. Unlike the passage 17 and passage 
18 viral stocks of the recombinant LSDV-BLV-Env-Gag, the parental virus did not outgrow the 
recombinant LSDV-BLV-Env and the recombinant LSDV-BLV-Env propagated extensively 
and formed large foci.  
The eGFP expressing recombinant LSDVs from the parental virus could have been purified 
by fluorescence-activated cell sorting (FACS) but further steps to further purify the final 
recombinant LSDVs from intermediate recombinant viruses by passaging would be required. 










Figure 4.36: PCR screening of the 
presence of possible final recombinant 
LSDV-BLV-Env at passage 15 viral. (A) 
Schematic diagrams showing binding sites 
of primer set 1 (purple arrows) and primer 
set 2B (blue arrows) on the LSDV-BLV-Env 
gnome and binding sites of primer set 3 
(purple and blue arrows) on the LSDV-
BLV-Env gnome and parental 
nLSDVSODis-UCT genome. PCR 
products are shown as a line with expected 
product size. See Figure 4.21 for the 
sequence annotation. (B) Agarose gels 
showing a 744bp fragment amplified with 
primer set 1 to detect the presence of 
recombinant LSDV-BLV-Env. (C) Agarose 
gels showing an 834bp fragment amplified 
with primer set 2B to detect the presence 
of recombinant LSDV-BLV-Env. (D) 
Agarose gels showing a 1,340bp fragment 
with primer set 3 which detects the 
presence of the parental nLSDVSODis-
UCT. NC (negative control), total DNA 
extracted from uninfected cells; 1-10, total 
DNA extracted from ten wells of a passage 
15 tissue culture plate where MDBK cells 
were infected with recombinant LSDV-
BLV-Env; WT, parental viral DNA; 5, PCR, 






4.3.3.2.4. Characterisation of the recombinant LSDV-BLV-Env  
4.3.3.2.4.1. Final confirmation of the presence of the BLV env gene in the recombinant 
LSDV-BLV-Env by PCR  
To determine whether an intermediate recombinant containing the entire transfer vector or the 
final recombinant only containing the BLV env gene and the egfp gene had been obtained, 
PCR was performed with different sets of primers as outlined in Table 4.3 and using viral 
stocks from passage 17 and passage 18 of the recombinant LSDV-BLV-Env. 
Using primer sets 1 and 2C, 744bp and 720bp fragments were amplified from the passage 17 
and 18 viral stocks of the recombinant LSDV-BLV-Env (Figure 4.37 C and D). To confirm the 
presence of a possible final recombinant LSDV-BLV-Env, another PCR was performed using 
primer set 3B. Amplification of a 3,537bp fragment covering the entire BLV expression 
cassette between the 049 and 050 genes of the LSDV-BLV-Env genome was not successful. 
This may have been due to the inefficient amplification of this large fragment. Using the same 
primer set 3, a 1,078bp fragment was amplified, confirming the presence of the parental virus 
in the passage 17 and 18 viral stocks (Figure 4.37 E).   
PCR confirmation of the presence or absence of an intermediate recombinant LSDV-BLV-Env 
virus in the passage 17 and 18 viral stocks was performed as no intermediate recombinant 
virus was detected in the passage 13 viral stock. The presence of an intermediate recombinant 
virus in the passage 17 and 18 viral stocks where recombination into the 050 ORF only had 
occurred was, however, confirmed by amplification of a 1,051bp fragment using primer set 5 
(Figure 4.38 A and C). Once again, no intermediate recombinant virus in the passage 17 and 
18 viral stocks where recombination into the 049 ORF only had occurred was detected as 
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Figure 4.37: PCR analysis of the putative LSDV-BLV-Env at passages 17 and 18. Schematic diagrams showing (A) binding sites of primer set 1 (purple arrows) and 
primer set 2C (blue arrows) on the LSDV-BLV-Env gnome and (B) binding sites of primer set 3B (purple and blue arrows) on the LSDV-BLV-Env gnome and parental 
nLSDVSODis-UCT genome. PCR products are shown as a line with expected product size. See Figure 4.21 for the sequence annotation. (C) Agarose gel showing a 744bp 
product amplified with primer set 1 to detect the presence of a final and intermediate recombinant LSDV-BLV-Env into 049 ORF. (D) Agarose gel showing a 720bp product 
amplified with primer set 2C to detect the presence of a final and intermediate recombinant LSDV-BLV-Env into 050 ORF. (E) Agarose gel showing a 1,078bp product amplified 
with primer set 3B which detects the presence of a final recombinant LSDV-BLV-Env- and/or parental nLSDVSODis-UCT. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, 
total DNA from uninfected cells; 2, total DNA from the passage 17 viral stock of recombinant LSDV-BLV-Env; 3, total DNA from the passage 18 viral stock of recombinant 
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Figure 4.38: PCR analysis of the putative intermediate LSDV-BLV-Env in passage 17 and 18 viral stocks. 
(A) Schematic diagrams showing binding sites of primer set 4 (yellow arrows) and primer set 5 (red arrows) on 
the genome of a possible intermediate recombinant virus that recombined into the 049 ORF only (top) or into 
050 ORF only (bottom). PCR products are shown as a line with expected product size. See Figure 4.25 A for 
the sequence annotation. (B) Agarose gel showing no amplification of a 1,420bp product using primer set 4. (C) 
Agarose gel showing amplification of a 1,051bp product with primer set 5. M, 1 kb DNA ladder (Thermo Scientific, 
USA); 1, total DNA from uninfected cells2, total DNA from the passage 17 viral stock of recombinant LSDV-BLV-
Env; 3, total DNA from the passage 18 viral stock of recombinant LSDV-BLV-Env; 4, parental viral DNA; 5, PCR 
control without template DNA. 
 
4.3.3.2.4.2. Confirmation of the integrity of the recombinant LSDV-BLV-Env by Sanger 
sequencing 
To confirm that the recombinant LSDV-BLV-Env from the passage 17 and passage 18 viral 
stocks contained the correct BLV env gene, amplification of a 2,244bp fragment using 49 
forward (fwd) and eGFP reverse (rev) 7 primers was performed (Table 4.7). This 2,244bp 
fragment containing 260bp of the 3’ end of the 49 flank, the mFP promoter, the tPA signal 
sequence the entire BLV env gene and 365bp region of the beginning of the egfp gene (Figure 
4.39 A) was selected for sequencing.  
The 2,244bp fragment was successfully amplified from the passage 17 and 18 viral stocks of 
the recombinant LSDV-BLV-Env (Figure 4.39 B) and these PCR products were sequenced 
using five primers outlined in Table 4.7. The integrity of the mFP promoter, the tPA signal 
sequence, the BLV env gene as well as 260bp of the 49 flank and 365bp region of the 





Table 4.7: Primers used to amplify and sequence a 2,244bp fragment of the LSDV-BLV-Env genome 
Primers Orientation Binding site Purposes 
49 fwd Forward 049 ORF 
Amplification of a 2,244bp fragment 
eGFP rev 7 Reverse  egfp 
Env rev 1 Reverse  Env gp51 
Sequencing of the 2,244 PCR products 
Env fwd 2 Forward Env gp51 
Env fwd 6 Forward Env gp51 









Figure 4.39: Amplification of a 2,244bp fragment from the LSDV-BLV-Env genome for sequencing. (A) A 
diagram showing binding sites of 49 forward (fwd) and eGFP reverse (rev) 7 primers (green arrows) on the 
recombinant LSDV-BLV-Env viral genome. PCR product is shown as a line with expected product size. (B) A 
diagram showing binding sites of five primers (blue arrows) on the recombinant LSDV-BLV-Env viral genome 
used to sequence the 2,244bp product.  (C) Agarose gel showing amplification of a 2,244bp product with primer 
49 fwd and eGFP rev7. M, 1 kb DNA ladder (Thermo Scientific, USA); 1, total DNA from passage 17 viral stock 
2, total DNA from passage 18 viral stock of recombinant LSDV-BLV-Env; 3, total DNA from uninfected cells; 4, 
PCR control without template DNA. 
 
4.3.3.2.4.3. Final confirmation of the BLV Env protein expression by 
immunofluorescence assay (IFA) 
Since the anti-BLV Env gp51 monoclonal antibody (Veterinary Medical Research and 
Development, USA) utilised in this study recognises a conformational epitope on the Env gp51 
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glycoprotein, BLV Env expression from the recombinant LSDV-BLV-Env-Gag was not 
detected by Western blotting (See Section 4.3.2.2.3.2). Therefore, immunofluorescence assay 
(IFA) using the anti-BLV Env gp51 monoclonal antibody (anti-Env mAb) and anti-mouse IgG 
conjugated with Cy3 (anti-mouse IgG-Cy3) was performed to detect the BLV Env protein 
expression from the recombinant LSDV-BLV-Env. To allow the anti-BLV Env gp51 primary 
antibody to recognise the conformational epitope on the BLV Env protein, live-cell staining 
was performed by infecting MDBK cells with the passage 16 viral stock of the recombinant 
LSDV-BLV-Env.    
In the technical control wells, no Cy3 expression was detected from MDBK cells that were not 
infected (Figure 4.40 A), infected with parental nLSDSODis-UCT virus (Figure 4.40 B) or 
infected with the recombinant LSDV-BLV-Env (Figure 4.40 C and D) and immunostained with 
the anti-mouse IgG-Cy3 only, confirming the absence of non-specific binding of the anti-mouse 
IgG-Cy3 to the MDBK cells, MDBK cells infected with parental nLSDVSODis-UCT virus and 
MSDBK cells infected with recombinant LSDV-BLV-Env. In experimental wells, no Cy3 
expression was detected from MDBK cells that were not infected (Figure 4.40 E and G) and 
those infected with parental nLSDVSODis-UCT virus (Figure 4.40 F and H) when they were 
immunostained with the anti-Env mAb (1:50 or 1:100) and the anti-mouse IgG-Cy3, confirming 
the absence of non-specific binding of the anti-Env mAb against MDBK cells and the parental 
nLSDVSODis-UCT virus. 
BLV Env expression was detected from all experimental wells, irrespective of the amount of 
the recombinant virus used for the infection and dilutions of the anti-Env mAb. Figure 4.41 
shows two representative images of the BLV Env expression in MDBK cells infected with two 
different amounts (3µl or 5µl) of the recombinant virus and with two different dilutions of the 
anti-Env mAb (1:50 or 1:100). The anti-Env mAb appeared to be highly specific to the BLV 
Env protein only with an insignificant degree of background binding, which is consistent with 
IF results in the experimental controls. BLV Env expression was detected from almost all foci 
in each experimental well and the BLV Env expression appeared to be specifically 
concentrated in the foci. Furthermore, the BLV Env appeared to be actively transported from 
the infected cells or expressed on the surface of the infected cells.    
Table 4.8 summaries the results from passaging potential recombinant LSDV-BLV-Env and 
assays to characterise the BLV env gene and its protein expression by PCR, sequencing and  
IFA.  potential recombinant LSDV-BLV-Env and assays to characterise the BLV env gene and 






Figure 4.40: Live-cell staining of technical controls. MDBK cells were immunostained with (A-D) donkey anti-mouse Cy3-conjugated secondary antibody (anti-mouse 
IgG-Cy3) (1:500) only or (E-H) mouse anti-BLV Env gp51 primary antibody (anti-Env mAb) (1:50 or 1:100) followed by the anti-mouse IgG-Cy3. MDBK cells were either not 
infected (cells only), infected with nLSDVSODis-UCT at an MOI of 0.01 or infected with 3µl or 5µl of passage 16 viral stock of the recombinant LSDV-BLV-Env. MDBK cells 
infected with the recombinant LSDV-BLV-Env (LSDV) were visualized by their eGFP expression (green). All images were taken at 48 hours post-infection using a Zeiss 





Figure 4.41: Detection of the in vitro expression of the BLV Env protein in MDBK cells infected with 
passage 16 viral stock of the recombinant LSDV-BLV-Env. (A) MDBK cells were infected with 3µl of the 
passage 16 viral stock of the recombinant LSDV-BLV-Env and immunostained with a mouse anti-BLV Env 
monoclonal antibody (anti-Env mAb) (1:50) followed by a donkey-anti-mouse IgG conjugated with Cy3 (anti-
mouse IgG-Cy3) (1:500) (B) MDBK cells were infected with 5µl of the passage 16 viral stock of the 
recombinant LSDV-BLV-Env and immunostained with anti-Env mAb (1:100) followed by anti-mouse IgG-
Cy3 (1:500). BLV Env protein expression was detected with the anti-mouse IgG-Cy3 (red). MDBK cells 
infected with the recombinant LSDV-BLV-Env (LSDV) were visualized by their eGFP expression (green). All 
images were taken at 48 hours post-infection using a Zeiss Axiovert 200M fluorescence inverted microscope 
at 400x magnification. Scale bars represent 200µm. 
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Table 4.8: Table summarising results from passaging potential recombinant LSDV-BLV-Env and assays to characterise BLV Env antigen  
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a, Checkmark (✓) indicates the presence of possible recombinant LSDV-BLV-Env-Gag. b, Relative number of parental virus was shown by, +, ++ and +++.  c, Checkmark represents 
amplification of expected PCR products which confirm the presence of a possible final or intermediate recombinant virus or parental virus and cross () indicates no amplification of 
expected PCR products. d, Checkmark indicates the integrity of the BLV env gene by Sanger sequencing. e, Checkmark indicates the confirmation of the BLV Env protein expression by 




Two recombinant LSDVs expressing BLV Env with (LSDV-BLV-Env-Gag) or without Gag 
(LSDV-BLV-Env) were constructed. The presence of BLV gag gene in the recombinant LSDV-
BLV-Env-Gag was confirmed by Western blotting, which demonstrated extracellular and 
intracellular expression of the BLV Gag protein from the recombinant LSDV-BLV-Env-Gag. 
Due to time constraints, the BLV env and gag sequences in the recombinant LSDV-BLV-Env-
Gag were not confirmed. The presence of the BLV env gene and the in vitro expression of the 
BLV Env protein from LSDV-BLV-Env was confirmed by PCR and sequencing and 
immunofluorescence assay (IFA), respectively. Parental viruses appeared to outgrow both the 
recombinants and thus, due to time constraints, purification of the final LSDV-BLV-Env-Gag 
and LSDV-BLV-Env recombinants was not achieved. Intermediate recombinant viruses were 
isolated whereby HR took place at the 050 ORF only and not at the 049 ORF. The implication 
of these results will be discussed, and some suggestions will be presented to address these 
issues. 
 
4.4.1. Selection of the BLV env and gag antigen sequences of the recombinant LSDVs 
The BLV env and gag nucleotide sequences of the BLV expression cassette were designed 
based on sequences from a Japanese isolate (GenBank accession number, AP018021). 
Precise design of antigen sequences is a first critical step in the development of efficacious 
vaccines but designing immunogenic antigens is one of the most difficult aspects in the 
vaccine development. Most pathogens have evolved to have various mechanisms to evade 
host immune responses, such as mutating their antigen sequences, reassorting their genome 
in co-infected cells and shielding surface antigens [534-536]. Consequently, some pathogens 
have extensive genetic diversity between and within genotypes or serotypes. It has been 
shown that despite being a member of the Retroviridae family, the BLV genome is less variable 
than HIV between different genotypes [341, 537]. Therefore, BLV Env and Gag antigen 
sequences were designed based on a sequence from a BLV natural isolate that was closest 
to the consensus sequence. The env and gag sequences of the selected Japanese isolate 
pvAK006 shared 99.5% and 99.8% nucleotide sequence identity, respectively and 100% 
amino acid sequence identity with the consensus Env and Gag sequences obtained by the 
alignment of 62 sequences of BLV natural isolates. Since the consensus Env and Gag 
sequences obtained from the sequence alignment are artificial sequences, they could be 
dissimilar to sequences that are currently circulating. Therefore, BLV env and gag sequences 
of a natural isolate that were closest to the consensus env and gag sequences were selected 
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for the design of the BLV transfer vectors to minimise sequence divergence between vaccine 
antigens and currently circulating strains (also see Chapter 2).   
 
4.4.2. Selection of the insertion site in the nLSDVSODis genome 
To construct the recombinant LSDVs, the BLV expression cassette was inserted into an 
intergenic region between 049 and 050 ORFs of the parental LSDV. The careful selection of 
an appropriate insertion site was made by analysing LSDV genomic sequence such that 
inserted transgenes would be expressed properly without altered functions or inactivation of 
protein products and the insertion of transgenes would not adversely affect the replication and 
gene expression of recombinant viruses (N. Douglass (University of Cape Town), personal 
communication). The LSDV genome has a central conserved region flanked by two identical 
inverted terminal repeats (ITRs) on both sides and contains 156 putative genes [532]. ORFs 
are located on both DNA strands [538]. A limited number of insertion sites in the poxvirus 
genome have been available as the central region of poxviruses has a complex structure of 
closely packed ORFs, which are continuous or partially overlapping or are spaced by short 
intergenic regions (IGRs) [532, 538, 539]. Transgenes can be inserted into loci of non-
essential genes, major deletion regions or IGRs of poxvirus genomes.  
Traditional insertion sites include non-essential genes such as thymidine kinase (TK) [510] 
and haemagglutinin (HA) genes [540, 541]. Since the parental LSDV viruses used in this study 
are based on the live-attenuated Neethling vaccine strain, we did not utilise traditional insertion 
sites to avoid possible insertional mutagenesis as well as a decrease in viral replication and 
immunogenicity. Furthermore, the use of the TK locus as an insertion site is restricted by the 
use of the murine LMTK- cell line, which is not permissive to LSDV.   
Previously, Wyatt et al. [480] observed genetic instability of recombinant viruses and 
overgrowth of the recombinant variants as a result of deletions and mutations in transgenes 
inserted into the deletion (del) II and del III regions of the MVA genome, respectively. They 
postulated that since the deletion in the transgene extended into the non-essential sequences 
adjacent to the del II region, the deletion mutants were viable without selective pressure [480]. 
They also postulated that since no deletion but only mutations occurred in the del III region, 
which is flanked by essential genes encoding DNA ligase [542] and protein kinase [543], 
deletion affecting essential genes would be deleterious [480]. Based on this observation, they 
selected an intergenic region (IGRs) between two convergent ORFs of essential genes located 
in the conserved central region to improve the genetic stability of their recombinants [480]. 
They selected an intergenic region between the I8R gene encoding for the DNA/RNA helicase 
[544] and the G1L gene for the putative metalloproteinase [545, 546] and demonstrated that 
158 
Chapter 4 
the resultant recombinant virus was genetically stable [480]. We employed the same approach 
to aim at genetic stability of the recombinant LSDV and an intergenic region between 
convergent 049 and 050 genes, which are orthologues of the vaccinia virus I8R and G1L 
genes, located in the conserved central region of the LSDV genome was selected.  
 
4.4.3. Selection of the heterologous poxvirus promoters and antigen expression 
The BLV env, gag and egfp genes were placed under the control of the modified early fowlpox 
virus promoter (mFP) [438, 439], modified early-late promoter of the H5 gene of VACV (mH5) 
[440] and early-late promoter of a 7.5 kilodalton (kDa) polypeptide gene (p7.5) of vaccinia virus 
(VACV) [419], respectively.   
The mFP promoter was designed from a native early-late FP promoter [439] to retain an early 
promoter activity by removing a late promoter element [438]. Since a previous study [446] 
demonstrated stronger activity of the native early-late FP promoter than the p7.5 promoter but 
weaker than the strong late p11 promoter (promoter for the 11kDa polyprotein of VACV), we 
speculated that the mFP promoter would also be a moderate or strong promoter, equivalent 
to the p7.5 promoter but weaker than the mH5 promoter and a compact synthetic promoter 
(pS). However, as described in Chapter 3, the activity of the mFP promoter appeared to be 
weaker than that of the p7.5 promoter. At that stage, it was uncertain if this may have had an 
impact on the expression of the BLV Env protein. However, the immunofluorescence assay 
demonstrated abundant expression of the BLV Env protein on the surface of cells infected 
with the recombinant LSDV-BLV-Env.  
The BLV gag gene was placed under the control of the mH5 promoter. As the retrovirus Gag 
protein is known to elicit T cell responses [244, 547-551] and the virion morphogenesis takes 
place at the late stage of the viral life cycle, the strong early-late mH5 promoter was selected 
for the expression of the BLV Gag from the recombinant LSDV-BLV-Env-Gag. Western blots 
confirmed the extracellular and intracellular BLV Gag expression at 24 hours post-infection 
and the sustained expression during the 72-hour study period. To confirm that the budding 
BLV Gag particles form virus-like particles, electron microscopy analysis will be necessary.  
  
4.4.4. Challenges in the screening of the recombinant LSDVs 
Two recombinant LSDVs were constructed using two different parental LSDV viruses. These 
parental viruses differ in the presence or absence of selectable genes. The first recombinant 
LSDV-BLV-Env-Gag was constructed using nLSDVSODis-M containing the Ecogp selection 
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gene and mCherry marker gene whereas the second recombinant LSDV-BLV-Env was 
constructed using nLSDVSODis-UCT, which does not contain any selectable genes.  
It was difficult to detect the parental nLSDVSODis-UCT during the passaging of the second 
recombinant LSDV-BLV-Env. This parental virus did not contain a marker gene and the 
detection of the parental virus relied solely on the detection of non-fluorescing foci. As a result, 
some slow-growing parental viruses were only detectable at 6 days post-infection and in some 
cases, parental viruses were not detectable at all even after further incubation. Longer 
incubation might have helped the detection of non-fluorescing foci but also appeared to have 
enhanced the propagation of parental viruses. It was also difficult to determine whether the 
CPEs were true foci formed by parental viruses or were simply cell aggregation. Furthermore, 
some viruses infect cells but do not always form characteristic foci. These viruses are only 
detectable if they produce fluorescent proteins. Lülf et al. [552] also observed that more than 
70% of the MVA virions existed as non-plaque forming viruses or single infected cells whereas 
only 20-30% of them resulted in the formation of plaques. This could be another reason why 
it was difficult to detect a small fraction of the non-fluorescing and non-plaque forming parental 
viruses during the purification of the recombinant LSDV-BLV-Env.  
These issues together highlight the need for more effective ways to screen and “rescue” 
recombinant viruses out of a large population of parental viruses. One approach is the use of 
dominant host-range selection [423, 553, 554]. The dominant host-range selection is a marker-
free selection method and is a derivative of the rescue techniques that utilise replication-
incompetent or functionally defective viruses [555, 556]. The dominant host-range selection 
method takes advantage of the poxvirus host-range genes that limit the replication of 
poxviruses in specific hots or cell lines. Discrimination between recombinant and parental 
viruses is based on the presence of a host-range gene in recombinant viruses and cultivation 
of recombinant viruses in a cell line that is permissive to recombinant viruses but non-
permissive to parental viruses. In the absence of the host-range gene, parental viruses are 
not able to replicate or only able to replicate less efficiently in the non-permissive cell line. To 
utilise this system, either a host-range gene can be deleted from the recombinant viral genome 
[553, 555, 556] or in the case of attenuated poxviruses, a host-range gene can be re-
introduced into the recombinant viral genome [423, 554]. One of the well-known examples is 
the restoration of the vaccinia virus K1L gene into the MVA genome, thereby enabling the 
recombinant MVA to grow in rabbit kidney cells where the wild-type MVA cannot replicate 
[423]. This method is not only a stringent way to screen recombinant viruses but also a more 
efficient way to purify recombinant viruses without issues regarding outgrowth of parental 
viruses or selection pressure that will potentially cause mutations/fitness cost to recombinant 
viruses. The wild-type LSDV is already host-restricted and only able to replicate in ovine and 
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bovine cells. It has not been determined whether the introduction of a heterologous host-range 
gene (e.g. K1L gene of vaccinia virus) into the LSDV genome confers a new host range that 
can be utilised for the dominant host-range selection. However, it is worth assessing and this 
will expand the utility of the LSDV as an expression vector.  
 
4.4.5. Challenges in the purification of the recombinant LSDVs  
Apart from the delayed or no visible detection of parental viruses during the purification 
process, another issue was the persistence of the parental viruses after numerous passages. 
During the purification of both recombinant LSDVs, parental viruses persisted up to the final 
passages. In addition, a significant outgrowth of parental viruses over the recombinant virus 
was observed during the passaging of the LSDV-BLV-Env-Gag. We speculated that since the 
purification of the recombinant LSDV-BLV-Env-Gag was performed mostly by using cell 
lysates and cell lysates would have contained numerous parental viruses, the purification of 
the recombinant LSDV-BLV-Env was carried out mainly by picked foci as picking individual 
foci several times during the first several rounds prior to the confirmation of the absence of 
parental viruses has been shown to be effective in the removal of parental viruses [557, 558]. 
Agarose overlay method was also attempted to reduce the chance of picking both recombinant 
and parental viruses [559].Despite these improved methods, the parental virus persisted in 
the recombinant LSDV-BLV-Env viral stocks. As the aim of the construction of the second 
recombinant LSDV-BLV-Env was to assess the effect of the presence of Gag in the first 
recombinant LSDV-BLV-Env-Gag on the slow growth, we can conclude that the presence or 
absence of Gag was unlikely to contribute to the slow growth.  
One possible explanation for the preferential growth of the parental viruses over the 
recombinant LSDVs concerns the fitness cost of the recombinant viruses. Since the parental 
viruses did not contain the BLV expression cassette as an extra metabolic burden, they had 
higher fitness than the recombinant viruses and were able to grow faster than recombinant 
viruses. Furthermore, the persistence and outgrowth of the parental viruses were also 
because there was no selective pressure that favoured the growth of slow-growing 
recombinant viruses or selective pressure that opposed the propagation of the fast-growing 
parental viruses (c.f., dominant host-range selection as described above).  
The persistence and overgrowth of the parental viruses could be also due to the presence of 
the intermediate recombinant viruses (“single cross-overs”). An intermediate recombinant 
virus whereby recombination into 050 ORF only had occurred and not 049 ORF was detected 
from both recombinant LSDVs using primer set 5. An intermediate recombinant virus that had 
recombined into 049 ORF was not detected using primer set 4. However, it is possible that 
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this was due to an inefficient PCR amplification as there was no positive control available to 
confirm that the PCR was working. Unsuccessful amplification of an approximately 800bp 
region spanning the end of the egfp gene and the 050 ORF (e.g., passage 9, 13 and 15 and 
more PCR experiments whose data are not shown) of the recombinant LSDV-BLV-Env, even 
using modified versions of primer set 2 (i.e., primer set 2B and 2C) as well as different DNA 
polymerase and thermocycling conditions during most passages of both recombinant LSDVs 
indicates the presence of an intermediate recombinant virus whereby recombination into 049 
ORF only had occurred.If this intermediate recombinant virus outnumbered final recombinant 
viruses, the primer set 2 would preferentially bind to this intermediate recombinant viral 
genome and would amplify an approximately 4.5 kb fragment (shown as a dashed line in 
Figure 4.42). However, the amplification of this large fragment using PCR conditions set to 
amplify an approximately 800bp fragment was impossible. Consequently, the remaining 
primers that had not bound to the intermediate recombinant virus bound to a small number of 
final recombinant LSDV genomes, thereby resulting in a smaller amount of the PCR products. 
If some of these intermediate recombinant viruses had a second intramolecular HR at the 
same locus used as the first HR, the entire BLV expression cassette would be excised and 
the virus would revert to the parental virus (Figure 4.42). 
HR is a rare event where generally only 1 in 103 to 104 progeny viruses are a recombinant 
virus [557, 560, 561]. However, the persistence of the intermediate recombinant virus was 
enigmatic. Since the intermediate recombinant viruses contained the entire transfer vectors, 
this would result in an extra 4,227bp for the recombinant LSDV-BLV-Env-Gag and an extra 
3,507bp for the recombinant LSDV-BLV-Env compared to the final recombinant viruses. It is 
also surprising that the consecutive plaque purification used to isolate the recombinant LSDV-
BLV-Env was not effective in removing the intermediate recombinant virus.  
HR efficiency can be influenced by sizes and types of transgenes. For example, insertion of a 
large sequence or multiple sequences as well as genes potentially toxic to cells, such as a 
protease, appears to be less efficient [562]. Since the intermediate recombinant virus was 
detected in both recombinant LSDVs, this indicates that neither the size of the BLV expression 
cassettes (3,732bp for the recombinant LSDV-BLV-Env-Gag vs 2,447bp for the recombinant 





Figure 4.42: A schematic diagram outlining a possible process of generation of intermediate recombinant viruses and the subsequent generation of the revertant 
parental virus and the final recombinant virus. (1) When the first recombination (dashed lines) between the pBLV-Env transfer vector and the parental nLSDVSODis-UCT 
occurs into 049 ORF only, this results in the intermediate recombinant LSDV-BLV-Env that had incorporated the entire transfer vector, instead of BLV expression cassette 
only. Binding sites of primer set 2 (blue arrows) and an expected PCR product size (dashed line) are indicated in the diagram of a possible intermediate recombinant viral 
genome. (2) The second recombination can occur intermolecularly into 049 ORF or 050 ORF. (3) The second recombination once again into 049 ORF generates a revertant 
parental virus that has lost the entire transfer vector whereas the second recombination into 050 ORF generates final recombinant LSDV-BLV-Env that contain BLV expression 
cassette between 049 and 050 ORFs. Possible intermediate recombinant LSDV-BLV-Env that recombined into 049 only was used as an example.  
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To overcome the low efficiency of HR and to circumvent the generation of intermediate 
recombinant variants, the HR system can be optimised. The topology of plasmid DNA 
significantly affects HR efficiency and one possible manipulation is linearisation of transfer 
vector plasmid DNA. Yao et al. [563] compared HR efficiency using a set of plasmids in VACV-
infected cells and demonstrated that HR efficiency between two liner plasmids was 
significantly high whereas the HR between two circular plasmids was 15 to 50 times less 
frequent than the linear-to-linear recombination. Since the poxviral genome is already linear, 
transfection of linearised plasmid DNA into poxvirus-infected cells is expected to increase the 
HR efficiency.  
Apart from the manipulation of the plasmid DNA, the target viral DNA and the HR system can 
be manipulated. The first approach takes advantage of the intrinsic DNA-repair mechanism. 
Since HR efficiency significantly increases when the double-stranded break (DSB) is created 
in genomes during the viral life cycle [564], DSB can be artificially introduced into the target 
viral genome by an exogenous nuclease [565-567]. In this method, it is critical to reduce the 
chance of random excision and insertion into non-target insertion sites [568]. CRISPR/Cas9 
system is able to meet both requirements of precise excision and insertion at target sites. Yet, 
another factor that may still potentially reduce HR efficiency is that DSB can be repaired either 
by HR or non-homologous end joining (NHEJ) [564]. These two DNA-repair pathways appear 
to compete with each other and the blockage of one pathway leads to the predominant use of 
the other pathway [569, 570]. NHEJ does not rely on homologous sequences to repair DSB 
and this DNA-repair mechanism is infamously known as an error-prone repair system where 
mutations can be introduced at the site of DSB [564]. This concerns the potency of vaccines. 
To circumvent this consequence, Hu et al. [571] and others [572-576] devised elegant 
methods utilising a cellular DNA ligase IV inhibitor SCR7 to block the NHEJ pathway. For 
example, they combined the use of the CRISPR/Cas9 system, cellular DNA ligase IV inhibitor 
SCR7 and single-stranded oligodeoxynucleotides (ssODN) as a guide template [577, 578] and 
demonstrated increased HR and decreased NHEJ compared to reaction without the SCR7 
and/or ssODN [571]. This method is applicable in the development of recombinant poxviruses 
as despite cytoplasmic replication [579], poxviruses utilise the cellular DNA ligase IV in their 
NHEJ pathway [580]. By combining these methods, HR efficiency during the generation of 
recombinant viruses could be dramatically improved. 
 
4.4.6. Concluding remarks and future work 
This study provided an opportunity to prove how critical it is to understand the virology of 
poxviruses in order to design and develop a poxvirus-vectored vaccine as the resultant 
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vaccine needs to be stable, safe and potent. Two recombinant LSDVs were constructed and 
both recombinant LSDVs appeared to have a slower growth rate than the parental viruses. 
Furthermore, the purification of the recombinant LSDVs was challenging and the non-
recombinant viruses (i.e., intermediate recombinant viruses and parental viruses) were 
detected in both recombinant LSDVs. Nevertheless, expression of the BLV Env and Gag 
antigens from the recombinant LSDVs were confirmed. Further purification of the recombinant 





APPENDIX A: REAGENT FORMULATIONS 
0.8% (w/v) agarose gel  
Agarose  3.2g 
TBE 400ml 
Ethidium bromide  20µl 
 
1x Bjerrum Schafer-Nielsen transfer buffer (500ml)  
Glycine  1.465g 
Tris  2.91g 
Methanol   100ml 
ddH2O Adjust to 500ml 
 
2.5% (w/v) BSA/PBS blocking buffer  
BSA  2.5g 
1x PBS  100ml 
 
10% (v/v) complete Dulbecco’s Modified Eagle Medium 
(cDMEM) 
 
Dulbecco’s Modified Eagle Medium (DMEM) 500ml 
1% Penicillin-Streptomycin (Pen-Strep) 5ml 
10% Heat-inactivated foetal calf serum (FCS) 50ml 
0.1% Fungin (optional) 0.5ml 
 
Freezing medium  Concentration (v/v) 
Heat-inactivated fetal calf serum (FCS) 80% 
Dimethyl sulfoxide (DMSO)  10% 
DMEM 10% 
 
Luria-Bertani agar (100ml)  
Tryptone 1g 
Yeast extract  0.5g 
NaCl (200mM) 0.5g 
Agar 1.5g  
ddH2O Adjust to 100ml 
 
Luria-Bertani broth (100ml)  
Tryptone 1g 
Yeast extract  0.5g 
NaCl (200mM) 0.5g 
ddH2O Adjust to 100ml 
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Lysis solution (P2 buffer)   
NaOH (200mM) 8g in 900ml of ddH2O  
1% (v/v) SDS 100ml of 10% SDS in 1L of ddH2O 
 
Naturalising solution (P3 buffer) (100ml)  
Potassium acetate (3.0M, pH 4.8-4.9) 4.41g 
Glacial acetate  7.5ml 
ddH2O Adjust to 15ml 
 
1x PCR buffer  
KCl  0.187g 
Tris-HCl (1M) 500µl 
MgCl2-6H2O  0.0255g  
ddH2O Adjust to 50ml 
Proteinase K (1 mg/ml)  500µl 
 
1x phosphate-buffered saline Tween (PBST) (1000ml)  
Tween 20  10ml 
10x PBS  100ml 
ddH2O Adjust to 1000ml 
 
4x protein loading buffer   
100% glycerol 4ml 
1.5M Tris/HCl (pH 6.8) 1.6ml 
SDS 0.8g 
Beta-mercaptoethanol 0.5ml 
Bromophenol blue 4mg 
ddH2O Adjust to 3.9ml 
 
8% (v/v) resolving gel (10ml)  
40% acryl-bisarylamide mix 2ml 
1.5M Tris (pH 8.8) 2.5ml 
10% SDS 0.1ml 




Resuspension solution (P1 buffer)  
Tris-HCL (1 M, pH 8.0)  2.5ml 
20% (w/v) glucose  0.91 g of glucose in 4.55ml of ddH2O 
EDTA (0.5 M, pH 8.0)   2ml 
ddH2O 0.95ml 




10x SDS PAGE running buffer  
SDS 10g 
Tris  30.3g 
Glycine  29g 
ddH2O Adjust to 1000ml 
 
4% (v/v) stacking gel (5ml)  
40% acryl-bisarylamide mix 0.5ml 
1.5M Tris (pH 6.8) 0.68ml 
10% SDS 50µl 




5x Tris-borate-EDTA (TBE) buffer (1L)  
Tris base  54g 
Boric acid  27.5g 
0.5 M EDTA (pH 8.0) 20ml 
ddH2O Adjust to 1L 
 
Tris-EDTA (T10E1) buffer   
Tris-HCL (1 M)  1ml 
EDTA (0.5 M, pH 8.0)   200µl 
ddH2O Adjust to 100ml 
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APPENDIX B: STANDARD PROTOCOLS 
B1. Molecular cloning 
B1.1. Restriction endonuclease digestion of plasmids 
One microgram (5µg in the case of the cloning of the pLEO-eGFP) of plasmid DNA was 
digested with 1µl of restriction endonuclease(s) in a 25µl (60µl in the case of the cloning of the 
pLEO-eGFP) reaction mixture containing 2.5µl of 10x reaction buffer and double-distilled 
water (ddH2O). Following a one-hour incubation at 37°C, the digested plasmid DNA was 
resolved on an ethidium-bromide (0.5μg/ml) stained 0.8% agarose gel in 1x tris- borate-EDTA 
(TBE) buffer (Appendix A) at 100V for up to 2 hours (Nippon Genetics, Japan). DNA fragments 
were gel purified using the Zymoclean Gel DNA Recovery Kit (Zymo Research, USA) as per 
the manufacturer’s protocol.    
 
B1.2. Blunting of restriction sites by T4 DNA polymerase 
Where necessary T4 DNA polymerase was used to blunt the 5’ and 3’ DNA overhangs 
generated by restriction endonuclease digestion. Plasmid DNA was transferred into a 30µl 
reaction mixture containing 1µl of T4 DNA polymerase (New England BioLabs, USA), 3µl of 
10x T4 DNA Ligase Reaction Buffer (New England BioLabs, USA), 1µl of Deoxynucleotide 
(dNTP) Solution Mix (10mM) (New England BioLabs USA) and ddH2O. The reaction mixture 
was incubated at 12°C for 15 minutes. The blunting reaction was terminated by heating the 
reaction mixture to 75°C for 20 minutes. 
 
B1.3. DNA ligation 
Linearised vector and insert plasmid DNA were ligated in a 50µl reaction mixture containing 
1µl of T4 DNA Ligase (New England BioLabs, USA), 5µl of 10x T4 Ligase Reaction Buffer 
(New England BioLabs, USA) and ddH2O with 1-hour incubation at room temperature (20°C 
to 25°C). For the p7.5-eGFP, pBLV-Gag-eGFP, pmH5-eGFP and pS-eGFP reporter plasmids, 
two experimental ligation mixtures were prepared. A reaction mixture without T4 DNA Ligase 
was included as a negative control. Prior to transformation, the ligation reactions were heat-
inactivated by incubating the reaction tubes in a heating block at 65°C for 10 minutes.  
 
B1.4. Transformation of plasmid DNA 
Once the heat-inactivated plasmid DNA was cooled down to room temperature, transformation 
of chemically competent E. coli cells was conducted. An aliquot of 1.5µl of the ligation mixture 
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was transferred into an ice-cold 1.5ml Eppendorf tube containing 15µl of defrosted E. cloni 
10G chemically competent cells (Lucigen, USA). The plasmid and E. coli cells were mixed 
gently, and the reaction mixture was left on ice for 20 minutes to allow the crystallisation of 
DNA molecules. The transformation was initiated with heat shock, in which the reaction 
mixture was first placed on the heating block at 42°C for 45 seconds and then immediately 
placed back on ice. The reaction mixture was left on ice for 2 minutes to allow the reaction to 
complete. An aliquot of 350µl of pre-warmed Recovery Medium (Lucigen, USA) was added to 
the transformed bacterial cells and the bacterial culture was incubated at 37°C for 1 hour. 
Then, the transformed bacterial cells were plated on Luria-Bertani agar plates (Appendix A) 
containing carbenicillin (50µg/ml) (Thermo Fisher Scientific, USA). The plates were incubated 
at 37°C overnight.   
 
B1.5. Small-scale plasmid DNA isolation 
Bacterial colonies were picked from the agar plates and inoculated into 1.6ml of the Luria-
Bertani (LB) broth (Appendix A) containing carbenicillin (50µg/ml) (Thermo Fisher Scientific, 
USA) in 2ml Eppendorf tubes. The bacterial cultures were incubated overnight in a 37°C 
shaking incubator at 250 rpm.  
Eight hundred microliter of each of the bacterial culture was transferred into sterile 2ml 
Eppendorf tubes and the bacterial cultures were centrifuged at 20,800g for 1 minute. After 
removing the supernatant, samples were placed on ice, and the bacteria pellets were re-
suspended in 250μl of resuspension solution (P1 buffer) (Appendix A) and the cell pellet was 
re-suspended completely by pipetting the solution up and down. Then, 500μl of lysis solution 
(P2 buffer) (Appendix A) was added and the lysis of the cells was facilitated by inverting the 
tube gently several times. Samples were incubated on ice for 5 minutes. Finally, 375μl of 
neutralising solution (P3 buffer) (Appendix A) was added to the lysate and the sample was 
inverted several times to mix it thoroughly. Following a 10-minute incubation on ice, white 
aggregates of denatured protein were removed by centrifugation at 20,800g for 10 minutes, 
and 700μl of the supernatant containing plasmid DNA was carefully transferred into new 2ml 
Eppendorf tubes. 
An aliquot of 700μl of ice-cold isopropanol was added to each of the reaction tubes to 
precipitate the plasmid DNA and the samples were mixed thoroughly by inverting the tubes 
gently several times. The reaction mixtures were kept on ice for 15 minutes to allow the 
reaction to complete. The plasmid DNA was then pelleted by centrifugation at 20,800g for 20 
minutes. The supernatant was discarded, and the residual salt was removed from the pellet 
by rinsing it with 180μl of ice-cold 70% ethanol. The samples were centrifuged at 20,800g for 
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10 minutes and the 70% ethanol was discarded. After air-drying the pellet, the plasmid DNA 
was re-suspended in 50μl of TE buffer (Appendix A). The sample was stored at 4°C for future 
use. 
 
B1.6. Large-scale purification of plasmid DNA 
Eight microliters of the bacterial culture were transferred into 5ml of LB broth (Appendix A) 
containing carbenicillin (50µg/ml) (Thermo Fisher Scientific, USA) and incubated for 6 to 8 
hours in a 37°C shaking incubator at 250rpm. This starter culture was then, transferred into a 
2-litre flask containing 150ml of LB broth (Appendix A) and carbenicillin (50µg/ml) (Thermo 
Fisher Scientific, USA). The flasks were incubated overnight at 37°C with shaking at 250rpm. 
Plasmid DNA was then extracted from overnight bacterial cultures using the ZymoPURE II 
Plasmid Maxiprep Kit (Zymo Research, USA) as per the manufacturer’s instructions. 
Concentration and purity of the extracted plasmid DNA were measured using Nanodrop®1000 
(Thermo Fisher Scientific, USA).  
 
B2. Western blotting  
B2.1. Crude extraction of total proteins from MDBK cell infected virus 
An aliquot of 500µl of culture media was aspirated and transferred into 1.5ml Eppendorf tubes. 
The remaining culture media were discarded and each well was washed twice with 500μl of 
1x phosphate-buffered saline (PBS) (Thermo Fisher Scientific, USA). Then, 100μl of 1x Glo 
lysis buffer (Promega, USA) was added to each well, and the plate was incubated at room 
temperature for 5 minutes. The entire volumes of the crude cell lysates were transferred into 
new 1.5ml Eppendorf tubes, and the cell lysates were centrifuged at 12,100g for 10 minutes. 
Following the centrifugation, the supernatant was carefully recovered and transferred into 
sterile 1.5ml Eppendorf tubes. Both culture media and cell lysates were stored at -20°C until 
needed.  
 
B2.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
electroblotting 
The total proteins contained in the culture media and cell lysate were resolved by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at 250 V, using 
discontinuous gels consisting of a 4% stacking gel (pH 6.8) and an 8% resolving gel (pH8.8) 
in a Tris-glycine buffer system (Appendix A). Following the completion of the SDS-PAGE, the 
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polyacrylamide gel was recovered and soaked in Bjerrum and Schafer-Nielsen transfer buffer 
(Appendix A) prior to the transfer of the resolved proteins onto polyvinylidene difluoride (PVDF) 
membranes. PVDF membranes were activated by soaking them briefly in methanol and 
immediately washing with the Bjerrum and Schafer-Nielsen transfer buffer. The resolved 
proteins were transferred onto the PVDF membranes using Trans-Blot SD Semi-Dry Transfer 
Cell (BioRad, USA) at 25V for 1 hour. 
 
B2.3. Western blotting 
Upon completion of the electroblotting, the PVDF membranes were incubated in a 2.5% 
BSA/PBST blocking buffer (Appendix A) on a shaker with gentle agitation for 2 hours at room 
temperature. Then, the PVDF membranes were incubated overnight at room temperature with 
an antigen-specific primary antibody at an appropriate dilution. The PVDF membranes were 
subjected to five cycles of washing with phosphate-buffered saline containing 1% Tween 20 
(PBST) (Appendix A) and a 15-minute incubation on a shaker with gentle agitation. 
Subsequently, the PVDF membranes were probed with an anti-goat/sheep IgG monoclonal 
antibody conjugated with alkaline phosphatase (Sigma-Aldrich, USA) at appropriate dilution 
and incubated at room temperature for 2 hours on a shaker with gentle agitation. The 
membranes were washed five times with PBST and incubated for 15 minutes each time as 
described above. Lastly, 5ml of BCIP/NTB phosphatase substrate (KPL/SeraCare, USA) was 
added to the PVDF membranes. The PVDF membranes were incubated at room temperature 
in the dark for 5 to 15 minutes prior to the termination of the reaction by washing the membrane 
with PBST. The membrane was left dry in the dark for 1 hour prior to scanning the membrane. 
 
B3. Standard protocol for PCR  
B3.1. Crude extraction of total DNA from MDBK cells infected with a virus by alkaline 
lysis  
Culture media was removed and 500µl of resuspension solution (P1 buffer) (Appendix A) were 
added to each well. Then, 500µl of lysis solution (P2 buffer) (Appendix A) was added to each 
well and cells were lysed and collected by pipetting the solution several times over the cell 
layer. Crude cell lysates were transferred into 1.5ml Eppendorf tubes and 700µl of neutralising 
solution (P3 buffer) (Appendix A) was added to each tube. The contents were mixed by 
inverting the tubes several times. White aggregates of denatured protein were then, removed 
by centrifugation at 12,100g for 10 minutes and 800μl of the supernatant was carefully 
transferred into new 1.5ml Eppendorf tubes. An aliquot of 560μl of ice-cold isopropanol was 
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added to each of the reaction tubes to precipitate DNA and mixed thoroughly by inverting the 
tubes gently several times. Following the incubation of the samples at -20°C for 2 hours, the 
DNA was pelleted by centrifugation at 12,100g for 20 minutes. The supernatant was discarded, 
and the residual salt was removed from the pellet by rinsing it with 180μl of ice-cold 70% 
ethanol. The samples were centrifuged at 12,100g for 1 minute and the ethanol was carefully 
removed. After air-drying the pellet, the DNA was re-suspended in 50μl of HPLC grade water 
(Merck, USA). The sample was stored at -20°C for future use. 
 
B3.2. Crude extraction of total DNA from MDBK cells infected with a virus using PCR 
buffer  
To isolate the total crude DNA, the culture media was aspirated, and the cells were washed 
with 500µl of 1x PBS. A volume of 600µl of 1x PCR buffer (Appendix A) containing 10µg/ml of 
proteinase K (Sigma-Aldrich, USA) was added to each well and the cells were frozen at - 80°C 
and thawed at 37°C. The cell lysate was transferred into 1.5ml Eppendorf tubes and incubated 
in a heating block at 56°C for 20 minutes. Then, the proteinase K was heat-inactivated at 85°C 
for 10 minutes. The reaction mixtures were centrifuged at 394g for 10 minutes and the 
supernatant was carefully transferred into new 1.5ml tubes. 
 
B3.3. Preparation of PCR reaction mixture 
The 25µl (or 20µl) reaction mixture consisted of 12.5µl (or 10µl) of 2x KAPA 2G Robust 
HotStart ReadyMix (KAPA BIOSYSTEMS, USA) or OneTaq 2x Master Mix with Standard 
Buffer (New England BioLabs, USA), 3µl (or 2µl)of total crude DNA, 0.5µl of 50mM MgCl2 
(Thermo Fisher Scientific, USA) (where necessary), 1.25µl or 2µl of each primer (10µM each) 
depending on DNA polymerases and recommended concentration per manufacturer’s 
protocol and HPLC water (Sigma-Aldrich, USA). A PCR control mixture was prepared using 
HPLC water instead of template DNA. The PCR products were analysed by gel 
electrophoresis on a 0.8% agarose gel stained with ethidium bromide (0.5μg/ml). 
 
B4. Live-cell staining of BLV Env glycoprotein using mouse anti-Env monoclonal 
antibody 
A 24-well tissue culture plate was coated with 500μl of poly-L-lysine (Sigma-Aldrich, USA) at 
a dilution of 1:29. Following the incubation at 37°C for 1 hour, the solution was aspirated and 
the plate was washed twice with 500μl of 1x PBS. The plate was left to dry prior to use. The 
plate was then seeded with MDBK cells at a concentration of 2x105 cells/ml and the cells were 
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infected with 3μl or 5μl of the cell lysate of the viral stock and incubated under the standard 
growth conditions for 48 hours. MDBK cells that were not infected and those infected with the 
parental nLSDVSODis-UCT virus (1x107.25 TCID50) at an MOI of 0.01 were included as 
experimental controls.  
Once enough mature foci were obtained, the culture media was aspirated and the cells were 
incubated with 250μl of the mouse anti-BLV Env gp51 monoclonal antibody (anti-Env mAb) 
(Veterinary Medical Research and Development, USA) diluted at 1:50 or 1:100 in cDMEM at 
room temperature for 1 hour. The primary antibody was aspirated, and the cells were washed 
thrice with 500μl of 1x PBS for 10 minutes at room temperature. The cells were then incubated 
with 250μl of the donkey-anti-mouse IgG conjugated with Cy3 (anti-mouse IgG-Cy3) diluted 
at 1:500 in cDMEM at room temperature for 30 minutes. The secondary antibody was 
aspirated, and the cells were washed twice as before. The cells were incubated with 500μl of 
the Hoechst nuclear stain diluted at 1:5,000 in 1x PBS at room temperature in the dark for 10 




APPENDIX C: SUPPLEMENTAL FIGURES FOR CHAPTER 2 
Table S2.1: GenBank accession number, the origin of the sequences and genotypes of the global isolates 
used for the phylogenetic analyses of the South African BLV env and gag sequences  
GenBank accession 
number  
Country of origin Genotype References 
AB934282  Japan 1 Direct submission by Mekata and Norimine 
(2014) 
AF033818  USA 4 Direct submission by Chappey (1997) 
AF067081 Poland 4 Direct submission by Mikiewicz et al. (1998) 
AF257515 Argentina  2 [247] 
AF399702 Brazil 5 [365] 
AF399703 Brazil 1 [365] 
AF399704 Brazil 2 [365] 
AF503581 Belgium 4 [253] 
AP018021 Japan ND [347] 
AY151262  Brazil 1 Direct submission by Stancek et al. (2002) 
AY185360 Brazil 6 Direct submission by Camargos et al. (2002) 
AY515279 Chile 4 [338] 
AY515280 Chile 7 [338] 
D00647 Australia 1 [189] 
EF065635 Costa Rica 5 [249] 
EF065637 Costa Rica 1 [249] 
EF065641 USA 1 [249] 
EF065646 Japan  1 [249] 
EF065647 USA 3 [249] 
EF065650 Japan 3 [249] 
EF600696 USA 1 [219] 
EU262555 Poland 7 Direct submission by Rola et al. (2016) 
EU266061 Iran 1 [53] 
FJ808571 Argentina  1 [328] 
FJ808582 Argentina 6 [328] 
FJ914764 Argentina 2 [364] 
FM209468 Uruguay 1 [353] 
GU724606 Croatia 8 Direct submission by Lojkic (2010) 
HE967301 Uruguay 1 Direct submission by Cristina (2012) 
HM563764 Ukraine 8 [151] 
HQ902258 Belarus 4 [151] 
HQ902261 Russia 7 [151] 
JF713455  Russia 8 Direct submission by Shaeva et al. (2011)  
JN695878 Russia 4 Direct submission by Lomakina and Gulyukin 
(2012) 
JN695879 Russia 7 Direct submission by Lomakina and Gulyukin 
(2012) 
JQ686091 Russia 4 Direct submission by Lomakina and Gulyukin 
(2012) 
K02251 Belgium 4 [581] 
KF801457 Moldova 7 [334] 
KJ707242 South Korea 1 [361] 
KT122858 Belgium 4 Direct submission by Rosewick et al. (2015) 
KU233527 Thailand 10 [329] 
KU233528 Thailand 1 [329] 
KU233530 Thailand 6 [329] 
KX674369 Saint Kitts and Nevis  1 [343] 
KX674372 Dominica 1 [343] 
LC005615 Japan 1 Direct submission by Okazaki et al. (2014)  
LC060792 Mongolia 4 [152] 
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Table S2.1: GenBank accession number, the origin of the sequences and genotypes of the global isolates 
used for the phylogenetic analyses of the South African BLV env and gag sequences (Continued) 
GenBank accession 
number  
Country of origin Genotype References 
LC060801 Mongolia 7 [152] 
LC075543 Peru 1 [330] 
LC075544 Peru 2 [330] 
LC075549 Peru 6 [330] 
LC075553 Paraguay 6 [330] 
LC075558 Paraguay 1 [330] 
LC075563 Bolivia 9 [330] 
LC075568 Bolivia 1 [330] 
LC075571 Bolivia 6 [330] 
LC075577 Bolivia 2 [330] 
LC080651 Paraguay 1 [330] 
LC080654 Peru 2 [330] 
LC080655 Paraguay 2 [330] 
LC080656 Paraguay 6 [330] 
LC080659 Bolivia 9 [330] 
LC080664 Bolivia 9 [330] 
LC154064 Myanmar 10 [341] 
LC154848 Myanmar 10 [341] 
LC193462 Zambia 4 [345] 
M35238 France 4 [348] 
MF580991 China 6 [344] 
MF580994 China 10 [344] 
MH170027 Vietnam 1 [342] 
MH170028 Vietnam 1 [342] 
MH170030 Vietnam 6 [342] 
MH341516 India 6 [359] 







Figure S2.1: Neighbour-joining phylogenetic tree based on the BLV partial env nucleotide sequences 
from South Africa and other geographic regions worldwide. BLV strains identified in this study are indicated 
by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant LSDV-BLV-Env-
Gag and LSDV-BLV-Env is indicated by a filled square (■). A black arrow indicates the Zamibain isolate which 
is most closely related to the seven South African isolates. Other strains are indicated by their genotype, 
GenBank accession number and country of origin. Numbers at the branches denote bootstrap support (1000 






Figure S2.2: Neighbour-joining phylogenetic tree based on the BLV full-length gag nucleotide 
sequences from South Africa and other geographic regions worldwide. BLV strains identified in this study 
are indicated by filled triangles (▲) followed by their sample ID. The BLV strain used to design recombinant 
LSDV-BLV-Env-Gag and LSDV-BLV-Env is indicated by a filled square (■). Other strains are shown by genotype 
followed by GenBank accession number and country of origin. Numbers at the branches denote bootstrap 









Amino acid sequence identities are shown in brackets. The lower matrix shows the percent identity of nucleotide and amino acid sequences in the BLV full-length Env sequences and the upper 
matrix shows differences in nucleotide and amino acid sequences in the BLV full-length env sequences. Each cell is highlighted according to the amino acid sequence identities and differences. 
The country of origin is indicated by 2-letter codes. AU, Australia; AR, Argentina; BE, Belgium; BO, Bolivia; BR, Brazil; BY, Belarus; CL, Chile; CR, Costa Rica; DM, Dominica; FR, France; IR, 
Iran; JP, Japan; KN, Saint Kitts and Nevis; KR, South Korea; MN, Mongolia; PE, Peru; PL, Poland; PY, Paraguay; RU, Russia; TH, Thailand; US, USA; UY, Uruguay; ZM, Zambia. 
 
 





Amino acid sequence identities are shown in brackets. The lower matrix shows the percent identity of nucleotide and amino acid sequences in the BLV partial Env sequences and the upper matrix 
shows differences in nucleotide and amino acid sequences in the BLV partial env sequences. Each cell is highlighted according to the amino acid sequence identities and differences. The country 
of origin is indicated by 2-letter codes. AU, Australia; AR, Argentina; BE, Belgium; BO, Bolivia; BR, Brazil; BY, Belarus; CL, Chile; CR, Costa Rica; DM, Dominica; FR, France; IR, Iran; JP, Japan; 
KN, Saint Kitts and Nevis; KR, South Korea; MN, Mongolia; PE, Peru; PL, Poland; PY, Paraguay; RU, Russia; TH, Thailand; US, USA; UY, Uruguay; ZM, Zambia. 
 
G5 G9
K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401 AP018021 JP D00647 AU AF399703 BR AY151262 BR EF065637CR KX674372 DM EF065646 JP LC080651 PY KX674369 KN HE967301 UY EF065641 US MH170027 VN MH170028 VN AF257515 AR AF399704 BR LC080655 PY LC080654 PE EF065650 JP EF065647 US AF503581 BE JN695878 RU AF033818 US EF065635 CR MF580991 CN AY185360 BR LC080656 PY MH170030 VN KF801457 MD JN695879 RU LC080659 BO MF580994 CN LC154848 MM
K1170 2 (1) 2 (1) 56 (15) 1 (0) 2 (0) 1 (0) 4 (0) 56 (14) 53 (14) 49 (14) 56 (16) 53 (16) 51 (15) 50 (14) 54 (16) 52 (15) 54 (15) 52 (14) 53 (16) 53 (15) 68 (29) 52 (13) 49 (12) 53 (14) 50 (13) 49 (13) 24 (7) 21 (6) 20 (6) 54 (17) 59 (13) 60 (15) 59 (12) 58 (13) 48 (13) 46 (13) 49 (14) 54 (14) 50 (13)
K1194 99.87 (99.81) 2  (2) 56 (15) 1 (1) 2 (1) 1 (1) 4 (1) 56 (15) 53 (15) 49 (15) 56 (17) 53 (17) 51 (16) 50 (15) 54 (17) 52 (16) 54 (16) 52  (15) 53 (17) 53 (16) 68 (30) 52 (14) 49 (13) 53 (15) 50 (14) 49 (14) 26 (8) 21 (7) 20 (7) 54 (18) 59 (14) 60 (16) 59 (13) 58 (14) 48 (14) 46 (14) 51 (15) 54 (15) 50 (14)
M1878 99.87 (99.81) 99.87 (99.61) 56 (16) 1 (1) 2 (1) 1 (1) 4 (1) 56 (15) 53 (15) 47 (13) 54 (15) 53 (17) 51 (16) 50 (15) 52 (15) 52 (16) 52 (14) 52 (15) 53 (17) 53 (16) 68 (30) 52 (14) 49 (13) 53 (15) 50 (14) 49 (14) 26 (8) 21 (7) 20 (7) 54 (18) 59 (14) 60 (16) 59 (13) 58 (14) 48 (14) 46 (14) 51 (15) 54 (15) 50 (14)
M2746 96.38 (97.09) 96.38 (96.90) 96.38 (96.90) 55 (15) 56 (15) 55  (15) 58 (15) 14 (1) 38 (9) 19 (7) 16 (3) 13 (3) 9 (2) 10 (3) 13 (3) 6 (2) 13 (2) 10 (1) 11 (3) 11 (2) 63 (25) 47 (11) 44 (10) 48 (13) 45 (11) 44 (11) 60 (14) 59 (13) 54 (13) 64 (18) 65 (15) 64 (18) 62 (15) 64 (16) 56 (12) 56 (13) 46 (12) 65 (19) 59 (16)
P591 99.94 (100.00) 99.94 (99.81) 99.94 (99.81) 96.45 (97.09) 1 (0) 0  (0) 3 (0) 55 (14) 52 (14) 48 (14) 55 (16) 52 (16) 50 (15) 49 (14) 53 (16) 51 (15) 53 (15) 51 (14) 52 (16) 52 (15) 67 (29) 51 (13) 48 (12) 52 (14) 49 (13) 48 (13) 25 (7) 20 (6) 19 (6) 53 (17) 58 (13) 59 (15) 58 (12) 57 (13) 47 (13) 45 (13) 50 (14) 53 (14) 49 (13)
P2152 99.87 (100.00) 99.87 (99.81) 99.87 (99.81) 96.38 (97.09) 99.94 (100.00) 1  (0) 4 (0) 56 (14) 53 (14) 49 (14) 56 (16) 53 (16) 51 (15) 50 (14) 54 (16) 52 (15) 54 (15) 52 (14) 53 (16) 53 (15) 68 (29) 52 (13) 49 (12) 53 (14) 50 (13) 49 (13) 26 (7) 21 (6) 20 (6) 54 (17) 59 (13) 60 (15) 59 (12) 58 (13) 48 (13) 46 (13) 51 (14) 54 (14) 50 (13)
P2677 99.94 (100.00) 99.94 (99.81) 99.94 (99.81) 96.45 (97.09) 100.00 (100.00) 99.94 (100.00) 3 (0) 55 (14) 52 (14) 48 (14) 55 (16) 52 (16) 50 (15) 49 (14) 53 (16) 51 (15) 53 (15) 51 (14) 52 (16) 52 (15) 67 (29) 51 (13) 48 (12) 52 (14) 49 (13) 48 (13) 25 (7) 20 (6) 19 (6) 53 (17) 58 (13) 59 (15) 58 (12) 57 (13) 47 (13) 45 (13) 50 (14) 53 (14) 49 (13)
L3401 99.74 (100.00) 99.74 (99.81) 99.74 (99.81) 96.25 (97.09) 99.81 (100.00) 99.74 (100.00) 99.81 (100.00) 58 (14) 55 (14) 51 (14) 58 (16) 55 (16) 53 (15) 52 (14) 56 (16) 54 (15) 56 (15) 54 (14) 55 (16) 55 (15) 70 (29) 54 (13) 51 (12) 55 (14) 52 (13) 51 (13) 28 (7) 23 (6) 22 (6) 56 (17) 61 (13) 62 (15) 61 (12) 60 (13) 48 (13) 46 (13) 53 (14) 54 (14) 50 (13)
AP018021 JP 96.38 (97.29) 96.38 (97.09) 96.38 (97.09) 99.10 (99.81) 96.45 (97.29) 96.38 (97.29) 96.45 (97.29) 96.25 (97.29) 36 (8) 19 (6) 16 (2) 13 (2) 9 (1) 10 (2) 13 (2) 10 (1) 13 (1) 10 (0) 11 (2) 11 (1) 63 (24) 47 (10) 44 (9) 48 (12) 47 (10) 46 (10) 60 (13) 59 (12) 54 (12) 64 (17) 65 (15) 64 (17) 62 (14) 64 (15) 56 (11) 56 (12) 46 (11) 63 (18) 57 (15)
D00647 AU 96.58 (97.29) 96.58 (97.09) 96.58 (97.09) 97.55 (98.26) 96.64 (97.29) 96.58 (97.29) 96.64 (97.29) 96.45 (97.29) 97.67 (98.45) 37 (10) 40 (10) 37 (10) 33 (9) 32 (8) 37 (10) 34 (9) 37 (9) 34 (8) 35 (10) 35 (9) 70 (27) 54 (11) 51 (10) 55 (13) 51 (11) 48 (11) 57 (13) 54 (12) 50 (12) 68 (21) 61 (13) 58 (15) 57 (12) 56 (13) 64 (14) 64 (15) 51 (12) 63 (18) 57 (15)
AF399703 BR 96.83 (97.29) 96.83 (97.09) 97.96 (97.48) 98.77 (98.64) 96.90 (97.29) 96.83 (97.29) 96.90 (97.29) 96.71 (97.29) 98.77  (98.84) 97.61 (98.06) 19 (6) 16 (8) 14 (7) 13 (6) 16 (6) 15 (7) 16 (5) 15 (6) 16 (8) 16 (7) 50 (26) 35 (10) 33 (9) 38 (12) 38 (10) 39 (10) 52 (13) 52 (12) 47 (12) 55 (17) 60 (15) 59 (17) 58 (14) 59 (15) 49 (11) 49 (12) 38 (11) 58 (18) 52 (15)
AY151262 BR 96.38 (96.90) 96.38 (96.71) 96.51 (97.09) 98.97 (99.42) 96.45 (96.90) 96.38 (96.90) 96.45 (96.90) 96.25 (96.90) 98.97 (99.61) 97.42 (98.06) 98.77 (98.84) 15 (4) 11 (3) 12 (4) 7 (2) 12 (3) 7 (1) 12 (2) 13 (4) 13 (3) 63 (26) 47 (12) 44 (11) 48 (14) 47 (12) 46 (12) 60 (15) 59 (14) 54 (14) 64 (19) 67 (17) 66 (19) 64 (16) 66 (17) 54 (11) 56 (14) 48 (13) 65 (20) 59 (17)
EF065637CR 96.58 (96.90) 96.58 (96.71) 96.58 (96.71) 99.16 (99.42) 96.64 (96.90) 96.58 (96.90) 96.64 (96.90) 96.45 (96.90) 99.16 (99.61) 97.61 (98.06) 98.97 (98.45) 99.03 (99.22) 8 (3) 9 (4) 12 (4) 9 (3) 12 (3) 9 (2) 10 (4) 10 (3) 60 (26) 44 (12) 40 (11) 45 (14) 44 (12) 43 (12) 57 (15) 56 (14) 51 (14) 59 (19) 64 (17) 63 (19) 61 (16) 63 (17) 53 (13) 53 (14) 45 (13) 62 (20) 56 (17)
KX674372 DM 96.71 (97.09) 96.71 (96.90) 96.71 (96.90) 99.42 (99.61) 96.77 (97.09) 96.71 (97.09) 96.77 (97.09) 96.58 (97.09) 99.42 (99.81) 97.87 (98.26) 99.10 (98.64) 99.29 (99.42) 99.48 (99.42) 5 (3) 8 (3) 5 (2) 8 (2) 5 (1) 6 (3) 6 (2) 58 (25) 42 (11) 39 (10) 43 (13) 42 (11) 41 (11) 55 (14) 54 (13) 49 (13) 59 (18) 62 (16) 61 (18) 59 (15) 61 (16) 51 (12) 51 (13) 43 (12) 60 (19) 54 (16)
EF065646 JP 96.77 (97.29) 96.77 (97.09) 96.77 (97.09) 99.35 (99.42) 96.83 (97.29) 96.77 (97.29) 96.83 (97.29) 96.64 (97.29) 99.35 (99.61) 97.93 (98.45) 99.16 (98.84) 99.22 (99.22) 99.42 (99.22) 99.68 (99.42) 9 (4) 6 (3) 7 (3) 6 (2) 5 (4) 7 (3) 57 (24) 41 (10) 38 (9) 42 (12) 41 (10) 40 (10) 54 (13) 53 (12) 48 (12) 60 (19) 61 (15) 60 (17) 58 (14) 60 (15) 50 (11) 50 (12) 42 (11) 57 (18) 53 (15)
LC080651 PY 96.51 (96.90) 96.51 (96.71) 96.64 (97.09) 99.16 (99.42) 96.58 (96.90) 96.51 (96.90) 96.58 (96.90) 96.38 (96.90) 99.16 (99.61) 97.61 (98.06) 98.97 (98.84) 99.55 (99.61) 99.22 (99.22) 99.48 (99.42) 99.42 (99.22) 9 (3) 2 (1) 9 (2) 10 (4) 10 (3) 62 (26) 46 (12) 43 (11) 47 (14) 46 (12) 45 (12) 58 (15) 57 (14) 52 (14) 63 (19) 66 (17) 65 (19) 63 (16) 65 (17) 55 (13) 55 (14) 47 (13) 64 (20) 58 (17)
KX674369 KN 96.64 (97.09) 96.64 (96.90) 96.64 (96.90) 99.61 (99.61) 96.71 (97.09) 96.64 (97.09) 96.71 (97.09) 96.51 (97.09) 99.35 (99.81) 97.8 (98.26) 99.03 (98.64) 99.22 (99.42) 99.42 (99.42) 99.68 (99.61) 99.61 (99.42) 99.42 (99.42) 9 (2) 6 (1) 7 (3) 7 (2) 59 (25) 43 (11) 40 (10) 44 (13) 43 (11) 42 (11) 56 (14) 55 (13) 50 (13) 60 (18) 63 (16) 62 (18) 60 (15) 62 (16) 52 (12) 52 (13) 42 (12) 61 (19) 55 (16)
HE967301 UY 96.51 (97.09) 96.51 (96.90) 96.64 (97.29) 99.16 (99.61) 96.58 (97.09) 96.51 (97.09) 96.58 (97.09) 96.38 (97.09) 99.16 (99.81) 97.61 (98.06) 98.97 (99.03) 99.55 (99.81) 99.22 (99.42) 99.48 (99.61) 99.55 (99.42) 99.87 (99.81) 99.42 (99.61) 9 (1) 8 (3) 10 (2) 62 (25) 46 (11) 43 (10) 47 (13) 46 (11) 45 (11) 58 (14) 57 (13) 52 (13) 63 (18) 66 (16) 65 (18) 63 (15) 65 (16) 55 (12) 55 (13) 47 (12) 62 (19) 58 (16)
EF065641 US 96.64 (97.29) 96.54 (97.09) 96.64 (97.09) 99.35 (99.81) 96.71 (97.29) 96.64 (97.29) 96.71 (97.29) 96.51 (97.29) 99.35  (100.00) 97.80 (98.45) 99.03 (98.84) 99.22 (99.61) 99.42 (99.61) 99.68 (99.81) 99.61 (99.61) 99.42 (99.61) 99.61 (99.81) 99.42 (99.81) 7 (2) 7 (1) 59 (24) 43 (10) 40 (9) 44 (12) 41 (10) 40 (10) 56 (13) 55 (12) 50 (12) 60 (17) 63 (15) 62 (17) 60 (14) 62 (15) 52 (11) 52 (12) 44 (11) 59 (18) 53 (15)
MH170027 VN 96.58 (96.90) 96.58 (96.71) 96.58 (96.71) 99.29 (99.42) 96.64 (96.90) 96.58 (96.90) 96.64 (96.90) 96.45 (96.90) 99.29  (99.61) 97.74 (98.06) 98.97 (98.45) 99.16 (99.22) 99.35 (99.22) 99.61 (99.42) 99.68 (99.22) 99.35 (99.22) 99.55 (99.42) 99.48 (99.42) 99.55 (99.61) 4 (1) 60 (26) 44 (12) 41 (11) 45 (14) 44 (12) 43 (12) 57 (15) 56 (14) 51 (14) 59 (19) 64 (17) 63 (19) 61 (16) 63 (17) 53 (13) 53 (14) 45 (13) 60 (20) 56 (17)
MH170028 VN 96.58 (97.09) 96.58 (96.90) 96.58 (96.90) 99.29 (99.61) 96.64 (97.09) 96.58 (97.09) 96.64 (97.09) 96.45 (97.09) 99.29 (99.81) 97.74 (98.26) 98.97 (98.64) 99.16 (99.42) 99.35 (99.42) 99.61 (99.61) 99.55 (99.42) 99.35 (99.42) 99.55 (99.61) 99.35 (99.61) 99.55 (99.81) 99.74 (99.81) 60 (25) 44 (11) 41 (10) 43 (13) 44 (11) 43 (11) 57 (14) 56 (13) 51 (13) 59 (18) 64 (16) 63 (18) 61 (15) 63 (16) 53 (12) 53 (13) 45 (12) 62 (19) 56 (16)
AF257515 AR 95.91 (94.38) 95.61 (94.19) 95.61 (94.19) 95.93 (95.16) 95.67 (94.38) 95.61 (94.38) 95.67 (94.38) 95.48 (94.38) 95.93 (95.35) 95.48 (94.77) 96.77 (94.96) 95.93 (94.96) 96.12 (94.96) 96.25 (95.16) 96.32 (95.35) 95.99 (94.96) 96.19 (95.16) 95.99 (95.16) 96.19 (95.35) 96.12 (94.96) 96.12 (95.16) 23 (18) 23 (17) 28 (20) 50 (20) 51 (20) 71 (28) 69 (27) 65 (26) 77 (31) 47 (30) 79 (30) 80 (30) 81 (31) 71 (26) 72 (28) 48 (21) 80 (34) 74 (31)
AF399704 BR 96.64 (97.48) 96.64 (97.29) 96.64 (97.29) 96.96 (97.87) 96.71 (97.48) 96.64 (97.48) 96.71 (97.48) 96.51 (97.48) 96.96 (98.06) 96.51 (97.87) 97.74 (98.06) 96.96 (97.67) 97.16 (97.67) 97.29 (97.87) 97.35 (98.06) 97.03 (97.67) 97.22 (97.87) 97.03 (97.87) 97.22 (98.06) 97.16 (97.67) 97.16 (97.87) 98.51 (96.51) 6 (1) 11 (4) 34 (4) 35 (4) 54 (12) 53 (11) 50 (11) 63 (19) 64 (15) 67 (17) 64 (14) 65 (15) 56 (11) 57 (13) 31 (5) 64 (18) 58 (15)
LC080655 PY 96.83 (97.67) 96.83 (97.48) 96.83 (97.48) 97.16 (98.06) 96.90 (97.67) 96.83 (97.67) 96.90 (97.67) 96.71 (97.67) 97.16 (98.26) 96.71 (98.06) 97.87 (98.26) 97.16 (97.87) 97.42 (97.87) 97.48 (98.06) 97.55 (98.26) 97.22 (97.87) 97.42 (98.06) 97.22 (98.06) 97.41 (98.26) 97.35 (97.87) 97.35 (98.06) 98.51 (96.71) 99.61 (99.81) 11 (3) 31 (3) 32 (3) 54 (11) 50 (10) 47 (10) 60 (18) 61 (14) 64 (16) 61 (13) 62 (14) 53 (10) 54 (12) 29 (4) 61 (17) 55 (14)
LC080654 PE 96.58 (97.29) 96.58 (97.09) 96.58 (97.09) 96.90 (97.48) 96.64 (97.29) 96.58 (97.29) 96.64 (97.29) 96.45 (97.29) 96.90 (97.67) 96.45 (97.48) 97.55 (97.67) 96.90 (97.29) 97.09 (97.29) 97.22 (97.48) 97.29 (97.67) 96.96 (97.29) 97.16 (97.48) 96.96 (97.48) 97.16 (97.67) 97.09 (97.29) 97.22 (97.48) 98.19 (96.12) 99.29 (99.22) 99.29 (99.42) 35 (6) 36 (6) 55 (13) 54 (12) 51 (12) 62 (20) 67 (16) 68 (18) 67 (15) 66 (16) 55 (12) 58 (14) 32 (7) 65 (19) 59 (16)
EF065650 JP 95.77 (97.48) 96.77 (97.29) 96.77 (97.29) 97.09 (97.87) 96.83 (97.48) 96.77 (97.38) 96.83 (97.48) 96.64 (97.48) 96.96 (98.06) 96.71 (97.87) 97.55 (98.06) 96.96 (97.67) 97.16 (97.67) 97.29 (97.87) 97.35 (98.06) 97.03 (97.67) 97.22 (97.87) 97.03 (97.87) 97.35 (98.06) 97.16 (97.67) 97.16 (97.87) 96.77 (96.12) 97.80 (99.22) 98.00 (99.42) 97.74 (98.84) 11 (0) 55 (12) 53 (11) 45 (11) 63 (19) 62 (15) 63 (17) 62 (14) 63 (15) 56 (11) 57 (13) 34 (6) 62 (18) 56 (15)
EF065647 US 96.83 (97.48) 96.83 (97.29) 96.83 (97.29) 97.16 (97.87) 96.90 (97.48) 96.83 (97.48) 96.90 (97.48) 96.71 (97.48) 97.03 (98.06) 96.90 (97.87) 97.48 (98.06) 97.03 (97.67) 97.22 (97.67) 97.35 (97.87) 97.42 (98.06) 97.09 (97.67) 97.29 (97.87) 97.09 (97.87) 97.42 (98.06) 97.22 (97.67) 97.22 (97.87) 96.71 (96.12) 97.74 (99.22) 97.93 (99.42) 96.67 (98.84) 99.29 (100.00) 54 (12) 52 (11) 44 (11) 64 (19) 59 (15) 62 (17) 59 (14) 62 (15) 55 (11) 56 (13) 34 (6) 60 (18) 55 (15)
AF503581 BE 98.45 (98.64) 98.32 (98.45) 98.32 (98.45) 96.12 (97.29) 98.39 (98.64) 98.32 (98.64) 98.39 (98.64) 98.19 (98.64) 96.12 (97.48) 96.32 (97.48) 96.64 (97.48) 96.12 (97.09) 96.32 (97.09) 96.45 (97.29) 96.51 (97.48) 96.25 (97.09) 96.38 (97.29) 96.25 (97.29) 96.38 (97.48) 96.32 (97.09) 96.32 (97.29) 95.41 (94.57) 96.51 (97.67) 96.51 (97.87) 96.45 (97.48) 96.45 (97.67) 96.51 (97.67) 29 (5) 25 (4) 60 (18) 65 (15) 62 (16) 61  (13) 62 (14) 54 (12) 52 (12) 55 (13) 60 (15) 56 (14)
JN695878 RU 98.64 (98.84) 98.64 (98.64) 98.64 (98.64) 96.19 (98.48) 98.71 (98.84) 98.64 (98.84) 98.71 (98.84) 98.51 (98.84) 96.19 (97.67) 96.51 (97.67) 96.64 (97.67) 96.19 (97.29) 96.38 (97.29) 96.51 (97.48) 96.58 (97.67) 96.32 (97.29) 96.45 (97.48) 96.32 (97.48) 96.45 (97.67) 96.38 (97.29) 96.38 (97.48) 95.54 (94.77) 96.58 (97.87) 96.77 (98.06) 96.51 (97.67) 96.58 (97.87) 96.64 (97.87) 98.13 (99.03) 23 (4) 59 (17) 62 (14) 63 (15) 60 (12) 59 (13) 49 (11) 51 (11) 56 (12) 57 (14) 53 (13)
AF033818 US 98.71 (98.84) 98.71 (98.64) 98.71 (98.64) 96.51 (97.48) 98.77 (98.84) 98.71 (98.84) 98.77 (98.84) 98.58 (98.84) 96.51 (97.67) 96.77 (97.67) 96.96 (97.67) 96.51 (97.29) 96.71 (97.29) 96.83 (97.48) 96.9 (97.67) 96.64 (97.29) 96.77 (97.48) 96.64 (97.48) 96.77 (97.67) 96.71 (97.29) 96.71 (97.48) 95.8 (94.96) 96.77 (97.87) 96.96 (98.06) 96.71 (97.67) 97.09 (97.87) 97.16 (97.87) 98.39 (99.22) 98.51 (99.22) 54 (16) 57 (13) 60 (15) 59 (12) 58 (13) 48 (9) 46 (9) 51 (12) 54 (14) 50 (13)
G5 EF065635 CR 96.51 (96.71) 96.51 (96.51) 96.51 (96.51) 95.87 (96.51) 96.58 (96.71) 96.51 (96.71) 96.58 (96.71) 96.38 (96.71) 95.87 (96.71) 95.61 (95.93) 96.45 (96.71) 95.87 (96.32) 96.19 (96.32) 96.19 (96.51) 96.12 (96.32) 95.93 (96.32) 96.12 (96.51) 95.93 (96.51) 96.12 (96.71) 96.19 (96.32) 96.19 (96.51) 95.03 (93.99) 95.93 (96.32) 96.12 (96.51) 95.99 (96.12) 95.93 (96.32) 95.87 (96.32) 96.12 (96.51) 96.19 (96.71) 96.51 (96.90) 71 (19) 68 (21) 69 (19) 68 (20) 66 (17) 62 (17) 64 (20) 68 (23) 62 (20)
MF580991 CN 96.19 (97.48) 96.19 (97.29) 96.19 (97.29) 95.80 (97.09) 96.25 (97.48) 96.19 (97.48) 96.25 (97.48) 96.06 (97.48) 95.8 (97.09) 96.06 (97.48) 96.12 (97.09) 95.67 (96.71) 95.87 (96.71) 95.99 (96.90) 96.06 (97.09) 95.74 (96.71) 95.93 (96.90) 95.74 (96.90) 95.93 (97.09) 95.87 (96.71) 95.87 (96.90) 94.9 (94.19) 95.87 (97.09) 96.06 (97.29) 95.67 (96.90) 95.99 (97.09) 96.19 (97.09) 95.80 (97.29) 95.99 (97.48) 96.32 (97.87) 95.41 (96.32) 31 (10) 22 (7) 33 (8) 65 (12) 63 (11) 61 (14) 52 (15) 47 (12)
AY185360 BR 96.12 (97.09) 96.12 (96.90) 96.12 (96.90) 95.87 (96.51) 96.19 (97.09) 96.12 (97.09) 96.19 (97.09) 95.99 (97.09) 95.87 (96.71) 96.25 (97.09) 96.19 (96.71) 95.74 (96.32) 95.93 (96.32) 96.06 (96.51) 96.12 (96.71) 95.8 (96.32) 95.99 (96.51) 95.8 (96.51) 95.99 (96.71) 95.93 (96.32) 95.93 (96.51) 94.9 (94.19) 95.67 (96.71) 95.87 (96.90) 95.61 (96.51) 95.93 (96.71) 95.99 (96.71) 95.99 (96.90) 95.93 (97.09) 96.12 (97.09) 95.61 (95.93) 98.00 (98.06) 11 (3) 22 (4) 66 (14) 64 (14) 64 (18) 56 (17) 50 (14)
LC080656 PY 96.19 (97.67) 96.19 (97.48) 96.19 (97.48) 95.99 (97.09) 96.25 (97.67) 96.19 (97.67) 96.25 (97.67) 96.06 (97.67) 95.99 (97.29) 96.32 (97.67) 96.25 (97.29) 95.87 (96.90) 96.06 (96.90) 96.19 (97.09) 96.25 (97.29) 95.93 (96.90) 96.12 (97.09) 95.93 (97.09) 96.12 (97.29) 96.06 (96.90) 96.06 (97.09) 94.83 (94.19) 95.87 (97.29) 96.06 (97.48) 95.67 (97.09) 95.99 (97.29) 96.19 (97.29) 96.06 (97.48) 96.12 (97.67) 96.19 (97.67) 95.54 (96.32) 98.58 (98.64) 99.29 (99.42) 19 (1) 65 (11) 63 (11) 63 (15) 53 (14) 47 (11)
MH170030 VN 96.25 (97.48) 96.25 (97.29) 96.25 (97.29) 95.87 (96.90) 96.32 (97.48) 96.25 (97.48) 96.32 (97.48) 96.12 (97.48) 95.87 (97.09) 96.38 (97.48) 96.19 (97.09) 95.74 (96.71) 95.93 (96.71) 96.06 (96.90) 96.12 (97.09) 95.9 (96.71) 95.99 (96.90) 95.8 (96.90) 95.99 (97.09) 95.93 (96.71) 95.93 (96.90) 94.77 (93.99) 95.80 (97.09) 95.99 (97.29) 95.74 (96.90) 95.93 (97.09) 95.99 (97.09) 95.99 (97.29) 96.19 (97.48) 96.25 (97.48) 95.61 (96.12) 97.87 (98.45) 98.58 (99.22) 98.77 (99.81) 64 (12) 62 (12) 62 (16) 54 (15) 48 (12)
KF801457 MD 96.90 (97.48) 96.90 (97.29) 96.90 (97.29) 96.38 (96.67) 96.96 (97.48) 96.90 (97.48) 96.96 (97.48) 96.90 (97.48) 96.38 (97.87) 95.87 (97.29) 96.83 (97.87) 96.51 (97.87) 96.58 (97.48) 96.71 (97.67) 96.77 (97.87) 96.45 (97.48) 96.64 (97.67) 96.45 (97.67) 96.64 (97.87) 96.58 (97.48) 96.58 (97.67) 95.41 (94.96) 96.38 (97.87) 96.58 (98.06) 96.45 (97.67) 96.38 (97.87) 96.45 (97.87) 96.51 (97.67) 96.83 (97.87) 96.90 (98.26) 95.74 (96.71) 95.80 (97.64) 95.74 (97.29) 95.80 (97.87) 95.87 (97.67) 18 (6) 58 (13) 62 (17) 55 (14)
JN695879 RU 97.03 (97.48) 97.03 (97.29) 97.03 (97.29) 96.38 (97.48) 97.09 (97.48) 97.03 (97.48) 97.09 (97.48) 97.03 (97.48) 96.38 (97.67) 95.87 (97.09) 96.83 (97.67) 96.38 (97.29) 96.58 (97.29) 96.71 (97.48) 96.77 (97.67) 96.45 (97.29) 96.64 (97.48) 96.45 (97.48) 96.64 (97.67) 96.58 (97.29) 96.58 (97.48) 95.35 (94.57) 96.32 (97.48) 96.51 (97.67) 96.25 (97.29) 96.32 (97.48) 96.38 (97.48) 96.64 (97.67) 96.71 (97.87) 97.03 (98.26) 95.99 (96.71) 95.93 (97.87) 95.87 (97.29) 95.93 (97.87) 95.99 (97.67) 98.84 (98.84) 58 (14) 60 (17) 53 (14)
G9 LC080659 BO 96.83 (97.29) 96.71 (97.09) 96.71 (97.09) 97.03 (97.67) 96.77 (97.29) 96.71 (97.29) 96.77 (97.29) 96.58 (97.29) 97.03 (97.87) 96.71 (97.67) 97.55 (97.87) 96.90 (97.48) 97.09 (97.48) 97.22 (97.67) 97.29 (97.87) 96.96 (97.48) 97.29 (97.67) 96.96 (97.67) 97.16 (97.87) 97.09 (97.48) 97.09 (97.67) 96.90 (95.93) 98.00 (99.03) 98.13 (99.22) 97.93 (98.64) 97.80 (98.84) 97.80 (98.84) 96.45 (97.48) 96.38 (97.67) 96.71 (97.67) 95.87 (96.12) 96.06 (97.29) 95.87 (96.51) 95.93 (97.09) 95.99 (96.90) 96.25 (97.48) 96.25 (97.29) 61 (19) 55 (16)
MF580994 CN 96.51 (97.29) 96.51 (97.09) 96.51 (97.09) 95.80 (96.32) 96.58 (97.29) 96.51 (97.29) 96.58 (97.29) 96.51 (97.29) 95.93 (96.51) 95.93 (96.51) 96.25 (97.51) 95.80 (96.12) 95.99 (96.12) 96.12 (96.32) 96.32 (96.51) 95.87 (96.12) 96.06 (96.32) 95.99 (96.32) 96.19 (96.51) 96.12 (96.12) 95.99 (96.32) 94.83 (93.41) 95.87 (96.51) 96.06 (96.71) 95.80 (96.32) 95.99 (96.51) 96.12 (96.51) 96.12 (97.09) 96.32 (97.29) 96.51 (97.29) 95.61 (95.54) 96.64 (97.09) 96.38 (96.71) 96.58 (97.29) 96.51 (97.09) 95.99 (96.71) 96.12 (96.71) 96.06 (96.32) 12 (5)










K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401 AP018021 FJ808571 AR D00647 AU LC075568 BO AF399703 BR EF065637 CR KX674372 DM EU266061 IR EF065646 JP LC075558 PY LC075543 PE KX674369 KN KJ707242 KR KU233528 TH FM209468 UY EF065641 US MH170027 VN MH170028 VN HQ902258 BY K02251 BE AY515279 CL M35238 FR LC060792 MN AF067081 PL JN695878 RU JQ696091 RU AF033818 US LC193462 ZM
K1170 0 (0) 1 (1) 13 (4) 0 (0) 1 (0) 0 (0) 1 (0) 12 (3) 12 (4) 12 (3) 13 (3) 11 (4) 11 (3) 12 (3) 13 (4) 11 (3) 11 (3) 12 (3) 11 (3) 16 (5) 12 (3) 13 (4) 13 (3) 12 (4) 13 (3) 6 (3) 4 (3) 9 (5) 2 (1) 3 (2) 4 (2) 5 (3) 6 (3) 4 (3) 1 (0)
K1194 100.00 (100.00) 1 (1) 13 (4) 0 (0) 1 (0) 0 (0) 1 (0) 12 (3) 12 (4) 12 (3) 13 (3) 11 (4) 11 (3) 12 (3) 13 (4) 11 (3) 11 (3) 12 (3) 11 (3) 16 (5) 12 (3) 13 (4) 13 (3) 12 (4) 13 (3) 6 (3) 4 (3) 9 (5) 2 (1) 3 (2) 4 (2) 5 (3) 6 (3) 4 (3) 1 (0)
M1878 99.77 (99.32) 99.77 (99.32) 14 (5) 1 (1) 2 (1) 1 (1) 2 (1) 13 (4) 13 (5) 13 (4) 14 (4) 10 (3) 12 (4) 13 (4) 14 (5) 12 (4) 12 (4) 13 (1) 12 (4) 17 (6) 13 (4) 12 (3) 14 (4) 13 (5) 14 (4) 7 (4) 5 (4) 10 (6) 3 (2) 4 (3) 5 (3) 6 (4) 7 (4) 5 (4) 2 (1)
M2746 97.07 (97.30) 97.07 (97.30) 96.85 (96.62) 13 (4) 14 (4) 13 (4) 14 (4) 3 (1) 3 (2) 3 (1) 4 (1) 4 (2) 4 (1) 3 (1) 4 (2) 2 (1) 2 (1) 3 (3) 2 (1) 8 (3) 3 (1) 5 (2) 4 (1) 3 (2) 4 (1) 13 (3) 13 (3) 16 (5) 13 (3) 10 (2) 13 (2) 14 (3) 15 (3) 13 (3) 12 (4)
P591 100.00 (100.00) 100.00 (100.00) 99.77 (99.32) 97.07 (97.30) 1 (0) 0 (0) 1 (0) 12 (3) 12 (4) 12 (3) 13 (3) 11 (4) 11 (3) 12 (3) 13 (4) 11 (3) 11 (3) 12 (3) 11 (3) 16 (5) 12 (3) 13 (4) 13 (3) 12 (4) 13 (3) 6 (3) 4 (3) 9 (5) 2 (1) 3 (2) 4 (2) 5 (3) 6 (3) 4 (3) 1 (0)
P2152 100.00 (100.00) 100.00 (100.00) 99.77 (99.32) 97.07 (97.30) 100.00 (100.00) 1 (0) 2 (0) 13 (3) 13 (4) 13 (3) 14 (3) 12 (4) 12 (3) 13 (3) 14 (4) 12 (3) 12 (3) 13 (3) 12 (3) 17 (5) 13 (3) 14 (4) 14 (3) 13 (4) 14 (3) 7 (3) 5 (3) 10 (5) 3 (1) 4 (2) 5 (2) 6 (3) 7 (3) 5 (3) 2 (0)
P2677 99.77 (100.00) 99.77 (100.00) 99.77 (99.32) 96.85 (97.30) 99.77 (100.00) 99.77 (100.00) 1 (0) 12 (3) 12 (4) 12 (3) 13 (3) 11 (4) 11 (3) 12 (3) 13 (4) 11 (3) 11 (3) 12 (3) 11 (3) 16 (5) 12 (3) 13 (4) 13 (3) 12 (4) 13 (3) 6 (3) 4 (3) 9 (5) 2 (1) 3 (2) 4 (2) 5 (3) 6 (3) 4 (3) 1 (0)
L3401 99.77 (100.00) 99.77 (100.00) 99.77 (99.32) 96.85 (97.30) 99.77 (100.00) 99.77 (100.00) 99.55 (100.00) 13 (3) 13 (4) 13 (3) 14 (3) 12 (4) 12 (3) 13 (3) 14 (4) 12 (3) 12 (3) 13 (0) 12 (3) 17 (5) 3 (3) 14 (4) 14 (3) 13 (4) 14 (3) 7 (3) 5 (3) 10 (5) 3 (1) 4 (2) 5 (2) 6 (3) 7 (3) 5 (3) 2 (0)
AP018021 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 2 (1) 2 (0) 3 (0) 3 (1) 3 (0) 2 (0) 3 (1) 1 (0) 1 (0) 2 (1) 1 (0) 7 (2) 2 (0) 4 (1) 3 (0) 2 (1) 3 (0) 12 (2) 12 (2) 15 (4) 12 (2) 9 (1) 12 (1) 13 (2) 14 (2) 12 (2) 11 (3)
FJ808571 AR 97.30 (97.33) 97.30 (97.33) 97.07 (96.62) 99.32 (98.65) 97.30 (97.33) 97.30 (97.33) 97.07 (97.33) 97.07 (97.33) 99.55 (99.32) 2 (1) 3 (1) 3 (2) 3 (1) 2 (1) 3 (2) 1 (1) 1 (1) 2 (0) 1 (1) 7 (3) 2 (1) 4 (2) 3 (1) 2 (2) 3 (1) 12 (3) 12 (3) 15 (5) 12 (3) 9 (2) 12 (2) 13 (3) 14 (3) 12 (3) 11 (4)
D00647 AU 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 99.55 (100.00) 99.55 (99.32) 3 (0) 3 (1) 3 (0) 2 (0) 1 (1) 1 (0) 1 (0) 2 (0) 1 (0) 7 (2) 2 (0) 4 (1) 3 (0) 2 (1) 3 (0) 12 (2) 12 (2) 15 (4) 12 (2) 9 (1) 12 (1) 13 (2) 14 (2) 12 (2) 11 (3)
LC075568 BO 97.07 (97.97) 97.07 (97.97) 96.85 (97.30) 99.10 (99.32) 97.07 (97.97) 97.07 (97.97) 96.85 (97.97) 96.85 (97.97) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 4 (1) 4 (0) 3 (0) 4 (1) 2 (0) 2 (0) 3 (0) 2 (0) 8 (2) 3 (0) 5 (1) 4 (0) 3 (1) 4 (0) 13 (2) 13 (2) 16 (4) 11 (2) 10 (1) 13 (1) 14 (2) 15 (2) 13 (2) 12 (3)
AF399703 BR 97.52 (97.30) 97.52 (97.30) 97.75 (97.97) 99.10 (98.65) 97.52 (97.30) 97.52 (97.30) 97.30 (97.30) 97.30 (97.30) 99.32 (99.32) 99.32 (98.65) 99.32 (99.32) 99.10 (99.32) 2 (1) 3 (1) 4 (2) 2 (1) 2 (1) 3 (1) 2 (1) 8 (3) 3 (1) 3 (0) 4 (1) 3 (2) 4 (1) 11 (3) 11 (3) 14 (5) 11 (3) 8 (2) 11 (2) 12 (3) 13 (3) 11 (3) 10 (4)
EF065637 CR 97.52 (97.97) 97.52 (97.97) 97.30 (97.30) 99.10 (99.32) 97.52 (97.97) 97.52 (97.97) 97.30 (97.97) 97.30 (97.97) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 99.1 (100.00) 99.55 (99.32) 3 (0) 4 (1) 2 (0) 2 (0) 3 (0) 2 (0) 8 (2) 3 (0) 5 (1) 4 (0) 3 (1) 4 (0) 11 (2) 11 (2) 14 (4) 11 (2) 8 (1) 11 (1) 12 (2) 13 (2) 11 (2) 10 (3)
KX674372 DM 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 3 (1) 1 (0) 1 (0) 2 (0) 1 (0) 7 (2) 2 (0) 4 (1) 3 (0) 2 (1) 3 (0) 12 (2) 12 (2) 15 (4) 12 (2) 9 (1) 10 (1) 13 (2) 14 (2) 12 (2) 11 (3)
EU266061 IR 97.17 (97.30) 97.17 (97.30) 96.85 (96.62) 99.10 (98.65) 97.07 (97.30) 97.07 (97.30) 96.85 (97.30) 96.85 (97.30) 99.32 (99.32) 99.32 (98.65) 99.77 (99.32) 99.1 (99.32) 99.10 (98.65) 99.10 (99.32) 99.32 (99.32) 2 (1) 2 (1) 3 (1) 2 (1) 8 (3) 3 (1) 5 (2) 4 (1) 3 (2) 4 (1) 13 (3) 13 (3) 16 (5) 13 (3) 10 (2) 13 (2) 14 (3) 15 (3) 13 (3) 12 (4)
EF065646 JP 97.52 (97.97) 97.52 (97.97) 97.30 (97.30) 99.55 (99.32) 97.52 (97.97) 97.52 (97.97) 97.30 (97.97) 97.30 (97.97) 99.77 (100.00) 99.77 (99.32) 99.77 (100.00) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.77 (100.00) 99.55 (99.32) 0 (0) 1 (0) 0 (0) 6 (2) 1 (0) 3 (1) 2 (0) 1 (1) 2 (0) 11 (2) 11 (2) 14 (4) 11 (2) 8 (1) 11 (1) 12 (2) 13 (2) 11 (2) 10 (3)
LC075558 PY 97.52 (97.97) 97.52 (97.97) 97.30 (97.30) 99.55 (99.32) 97.52 (97.97) 97.52 (97.97) 97.30 (97.97) 97.30 (97.97) 99.77 (100.00) 99.77 (99.32) 99.77 (100.00) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.77 (100.00) 99.55 (99.32) 100.00 (100.00) 1 (0) 0 (0) 6 (2) 1 (0) 3 (1) 2 (0) 1 (1) 2 (0) 11 (2) 11 (2) 14 (4) 11 (2) 8 (1) 11 (1) 12 (2) 13 (2) 11 (2) 10 (3)
LC075543 PE 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 99.55 (100.00) 99.32 (99.32) 99.77 (100.00) 99.77 (100.00) 1 (0) 7 (2) 2 (0) 4 (1) 3 (0) 2 (1) 3 (0) 12 (2) 12 (2) 13 (4) 12 (2) 9 (1) 12 (1) 11 (2) 14 (2) 12 (2) 11 (3)
KX674369 KN 97.52 (97.97) 97.52 (97.97) 97.30 (97.30) 99.55 (99.32) 97.52 (97.97) 97.52 (97.97) 97.30 (97.97) 97.30 (97.97) 99.77 (100.00) 99.77 (99.32) 99.77 (100.00) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.77 (100.00) 99.55 (99.32) 100.00  (100.00) 100.00 (100.00) 99.77 (100.00) 6 (2) 1 (0) 3 (1) 2 (0) 1 (1) 2 (0) 11 (2) 11 (2) 14 (4) 11 (2) 8 (1) 11 (1) 12 (2) 13 (2) 11 (2) 10 (3)
KJ707242 KR 97.40 (96.62) 97.40 (96.62) 96.17 (95.95) 98.20 (97.97) 96.40 (96.62) 96.40 (96.62) 97.17 (96.62) 97.17 (96.62) 98.42 (98.65) 98.42 (97.97) 98.42 (98.65) 98.2 (98.65) 98.20 (97.97) 98.20 (98.65) 98.42 (98.65) 98.20 (97.97) 98.65 (98.65) 98.65 (98.65) 98.42 (98.65) 98.65 (98.65) 7 (2) 9 (3) 8 (2) 7 (3) 8 (2) 17 (4) 16 (4) 20 (6) 16 (4) 14 (3) 16 (3) 17 (4) 18 (4) 16 (4) 16 (5)
KU233528 TH 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 99.55 (100.00) 99.55 (99.32) 99.55 (100.00) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 99.55 (100.00) 99.32 (99.32) 99.77 (100.00) 99.77 (100.00) 99.55 (100.00) 99.77 (100.00) 98.42 (98.65) 4 (1) 3 (0) 2 (1) 1 (0) 12 (2) 12 (2) 15 (4) 12 (2) 9 (1) 12 (1) 13 (2) 14 (2) 12 (2) 11 (3)
FM209468 UY 97.07 (97.30) 97.07 (97.30) 97.30 (97.97) 98.87 (98.65) 97.07 (97.30) 97.07 (97.30) 96.85 (97.30) 96.85 (97.30) 99.1 (99.32) 99.10 (98.65) 99.10 (99.32) 98.87 (99.32) 99.32 (100.00) 98.87 (99.32) 99.10 (99.32) 98.87 (98.65) 99.32 (99.32) 99.32 (99.32) 99.10 (99.32) 99.32 (99.32) 97.97 (97.97) 99.10 (99.32) 5 (1) 4 (2) 5 (1) 13 (3) 13 (3) 16 (5) 13 (3) 10 (2) 13 (2) 14 (3) 15 (3) 13 (3) 12 (4)
EF065641 US 97.07 (97.97) 97.07 (97.97) 96.85 (97.30) 99.10 (99.32) 97.07 (97.97) 97.07 (97.97) 96.85 (97.97) 96.85 (97.97) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 99.1 (100.00) 99.10 (99.32) 99.10 (100.00) 99.32 (100.00) 99.10 (99.32) 99.55 (100.00) 99.55 (100.00) 99.32 (100.00) 99.55 (100.00) 98.20  (98.65) 99.32 (100.00) 98.87 (99.32) 3 (1) 4 (0) 13 (2) 13 (2) 16 (4) 13 (2) 10 (1) 13 (1) 14 (2) 15 (2) 13 (2) 12 (3)
MH170027 VN 97.30 (97.97) 97.30 (97.97) 97.07 (97.30) 99.32 (99.32) 97.30 (97.97) 97.30 (97.97) 97.07 (97.97) 97.07 (97.97) 99.55 (99.32) 99.55 (98.65) 99.55 (99.32) 99.32 (99.32) 99.32 (98.65) 99.32 (99.32) 99.55 (99.32) 99.32 (98.65) 99.77 (99.32) 99.77 (99.32) 99.55 (99.32) 99.77 (99.32) 98.42 (97.97) 99.55 (99.32) 99.10 (98.65) 99.32 (99.32) 3 (1) 12 (3) 12 (3) 15 (5) 12 (3) 9 (2) 12 (2) 13 (3) 14 (3) 12 (3) 11 (4)
MH170028 VN 97.07 (97.30) 97.07 (97.30) 96.58 (96.62) 99.10 (98.65) 97.07 (97.30) 97.07 (97.30) 96.85 (97.30) 96.85 (97.30) 99.32 (100.00) 99.32 (99.32) 99.32 (100.00) 99.1 (100.00) 99.10 (99.32) 99.10 (100.00) 99.32 (100.00) 99.10  (99.32) 99.55 (100.00) 99.55 (100.00) 99.32 (100.00) 99.55 (100.00) 98.20 (98.65) 99.77 (100.00) 98.87 (99.32) 99.10  (100.00) 99.32 (99.32) 13 (2) 13 (2) 16 (4) 13 (2) 10 (1) 13 (1) 14 (2) 15 (2) 13 (2) 12 (3)
HQ902258 BY 98.65 (97.97) 98.65 (97.97) 98.42 (97.30) 97.07 (97.97) 98.65 (97.97) 98.65 (97.97) 98.42 (97.97) 98.42 (97.97) 97.3 (98.65) 97.30 (97.97) 97.30 (98.65) 97.07 (98.65) 97.52 (97.97) 97.52 (98.65) 97.30 (98.65) 97.07 (97.97) 97.52 (98.65) 97.52 (98.65) 97.30 (98.65) 97.52 (98.65) 96.17 (97.30) 97.30 (98.65) 97.07 (97.97) 97.07 (98.65) 97.30 (97.97) 97.07 (98.65) 6 (2) 9 (4) 6 (2) 3 (1) 6 (1) 7 (2) 8 (2) 6 (2) 5 (3)
K02251 BE 99.10 (97.97) 99.10 (97.97) 98.87 (97.30) 97.07 (97.97) 99.10 (97.97) 99.10 (97.97) 98.87 (97.97) 98.87 (97.97) 97.3 (98.65) 97.30 (97.97) 97.30  (98.65) 97.07 (98.65) 97.52 (97.97) 97.52 (98.65) 97.30 (98.65) 97.07 (97.97) 97.52 (98.65) 97.52 (98.65) 97.30 (98.65) 97.52 (98.65) 96.40 (97.30) 97.30 (98.65) 97.07 (97.97) 97.07 (98.65) 97.30 (97.97) 97.07 (98.65) 98.65 (98.65) 9 (4) 4 (2) 3 (1) 4 (1) 5 (2) 6 (2) 0 (0) 5 (3)
AY515279 CL 97.97 (96.62) 97.97 (96.62) 97.75 (95.95) 96.40 (96.62) 97.97 (96.62) 97.97 (96.62) 97.75 (96.62) 97.75 (96.62) 96.62 (97.30) 96.62 (96.62) 96.62 (97.30) 96.4 (97.30) 96.85 (96.62) 96.85 (97.30) 96.62 (97.30) 96.40 (96.62) 96.85 (97.30) 96.85 (97.30) 97.07 (97.30) 96.85 (97.30) 95.50 (95.95) 96.62 (97.30) 96.40 (96.62) 96.40 (97.30) 96.62 (96.62) 96.40 (97.30) 97.97 (97.30) 97.97 (97.30) 9 (2) 6 (3) 9 (3) 4 (2) 11 (4) 9 (4) 8 (5)
M35238 FR 99.55 (99.32) 99.55 (99.32) 99.32 (98.65) 97.07 (97.97) 99.55 (99.32) 99.55 (99.32) 99.32 (99.32) 99.32 (99.32) 97.3 (98.65) 97.30 (97.97) 97.3 (98.65) 97.52 (98.65) 97.52 (97.97) 97.52 (98.65) 97.3 (98.65) 97.07 (97.97) 97.52 (98.65) 97.52 (98.65) 97.30 (98.65) 97.52 (98.65) 96.40 (97.30) 97.30 (98.65) 97.07 (97.97) 97.07 (98.65) 97.30 (97.97) 97.07 (98.65) 98.65 (98.65) 99.10 (98.65) 97.97 (97.30) 3 (1) 4 (1) 5 (2) 6 (2) 4 (2) 3 (1)
LC060792 MN 99.32 (98.65) 99.32 (98.65) 99.10 (97.97) 97.75 (98.65) 99.32 (98.65) 99.32 (98.65) 99.10 (98.65) 99.10 (98.65) 97.97 (99.32) 97.97 (98.65) 97.97 (99.32) 97.75 (99.32) 98.20 (98.65) 98.20 (99.32) 97.97 (99.32) 97.75 (98.65) 98.20 (99.32) 98.20 (99.32) 97.97 (99.32) 98.20 (99.32) 96.85 (97.97) 97.970 (99.32) 97.75 (98.65) 97.75 (99.32) 97.97 (98.65) 97.75 (99.32) 99.32 (99.32) 99.32 (99.32) 98.65 (97.97) 99.32 (99.32) 3 (0) 4 (1) 5 (1) 3 (1) 2 (2)
AF067081 PL 99.10 (98.65) 99.10 (98.65) 98.87 (97.97) 97.07 (98.65) 99.10 (98.65) 99.10 (98.65) 98.87 (98.65) 98.87 (98.65) 97.3 (99.32) 97.30 (98.65) 97.30 (99.32) 97.07 (99.32) 97.52 (98.65) 97.52 (99.32) 97.75 (99.32) 97.07 (98.65) 97.52 (99.32) 97.52 (99.32) 97.30 (99.32) 97.52 (99.32) 96.40 (97.97) 97.30 (99.32) 97.07 (98.65) 97.07 (99.32) 97.30 (98.65) 97.07 (99.32) 98.65 (99.32) 99.10 (99.32) 97.97 (97.97) 99.10 (99.32) 99.32 (100.00) 5 (1) 6 (1) 4 (1) 5 (2)
JN695878 RU 98.87 (97.97) 98.87 (97.97) 98.65 (97.30) 96.85 (97.97) 98.87 (97.97) 98.87 (97.97) 98.65 (97.97) 98.65 (97.97) 97.07 (98.65) 97.07 (97.97) 97.07 (98.65) 96.85 (98.65) 97.30 (97.97) 97.30 (98.65) 97.07 (98.65) 96.85 (97.97) 97.30 (98.65) 97.30 (98.65) 97.52 (98.65) 97.30 (98.65) 96.17 (97.30) 97.07 (95.65) 96.85 (97.97) 96.85 (98.65) 97.07 (97.97) 96.85 (98.65) 98.42 (98.65) 98.87 (98.65) 99.10 (98.65) 98.87 (98.65) 99.10 (99.32) 98.87 (99.32) 7 (2) 5 (2) 6 (3)
JQ696091 RU 98.65 (97.97) 98.65 (97.97) 98.42 (97.30) 96.62 (97.97) 98.65 (97.97) 98.65 (97.97) 98.42 (97.97) 98.42 (97.97) 96.85 (98.65) 96.85 (97.97) 96.85 (98.65) 96.62 (98.65) 97.07 (97.97) 97.07 (98.65) 96.85 (98.65) 96.62 (97.97) 97.07 (98.65) 97.07 (98.65) 96.85 (98.65) 97.07 (98.65) 95.95 (97.30) 96.85 (98.65) 96.62 (97.97) 96.62 (98.65) 96.85 (97.97) 96.62 (98.65) 98.20 (98.65) 98.65 (98.65) 97.52 (97.30) 98.65 (98.65) 98.87 (99.32) 98.65 (99.32) 98.42 (98.65) 6 (2) 7 (3)
AF033818 US 99.10 (97.97) 99.10 (97.97) 98.87 (97.30) 97.07 (97.97) 99.10 (97.97) 99.10 (97.97) 98.87 (97.97) 98.87 (97.97) 97.3 (98.65) 97.30 (97.97) 97.30 (98.65) 97.07 (98.65) 97.52 (97.97) 97.52 (98.65) 97.30  (98.65) 97.07 (97.97) 97.52 (98.65) 97.52 (98.65) 97.30 (98.65) 97.52 (98.65) 96.40 (97.30) 97.30 (98.65) 97.07 (97.97) 97.07 (98.65) 97.30 (97.97) 97.07 (98.65) 98.35 (98.65) 100.00 (100.00) 97.97 (97.30) 99.10 (98.65) 99.32 (99.32) 99.10 (99.32) 98.87 (98.65) 98.65 (98.65) 5 (3)











Amino acid sequence identities are shown in brackets. The lower matrix shows the percent identity of nucleotide and amino acid sequences in the BLV full-length Gag sequences and the upper 
matrix shows differences in nucleotide and amino acid sequences in the BLV full-length Gag sequences. Each cell is highlighted according to the amino acid sequence identities and differences. 
The country of origin is indicated by 2-letter codes. AU, Australia; AR, Argentina; BE, Belgium; BO, Bolivia; CN, China; JP, Japan; MM, Myanmar; PE, Peru; PY, Paraguay; US, USA; UY, Uruguay; 
VN, Vietnam. 
G9
K1170 K1194 M1878 M2746 P591 P2152 P2677 L3401 AP018021 JP D00647 AU AB934282 JP LC005615 JP LC080651 PY HE967301 UY EF600696 US MH170027 VN MH170028 VN FJ914764 AR LC080655 PY LC080654 PE KT122858 BE AF033818 US MF580991 CN LC080656 PY MH170030 VN LC080659 BO MF580994 CN LC154848 MM
K1170 5 (1) 8 (3) 46 (9) 3 (1) 7 (2) 2 (0) 6 (2) 44 (8) 51 (23) 48 (9) 50 (11) 46 (9) 47 (9) 46 (9) 50 (11) 49 (10) 52 (11) 50 (8) 49 (8) 22 (6) 30 (6) 53 (11) 45 (6) 49 (8) 43 (8) 69 (21) 57 (12)
K1194 99.58 (99.75) 9 (3) 45 (10) 4 (2) 8 (2) 3 (1) 7 (2) 43 (9) 50 (24) 47 (10) 51 (12) 45 (10) 46 (10) 45 (10) 49 (12) 48 (11) 51 (12) 49 (9) 48 (9) 23 (7) 31 (7) 50 (10) 46 (7) 48 (9) 44 (9) 70 (22) 58 (13)
M1878 99.32 (99.24) 99.24 (99.24) 47 (10) 9 (4) 3 (1) 8 (3) 2 (1) 45 (9) 54 (26) 47 (8) 51 (12) 47 (10) 48 (10) 47 (10) 51 (12) 50 (11) 53 (12) 51 (9) 50 (9) 25 (9) 31 (9) 54 (13) 48 (9) 50 (9) 44 (9) 72 (23) 60 (15)
M2746 96.11 (97.72) 96.19 (97.46) 96.02 (97.46) 45 (10) 44 (9) 44 (9) 45 (9) 5 (1) 66 (25) 9 (2) 7 (2) 7 (2) 8 (2) 7 (3) 5 (2) 4 (1) 44 (8) 40 (5) 43 (5) 44 (9) 52 (9) 63 (12) 56 (7) 60 (9) 37 (5) 75 (20) 65 (11)
P591 99.75 (99.49) 99.66 (99.24) 99.24 (98.73) 96.19 (97.72) 8 (3) 1 (1) 7 (3) 43 (9) 50 (24) 47 (10) 51 (12) 45 (10) 46 (10) 45 (10) 49 (12) 48 (11) 51 (12) 49 (9) 48 (9) 23 (7) 31 (7) 54 (12) 46 (7) 48 (9) 44 (9) 70 (22) 58 (13)
P2152 99.41 (99.49) 99.32 (99.49) 99.75 (99.75) 96.28 (97.72) 99.32 (99.24) 7 (2) 1 (0) 43 (8) 52 (25) 47 (9) 49 (11) 45 (9) 46 (9) 45 (9) 49 (11) 48 (10) 51 (11) 49 (8) 48 (8) 24 (8) 32 (8) 54 (12) 46 (8) 50 (10) 42 (8) 70 (23) 58 (14)
P2677 99.83 (100.00) 99.75 (99.75) 99.32 (99.24) 96.28 (97.72) 99.92 (99.75) 99.41 (99.49) 6  (2) 42 (8) 49 (23) 46 (9) 50 (11) 44 (9) 45 (9) 44 (9) 48 (11) 47 (10) 50 (11) 48 (8) 47 (8) 22 (6) 30 (6) 53 (11) 45 (6) 47 (8) 43 (8) 69 (21) 57 (12)
L3401 99.49 (99.49) 99.41 (99.49) 99.83 (99.75) 96.19 (97.72) 99.41 (99.24) 99.92 (100.00) 99.49 (99.49) 43 (8) 52 (25) 47 (9) 49 (11) 45 (9) 46 (9) 45 (9) 49 (11) 48 (10) 51 (11) 49 (8) 48 (8) 23 (8) 31 (8) 54 (12) 46 (8) 50 (10) 42 (8) 70 (23) 58 (14)
AP018021 JP 96.28 (97.97) 96.36 (97.72) 96.19 (97.72) 99.58 (99.75) 96.36 (97.72) 96.36 (97.97) 96.45 (97.97) 96.36 (97.97) 61 (24) 6 (1) 8 (3) 4 (1) 5 (1) 2 (2) 8 (3) 7 (2) 41 (7) 37 (4) 40 (4) 42 (8) 50 (8) 60 (11) 51 (6) 55 (8) 34 (4) 73 (19) 63 (10)
D00647 AU 95.96 (94.16) 95.78 (93.91) 95.44 (93.40) 94.43 (93.65) 95.78 (93.91) 95.61 (93.65) 95.86 (94.16) 95.61 (93.65) 94.85 (93.91) 67 (25) 69 (27) 65 (25) 65 (25) 63 (25) 69 (27) 68 (26) 68 (28) 66 (25) 63 (25) 48 (23) 53 (22) 50 (26) 32 (21) 30 (23) 58 (25) 66 (33) 53 (28)
AB934282 JP 95.94 (97.72) 96.02 (97.46) 96.02 (97.97) 99.24 (99.49) 96.02 (97.46) 96.02 (97.72) 96.11 (97.72) 96.02 (97.72) 99.49 (99.75) 94.34 (93.65) 14 (4) 8 (2) 9 (2) 8 (3) 12 (4) 11 (3) 44 (8) 40 (5) 43 (5) 46 (9) 52 (6) 64 (12) 57 (7) 59 (7) 37 (5) 77 (19) 67 (11)
LC005615 JP 95.77 (97.21) 95.69 (96.95) 95.69 (96.95) 99.41 (99.49) 95.69 (96.95) 95.85 (97.21) 95.77 (97.21) 95.85 (97.21) 99.32 (99.24) 94.17 (93.15) 98.82 (98.98) 12 (4) 13 (4) 10 (5) 8 (4) 7 (3) 49 (10) 45 (7) 48 (7) 48 (11) 52 (10) 64 (14) 55 (9) 61 (11) 40 (7) 78 (22) 68 (13)
LC080651 PY 96.11 (97.72) 96.19 (97.46) 96.02 (97.46) 99.41 (99.49) 96.19 (97.46) 96.19 (97.72) 96.28 (97.72) 96.19 (97.72) 99.66 (99.75) 94.51 (93.65) 99.32 (99.49) 98.98 (98.98) 1 (0) 6 (3) 10 (4) 9 (3) 41 (8) 37 (5) 40 (5) 40 (9) 52 (8) 62 (12) 55 (7) 59 (9) 36 (5) 75 (20) 65 (11)
HE967301 UY 96.02 (97.72) 96.11 (97.46) 95.94 (97.46) 99.32 (99.49) 96.11 (97.46) 96.11 (97.72) 96.19 (97.72) 96.11 (97.72) 99.58 (99.75) 94.51 (93.65) 99.24 (99.49) 98.90 (98.98) 99.92 (100.00) 7 (3) 11 (4) 10 (3) 42 (8) 38 (5) 41 (5) 41 (9) 53 (8) 63 (12) 56 (7) 60 (9) 37 (5) 76 (20) 66 (11)
EF600696 US 96.11 (97.72) 96.19 (97.46) 96.02 (97.46) 99.41 (99.24) 96.19 (97.46) 96.19 (97.72) 96.28 (97.72) 96.19 (97.72) 99.83 (99.49) 94.68 (93.65) 99.32 (99.24) 99.15 (98.73) 99.49 (99.24) 99.41 (99.24) 10 (5) 9 (4) 43 (8) 39 (5) 42 (5) 42 (9) 50 (7) 62 (12) 53 (7) 57 (9) 36 (5) 73 (19) 63 (10)
MH170027 VN 95.77 (97.21) 95.85 (96.95) 95.69 (96.95) 99.58 (99.49) 95.85 (96.95) 95.85 (97.21) 95.94 (97.21) 95.85 (97.21) 99.32 (99.24) 94.17 (93.15) 98.98 (98.98) 99.32 (98.98) 99.15 (98.98) 99.07 (98.98) 99.15 (98.73) 5 (3) 47 (9) 43 (7) 46 (7) 46 (11) 54 (10) 66 (14) 59 (9) 63 (11) 40 (7) 78 (22) 68 (13)
MH170028 VN 95.85 (97.46) 95.94 (97.21) 95.77 (97.21) 99.66 (99.75) 95.94 (97.21) 95.94 (97.46) 96.02 (97.46) 95.94 (97.46) 99.41 (99.49) 94.26 (93.40) 99.07 (99.24) 99.41 (99.24) 99.24 (99.24) 99.15 (99.24) 99.24 (98.98) 99.58 (99.24) 44 (7) 40 (4) 43 (4) 43 (10) 53 (9) 65 (13) 58 (8) 62 (10) 37 (4) 77 (21) 65 (10)
FJ914764 AR 95.60 (97.21) 95.69 (96.95) 95.52 (96.95) 96.28 (97.97) 95.69 (96.95) 95.69 (97.21) 95.77 (97.21) 95.69 (97.21) 96.53 (98.22) 94.26 (92.89) 96.28 (97.97) 95.85 (97.46) 96.53 (97.97) 96.45 (97.97) 96.36 (97.97) 96.02 (97.72) 96.28 (98.22) 6 (4) 9 (3) 47 (11) 54 (11) 65 (13) 58 (8) 61 (10) 29 (3) 77 (21) 65 (10)
LC080655 PY 95.77 (97.97) 95.85 (97.72) 95.69 (97.72) 96.62 (98.73) 95.85 (97.72) 95.85 (97.97) 95.94 (97.97) 95.85 (97.97) 96.87 (98.98) 94.43 (93.65) 96.62 (98.73) 96.19 (98.22) 96.87 (98.73) 96.79 (98.73) 96.70 (98.73) 96.36 (98.22) 96.62 (98.98) 99.49 (98.98) 7 (1) 45 (8) 52 (8) 64 (12) 56 (7) 61 (9) 27 (1) 77 (21) 65 (10)
LC080654 PE 95.85 (97.97) 95.94 (97.72) 95.77 (97.72) 96.36 (98.73) 95.94 (97.72) 95.94 (97.97) 96.02 (97.97) 95.94 (97.97) 96.62 (98.98) 94.68 (93.65) 96.36 (98.73) 95.94 (98.22) 96.62 (98.73) 96.53 (98.73) 96.45 (98.73) 96.11 (98.22) 96.36 (98.98) 99.24 (99.24) 99.41 (99.75) 44 (8) 51 (8) 62 (12) 55 (7) 58 (9) 26 (0) 78 (20) 64 (9)
KT122858 BE 98.14 (98.48) 98.05 (98.22) 97.88 (97.72) 96.28 (97.72) 98.05 (98.22) 97.97 (97.97) 98.14 (98.48) 98.05 (97.97) 96.45 (97.97) 98.98 (94.16) 96.11 (97.72) 95.94 (97.21) 96.28 (97.72) 96.19 (97.72) 96.28 (97.72) 95.94 (97.21) 96.02 (97.46) 96.06 (97.21) 96.19 (97.97) 96.28 (97.97) 26 (6) 49 (11) 41 (6) 45 (8) 39 (8) 65 (21) 53 (12)
AF033818 US 97.46 (98.48) 97.38 (98.22) 97.38 (98.22) 95.60 (97.97) 97.37 (98.22) 97.29 (97.97) 97.46 (98.48) 97.38 (97.97) 95.77 (98.22) 95.52 (94.42) 95.60 (98.48) 95.60 (97.46) 95.60 (97.97) 95.52 (97.97) 95.77 (98.22) 95.43 (97.46) 95.52 (97.72) 95.43 (97.21) 95.60 (97.97) 95.69 (97.97) 97.80 (98.48) 53 (10) 42 (5) 45 (5) 45 (8) 69 (18) 57 (10)
MF580991 CN 95.52 (97.21) 95.77 (97.46) 95.43 (96.70) 94.67 (96.95) 95.43 (96.95) 95.43 (96.95) 95.52 (97.21) 95.43 (96.95) 94.92 (97.21) 98.78 (94.40) 94.59 (96.95) 94.59 (96.45) 94.75 (96.95) 94.67 (96.95) 94.75 (96.95) 94.42 (96.45) 94.50 (96.70) 94.50 (96.70) 94.59 (96.95) 94.75 (96.95) 95.85 (97.21) 95.52 (97.46) 33 (5) 34 (7) 55 (12) 68 (21) 56 (12)
LC080656 PY 96.19 (98.48) 96.11 (98.22) 95.94 (97.72) 95.26 (98.22) 96.11 (98.22) 96.11 (97.97) 96.19 (98.48) 96.11 (97.97) 95.69 (98.48) 97.30 (94.67) 95.18 (98.22) 95.35 (97.72) 95.35 (98.22) 95.26 (98.22) 95.52 (98.22) 95.01 (97.72) 95.09 (97.97) 95.09 (97.97) 95.26 (98.22) 95.35 (98.22) 96.53 (98.48) 96.45 (98.73) 97.21 (98.73) 16 (2) 48 (7) 60 (16) 48 (7)
MH170030 VN 95.85 (97.97) 95.94 (97.72) 95.77 (97.72) 94.92 (97.72) 95.94 (97.72) 95.77 (97.46) 96.02 (97.97) 95.77 (97.46) 95.35 (97.97) 97.47 (94.16) 95.01 (98.22) 94.84 (97.21) 95.01 (97.72) 94.92 (97.72) 95.18 (97.72) 96.47 (97.21) 94.75 (97.46) 94.84 (97.46) 94.84 (97.72) 95.09 (97.72) 96.19 (97.97) 96.19 (98.73) 97.12 (98.22) 98.65 (99.49) 52 (9) 60 (17) 50 (9)
G9 LC080659 BO 96.36 (97.97) 96.28 (97.72) 96.28 (97.72) 96.87 (98.73) 96.28 (97.72) 96.45 (97.97) 96.36 (97.97) 96.45 (97.97) 97.12 (98.98) 95.10 (93.65) 96.87 (98.73) 96.62 (98.22) 96.95 (98.73) 96.87 (98.73) 96.95 (98.73) 96.62 (98.22) 96.87 (98.98) 97.55 (99.24) 97.72 (99.75) 97.80 (100.00) 96.70 (97.97) 96.19 (97.97) 95.35 (96.95) 95.94 (98.22) 95.60 (97.72) 70 (20) 58 (9)
MF580994 CN 94.16 (94.67) 94.08 (94.42) 93.91 (94.16) 93.65 (94.92) 94.08 (94.42) 94.08 (94.16) 94.16 (94.67) 94.08 (95.18) 93.82 (95.18) 94.43 (91.62) 93.49 (95.18) 93.40 (94.42) 93.65 (94.92) 93.57 (94.92) 93.82 (95.18) 93.40 (94.42) 93.49 (94.67) 93.49 (94.67) 93.49 (94.67) 93.65 (94.92) 94.50 (94.67) 94.16 (95.43) 94.25 (94.67) 94.92 (95.94) 94.92 (95.69) 94.08 (94.92) 24 (13)










APPENDIX D: SUPPLEMENTAL FIGURES FOR CHAPTER 4 
Table S4.1: GenBank accession numbers of 62 BLV natural isolates used to select consensus Env and 
Gag sequences 
 GenBank accession number References 
1.  AB934282 Direct submission by Mekata and Norimine (2014) 
2.  AB987702 [582] 
3.  AF033818 Direct submission by Chappey (1997) 
4.  AF257515 [247] 
5.  AP018006 [347] 
6.  AP018007 [347] 
7.  AP018008 [347] 
8.  AP018009 [347] 
9.  AP018010 [347] 
10.  AP018011 [347] 
11.  AP018012 [347] 
12.  AP018013 [347] 
13.  AP018014 [347] 
14.  AP018015 [347] 
15.  AP018016 [347] 
16.  AP018017 [347] 
17.  AP018018 [347] 
18.  AP018019 [347] 
19.  AP018020 [347] 
20.  AP018021 [347] 
21.  AP018022 [347] 
22.  AP018023 [347] 
23.  AP018024 [347] 
24.  AP018025 [347] 
25.  AP018026 [347] 
26.  AP018027 [347] 
27.  AP018028 [347] 
28.  AP018029 [347] 
29.  AP018030 [347] 
30.  AP018031 [347] 
31.  AP018032 [347] 
32.  D00647 [189] 
33.  EF600696 [219] 
34.  FJ914764 [364] 
35.  HE967301 Direct submission by Cristina (2012) 
36.  HE967302 Direct submission by Cristina (2012) 
37.  HE967303 Direct submission by Cristina (2012) 
38.  K02120 [206] 




Table S4.1: GenBank accession numbers of 62 BLV natural isolates used to select consensus Env and 
Gag sequences (Continued) 
 GenBank accession number References 
40.  KT122858 Direct submission by Rosewick et al. (2015) 
41.  LC080656 [330] 
42.  LC080657 [330] 
43.  LC080658 [330] 
44.  LC080659 [330] 
45.  LC080660 [330] 
46.  LC080663 [330] 
47.  LC080666 [330] 
48.  LC080669 [330] 
49.  LC080672 [330] 
50.  LC080675 [330] 
51.  LC154848 [341] 
52.  LC154849 [341] 
53.  LC164083 [583] 
54.  LC164084 [583] 
55.  LC164085 [583] 
56.  LC164086 [583] 
57.  MF580990 [344] 
58.  MF580991 [344] 
59.  MF580992 [344] 
60.  MF580993 [344] 
61.  MF580994 [344] 
62.  MF580995 [344] 
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DSDYQALLPSAPEIYSHLSPVKPDYINLRPCP* (515 aa) 
Start codon and stop codon are highlighted in gre
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GPCYRCLKEGHWARDCPTKATGPPPGPCPICKDPSHWKRDCPTLKSKN* (393 aa) 
Start codon and stop codon are highlighted in grey
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                                                                     mFP promoter                                                                                                    
ACCATTATTTGGTTATATTACTATGATAACAGATAGTACTTTTATAACTGATGATTAATTTTTCTGGGCCCAGAAAAATAT 
                                          Human tPA leader                                                      
CCTAAAATTGAATTGTAATTATCGATAATAAAAGCTTCCACCATGGATGCTATGAAAAGAGGACTGTGCTGCGTGCTGCTG 








































        MfeI        mH5 promoter 
GACTCGAGCAATTGCCCGGGAAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAATAA 






























                                                                            EcoRI  
TGTCCTATCTGTAAAGACCCATCTCATTGGAAAAGGGACTGCCCCACTCTGAAAAGCAAGAACTAATTTTTATCTCGAGAA 
   p7.5 
TTCTCCAAACCCACCCGCTTTTTATAGTAAGTTTTTCACCCATAAATAATAAATACAATAATTAATTTCTCGTAAAAGTAG 

































































































Figure S4.1: Binding sites of sequencing primers on the pBLV-Env-Gag transfer vector. Binding sites of 
five forward primers and two reverse primers on the pBLV-Env-Gag transfer vector plasmid are shown as orange 
arrows. Blue triangle, mFP promoter; purple arrow, human tPA signal sequence; Pink triangle, Gly linker; red 
arrow, mH5 promoter; green arrow, p7.5 promoter; gp51, BLV env gp51; gp30, BLV env gp30; gag, BLV gag. 
LacZ, LacZ alpha fragment of the beta-galactosidase gene; bla (ApR), beta-lactamase (bla) gene; Ori, ColE1 




Figure S4.2:  Plasmid map of the pUC57-simple cloning vector used to construct the pBLV-Env-Gag 
transfer vector. Plasmid map of pUC57-simple cloning vector (GenScript, China) showing cloning sites and 
binding sites of M13F and M13R universal primers. LacZ, LacZ alpha fragment of the beta-galactosidase 
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